

AUTHOR INDEX*

Volume 63

A

Aaltonen, L. A., 154, 7595
 Aaron, J., 1999
 Aaronson, S. A., 3883
 Aarts, W. M., 3894, 7942
 Abaji, C., 3334
 Abate-Shen, C., 3886
 Abbou, C. C., 8108
 Abdollahi, A., 3755, 4521, 8890
 Abdollahi, T., 4521
 Abdulkadir, S. A., 8079
 Abdullah, R., 8912
 Abe, T., 2300
 Abei, M., 4434
 Abendstein, B., 7507
 Abernethy, D. J., 929
 Abken, H., 3234
 Aboagye, E., 2409, 3791, 8558, 8560
 Abounader, R., 2990
 Abraham, J. M., 4577
 Abraham, R. T., 8451
 Abrahams, V. M., 5573
 Abrams, M. T., 172
 Aburatani, H., 4882, 7791, 8629
 Aceto, G., 342
 Ackermann, S., 3066
 Ackert-Bicknell, C. L., 8197
 Adachi, Y., 6432
 Adam, J-F., 3221
 Adair, R. M., 484
 Adelman, M. K., 1860
 Adema, G. J., 12
 Adkins, H., 1192
 Adler, G., 4945, 6265
 Adsay, N. V., 8614
 Afar, D. E. H., 4196, 6387
 Afdhal, N., 8312
 Aft, R. L., 3413, 5496
 Agani, F., 1138
 Agathangelou, A., 5344
 Agelopoulos, K., 1172
 Aggarwal, A., 3309
 Aggarwal, B. B., 4375
 Aggarwal, S., 4136
 Agirre, X., 3079
 Agostara, B., 5041
 Aguirre-Ghiso, J. A., 1684
 Agus, D. B., 4196
 A'Hern, R., 6516
 Ahlstedt-Soini, M., 8861
 Ahluwalia, R., 6170
 Ahmad, S. A., 2079, 3370
 Ahmed, A., 2145
 Ahmed, M., 6327
 Ahmed, W., 8420
 Ahmed-Choudhury, J., 5344
 Ahn, D., 1615
 Ahn, N. G., 6716
 Ahnen, D. J., 616
 Ai, N., 7563
 Aiba, A., 2404
 Aigner, A., 8085
 Aimone, L., 5978
 Ain, K. B., 4561
 Ait-Si-Ali, S., 3919
 Akagi, M., 3632
 Akaike, T., 3567
 Akbari, M., 3575
 Akinaga, S., 2762, 3931

Akiri, G., 1657
 Akiyama, M., 18, 5850, 6187, 8428
 Akporiaye, E. T., 1860
 Akuta, T., 3567
 Alaminos, M., 4538
 Alanen, K., 4671
 Alaoui-Jamali, M. A., 3764
 Alauddin, M. M., 3667
 Al-Azzawi, F., 8461
 Albanese, D., 3991
 Albanese, C., 3395, 6802
 Albelda, S. M., 7845
 Alber, S. M., 6378
 Albers, A., 3675
 Albert, D. H., 7861
 Albert, P. S., 8877
 Alberts, D. S., 3891
 Albertson, D., 2872, 5266
 Albom, M., 5978
 Aldape, K., 1589
 Alder, H., 3352, 3724
 Aldosari, N., 4773, 8097
 Aldred, M. A., 2864
 Alemán, C., 3084
 Alemany, R., 5544
 Alexander, A., 567, 2067
 Alexander, H. R., 5957, 8022
 Alexander, J., 1000, 5243
 Algara, P., 8226
 al-Kofahi, K., 8073
 Allan, J. M., 4327
 Allard, B., 4588
 Allard, D., 140
 Allavena, P., 7451
 Allegra, C. J., 4602
 Allen, C., 2462
 Allen, J. D., 1339
 Allen, J. S., 5838
 Allen, S. M., 567
 Allen, T. M., 86, 7400
 Allen, W., 1667, 4602
 Allendorf, D. J., 9023
 Allison, 1040
 Allison, S. J., 6674
 Allport, J. R., 6838
 Allred, D. C., 2434
 Alm, K., 3619
 Almasan, A., 4713
 Almenara, J., 2118, 3637
 Almunia, C., 6506
 Al-Nafussi, A., 8648
 Alnemri, E. S., 1712
 Aloisi, A., 5829
 Alonso, D. F., 2284
 Al-Saleem, T., 8695
 Alsina, M., 7900
 Altieri, D. C., 230, 567
 Altucci, L., 6350
 Altuwajiri, S., 7106
 Alvarez, K. M., 2425
 Alvarez, R. D., 847
 Alves, P. M. S., 8476
 Alvey, S. J., 6602
 Alvis, L. B., 2194
 Alyea, E. P., 2561
 Amelse, L. L., 8664
 Amici, A., 2518
 Amin, A. R. M. R., 6334
 Ammanamanchi, S., 3340
 Amornphimoltham, P., 2948
 Amos, C. I., 4805, 8531
 An, H., 8323
 Anastassiou, G., 2578
 Andarawewa, K. L., 5844
 Anders, M., 2088
 Andersen, R. J., 1838
 Anderson, C. J., 6864
 Anderson, C. P., 1520
 Anderson, D. E., 4295
 Anderson, D. M., 8912
 Anderson, G., 6096
 Anderson, J., 4211
 Anderson, K. C., 18, 2561, 5850, 6174, 6187, 6689, 7539, 8428
 Anderson, R. G. W., 6571
 Andrechek, E. R., 4920
 Andreeff, M., 1242, 4174, 5213, 5926
 Andreola, F., 5257
 Andreola, S., 4507
 Andujar, M., 5697
 Ang, K. K., 3263
 Angel, J. M., 2747
 Angèle, S., 8717
 Angeles, T., 5978
 Anichini, A., 2535
 Anilkumar, G., 2645
 Annable, T., 1838
 Annereau, J-P., 3084
 Antalis, T. M., 887
 Antoine, M., 1405
 Antony, S., 7428
 Anttila, S., 8623
 Aoki, J., 5446
 Aoshiba, K., 5054
 Aouali, N., 6149
 Aoyagi, M., 8338
 Aoyama, M., 4167
 Aozasa, K., 4888, 7606
 Apblett, R., 8912
 Appella, E., 2373, 3675
 Appelman, H., 67
 Aprelikova, O., 6
 Aquilano, K., 5940
 Aragaki, J., 8132
 Aragon, G., 923
 Aragonese, J., 6877
 Arai, T., 4287
 Arai, Y., 801
 Arakelian, A., 2072
 Araki, H., 149, 5622
 Araki, Y., 728
 Aramaki, H., 7277
 Aranes, M. J., 8791
 Arango, D., 5401, 8791
 Arbeit, J. M., 4862, 5257
 Arboleda, M. J., 196
 Arcangeli, A., 4281
 Arechiga, A. F., 5716
 Argast, G., 6716
 Argilagos, R. F., 7900
 Arienti, F., 6948
 Ariga, H., 8338
 Arima, T., 8768
 Arlinghaus, R. B., 298, 4724
 Arlt, V. M., 2752
 Armanios, M., 8188
 Armatas, P., 7913
 Armeanu, S., 2369
 Arndt, K., 375
 Arnold, A., 8022
 Arnold, C. N., 1608

Arnold, R., 1333
 Aronson, M., 1769
 Arora, S., 6894
 Arteaga, C. L., 1860
 Artemov, D., 2723
 Arumugam, T., 2649
 Asa, S. L., 3716
 Asabe, S., 4112
 Asahi, K-i., 3659
 Asai, A., 3931
 Asai, T., 7920
 Asakuma, J., 1365
 Asano, S., 6809
 Asano, T., 1365, 1365
 Ascenseo, J. L., 6096
 Ashfaq, R., 8614
 Ashhab, Y., 6340
 Ashton, A. W., 527
 Asim, M., 5390
 Asosingh, K., 287, 3019
 Assfalg, G., 5582
 Astancolle, S., 3469
 Astolfi, A., 2728
 Aszalos, A., 3084
 Aszterbaum, M., 923
 Atadja, P., 5126
 Atala, A., 8345
 Aten, J., 3894
 Athanasiadis, G., 8051
 Atherton, J., 7301
 Atkins, G. J., 5438
 Atkins, T. A., 3092
 Atkinson, E. N., 1073
 Ator, M., 5978
 Au, J. L-S., 579
 Aube, J., 1769
 Auersperg, N., 1073
 Augenlicht, L. H., 4990, 5401, 6311, 8791
 Aukerman, S. L., 3145
 Aulwurm, S., 8996
 Austin, S., 4677
 Avila, S., 1114
 Avril, M-F., 3061
 Awwad, R. A., 4731
 Ayala, G., 6244
 Ayala, R., 196
 Ayhan, A., 417
 Ayril-Kaloustian, S., 1838
 Ayres, M., 7968
 Ayyoub, M., 5601
 Azañedo, M., 1814
 Aziz, R., 2399
 Azizuddin, K., 5194
 Azuma, H., 8090
 Azuma, K., 854
 Azuma, T., 4516
 Azzam, E. I., 7128

B

Baasner, S., 7221
 Baba, M., 5320
 Baba, T., 4112
 Bachelder, R. E., 5230
 Bach-Elias, M., 5178
 Bachrich, T., 3325
 Back, T. C., 5320
 Badary, O. A., 4062
 Bading, J. R., 3667
 Bae, S-Y., 8700

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

- Baek, J. H., 7291
 Bagdasaryan, R., 6772
 Bagley, R. G., 5866
 Baglioni, M., 7256
 Bagnato, A., 2447
 Bai, T., 5046
 Bai, X-F., 6051
 Bailey, E. C., 1636
 Baillie, R., 8827
 Bailly, C., 7392
 Bain, J., 1667
 Bainbridge, T., 5761
 Baiocchi, R. A., 965
 Bair, E. L., 2292
 Bajenaru, M. L., 8573
 Bajetto, A., 1969
 Baker, C., 2940
 Baker, C. C., 7815
 Baker, J. H. E., 5707
 Baker, S. J., 705, 3001, 3464
 Bakin, R. E., 1975, 1981
 Bakkar, A. A., 8108
 Bakker, A., 5595
 Baksh, S., 5344
 Balansky, R. M., 793
 Balatoni, C. E., 4472
 Bal de Kier Joffé, E., 6370
 Baldetorp, B., 8861
 Baldi, A., 1430, 6350
 Baldwin, C., 8582
 Baldwin, P. J. W., 400
 Baldwin, R. L., 1106, 1413
 Bales, E., 6626
 Bali, P., 93, 5126, 7950
 Balkwill, F. R., 8360
 Ball, D. W., 5559
 Ballangrud, A. M., 8393
 Balligand, J.-L., 1012
 Ballman, K. V., 6501
 Bal-Mahieu, C., 7392
 Balmain, A., 4849
 Balosso, J., 3221
 Balz, V., 1188
 Balzano, G., 7451
 Balzi, M., 4281
 BaMaung, N., 7861
 Banach-Petrosky, W. A., 3886
 Banáth, J. P., 4347
 Bancroft, L., 4990
 Bander, N. H., 2645
 Bandle, R. W., 5446
 Bandyopadhyay, S., 1731
 Banerjee, A. G., 7769
 Banerjee, S., 4375
 Bang, S., 8248
 Bangerter, M., 2681
 Banks, R. E., 6971
 Bansal, N., 8813
 Bansal, R. K., 994
 Bao, L., 6244
 Bao, R., 1311, 1389, 4967
 Baojun, H., 6469
 Bar, J., 25
 Baran, J. T., 9023
 Baras, A., 2194
 Barbacci, E. G., 4450
 Barber, G. N., 8366
 Barbero, S., 1969
 Barbieri, O., 2855
 Barbin, A., 4351, 7699
 Barbour, A. P., 887
 Barbouti, A., 1202
 Barclay, E., 7595
 Bardelli, A., 4144
 Bardy, P., 5438
 Bar-Eli, M., 3632
 Barents, J. O., 5408
 Barfoot, R., 8596
 Barkardottir, R. B., 2024
 Barlogie, B., 8749
 Barnes, B. J., 6424
 Barnes, E. A., 3701
 Barnes, G. L., 2631
 Barnes, W. A., 7215
 Barraclough, R., 140
 Barrett, J. C., 6
 Barrett, M. T., 4211
 Barry, M. A., 5213
 Barsoum, J., 5299
 Barth, C., 6265
 Barth, R. F., 965
 Barth, S., 8414
 Barthel, H., 3791, 8558, 8560
 Bartoli, C., 1871, 2535
 Bascombe, L., 8596
 Basechess, O., 6996
 Bashenko, Y., 7733
 Basik, M., 4588
 Basilico, C., 5754
 Basilion, J. P., 2300
 Bassi, D. E., 4997
 Bassi, R., 8912
 Basso, A., 7777
 Basso, A. D., 2139
 Bast, R. C., Jr., 4174
 Batchelor, T. T., 1602
 Bates, S. E., 3228, 4048
 Batra, R. K., 642, 766
 Battagli, C., 8695
 Bauer, A. K., 929
 Baumann, H., 3812
 Bauskin, A. R., 5034
 Bauzon, M., 6900
 Bavetsias, V., 3612
 Bavinck, J. N. B., 2695
 Baxter, M., 1838
 Baylin, S. B., 1596, 3133, 4620, 7089
 Bayliss, J., 2251
 Bazzoli, F., 787, 7256
 Beam, C. A., 7900
 Beamer, W. G., 8197
 Beard, K. S., 616
 Beard, L., 1568
 Beard, P., 8687
 Bebbington, C. R., 5526
 Béchard, D., 6084
 Beck, A., 6076
 Beck, M. T., 3598
 Becker, J. C., 8221
 Beckers, T., 7221
 Beckman, S., 1441
 Beckmann, M. W., 3066
 Bedja, D., 6602
 Beebe, J. S., 7301
 Beecken, W.-D., 1990
 Beer, D. G., 4136
 Begum, S., 5723
 Béhé, M., 1333
 Behr, T. M., 1333
 Behrens, J., 5203
 Behringer, R., 8167
 Bei, T., 5308
 Beijnen, J. H., 6447
 Beland, F. A., 5999
 Belani, J., 2033
 Belinsky, M. G., 4048
 Belinsky, S. A., 4620, 4842, 7089
 Beljin, M., 4074
 Bell, A., 2338
 Bell, D. A., 7530
 Bellacosa, A., 2172
 Bellahcene, A., 2631
 Beldegrun, A., 2306, 4952
 Bellemare-Pelletier, A., 2836
 Bellet, D., 3682
 Belli, F., 4507
 Bellino, R., 807
 Bellnier, D. A., 1806, 7584, 8126
 Bello, L., 2499
 Bellocq, J.-P., 5844
 Bellone, M., 3688
 Bellucci, R., 2561
 Belmaaza, A., 3334
 Belotti, D., 5224
 Beltrán, L., 4819
 Belzacq, A.-S., 541
 Benard, O., 3883
 Benatti, U., 3490, 6144
 Benbrook, D. M., 3826
 Benckert, C., 1083
 Bendahl, P.-O., 8861
 Bende, R. J., 3894
 Benedict, W. F., 760, 4017
 Beneski, J. T., 3092
 Benet, M., 4188
 Benitez, J., 1814
 Benjannet, S., 1458
 Benlimame, N., 3764
 Benner, A., 1179
 Ben-Neriah, Y., 25
 Bennett, D. C., 1667
 Bennicelli, C., 793
 Bennington, J. L., 7098
 Benoit, N., 2351, 7694
 Ben-Porat, L., 1759
 Benton, M. E., 5808
 Bentrem, D., 7490
 Ben-Yehuda, D., 6340
 Ben-Ze'ev, A., 6626
 Beothe, T., 455
 Berchuck, A., 6
 Berdel, W. E., 7241
 Berg, K., 3490, 8614
 Bergant, A., 7507
 Berg-Dixon, S., 1138
 Berger, A. J., 8103
 Berger, F., 4952
 Berger, M. S., 1962
 Bergert, E. R., 7840
 Bergstrahl, D. T., 5095
 Berlin, A., 5291
 Berlin, J., 5194
 Berlin, K. D., 3826
 Bernacki, R. J., 2477
 Bernard, D., 5874
 Bernard, K., 6716
 Bernard, S., 3904
 Bernard-Gallon, D., 6607
 Berndt, A., 3202
 Bernhard, E. J., 5656
 Bernhardt, W., 2052
 Berns, A., 7042
 Bernstein, A., 4412
 Berrigan, D., 1752
 Berry, S. E., 5490
 Bersani, L., 2535
 Bert, T., 1333
 Bertagna, X., 5308
 Bertagnoli, M. M., 1608
 Bertherat, J., 5308
 Bertolini, F., 4342
 Bertolino, P., 4836
 Besaratinia, A., 8708
 Besley, B. D. A., 4829
 Betensky, R. A., 1602
 Bettaieb, A., 7475
 Bettegowda, C., 8578
 Betti, C. J., 1377
 Bettuzzi, S., 3469
 Bevaart, L., 5595
 Bevan, S., 154
 Beyer, C., 1838
 Beyer, I., 2052
 Bhalla, K., 93, 1483, 5126, 7950
 Bhaskar, V., 6387
 Bhat, B. M., 5357
 Bhatt, D., 965
 Bhattacharya, A., 8167
 Bhattacharya-Chatterjee, M., 2844
 Bhattacharyya, A. K., 3891
 Bhattacharyya, I., 7769
 Bhogte, E., 7760
 Bhowmick, D., 7051
 Bhujwala, Z. M., 2723
 Biaglow, J. E., 4705
 Bianchi, M. E., 100
 Bianchi, S., 342
 Bianco, C., 1192
 Biccato, S., 555
 Bickers, D. R., 923
 Biebl, A., 4945
 Bièche, I., 5344
 Bieker, R., 7241
 Bien, H., 9007
 Bier, H., 1188
 Bignon, Y.-J., 6607
 Bikfalvi, A., 2499
 Bilke, S., 7158
 Bingham, S. A., 2358
 Binkley, C., 2649
 Bird, R. P., 6595
 Birembaut, P., 2658
 Birrer, M. J., 1235
 Bischof, F., 8996
 Bischof, M., 8890
 Bisgaard, M.-L., 7595
 Bishop, A. J. R., 5335
 Bishop, J. B., 44
 Bisht, K. S., 8984
 Bissonette, E. A., 1975, 1981
 Bissonette, M., 3517
 Biston, M.-C., 3221
 Biswas, D. K., 290
 Bitzer, M., 2369
 Björkholm, M., 1743
 Black, E. P., 3716
 Black, K. L., 8899
 Black, P. M., 1602
 Blackburn, A. C., 2364
 Blackwell, J. L., 1262
 Blackwell, K. L., 6162
 Blais, A., 277
 Blake, M., 7291
 Blake, R., 7345
 Blakey, D. C., 1144
 Blank, M., 8241
 Blankenship, J. R., 4773
 Blankenstein, T., 4095
 Blasco, M. A., 7047
 Blaskovich, M. A., 1270
 Blass, K., 8221
 Blattler, W. A., 5073
 Blaydes, J. P., 2616
 Blenkiron, C., 8648
 Blessington, D., 8813

- Blum, A., 7515
 Blumberg, P. M., 780
 Blustajn, J. K., 214
 Boardman, L. A., 5209
 Bobrow, L., 417
 Bocchetta, M., 6125
 Bocklage, T. J., 4842
 Bockmühl, U., 1188
 Bode, A. M., 4396
 Bodmer, W. F., 3819
 Boecker, A., 1172
 Boecker, W., 1172
 Boeglin, W. E., 2256
 Boer, J. M. A., 1249
 Boerman, O. C., 12
 Boffa, L. C., 6144
 Bogdan, C. A., 2067
 Bogdanov, A., Jr., 1936
 Bögl, O., 6579
 Bohlen, P., 8264, 8912
 Bohr, V. A., 7136
 Boige, V., 5738
 Boissonnas, A., 7468
 Boitano, A., 6870
 Boix, L., 859
 Bokemeyer, C., 2244
 Bol, D. K., 4819
 Boland, C. R., 787, 1608, 7256
 Bollen, A. W., 7600
 Boman, B. M., 1748
 Bommer, M., 2681
 Bonavia, R., 1969
 Bonduelle, O., 7468
 Bonehill, A., 5587
 Bongarzone, I., 2234
 Bonham, L., 8428
 Boni, A., 3688
 Bonifas, J. M., 923
 Bonn, V. E., 5821
 Bonnefin, P., 5785
 Bonnotte, B., 2145
 Bono, A., 2535
 Bono, F., 5978
 Boocock, D. J., 8461
 Bookstein, R., 2300
 Boone, C. W., 3556
 Boquo, A., 5105
 Borchardt, P. E., 5084
 Borer, J. G., 484
 Borg, A., 2024, 8861
 Borgel, S. D., 2812
 Borghoff, S., 929
 Borgoño, C., 3958, 9032
 Borgstrom, P., 3646, 5895
 Borisch, B., 534
 Bornfeld, N., 2578
 Bornmann, W. G., 6395
 Borowsky, A. D., 3886
 Borrani, E., 4281
 Borrelli, M., 3268
 Borrello, I. M., 9007
 Borri, P., 4281
 Borri, F., 5738
 Borsi, L., 3202
 Borsotti, P., 1534
 Bosch, F. X., 1179
 Boschelli, D. H., 375
 Boschelli, F., 375
 Boscoe, B. P., 4450
 Boss, G. R., 3517
 Bostick, R. M., 8549
 Boswell, C. M., 6032
 Bothos, J., 7185
 Bouchard, L., 7679
 Boucher, Y., 8556
 Boulay, A., 5844
 Boulwood, J., 3940
 Boulware, D., 7708, 7900
 Bourdeau, I., 5308
 Bourhis, J., 2513
 Bourie, B., 5978
 Bouska, J., 7861
 Boussiotas, A., 2569
 Bouvet, M., 80, 5521
 Bovin, L. F., 1943
 Bowden, G. T., 2292
 Bowtell, D. D. L., 2569
 Boxer, L. M., 6666
 Boyd, G., 8443
 Boyer, J., 4602
 Braakhuis, B. J. M., 1727, 5167
 Brackett, D. J., 5251
 Bradbury, C. M., 3413, 8984
 Brady, F., 2409, 3791
 Brady, K., 7377
 Brady, N., 1798
 Brain, J. M., 4895
 Brake, T., 4862, 8173
 Brakenhoff, R. H., 1727, 5167, 5679
 Branam, D. E., 5251
 Branch, C. D., 5105
 Brandi, G., 4028
 Brändlein, S., 2052, 7995
 Brandli, D. W., 6063
 Brandt, B., 1172
 Brash, A. R., 2256
 Brasher, P. M. A., 3162
 Brat, D. J., 4218
 Brattain, M. G., 3340, 4731
 Braun, K., 4766
 Braun, R. D., 4705
 Braunewell, K.-H., 4997
 Bräuninger, A., 1644
 Braunstein, G., 8516
 Brausi, M., 3469
 Bray, M. R., 196
 Brayer, J., 9007
 Breast Cancer Susceptibility
 Collaboration (UK), 8596
 Brechbiel, M. W., 271, 8984
 Breinberg, D., 6387
 Breit, S. N., 5034
 Brekken, R. A., 5376
 Brembeck, F. H., 2005
 Brechley, P. E., 812
 Brennan, C. W., 5352
 Brenner, C., 541
 Brenner, M. K., 5213
 Brenner, W., 7221
 Brensinger, C., 742
 Brent, G. A., 5065
 Bretsky, P., 6984
 Bribe, E., 4809
 Bridge, J. A., 449
 Briest, S., 7634
 Bright, R. K., 1040
 Brignole, C., 86, 7400
 Brimmell, M., 4150
 Brink, M., 3133
 Brinkhuis, R. F., 6447
 Brinton, L. A., 7215
 Bristow, R. E., 3966
 Brizel, D. M., 4705, 6162
 Broadus, R. R., 1221
 Broadwater, G., 6162
 Brochard, T., 3221
 Brock, C. S., 2409
 Bröcker, E.-B., 8221
 Brodie, A. M., 8037
 Brodt, P., 1166
 Broer, R., 2695
 Bronson, R. T., 6689
 Brooks, A. D., 207
 Brophy-Ebbers, M., 2033
 Brose, M. S., 756
 Brouet, A., 1012
 Brower, M. A., 413
 Brown, A. M. C., 1906
 Brown, D., 5034, 5257
 Brown, G. D., 2409
 Brown, J. R., 2775
 Brown, J. S., 2364
 Brown, K., 1865, 8461
 Brown, S., 7497
 Brown, T. J., 2416
 Bruchelt, G., 1772
 Bruix, J., 859
 Brunicardi, F. C., 3593
 Brunner, T. B., 5656
 Bruno, I. G., 6154
 Brunswig, E. B., 1568
 Brusselmans, K., 3799
 Bryant, B., 1927
 Bryant, J. L., 1712
 Bub, J., 1359
 Bucana, C. D., 1345, 2079, 3370
 Bucher, P., 6613
 Buchholz, M., 4945, 6265
 Buchhop, S., 2596
 Bucholtz, V., 6340
 Buck, A., 2681
 Buckhaults, P., 4144
 Buckman, D., 5526
 Budanov, A. V., 2905
 Budhu, A., 4426
 Buerger, H., 1172
 Buerk, D. G., 7232
 Buetow, K. H., 647, 655, 4594
 Bühring, H.-J., 8996
 Bui, M. H. T., 4952
 Buitelaar, M., 1339
 Bukowski, R. M., 1676, 4481
 Bukur, J., 4107
 Bulankin, A., 513
 Bumgarner, R. E., 859
 Bunce, C. M., 505
 Burchell, B., 8443
 Burchiel, S. W., 7825
 Burck, C., 6125
 Burczynski, M. E., 6069
 Burd, C. J., 4903
 Burda, C., 5194
 Burdelya, L. G., 2905
 Burdick, A. D., 7825
 Burdick, M. D., 5011
 Burgan, W. E., 7377
 Burgart, L. J., 5209
 Burger, R., 5850
 Burghardt, R., 958
 Burk, R. D., 7215
 Burke, S. P., 2933
 Burns, A. L., 8022
 Burns, M. J., 1589
 Burrows, J., 7345
 Burston, H. E., 5707
 Burtrum, D., 8912
 Busam, K., 3955
 Busciglio, B., 8922
 Bussey, K. J., 5243, 8634
 Bussolino, F., 1500
 Busto, R., 7913
 Butterfield, L. H., 5607
 Butterworth, B. E., 929
 Bützow, R., 6258, 7591
 Byers, S. W., 8085
 Byfield, S. D. C., 8284
 Byrd, J. C., 36
 Byun, D.-S., 7068

C

- Caballero, M., 2747
 Cabal-Manzano, R., 1696, 8085
 Cabelof, D. C., 5799
 Cabon, F., 3919
 Cabral, H., 8977
 Caderni, G., 2388
 Cadranet, J., 1405
 Caffrey, T. C., 5011
 Cai, D., 6802, 7410
 Cai, Q., 3980, 5727, 7624
 Cai, T., 319
 Cai, Y. L., 4258
 Cai, Z., 1776, 4232
 Caignard, A., 7475
 Cairncross, J. G., 1602
 Cairns, P., 2216, 8695
 Calabrese, C., 140
 Calasanz, M. J., 3079
 Calero, M., 4188
 Califano, J., 2316, 2351, 7694
 Caligiuri, M. A., 965
 Calili, R. R., 4952
 Calin, G. A., 1183
 Callahan, M., 8939
 Calori, G., 7451
 Calvete, J. J., 2020
 Calvo, F., 7575
 Cama, A., 342
 Camacho, F. I., 8226
 Camacho, S. H., 7584
 Cameron, J. L., 3735, 8614
 Cammer, M., 7891
 Camoirano, A., 793
 Camp, R. L., 1101, 1445
 Campa, M. J., 1652
 Camphausen, K., 1990, 7377
 Campi, G., 8481
 Campisi, I., 5041
 Campisi, J., 6626
 Camporeale, A., 3688
 Camps, J., 5731
 Canaple, L., 7545
 Cancer Genome Project, 4878
 Cande, C., 8233
 Canevari, S., 696
 Cannavó, E., 8113
 Canning, C., 2561
 Cannon, R., 4232
 Cantor, A., 1270, 3021
 Canzian, F., 3560
 Cao, C., 6920
 Cao, G., 3403, 7853
 Cao, T., 6666
 Cao, X., 5866, 7384, 8323, 8939
 Cao, Z., 6815
 Caorsi, C., 2518
 Capella, G., 3560, 5544, 5731, 7206
 Capo-chichi, C. D., 4967
 Caporali, A., 3469
 Cappellacci, S., 4119
 Cappello, P., 2518
 Carayon, P., 4809
 Carbajal, S., 4819
 Carbone, D. P., 6432, 7113

- Carbone, M., 6125
 Cardarelli, C. O., 3084
 Cardarelli, P. M., 5526
 Cardiff, R. D., 3886, 4920
 Cardillo, M. R., 4747
 Cardones, A. R., 6751
 Cardounel, A. J., 6602
 Carethers, J. M., 1608
 Carey, F. A., 4656
 Carey, M., 4552
 Carles-Kinch, K., 7907
 Carlton, P. S., 2399
 Carmeliet, P., 1500
 Carniti, C., 2234
 Carroll, R., 2338
 Caronzolo, D., 2499
 Carpaneto, E. M., 6144
 Carpenter, G., 39
 Carpten, J. D., 6795
 Carr, A., 2546
 Carrabba, G., 2499
 Carrabba, M. G., 1560
 Carrascal, M. T., 491
 Carreras, M. C., 6370
 Carrier, F., 7291
 Carrière, D., 4809
 Carroll, J. S., 4322
 Carroll, N. M., 5957
 Carroll, P., 2872
 Carruba, G., 5041
 Carter, V. S., 859
 Cartos, V., 296
 Carty, M., 6221
 Caruano, A. L., 6864
 Caruthers, S. D., 5838
 Carver, L. A., 6571
 Casalbone, P., 3750
 Casati, C., 4507
 Cascalló, M., 5544
 Casciano, J., 8749
 Cascinelli, N., 2535
 Case, C. C., 8968
 Casellas, P., 4809, 5978
 Casey, G., 6795
 Casorati, G., 8481
 Cass, K. M., 6387
 Casse, H., 4836
 Cassia, R., 5697
 Castagnetta, L. A. M., 5041
 Castellanos, M. C., 6877
 Castell, C., 1560, 4507, 6948
 Castranova, V., 7689
 Catalona, W. J., 2033
 Cataltepe, S., 1871
 Cathcart, M. K., 1676
 Catley, L., 5850
 Catricalà, C., 4119
 Cattaneo, R., 6463
 Cattaruzza, M. S., 8158
 Caucig, P., 8735
 Cauwels, C., 5352
 Cavarec, L., 164
 Cebrián, A., 1814
 Cejka, P., 8113, 8158
 Celestino, J., 6195
 Celis, E., 3281
 Celli, C. M., 6016
 Cenacchi, G., 7256
 Cerda, S., 3517
 Cerottini, J.-C., 5601, 5712
 Cerra, M. A., 7377
 Cerundolo, V., 8408
 Cervasi, B., 4028
 Cesareni, G., 3860
 Cesari, R., 1183
 Cesarone, G., 2898
 Cessac, J. W., 1538, 3211
 Cetin-Atalay, R., 6707
 Cha, I., 2347
 Chabot, B., 7679
 Chada, S., 5105
 Chadborn, N. H., 5230
 Chain, B. M., 5143
 Chakrabarty, S., 67
 Chakraborty, N. G., 5607
 Chamberlain, R. M., 1157
 Chambers, A. F., 4763
 Chan, A. O.-O., 3819, 7724
 Chan, A. T. C., 2028
 Chan, D. W., 3966
 Chan, E., 7345
 Chan, H. T. C., 5480
 Chan, J. Y., 5636
 Chan, K., 824
 Chan, K. C. A., 2028
 Chan, L. Y. S., 2028
 Chan, P.-C., 3958
 Chan, T. L., 4878
 Chan, T. O., 1
 Chan, V., 3145
 Chance, B., 8813
 Chandaroy, P., 4331
 Chandel, N., 4275
 Chandramouli, G. V. R., 6
 Chang, A. E., 2546, 8466
 Chang, B.-I., 7624
 Chang, C., 4888, 7106
 Chang, C.-M., 7443
 Chang, C.-y., 8029
 Chang, D. K., 787, 1608
 Chang, H., 5978
 Chang, H. R., 1280
 Chang, H.-C., 3069, 4888
 Chang, J.-G., 647
 Chang, K., 354
 Chang, Y. T., 4331
 Chang-Claude, J., 2610
 Chao, Y., 6229
 Chaplin, D. J., 1144
 Chapot, B., 8717
 Charboneau, L., 5243
 Charmsangavej, C., 7870
 Charrin, S., 2665
 Chartrand, S. D., 5866
 Charvet, A.-M., 3221
 Chatterjee, S. K., 2844
 Chatterton, R. T., 2425
 Chaudhary, N. D., 2477
 Chaudhuri, G., 5470, 8853
 Chaudri-Ross, H. A., 6523
 Chauhan, D., 18, 5850, 6174, 6689, 8428
 Chavaudra, N., 2513
 Chavez-Reyes, A., 8664
 Checinska, A., 6566
 Chedid, M., 6056
 Chen, B., 1025
 Chen, D., 6626
 Chen, D. J., 22
 Chen, D.-T., 386
 Chen, F., 7689
 Chen, G.-Q., 1853
 Chen, H., 8680
 Chen, J., 1153, 3049, 4583, 5685, 7345, 7613
 Chen, J.-G., 7891
 Chen, J.-Y., 256
 Chen, K., 6056
 Chen, L., 4538, 6501, 7462
 Chen, L. C., 3524
 Chen, M. L., 2292
 Chen, N. Y., 3598
 Chen, P., 5950
 Chen, P.-H., 647
 Chen, P.-L., 2589
 Chen, S., 111, 3546, 5041, 8516
 Chen, S.-T., 2440, 5243
 Chen, S.-Y., 256, 3257, 7321
 Chen, T., 4368
 Chen, T.-H., 5526
 Chen, W. Y., 3598
 Chen, X., 1059, 2553, 5390
 Chen, Y., 1927, 3619, 4801, 5685, 7158
 Chen, Y.-C., 3966, 4144
 Chen, Y.-J., 817
 Chen, Y.-M. A., 647
 Chen, Y.-T., 6076, 6948
 Chen, Y.-Y., 7167
 Chen, Z., 1853, 5917
 Chen, Z.-S., 4048
 Chenard, M.-P., 5844
 Cheney, R. T., 7584
 Cheng, C., 1046
 Cheng, C.-C., 3966
 Cheng, E., 1420
 Cheng, F., 4441, 9007
 Cheng, G., 6258
 Cheng, H. Y., 3923
 Cheng, J., 179
 Cheng, J. Q., 4368, 7081, 7708
 Cheng, J.-R., 3980
 Cheng, J.-Z., 3495
 Cheng, K., 6744
 Cheng, L., 6063
 Cheng, S.-Y., 1962, 4684, 5274
 Cheng, T., 8323
 Cheng, T.-C., 2440
 Cheng, W.-F., 2393
 Chengming, L., 6469
 Cheong, D., 6658
 Chernoff, J., 6802
 Cherrington, J. M., 7345
 Chester, J., 3173
 Cheung, C., 7232
 Cheung, J. M., 7158
 Cheung, L. H., 3995
 Cheung, M., 1798, 2881
 Cheung, N.-K. V., 4538
 Cheung, S.-T., 3121
 Cheville, J. C., 3877, 6501, 7840
 Chew, K., 1596, 2347, 7167
 Chi, S.-G., 7068
 Chiang, C., 5143
 Chiang, G. G., 8451
 Chiang, L.-C., 3069
 Chiaretti, S., 4497
 Chiariotti, L., 882
 Chiaverotti, T. A., 4914
 Chiba, T., 8674
 Chida, K., 2404
 Chihara, H., 394
 Chikamatsu, K., 3675
 Childs, K., 593
 Chin, A. C., 3931
 Chin, L., 5352
 Chin, S.-F., 4568
 Chinen, L. K., 5838
 Ching, Y.-P., 7646
 Chinnaiyan, A. M., 132
 Chiocca, E. A., 2300
 Chittenden, T., 5073
 Cilebowski, R. T., 6096
 Chlenski, A., 6299
 Cho, E., 4677
 Cho, E.-J., 6135
 Cho, J.-Y., 2206
 Cho, K., 7068
 Cho, K. R., 2913
 Cho, Y., 1555
 Choe, G., 2742
 Choe, K. S., 6363
 Choi, E., 8700
 Choi, E. A., 5299
 Choi, I., 4648
 Choi, J.-Y., 5357
 Choi, K., 8248
 Choi, K.-C., 3459
 Choi, Y. R., 2188
 Choi, Y. S., 7539
 Cholewa, M., 1776
 Chompret, A., 3061
 Chong, H., 2145, 3173
 Chong, T. W., 8408
 Chopin, D. K., 8108
 Chouaib, S., 3682, 7475, 8476
 Choudhury, S., 7704
 Chow, K. C. K., 2028
 Chow, S.-N., 6537
 Choy, H., 6920
 Chrétien, M., 1458
 Christensen, J. G., 5462, 7345
 Christian, C., 2088
 Chu, B., 8523
 Chu, G., 3325
 Chu, S. C., 5462
 Chua, H.-H., 256
 Chuang, E. Y., 3872
 Chuang, K.-H., 7106
 Chulada, P. C., 4872
 Chumakov, P. M., 2905
 Chun, K.-H., 3826, 4796
 Chun, Y.-S., 8700
 Chung, E. J., 7777
 Chung, F.-L., 3980, 7704
 Chung, H.-H., 7384
 Chung, J., 4792
 Chung, K. H., 6458
 Chung, L., 6195
 Chung, M. A., 1280
 Chung, T.-W., 3453
 Chunsong, H., 6469
 Churchwell, M. I., 5999
 Chuyen, N. V., 1900
 Cifuentes, D., 5178
 Cigudosa, J. C., 3079, 5697
 Cilli, M., 7400
 Cinatl, J., 1508
 Cinatl, J., Jr., 1508
 Cindrova, T., 8351
 Ciobanu, L. C., 6442
 Ciriolo, M. R., 5940
 Cito, L., 7423
 Citro, G., 3860
 Citti, L., 2855
 Civantos, F., 2638
 Cividalli, A., 1500
 Clackson, T., 3173
 Claij, N., 2062
 Clair, T., 2042, 5446
 Claret, F.-X., 2977
 Clarijs, R., 2965
 Clark, A. S., 780
 Clark, G. M., 2434
 Clarke, I. A., 593
 Clarke, I. D., 5821

- Clarke, L., 1490
 Clarke, P., 6971
 Clarke, P. A., 6855
 Clarkson, B., 6395
 Clausen, J., 8827
 Cleary, S. P., 1769
 Cleaver, J. E., 3909
 Cleij, M. C., 3791
 Clements, C., 5095, 6928
 Clézardin, P., 3919
 Clifford, B., 4074
 Clinger, J., 7694
 Clodomiro, A., 882
 Clohisy, D. R., 6847
 Cloos, J., 5679
 Cloughesy, T. F., 2742
 Cobben, D. C. P., 8558
 Cobbs, C. S., 8670
 Coffey, M. C., 348
 Coffey, R. J., 1748
 Coffman, K. T., 7907
 Cohen, C., 4967
 Cohen, G., 3517
 Cohen, I., 541, 8821
 Cohen, K. A., 1834
 Cohen, M. B., 2905
 Cohen, T., 1657
 Cohen, Y., 2316, 2351
 Cohn, S. L., 6299
 Colbert, L. H., 1752
 Colditz, G. A., 5236, 8536
 Coleman, D., 2127
 Coleman, N., 4568
 Colligan, T., 8051
 Collingridge, D. R., 3791
 Colini, P., 6948
 Collins, F. S., 8022
 Collis, S. J., 1550
 Collisson, E. A., 5669
 Colmenares, C., 6626
 Colombo, T., 5902
 Colson, P., 7392
 Combadière, B., 7468
 Combadière, C., 7468
 Combes, T., 4809
 Commes, T., 1731
 Compton, C., 1608
 Conacci-Sorelli, M., 6626
 Conaway, C., 3980
 Cong, F., 873
 Connelly, M., 2733, 5428
 Conney, A. H., 6532, 7005
 Connolly, D. C., 1389
 Connor, J. P., 8173
 Connors, K. M., 5073
 Conrad, D., 1822, 2118
 Consogno, G., 8481
 Contente, A., 1756, 3904
 Conti, P. S., 3667
 Conti-Fine, B. M., 8481
 Contreras, A., 1067
 Contreras, J. I., 4136
 Conway, K., 7530
 Cook, B. P., 5866
 Cook, C. E., 8029
 Cook, J. L., 3435
 Cook, R. G., 3923
 Cook, S. L., 4903
 Cooley, M., 7760
 Cooney, K. A., 3486
 Coop, A., 6523
 Cooper, R., Jr., 8877
 Copeland, T. D., 3991
 Copland, J. A., 1221
 Coppe, J.-P., 7098
 Coppelli, F. M., 5629
 Coppola, D., 3021, 4368, 7708, 8922
 Corazzari, M., 7310
 Corban-Wilhelm, H., 4766
 Corde, S., 3221
 Cordon-Cardo, C., 179, 2872, 5703, 7799
 Corey, D. R., 5917
 Corless, C. L., 5761
 Cornelisse, C. J., 1148, 1249, 8153
 Cornelius, S. C., 4358
 Corner, G. A., 8791
 Cornet, S., 8476
 Corti, A., 3469, 7400
 Corvol, P., 5615
 Cosset, F. L., 3173
 Costa, A., 4507
 Costa, F., 2499
 Costa, M., 3524
 Costello, J. F., 7600
 Coster, M., 2361
 Cote, G. J., 6154
 Coukos, G., 3403, 4225
 Courtin, A., 3919
 Cousineau, I., 3334
 Cova, A., 1560
 Coval, K., 6506
 Cover, T. L., 951
 Cox, A. D., 7807, 7959
 Cox, D. G., 8717
 Cox, E. D., 4450
 Cox, M., 3575
 Cox, R., 2361
 Coxam, V., 6607
 Crabtree, J. S., 8022
 Cragg, M. S., 5480
 Craig, L., 2005
 Craige, B., 4218
 Cramer, T., 1083
 Cranston, A. N., 4777
 Crespin, M., 5615
 Cress, A. E., 2292
 Crestani, B., 1405
 Creswell, K., 5685
 Cristiano, R. J., 4017
 Crittenden, M., 3173, 5505
 Croce, C. M., 186, 878, 1183, 3352, 3724
 Croci, S., 2728
 Cronin, F., 1927
 Crooks, P. A., 5636
 Crosby, K., 2742
 Cross, A. J., 2358
 Crosti, M., 8481
 Croucher, P., 287, 912
 Crume, K. P., 4620
 Cruz, A. P., 290
 Cruz, F., III, 5761
 Crystal, R. G., 1475
 Cuadros, C., 5895
 Cuenca, A., 9007
 Cuevas, C., 7392
 Cuevas, Y., 6877
 Cui, J. J., 7345
 Cui, J. T., 7724
 Cui, K., 4384
 Cui, X., 5203
 Cullen, J. J., 1297, 5513
 Cullen, K. J., 312, 8097
 Cullinan, C., 4568
 Culver, J. P., 7232
 Cummings, C., 7595
 Cummings, J., 8443
 Cummings, O. W., 6063
 Cundiff, D. L., 4275
 Cunliffe, H. E., 7158
 Cunningham, D., 6855
 Cunningham, J. M., 5209
 Curiel, D. T., 847, 1262
 Curran, T., 2733, 3162, 5428
 Curtin, N. J., 6008
 Cushman, M., 7428
 Cuthbert, A. P., 689
 Cuthbert-Heavens, D., 7652
 Cutler, N. S., 1748
 Cutress, R. I., 4150
 Cutrona, G., 6144
 Cutrone, R., 6125
 Czajka, A., 593
 Czarnomska, A., 4533
- D**
- Daaka, Y., 2037
 Dabizzi, S., 4281
 Dabrosin, C., 8742
 Dadke, D., 8837
 Dafni, H., 1657
 Dagdigian, N. E., 5073
 Dagenais, S. L., 4136
 D'Agostini, F., 793
 Dahiya, R., 3101, 3913, 7717
 Dahl, N., 1894
 Dahle, C. E., 5595
 Dahle, J., 1464
 Dai, C. Y., 742
 Dai, J., 7883
 Dai, Q., 1153, 7624
 Dai, S.-c., 290
 Dai, Y., 1822, 8420
 Daidone, M. G., 3490
 Daigo, Y., 7038
 Dairkee, S. H., 7167
 Dajee, M., 319
 Dal Cin, P., 1351, 7423
 Dalerba, P., 4507, 6948
 Dalgleish, A. G., 593
 Dallol, A., 1054
 Dalton, W. S., 7900
 Daly, R. J., 4322
 D'Amico, C., 342
 D'Amico, M., 3395
 Dammann, R., 1639, 1888, 5344
 Dan, H. C., 7081, 7708
 Danchek, B., 5257
 Danciu, T., 484
 D'Andrea, A. D., 2688, 4204
 Danenberg, K. D., 3891
 Danenberg, P. V., 3891
 Dang, T. D., 5859
 Dangles-Marie, V., 3682
 Danielpour, D., 4358
 Danilenko, M., 1325
 Danino, M., 196
 Danks, M. K., 3840, 6900
 Dannull, J., 2127
 Daoud, S. S., 2782
 D'Arca, D., 3469
 Darcy, K. M., 1235
 D'Argenio, D. Z., 3667
 Darley, M., 2616
 Da Rocha, S., 7475
 Daroui, P., 8400
 Darwish, D., 6583
 Das, S. K., 906
 Dasari, R. R., 3556
 Dashwood, R. H., 1254
 Da Silva, D. M., 3478
 Davalli, P., 3469
 Dave, D. S., 2256
 Davey, S., 4829
 Davicco, M.-J., 6607
 Davidson, A., 3955
 Davidson, E. J., 400, 6032
 Davidson, J. A., 400
 Davidson, T., 3524
 Davies, G., 2338
 Davila, E., 3281
 Davis, J. W., II, 7825
 Davis, M. A., 8466
 Davis, R. W., 3325
 Davol, P. A., 6772
 Dawling, S., 3127, 8492
 Dawsey, S. M., 3872
 Dawson, D., 1568
 Dawson, M. I., 3531
 De, A., 5669
 Deacon, G. B., 1776
 Deacu, E., 4577
 DeAnglis, A. P., 7314
 Deans, B., 8181
 Dear, A. E., 4460
 Debatin, K.-M., 3112
 Debes, J. D., 7638
 de Bock, T. H., 8153
 Debré, P., 7468
 de Bruijn, H., 807
 de Bruïne, A. P., 3133
 Debus, J., 3755, 4766, 8890
 Decesse, J., 164
 Déchelotte, P., 6607
 Declerck, P., 1500
 DeClerck, Y. A., 3026, 4750
 de Crombrughe, B., 8167
 Deeds, J., 1927
 Deen, D. F., 1962
 De Flora, S., 793
 DeFranco, D. B., 4927
 De Geer, A., 8006
 Degg, N. L., 2361
 De Giovanni, C., 2158, 2728
 Degl'Innocenti, E., 3688
 de Goeij, A. F. P. M., 3133
 de Gouveia Brazao, C. A., 2244, 7674
 Deguchi, A., 6825
 Deho, P., 4507
 de Jong, A., 636
 de Jong, P. J., 5266
 Dekker, M., 2062
 de Kok, J. B., 4748
 de La Iglesia, N., 5178
 Delaporte, C., 164
 De Leenheer, E., 287
 de Leeuw, H., 2244, 7674
 de Leeuw, W. J. F., 1148
 Delehouzee, S., 4607
 DeLeo, A. B., 3675
 Delikatny, E. J., 8813
 Dellabona, P., 2158, 8481
 Dellinger, R. W., 3701
 DeLong, P., 7845
 Delorenzi, M., 6613
 Delorme, S., 8264
 del Peso, L., 6877
 De Luca, A., 1430, 6350
 De Luca, L., 787, 5257
 Demant, P., 125, 4533
 De Marco, C., 4028
 De Marco, M., 342

AUTHOR INDEX TO VOLUME 63

- De Maria, R., 6784
De Marzo, A. M., 7365
Demenais, F., 3061
Demers, G. W., 4003
Demeure, M. J., 2016
DeMichele, A., 8051
Demidenko, E., 1025
Demierre, M-F., 5649
den Besten, W., 1046
Deneen, B., 4268
Deng, H-X., 600
Deng, J. M., 8167
Deng, W., 5203
Deng, X., 3764
Deng, Y., 6488
Deng, Z., 8549
Denis, S., 7365
Denmeade, S. R., 5559
Dennis, P. A., 780
Denny, C. T., 4268
Denny, W. A., 5970
Dent, C., 8968
Dent, P., 1822, 2118, 8138, 8420
Dentice, M., 7423
de Oca, J., 3560
DePeralta-Venturina, M., 7497
DePinho, R. A., 742, 1589, 3395, 5021
Deramautd, T. B., 2005
DeRemer, S., 658
Desai, N., 3886
Desai, P. B., 7314
Desai, S. D., 8400
de Saint-Vincent, B. R., 164
Desbaillets, I., 6613
De Schrijver, E., 3799
Desjardins, L., 3061
Desmond, J. C., 505
Desmond, P. V., 2569
Desprez, P-Y., 7098
Dessy, C., 1012
de Stanchina, E., 5703
de Toledo, S. M., 7128
Detre, S., 6516
de Tribolet, N., 6613
Dettin, L. E., 6290
Deutsch, E., 2513
Deutscher, S. L., 3805
Devens, F., 1179
deVere White, R. W., 2228
Devilee, P., 8153
De Vivo, I., 5236, 8536
de Vries, I. J. M., 12
de Vries, P., 8428
DeVries, S., 2872, 7167
de Waal, R. M. W., 5408
DeWeese, T. L., 1550
Dewhirst, M. W., 4705, 6162
de Winter, J. P., 2688
Dey, S. K., 906
Diamandis, E. P., 807, 2223, 2771, 3958, 6543, 9032
Diamond, A. M., 3347
Díaz, G. D., 1254
Diaz, M. O., 1377
Diaz, R., 1615, 3173, 4188
Díaz-Urriarte, R., 5697
Di Bello, C., 555
Di Carlo, E., 2518, 2728
Di Carlo, V., 7451
Di Castro, V., 2447
Dichgans, J., 8996
Dicioccio, R., 417
Dickson, R. B., 1101
Diedrich, M. J., 567
Diegelman, P., 3619
Diehl, J. A., 7056
Diehl, S. R., 296
Diehl, V., 2606
Diepstra, J. H. S., 12
Dietrich, P-Y., 6613
Diez de Medina, S. G., 8108
Di Gaudio, F., 6784
Di Gesù, G., 6784
DiGiovanni, J., 2747, 4819
Digweed, M., 7263
Di Liberto, D., 6784
Dimmock, J. R., 7975
Dinarello, C. A., 491
D'Incalci, M., 5902
Ding, H., 1106
Ding, I., 4684
Ding, J., 4527
Ding, Q., 7630
Ding, T., 3872
Dingley, K., 8461
Dings, R. P. M., 382
Dinh, D. H., 2454
Di Nicola, N., 1769
Dinney, C. P. N., 4017
Dionne, C., 5559, 5978
di Pietro, M., 8158
D'Ippolito, G., 6327
Dirks, P. B., 5821
Dirks, A. E. M., 2322
Dirmeier, U., 2982
Dirsch, V. M., 8869
Di Sano, F., 3860
Discafani, C. M., 1838
Diserens, A-C., 6613
di Summa, F. M., 2695
di Tomaso, E., 747
Dittmer, D. P., 2010
DiTullio, R. A., Jr., 8586
Divi, R. L., 4402, 5999
Divine, K. K., 4842
Di Vizio, D., 3395
Dix, D. J., 8233
Djeu, J., 8523
Do, S., 7345
Dobbelstein, M., 1756, 3904
Dobrzanski, P., 5978
Dobson, J., 6032
Dockray, G., 942
Doerge, D. R., 5999
Doerr, H. W., 1508
Dohadwala, M., 642
Doki, Y., 424
Dolara, P., 2388
Dollard-Filhart, M., 1445
Dolled-Filhart, M., 1101
Domann, F. E., 1297, 5513
Domany, E., 6613
Dominguez, A. L., 5895
Dominguez, O., 1382, 5697
Dommering, C., 1449
Donacki, N., 7907
Donald, S., 5902
Donapaty, S., 93
Donawho, C., 1345, 3503
Dong, H., 6501
Dong, J., 3883
Dong, J-M., 2716
Dong, L., 760
Dong, S. M., 2351
Dong, Y., 52
Dong, Z., 1345, 4396, 7606
Donnelly, E., 4009
Donner, D. B., 3585
D'Onofrio, V., 6350
Donoghue, D. J., 3701
Donovan, M., 5352
Donowitz, M., 2172
Dopazo, A., 1382, 8226
Dorn, J., 2771, 3958
Dorner, A. J., 6069
Dorocicz, I., 7122
Dorothee, G., 3682
Dorsky, D. I., 5607
Dorward, A. M., 8197
Douarre, C., 6149
Doucet, M., 2940
Dougall, W., 7883
Dougherty, E., 60
Dougherty, T. J., 1806
Douglas, L., 5118
Douglass, C. W., 296
Dowell, J. M., 1608
Downward, J., 5344
Dowsett, M., 6516
Doxsey, S. J., 1398
Dracheva, T., 2351
Dragani, T. A., 1871, 3011
Dragowska, W. H., 7122
Dralle, H., 2864, 8500
Drayson, M. T., 505
Dredge, K., 593
Dreisbach, S. K., 4067
Drenning, S. D., 5629
Drescher, C., 3695
Dresen, I. G., 2578
Dressel, R., 8212
Dressman, D., 1865
Dressman, H., 3716
Dressman, M. A., 2194
Drevs, J., 4062
Drew, L., 1527
Drexler, H. G., 5329
Drexler, I., 4107
Dries, V., 2606
Drier, P. H., 1508
Driggers, L. J., 616
Drijfhout, J. W., 636
Drinkwater, N. R., 4914
Driscoll, D., 6076
Drize, O., 6340
Dröge, W., 4310
Drummond, D. C., 3154
Drysdale, S. B., 3969
Duan, H., 6666
Duan, Z., 2200
Dubart, A., 164
Dubeau, L., 5813
Dubensky, T., 6900
Dubinett, S. M., 642, 766, 5065
DuBois, R. N., 906
DuBridge, R. B., 6387
Ducreux, M., 5738
Duensing, S., 476, 4862
Duff, M. J. B., 3969
Dukart, G., 6069
Duke, L., 4724
Dulaimi, E., 8695
Dumon, K. R., 878, 882
Dumon-Jones, V., 7263
Dumoutier, L., 5105
Duncan, R. C., 2638
Duncavage, E. J., 1046
Dunn, R. L., 3486
Dunning, A. M., 2610
Dupon, C., 8203
Dupuy, P-H., 4809
Durden, D. L., 3585
Durkacz, B. W., 6008
Dutcher, J., 6069
Duyser, J., 6395
Dwyer-Nield, L. D., 5889
- ## E
- Eagleton, H., 3940
Earle, J. D., 7190
Earley, K., 386
Easdale, S., 6855
Eastman, A., 31
Easton, D. F., 2610, 8596
Easton, J., 364
Easwaran, V., 3145
Ebara, S., 7853
Eberhart, C., 5420
Eberly, J. L., 5962
Ebert, O., 3605
Eble, J. N., 6063
Eccles, D., 8596
Echchakir, H., 3682
Eck, M., 2052
Economides, K. D., 3886
Economou, J. S., 5607
Eden, O. B., 6563
Eder, J. P., Jr., 8345
Edgerton, M. E., 7113
Edgerton, S. M., 2425
Edgington, T., 2957
Eddinger, A. L., 8451
Edwards, A., 2361
Eeles, R. A., 6643
Efimova, E., 8768
Eger, K., 3189
Eggert, A. A. O., 8221
Egilegor, E., 491
Egorin, M. J., 312
Eguchi, H., 4739
Eibenschutz, L., 4119
Eicher, E. M., 8197
Eichhorst, S. T., 8869
Eickholt, B. J., 5230
Eilam, R., 8777
Einhaus, C. M., 7314
Einspahr, J. G., 3891
Einspanier, A., 1756
Eisenbeis, C. F., 965
Eisenmann, K. M., 8330
Eizuru, Y., 7062
Ekici, S., 2638
Eksioglu-Demiralp, E., 1242
Elaraj, D. M., 5957
El Behi, M., 3682
El-Deiry, W. S., 5299
Elder, D. E., 756
Elder, R. H., 7699
Elfenbein, G. J., 6772
El-Gamil, M., 6735
El-Hashemite, N., 5173
Elia, G., 3819
Elkahloun, A. G., 8877
Elkin, M., 8821
Elleau, H., 3221
Ellender, M., 2361
Ellis, I. R., 8827
Ellis, L. M., 2079, 2990, 3370, 3632
Ellis, M. J., 6523
Ellis, P. D., 2610
Ellman, J. A., 6870
Elovaara, E., 8623
Elsinga, P. H., 8558

- Eltom, I-E., 8079
 Elwood, P. C., 696
 Emberley, E. D., 1954
 Emerson, E., 4450, 7301
 Emlet, D. R., 250
 Emmert-Buck, M. R., 3872, 8022
 Enders, G. H., 742
 Endo, T., 8606
 Endres, S., 6478, 8962
 Eng, C., 282, 2864
 Eng, E. T., 8516
 Eng, J. P., 3459
 Engelman, R. W., 3021
 England, D., 2338
 Engler, H., 4003
 Engles, J. M., 5723
 Enkemann, S. A., 7900
 Enmon, R., 8293
 Enslinger, W. D., 658
 Epling-Burnette, P. K., 8523
 Epstein, A. L., 5046, 8384
 Epstein, E. H., Jr., 923
 Erdamar, S., 4662
 Erdman, S. E., 6042
 Erez, N., 7147, 8777
 Erickson, K., 4705
 Erickson, S. A., 7861
 Erkinheimo, T.-L., 7591
 Ernst, H., 5745
 Eschwege, F., 2513
 Escobedo, J., 3145
 Escudier, B., 7475
 Eshhar, Z., 2470
 Esko, J. D., 2775
 Espada, J., 4984
 Esposito, J. M., 413
 Esser, N., 4062
 Esserman, L. J., 2347
 Esslinger, B., 6496
 Esteban, M. A., 6877
 Esteller, M., 1114, 1596, 4620, 4984, 5731
 Estep, A. L. H., 7167
 Estève, F., 3221
 Estrada, Y., 1684
 Ethell, B. T., 8443
 Ethier, S. P., 132
 Etienne, C., 375
 Etzel, C. J., 8531
 Evangelista, F., 6387
 Evangelou, A., 2416
 Evans, A. A., 4594
 Evans, C.-O., 4218
 Evans, D. B., 6523
 Evans, D. G., 8596
 Evans, J. F., 586
 Evans, R. J., 4854
 Evans, W. E., 100
 Everett, A. D., 6716
 Everitt, J., 929
 Evers, B. M., 5218
 Ewing, C. M., 7365
 Eyehene, A., 3061
 Ezaki, T., 3747
- F**
- Fabbri, A., 1871
 Facchinetti, V., 8481
 Facompré, M., 7392
 Fagin, J. A., 1454
 Fahrig, R., 5745
 Faiola, B., 929
 Falchetti, M., 342, 3750
 Fallavollita, L., 1166
 Fallik, D., 5738
 Falvella, F. S., 1871
 Fan, F., 2079, 3370, 3632
 Fan, P.-D., 873
 Fan, Q.-W., 8930
 Fan, R., 4731
 Fan, S.-T., 3121
 Fan, T., 4677
 Fan, T.-P. D., 8351
 Fang, J., 3567
 Fang, M. Z., 7563
 Fang, Q., 4684, 7708
 Fang, X., 1073
 Fantl, W. J., 3145
 Farazi, P. A., 5021
 Farber, J. L., 186
 Farhan, N., 8264
 Farley, J., 1235
 Farmer, P., 6613
 Farrar, W. L., 2046
 Farrell, F., 6162
 Farrugia, A. N., 5438
 Fasheh, R., 140
 Fattaey, A., 6900
 Fattah, E. M. A., 7853
 Faure, O., 8476
 Fausch, S. C., 3478
 Fausto, N., 859
 Favier, J., 5615
 Favuzza, A., 2388
 Fawcett, J., 887
 Fazi, B., 3860
 Fazio, V. M., 8507
 Fearon, E. R., 2913, 8726
 Febbo, P. G., 4781
 Fedele, M., 7423
 Fedorov, L. M., 2268
 Feeney, L., 3909
 Feith, D. J., 3945
 Feld, M. S., 3556
 Feldman, E. D., 5957
 Feldman, M., 8813
 Feldman, R. J., 4626
 Feldser, D., 1138
 Felekis, K. N., 6802
 Felici, A., 8284
 Felix, E. A., 1073
 Feltkamp, M. C. W., 2695
 Femia, A. P., 2388
 Feng, C., 9016
 Feng, D., 7356
 Feng, G.-S., 6334
 Feng, N., 2802
 Feng, W. Y., 824
 Feng, X., 5785
 Feng, Y., 3296, 6042, 8726
 Fensterer, H., 6265
 Fenton, B. M., 4684
 Ferdinandusse, S., 7365
 Ferketich, A., 965
 Fernandez, P., 1382
 Fernández-Larrea, J., 5178
 Fernando, G. J. P., 3058
 Feron, O., 1012
 Ferrara, G. B., 4119
 Ferrari, N., 8877
 Ferrarini, M., 6144
 Ferreira, C. G., 6566
 Ferreira, G., 1138
 Ferrer, J. C., 5178
 Ferris, D., 4677
 Feskens, E. J. M., 1249
 Fessler, S., 7507
 Fichtner, I., 4062
 Fidler, I. J., 1345, 2940, 2971
 Fiedler, B., 5745
 Fiegl, H., 7641
 Field, J., 8837
 Fielding, A. K., 6463
 Figdor, C. G., 12
 Figg, W. D., 3189
 Fike, J. R., 4021
 Filion, C., 449
 Filippone, P., 4028
 Filleur, S., 3919
 Filomeni, G., 5940
 Fina, M. F., 8549
 Findlay, D. M., 5438
 Findley, H. W., 6357
 Fine, H. A., 8877
 Fine, R. L., 1527
 Finke, J. H., 1676, 4481
 Finkelstein, M., 7301
 Finner, R., 8414
 Fioretos, T., 1202
 Fiorini, T., 787
 Fiorucci, C., 4028
 Fischbach, M. A., 4089
 Fischer, R., 8414
 Fischer, S. M., 1221
 Fishel, M. L., 608
 Fisher, D. E., 6626
 Fisher, J. H., 5389
 Fisher, P. B., 8138
 Fishman, A., 417
 Fissekis, J. D., 3667
 Fitzgerald, M. C., 1652
 Fitzpatrick, J. L., 6716
 Flanders, W. D., 6556
 Flechtenmacher, C., 1179
 Flesken-Nikitin, A., 3459, 4426
 Fletcher, J. A., 304
 Fleuren, G. J., 636
 Flies, D. B., 6501
 Flinn, I. W., 36
 Florell, S. R., 567
 Florena, A., 6784
 Flores, J. M., 7047
 Florio, T., 1969
 Floyd, E., 7301
 Foa, R., 4497
 Fodde, R., 154
 Födinger, D., 8735
 Foekens, J. A., 337
 Foidart, J.-M., 2658
 Fojo, T., 1838
 Folini, M., 3490
 Folkard, M., 8437
 Folkes, L. K., 776
 Folkman, J., 1990, 8345
 Follen, M., 1999
 Fong, L. Y. Y., 186, 3945, 4244
 Fong, S., 1020
 Foon, K. A., 2844
 Foray, N., 3221
 Forbes, N. S., 5188
 Force, J., 8345
 Fornace, A. J., Jr., 5335
 Forni, G., 2518
 Forry-Schadues, S., 1490
 Forsyth, P. A., 3162
 Fosså, S. D., 7674
 Fossati-Bellani, F., 6948
 Fossi, S., 787
 Foster, B., 6237, 7301, 8784
 Foster, R. S., 6063
 Fowke, J. H., 3980
 Fox, E. A., 6272
 Fox, J. E., 7490
 Fox, J. G., 942, 6042
 Fracchioli, S., 807, 2223, 3403, 4225, 9032
 Frackelton, A. R., Jr., 6772
 Fradet, Y., 8511
 Fraga, M. F., 1114, 4984
 Fraig, M. M., 4626
 Fraker, D. L., 5299, 7232
 Franchitto, A., 3289
 Frandsen, J. L., 1304
 Franek, K. J., 3598
 Frank, A. J., 140
 Frank, S., 7051
 Frankel, A. E., 1834
 Frankel, W., 2399
 Franken, K. L. M. C., 636
 Frapolli, R., 5902
 Frappart, P.-O., 7263
 Frasca, F., 5829
 Frascogna, V., 2513
 Fraser, M., 7081
 Frauenhoffer, E., 3092
 Frazer, I. H., 3058
 Frazier, M. L., 4805
 Frech, M. S., 7668
 Freedman, L. P., 432
 Freeman, J. W., 2624
 Freeman, K. W., 6237, 8256
 Freeman, M. L., 5636, 6920
 Freeman, M. R., 484
 Freire, K., 1179
 Freije, W. A., 8853
 French, A. J., 5209
 French, C. A., 304
 French, K. J., 5962
 French, R. R., 5480
 French Hereditary Melanoma Study Group, 3061
 Frenkel, E., 8377, 8680
 Frenkel, K., 7704
 Frey, S., 164
 Freytag, S. O., 7497
 Frias, S., 44
 Frid, D. J., 6096
 Fridlyand, J., 2872, 5266, 7167
 Fridman, J. S., 5703
 Friedlander, G., 7284
 Friedlander, P. L., 7936
 Friedman, D. B., 5636
 Friedman, R., 4927
 Fries, M. A., 8996
 Friesen, M., 8717
 Frieser, M., 6496
 Frigyesi, A., 7094
 Frisano, J. A., 6424
 Frisque, R. J., 7256
 Fritsch, T., 6200
 Frolov, A., 6244
 Frost, D., 7861
 Frost, G. I., 5895
 Frost, P., 375
 Fruehauf, A., 513
 Fryer, B. H., 8837
 Fu, B., 7815
 Fu, L., 7215
 Fu, M., 3395
 Fu, V. X., 4614
 Fu, Y.-P., 2440
 Fuccio, L., 787
 Fuino, L., 5126, 7950
 Fujii, S., 4174
 Fujii, T., 854

- Fujino, S., 7920
 Fujita, M., 8606
 Fujita, T., 5564
 Fujita-Yamaguchi, Y., 627
 Fukai, K., 8674
 Fukasawa, K., 6716
 Fuks, Z., 4338
 Fukuda, K., 4434
 Fukuda, R., 2330
 Fukumori, T., 8302
 Fukumura, D., 747, 5188
 Fukunaga, A., 1555
 Fukushige, S., 3302
 Fukushima, N., 3735, 4158
 Fuller, G. N., 4315
 Fuller, J. H., 3145
 Funakoshi, A., 222
 Funk, C. D., 2256
 Funkhouser, W. K., 560
 Fuqua, S. A. W., 2434
 Furneaux, H., 2067, 7591
 Furrie, E., 8827
 Furth, E. E., 742
 Furth, P. A., 7668
 Furuhashi, M., 801
 Furuichi, M., 902
 Furukawa, Y., 3043, 6116
 Furusawa, Y., 4253
 Fusco, A., 882, 7423
 Fusenig, N. E., 8264
 Fuster, M. M., 2775
 Füzesi, L., 6200
- G**
- Gabra, H., 8648
 Gabriele, P., 1500
 Gabrielson, E., 3430
 Gabrielson, K. L., 6602
 Gabrilovich, D., 4441
 Gabut, M., 8203
 Gackowski, D., 4351, 4899
 Gafner, V., 3202
 Gai, W., 3955
 Galanis, E. C., 2462
 Galappathi, K., 4055
 Galiègue, S., 4809
 Galimberti, S., 8955
 Galindo, M., 5357
 Galli, S., 6370
 Gallick, G. E., 2079, 2990, 3632
 Gallinger, S., 1769
 Gallino, G., 4507
 Gallo, A. P., 8507
 Gallo, J. M., 5114
 Galmozzi, E., 696
 Gama, S., 3940
 Gambhir, S. S., 1160, 4552, 4952, 5669
 Gambini, C., 7400
 Gamboa da Costa, G., 5999
 Gambotto, A., 6378
 Gan, N., 1657
 Gan, Y., 579
 Gandhi, V., 7968
 Gandini, O., 4747
 Gangula, R. D., 6237, 8256
 Gangwar, S., 5526
 Gant, T., 5902, 7301
 Ganther, H. E., 52
 Gao, B., 5344
 Gao, C.-X., 6282
 Gao, F., 5685
 Gao, J., 7613
 Gao, J.-L., 7468
 Gao, J.-Q., 4420
 Gao, Y.-T., 3980, 5727, 7624
 Gao, Z., 1748
 Garbe, C., 7515
 Garbow, J., 3001, 8573
 Garcia, P. D., 3145
 García-Conde, J., 8226
 García-Sastre, A., 3605
 Garde, S., 2072
 Gardiner-Garden, M., 4196
 Garfield, S., 5909
 Garfield, S. H., 2596
 Gariboldi, M., 1871
 Garner, R. C., 8461
 Garnis, C., 8582
 Garofalo, A., 5224
 Garrett, E., 3145
 Garrett, L. M., 5073
 Garrido, C., 8233
 Garvin, S., 8742
 Garwood, M., 7571
 Gary, B., 8079
 Gascoyne, R., 7122
 Gaskell, M., 8461
 Gasparetto, M., 5126
 Gatenby, R. A., 3847, 6212
 Gati, A., 7475
 Gatter, K. C., 5376
 Gattuso, P., 4561
 Gaudin, C., 7475
 Gauduchon, P., 1722
 Gaut, A. W., 5513
 Gauthier, M. L., 2347
 Gawlinski, E. T., 3847
 Gawron, A. J., 5011
 Gayed, M., 4626
 Gaymes, T. J., 1798
 Gayther, S. A., 417
 Ge, X., 4882
 Ge, Z., 6042
 Gebhard, S., 7221
 Gee, M. S., 742, 8073
 Gehlhaus, K. S., 8634
 Geil, L., 1888
 Geisinger, K. R., 8549
 Geiss, G. K., 859
 Geisslinger, G., 1846
 Gelfand, E. W., 5889
 Gelman, R., 2024
 Gemma, A., 4641
 Gendron, D., 7679
 Geng, L., 4009, 7619
 Gentina, T., 6084
 George, M. L., 6855
 Gerald, W. L., 4538
 Gérard, J.-P., 8717
 Gercel-Taylor, C., 4067
 Gere, S., 655
 Germà, J.-R., 5731
 Germain, G. S., 364
 Germano, I., 2103
 Guerrero, M. R., 756
 Gerstenfeld, L. C., 2631
 Gescher, A. J., 5902
 Geschwind, J.-F. H., 6252
 Gestl, S. A., 3092
 Gestri, D., 342
 Getz, G., 6613
 Getzenberg, R. H., 4927
 Gewies, A., 682
 Ghali, L. R., 4692
 Ghataura, S., 2338
 Gherardi, E., 8351
 Ghia, P., 2561
 Ghosh, H. P., 7979
 Ghosh, K., 7979
 Giaccone, G., 4101, 6566
 Giachi, M., 4281
 Giacomelli, S., 2158
 Giacomini, P., 4119
 Giannini, A., 2388
 Giannini, C., 2462
 Giardullo, N., 6350
 Giatromanolaki, A., 5376
 Giavazzi, R., 1534, 5224
 Gibbons, J., 375
 Gibbs, D., 3612
 Gibson, S. L., 742
 Gicquel, C., 5308
 Giedzinski, E., 3107
 Giehl, K., 6265
 Giese, T., 6478
 Gietz, R. D., 1954
 Giffen, C., 3872
 Gil, L., 1814
 Gilbert, S., 7221
 Gilbertson, R. J., 140, 5428
 Gilboa, E., 2127, 7483
 Gille, J. J. P., 1449
 Gilles, C., 2658
 Gillespie, K., 4656
 Gillet, D., 6506
 Gilliland, F. D., 4842
 Gillis, A. J. M., 2244, 7674
 Gilmore, P. M., 6221
 Gimenez-Roqueplo, A.-P., 5615
 Gimm, O., 2864
 Gingrich, D., 5978
 Ginn-Pease, M. E., 282, 2864
 Ginsberg, D., 7147
 Gintz, M., 5844
 Gioeli, D., 1975, 1981
 Gioia-Patricola, L., 3560
 Giorda, E., 4119
 Giordanetto, F., 8233
 Giordano, T. J., 2649
 Giovannini, C., 7256
 Giovannini, M., 3001
 Giovannucci, E., 8542
 Giovarelli, M., 2518
 Gippner-Stoppert, C., 337
 Giraud, S., 4583
 Gires, O., 6478
 Girgis-Gabardo, A. A., 4920
 Girmun, G., 6327
 Girouard, S., 4588
 Gish, K., 4196
 Gishizky, M., 3356
 Gisselsson, D., 3378, 7094
 Giuliano, A. E., 1884
 Gius, D., 3413, 8984
 Giussani, C., 2499
 Gjerset, R. A., 3646
 Gladden, A. B., 7056
 Glazer, P., 1420
 Glazer, R. I., 5370
 Gleason-Guzman, M., 3247
 Gleave, M. E., 3575
 Glennie, M. J., 5480
 Glick, A., 7760
 Glick, A. B., 3447
 Glick, G. D., 6870
 Glickman, J., 5021
 Glickson, J. D., 8813
 Glinskii, O. V., 3805
 Glinsky, A. B., 4239
 Glinsky, G. V., 3805, 4239
 Glinsky, V. V., 3805
 Glover, C. L., 5793
 Glover, T. W., 4136
 Glozak, M., 5126
 Gnjatich, S., 6076
 Gobbi, A., 4342
 Goblirsch, M., 6847
 Godard, S., 6613
 Godwin, A. K., 664, 4967
 Goebel, G., 7641
 Goel, A., 787, 1608, 7256
 Goff, S. P., 873
 Goggins, M., 3735, 4158, 8614
 Going, J. J., 3275
 Göke, R., 1333
 Gokmen-Polar, Y., 3425
 Golas, J. M., 375
 Gold, D., 5926
 Goldbeck, C., 3145
 Goldberg, I., 25, 3899
 Goldberg, S. F., 432
 Goldberg, S. N., 6327
 Goldbohm, R. A., 3133
 Goldenberg, D. D., 8930
 Goldenberg, D. M., 111, 354, 8069
 Goldfinger, N., 7147, 8777
 Goldgar, D. E., 6643
 Goldman, C. K., 6453
 Goldring, M. B., 449
 Goldstein, A. M., 3872
 Golemis, E. A., 8837
 Gollnick, S. O., 7584
 Golub, T. R., 1602
 Gomez, D., 2284, 6149
 Gondi, C. S., 2454
 Gong, B., 8428
 Gong, J. G., 3340
 Gonzalez, A. L., 7113
 Gonzalez, F. J., 929
 González, S., 5731
 González-Guerrero, A. M., 4997
 González-Suárez, E., 7047
 Goode, R. L., 6056
 Goodfellow, P. J., 2033
 Gooding, W. E., 5629, 6378, 6763
 Goodlad, R. A., 3819
 Goodluck-Griffith, J., 5793
 Goodrow, T., 4997
 Goodwin, I. A., 1025
 Goodwin, P., 7301
 Goodyer, N., 4895
 Gor, P., 8051
 Goranov, B., 7310
 Gorden, A., 3955
 Gordon, K. E., 458
 Gore, M., 417
 Gorgoulis, V. G., 7185
 Gorlick, R., 1759, 9042
 Gorny, M. K., 2067
 Gorosquieta, A., 3079
 Gorringer, K., 2569
 Gorschlüter, M., 8962
 Gorski, D. H., 308
 Gorziglia, M., 1490
 Gostout, B. S., 1927
 Goswami, P. C., 2109
 Gotley, D. C., 887
 Gottardis, M. M., 1221
 Götte, K., 1188
 Gottenger, E., 5874
 Gottesman, M. M., 3084, 5909
 Götz, R., 2268
 Gough, M., 2145, 3173, 5505
 Gould, M. N., 5808

- Gounder, M. K., 3228
 Govinda, S., 593
 Govindan, S. V., 111
 Gowda, S., 7975
 Goya, M., 2096
 Goytisoló, F. A., 7047
 Gozzini, A., 8955
 Grady, M., 5513
 Graff, C. P., 1288
 Graff, J. R., 6056
 Graff-Dubois, S., 8476
 Gramlich, J. L., 5462
 Grammatico, P., 4119
 Grana, T. M., 7807
 Granada, E., 5813
 Grandis, J. R., 5629, 6763
 Graner, E., 290
 Grant, S., 1822, 2118, 3637, 8420
 Grass, L., 2771, 3958, 9032
 Grassauer, A., 8735
 Grau, M., 5731
 Graves, E. E., 6838
 Graves-Deal, R., 1748
 Gravitt, P. E., 7215
 Gray, J. P., 5767
 Gray, J. W., 5266
 Grądziewicz, M. A., 4351
 Greaves, M. F., 6563
 Greaves, P., 5902
 Greco, W. R., 1806, 2477, 7584, 8126
 Grecula, J., 965
 Green, J. E., 4384
 Green, J. L., 4692
 Green, S. J., 468, 2997
 Greenberg, M. D., 7215
 Greenberg, N. M., 5754, 6237, 8256, 8757, 8784
 Greenberg, R. E., 8695
 Greenberger, L. M., 1838
 Greenson, J. K., 2649
 Greenwald, P., 4295
 Greer, D. A., 4829
 Gregg, J. P., 3886
 Grégoire, V., 1012
 Gregor, M., 2369
 Gregory, P. D., 8968
 Greider, C. W., 8188
 Greiner, S., 2462
 Greiser, U., 3154
 Grénman, R., 1920, 4671, 8556
 Gress, T. M., 4945, 6265
 Gribble, G. W., 1371, 5551
 Grier, H. E., 304
 Griffin, C. S., 8181
 Griffin, J. D., 6272
 Griffin, J. L., 3195
 Griffioen, A. W., 382, 2322
 Griffiths, G. L., 111, 354
 Griffiths, J. R., 4960
 Grigoriu, B., 6084
 Grille, S. J., 2172
 Grimes, M. J., 4620
 Grimm, C., 3066
 Grimm, E. A., 5105
 Grimm, S., 682
 Grioni, M., 3688
 Grippeling, M., 1449
 Grippo, P., 2005, 2016
 Griswold, M. D., 865
 Gritz, L., 7942
 Gröhn, O. H. J., 3195, 7571
 Grohs, U., 1772
 Grollman, A. P., 4402
 Grone, H.-J., 8890
 Groot, K., 7913
 Gros, L., 164
 Grösch, S., 1846
 Gross, D.-A., 8476
 Gross, S. C., 1731
 Grosse-Wilde, H., 4107
 Grossman, D., 567
 Grossman, H. B., 1157
 Grote, D., 6463
 Grothey, A., 513
 Groussin, L., 5308
 Grove, J. I., 5532
 Gruman, L. M., 5381
 Gruntmanis, U., 8516
 Gryaznov, S., 3931, 6187
 Gryfe, R., 1769
 Grygiel, J. J., 4196
 Grzesik, C., 8212
 Grzywacz, M. J., 2492
 Gu, J., 6282
 Gu, L., 6357, 9007
 Gu, Q., 7321
 Guarini, A., 4497
 Guatta-Rangini, Z., 8821
 Gudkov, A. V., 164, 2905
 Guenther, J. C., 5209
 Guerra, N., 7475
 Guerrero-Santoro, J., 4927
 Guglielmi, J., 3919
 Guha, A., 1106
 Guha, S., 2379
 Gui, J.-H., 3257
 Guikema, J. E. J., 3894
 Guil, S., 5178
 Guillaume, P., 5601
 Guino, E., 3560, 5731
 Guinovart, J. J., 5178
 Guise, C., 5532
 Gujrali, M., 2454
 Gumerlock, P. H., 7190
 Gunawan, B., 6200
 Gundel, R., 3145
 Gundersen, G. G., 6825
 Günther, E., 8212
 Guo, C., 1631, 2033, 5320
 Guo, F., 93, 7950
 Guo, H., 5218
 Guo, K., 2716
 Guo, L., 3145
 Guo, M., 1114
 Guo, P., 4684, 5114
 Guo, R., 2037
 Guo, W., 8784
 Guo, Y., 8763
 Guo, Y.-S., 3495
 Guo, Z., 2316, 2351, 5799, 8323
 Gupta, A., 664, 2399, 3899, 5656
 Gupta, N., 965
 Gupta, R. A., 906
 Gurbuxani, S., 8233
 Gurfinkel, M., 7870
 Gurova, K. V., 2905
 Gustafsson, J.-A., 6258
 Gutin, P. H., 3268
 Gutkind, J. S., 2948
 Gulkovich, E., 25
 Gutmann, D. H., 1106, 2933, 3001, 8573
 Gütschow, M., 3189
 Gwadry, F. G., 5243
 Habuchi, T., 4407, 7652
 Haché, R. J. G., 1198, 7197
 Hachey, D. L., 8492
 Hackbarth, M. L., 36
 Hackett, C., 1589
 Hackett, C. S., 5266
 Hackett, N. R., 1475
 Haddad, B. R., 8097
 Haddad, R., 1769
 Hadjimichael, O. C., 7215
 Hadsell, D. L., 5203
 Hagemeijer, A., 1202
 Hagemeister, F. B., 44
 Haglund, C., 7591
 Hahn, E. G., 6496
 Hahn, S. M., 5656
 Hahnfeldt, P., 3755, 8890
 Haiman, C. A., 6984
 Haimovitz-Friedman, A., 4338, 5950
 Hainaut, P., 6643
 Haines, D. C., 1752
 Haines, J., 2361
 Hait, W. N., 1515, 2492, 6894
 Hakama, M., 2701
 Hakkola, J., 8623
 Halaban, R., 1420, 8103
 Halama, E. D., 7668
 Halazonetis, T. D., 7185, 8586
 Haley, A., 5761
 Halford, S. E., 7595
 Halin, C., 3202
 Hall, J., 8717
 Hallahan, D. E., 4009, 7663
 Hallenbeck, P. L., 1490
 Halmos, G., 7913
 Halpern, A., 308
 Hamada, A., 3567
 Hamada, F. M., 4062
 Hamada, H., 4434
 Hamada, K., 674, 2506, 6651
 Hamada, Y., 4253
 Hamaguchi, M., 6334
 Hamasaki, M., 6187
 Hamidi, H., 4268
 Hamilton, A. D., 8922
 Hamilton, M., 3162
 Hamilton, T. C., 1311, 1389, 4967
 Hammann, A., 8233
 Hammerschmidt, W., 2982
 Hamou, M.-F., 6613
 Han, J., 3473, 3743, 6206, 8536
 Han, X., 3755, 6363, 8890
 Hanada, R., 4882
 Hanahan, D., 3005
 Hanash, S., 2649
 Hanash, S. M., 2913
 Hanazono, Y., 5091
 Hanchett, L. R. A., 7106
 Hanczaruk, B., 5573
 Handa, H., 4607
 Handerson, T., 5363
 Handgretinger, R., 1772
 Hanford, H. A., 4275
 Hang, H., 5291
 Hankinson, O., 2645
 Hankinson, S. E., 5236, 8536
 Hanks, A. N., 567
 Hannah, S. E., 2256
 Hansel, D. E., 7032
 Hansen, G. B., 3378
 Hansen, H. J., 111, 354
 Hansen, L. A., 5257
 Hansen, N. M., 1884
 Hansen, R. D., 9023
 Hänsler, J., 6496
 Hansmann, M.-L., 1644
 Hanyu, A., 7791
 Hanyu, N., 5159
 Hao, B., 8057
 Hao, P., 6488
 Hara, N., 4044
 Hara, T., 149, 2404, 5622
 Hara, Y., 5785
 Harada, Y., 4888
 Harbeck, N., 2771, 3958
 Hardisson, D., 5697
 Hardy, C., 1838
 Harel, F., 8511
 Harel-Bellan, A., 3919
 Hari, M., 1838
 Harkin, D. P., 4602, 6221
 Harkins, L. E., 8670
 Harley, C. B., 3931
 Harmelin, A., 2470
 Harrigan, J. A., 7136
 Harriman, S., 7301
 Harrington, K., 3173, 5505
 Harrington, P., 417
 Harris, A. L., 1764, 5376, 6130, 8408
 Harris, C. C., 728, 2373, 2596, 5785, 7147
 Harris, L. C., 3840
 Harris, R. E., 6096
 Harris, S. S., 1389
 Harris, T. D., 5838
 Hars, E. S., 8400
 Hart, J., 3517
 Hartell, J. S., 627
 Hartley, S., 7760
 Hartmann, C., 1602
 Hartmann, E., 6478
 Hartmann, G., 6478
 Harvey, B.-G., 1475
 Harwood, F. C., 364
 Hasan, T., 1025
 Hasebe, T., 2096
 Hasegawa, K., 7834
 Hasegawa, S., 3043
 Hasegawa, Y., 1073
 Hashimoto, H., 737
 Hashimoto, K., 2506
 Hashimoto, N., 5159
 Hashimoto, T., 4396
 Hashimoto, Y., 6320
 Hashizume, T., 5281
 Hasina, R., 555
 Hasmann, M., 7436
 Hassan, K., 4796
 Hassan, M. Q., 2631
 Hassane, S., 636
 Hasskarl, J., 476
 Hast, J., 7221
 Hatanaka, Y., 4420
 Hatano, T., 2096
 Hatta, M., 8338
 Hatta, N., 432
 Haugen, D. A. L., 7638
 Hauschildt, S., 3189
 Häussler, A., 1846
 Havaux, X., 1012
 Haviv, I., 2569
 Hawk, E. T., 5649
 Hawkins, C., 5821
 Hawkins, L. K., 1490
 Hawthorn, L., 52
 Hay, C., 1490

H

Haag, J. D., 5808
 Haas-Kogan, D. A., 236

- Hayakawa, M., 1365
 Hayakawa, T., 4420
 Hayakawa, Y., 207
 Hayashi, N., 6282, 6726
 Hayashi, R., 895
 Hayashi, S., 1731
 Hayashi, T., 18, 6187, 8428
 Hayashi, Y., 4882
 Hayashizaki, Y., 1871
 Hayden, R. E., 505
 Hayden-Ledbetter, M., 3695
 Hayes, D. L., 4082
 Hazlehurst, L. A., 7900
 Hazra, A., 1157
 He, B., 4547
 He, D., 3955
 He, F., 3268, 8057
 He, J., 1345
 He, L., 1207, 2393
 He, P., 728
 He, Q., 3791
 He, Q-M., 600
 He, Y., 3855
 He, Z., 4396
 Healey, C. S., 2610
 Healey, J., 1759, 9042
 Hebbbar, V., 7520
 Heber, W., 1280
 Hebert, F., 7913
 Hebert, K. E., 2631
 Hecker, T. K., 3189
 Heckl, S., 4766
 Heckman, C. A., 6666
 Heerdt, B. G., 5401, 6311
 Heerema, N. A., 36
 Heerschap, A., 5408, 7609
 Hefler, L. A., 3066
 Hegen, M., 713
 Hegi, M. E., 6613
 Heguy, A., 1475
 Heijmans, B. T., 1249
 Heijnen, V. V. T., 2322
 Heikkilä, P., 4671, 5005
 Heimerdinger, C. K., 7221
 Heinrich, J.-C., 5745
 Heinrich, M. C., 5761
 Heirman, C., 5587
 Heiser, A., 2127
 Heiss, E. H., 1371
 Helczynska, K., 1441
 Helling, A., 7221
 Heller, G., 8393
 Hellmich, M. R., 3495
 Hellrung, D., 987
 Hellström, I., 3695
 Hellström, K. E., 3695
 Hemann, M. T., 5703
 Hembrough, T. A., 2997
 Hembrough, W. A., 468
 Hemmerle, C., 8113
 Hemminki, A., 847
 Hempen, P. M., 994
 Hemscheidt, T. K., 3211
 Henderson, B., 1235
 Henderson, B. E., 6984
 Henderson, B. W., 8126
 Henderson, R., 2553
 Henderson, S. O., 6984
 Hendriks, B. S., 1130
 Hendrix, M. J. C., 4757, 5381
 Hendrix, N., 2913
 Hengstler, J. G., 7221
 Henke, R. T., 1696
 Henkin, J., 7861
 Henley, S. J., 6556
 Hennighausen, L., 4384
 Henning, W., 2596
 Henrik, A., 807
 Henriksen, K., 4055
 Henriksson, M., 1743
 Henry, A. C., 878, 7845
 Henry, K., 3708
 Henry, M. K., 1034
 Hensel, F., 2052
 Henshall, S. M., 4196, 6387
 Her, C., 865
 Herbert, B.-S., 1914, 5813
 Herbert, J.-M., 5978
 Herbstritt, C. J., 468
 Herceg, Z., 7263
 Herlyn, M., 756, 5198
 Herman, J. G., 1114, 1596, 3133, 5731, 7089
 Hermans, I. F., 8408
 Hernan, R., 140, 5428
 Hernandez, M. R., 8573
 Hernández, M.-I., 1615
 Hernandez, R., 1838
 Hernández-Alcoceba, R., 6877
 Hernández-Muñoz, I., 4188
 Hernandez-Perez, M., 3764
 Hernandez-Saavedra, D., 159
 Hernando, E., 5703
 Herness, E. A., 329
 Herr, I., 3112
 Herrem, C. J., 4481
 Herrera, F., 7241
 Herrera, P. L., 4836
 Herrmann, T., 8212
 Herschenhou, N., 4739
 Hershman, J. M., 5065
 Herynk, M. H., 2990
 Herzer, K., 3112
 Herzog, C. R., 5239
 Herzog, V., 7032
 Hess, A. R., 4757
 Hesselager, G., 4305
 Hessels, D., 4748
 Hettmer, S., 3654, 7270
 Heufelder, A. E., 1333
 Heuze-Vourc'h, N., 766
 Hevezi, P., 6387
 Hewer, A., 2752
 Hewison, M., 505
 Hewitt, S. M., 5243, 5957, 8022
 Heydari, A. R., 5799
 Heymach, J. V., 8345
 Heyns, W., 3799
 Hibi, T., 3747
 Hibino, S., 5060
 Hicklin, D. J., 747, 8912
 Hickling, J., 6032
 Hicks, K. O., 5970
 Hida, Y., 1555
 Hidaka, H., 6942
 Hidalgo, M., 6069
 Hideshima, T., 18, 5850, 6174, 6187, 6689, 8428
 Higashi, M., 5011
 Higashikubo, R., 2109
 Higashimoto, Y., 2373
 Higashino, F., 8338
 Higdon, C., 7301
 Higuchi, S., 8592
 Hii, G., 1631
 Hikiba, Y., 8132
 Hildesheim, A., 7215
 Hill, J. R., 1589
 Hill, M. E., 6855
 Hiller, J., 4196
 Hillerman, S., 7301
 Himmelfarb, E., 4009
 Hinds, P. W., 476
 Hingorani, S. R., 5198
 Hinkhouse, M. M., 1297, 5513
 Hippo, Y., 8629
 Hiraga, T., 5028
 Hirai, H., 4516, 4967
 Hirai, T., 2404
 Hirakawa, H., 2762
 Hirakawa, K., 8629, 8848
 Hiramatsu, Y., 7834
 Hirano, F., 6501
 Hirano, H., 6962
 Hiraoka, K., 1555
 Hirasawa, K., 348
 Hirasawa, Y., 8674
 Hirohashi, S., 895, 4641
 Hirose, S., 2506
 Hirota, M., 1192
 Hirota, S., 1731
 Hirsch, S., 8735
 Hirvonen, A., 8623
 Hissong, B., 2179
 Hla, T., 7591
 Hlatky, L., 3755, 8890
 Ho, H.-N., 6537
 Ho, V., 7122
 Hoang-Vu, C., 2864, 8500
 Hoatlin, M. E., 2688
 Höckel, M., 7634
 Höcker, M., 1083
 Hod, Y., 6928
 Hodge, J. C., 1359
 Hodge, J. W., 7942
 Hodgson, J. G., 5266
 Hodgson, S. V., 7595
 Hoessli, D. C., 534
 Hofele, C., 1179
 Hoffman, A. R., 1759, 1900
 Hoffman, R. M., 80, 2477, 4239, 5521, 6689, 7785, 8377
 Hoffman, T. J., 4082
 Hofmann, T. G., 4310, 8271
 Hofmann, U. B., 8221
 Hofseth, L. J., 2596
 Hogan, V., 242, 8302
 Hogarty, M. D., 1631
 Hogervorst, F. B. L., 1449
 Höglund, M., 1202, 3378, 7094
 Holden, P. E., 8556
 Holgado-Madruga, M., 250
 Hollander, M. C., 5335
 Hollingshead, M. G., 2812
 Hollingsworth, M. A., 5011, 8614
 Holloway, A. J., 2569
 Holman, P., 6900
 Holst, C. R., 1596
 Hölter, T., 2578
 Holzmann, K.-H., 6265
 Hombach, A., 3234
 Honda, T., 1371, 5551
 Honecker, F., 2244
 Hong, C., 7600
 Hong, C. Y., 621
 Hong, F., 9023
 Hong, K., 3154
 Hong, S.-B., 5320
 Hong, W., 2716
 Hong, W. K., 3826, 4796
 Hongo, A., 7834
 Honke, K., 6282
 Honma, Y., 3659
 Honn, K. V., 4258
 Hoogerbrugge, N., 8153
 Hooi, S. C., 6658
 Hoon, D. S. B., 441, 1639, 1884
 Hooper, A., 747
 Hooper, A. T., 8912
 Hopkins, K. M., 5291
 Hoque, M. O., 2216, 2351, 5723
 Horcajada, M.-N., 6607
 Horgan, K., 5526
 Hori, M., 6282, 6726
 Horiguchi, Y., 107
 Horii, A., 3302
 Horimoto, M., 6726
 Horn, M. T., 6697
 Horna, P., 9007
 Horsfall, D. J., 4786
 Horsthemke, B., 2578
 Horton, C., 1676
 Horvath, L. G., 4196
 Horvath, N., 5438
 Horvath, S., 2742
 Horwitz, B. H., 6042
 Horwitz, S. B., 1207, 7891
 Hosobe, S., 1731
 Hosoi, H., 1876
 Hosokawa, M., 8606
 Hotchkiss, K. A., 527
 Hothersall, J. S., 1818
 Hou, C., 6488
 Hou, M., 1743
 Hou, Z., 7563
 Houghton, A. N., 3955
 Houghton, J. A., 5118
 Houghton, P., 7926, 7950
 Houghton, P. J., 364, 8400
 Houlston, R. S., 154
 Housseau, F., 2836
 Houston, K. D., 1221
 Houston, M. A., 6311
 Howard, B., 1652
 Howarth, D. H. C., 9032
 Howe, J. A., 4003, 6697
 Howe, L. R., 1906
 Howell, G. M., 4731
 Howlett, A. R., 3755
 Hruban, R. H., 994, 2585, 3735, 4144, 6999, 8614
 Hsi, A., 7232
 Hsiao, A. H.-A., 6178
 Hsiao, T. H.-C., 6178
 Hsieh, J.-T., 8680
 Hsu, G.-C., 2440
 Hsu, S.-M., 6537
 Hu, B., 600, 4684
 Hu, F., 7321
 Hu, G., 3775
 Hu, L., 4315
 Hu, M., 7907
 Hu, N., 3872
 Hu, P., 5046, 8384
 Hu, R., 7520
 Hu, W., 4174
 Hu, Y., 655, 3872
 Hu, Y. J., 3347
 Hu, Z., 923
 Hua, P., 522
 Hua, X., 1389, 4204
 Huang, C.-C., 2913
 Huang, E., 3716
 Huang, H., 179, 2957, 4315
 Huang, H.-Y., 1759, 3966
 Huang, J., 4677, 6378

- Huang, L. E., 8700
Huang, M., 93, 5065
Huang, P., 747
Huang, R., 3775
Huang, S., 364, 817, 3855, 7619
Huang, S-C., 6537
Huang, T. H-M., 2164, 6110, 6178
Huang, T-G., 3605
Huang, W., 3955, 4225
Huang, X. F., 7321
Huang, Y., 1490, 3646, 4181, 8749
Huang, Y-C., 647
Huang, Z-y., 2933
Hubbard, G. B., 6121
Huber, C., 4107
Huber, J., 747
Huber, P. E., 3755, 8890
Huber, W., 6200
Hudes, G., 6069
Hudgins, S. L., 7668
Hudkins, R., 5978
Hudson, L. G., 7825
Huebner, K., 186, 878, 4244
Hughes, D., 5480
Huhn, M., 8414
Hulett, K., 555
Hulla, W., 7263
Humphrey, L. E., 4731
Hundley, T. R., 7613
Hung, C-F., 2393
Hung, M-C., 6229, 7630
Hung, W-C., 3069
Hunt, C. R., 8233
Hunter, D. J., 5236, 8536
Hunter, K., 2179, 4594, 5978
Hurley, L. H., 3247
Hursting, S. D., 1752
Hurwitz, E. E., 413
Husgafvel-Pursiainen, K., 8623
Hüsing, J., 2578
Huso, D. L., 8188
Hussain, S. P., 728
Hutchinson, O. C., 3791
Huvos, A., 9042
Huvos, A. G., 1759
Huxham, L. A., 5707
Huxley, V. H., 3805
Hwang, E. S., 7167
Hwang, H-s., 838
Hwang, S. T., 6751
Hwu, E. B., 6583
Hwu, P., 2836, 9016
Hyde, E. I., 5532
Hynan, L. S., 1914
Hyun, W., 3107
- I**
- Iacobuzio-Donahue, C. A., 994, 4158, 8614
Iaquinto, G., 6350
Ibanez de Caceres, I., 8695
Ibsen, E., 6387
Ichihara, Y., 8869
Iezzi, G., 3688
Iezzi, M., 2518, 2728
Iftner, A., 7515
Iftner, T., 7515
Iga, M., 7468
Igawa, M., 7717
Ignatowski, K. W., 132
Ihrig, M., 942
Ihrig, M. M., 6042
Ijichi, H., 8132
Ikeda, H., 2688
Ikeda, M., 7581
Ikeda, S., 4253
Ikeda, T., 5551
Ikejiri, B., 7051
Ikenoue, T., 8132
Ikenoya, M., 6942
Iklé, D. N., 3435
Ikram, M. S., 4692
Ilagan, R., 4552
Ilan, N., 7733
Ilinski, P., 1776
Illmensee, K., 7507
Im, M. M., 6935
Imai, K., 6432, 8145, 8606
Imaida, K., 7581
Imaki, H., 4607
Imamura, J., 8132
Imamura, M., 5691, 6320
Imamura, T., 7791, 8132
Imazeki, F., 8674
Imberti, B., 1534
Imoto, I., 1876, 5691
Imoto, M., 424
Inaba, T., 6914
Inamoto, T., 8090
Inazawa, J., 1876, 5691
Ince, G., 6707
Indig, F. E., 7136
Indino, E., 2855
Inge, L., 2742, 3145
Ino, K., 2278
Ino, Y., 895
Inohara, H., 8302
Inoue, H., 6575
Inoue, J., 1876
Inoue, M., 3708, 8869
Inoue, N., 3747
Inoue, R., 2300
Inoue, T., 674
Intengan, M., 6076
Ip, C., 52, 6988
Iraqi, F. A., 3317
Irby, R., 4368
Ireland, H., 458
Irie, T., 6726
Irrjala, H., 4671
Irmak, M. B., 6707
Isaacs, J., 5978
Isaacs, J. S., 8984
Isaacs, W. B., 6795, 7365
Ise, T., 8592
Ishibashi, Y., 5159
Ishida, E., 737
Ishida, S., 3716, 8145
Ishida, T., 2762
Ishiguchi, H., 3729
Ishii, E., 4882
Ishii, H., 186, 1183, 3747
Ishii, S., 6626
Ishii, Y., 3659
Ishikawa, S., 6791
Ishikawa, T., 5564
Ishikura, H., 4017
Ishimaru, Y., 6962
Isola, J., 4978, 5005, 8861
Israel, D. A., 951
Israel, M. A., 923, 1589
Issa, J-P., 4174, 7089
Issa, J-P. J., 4805
Itahana, Y., 7098
Itami, S., 674
Ito, F., 2546, 8466
Ito, H., 2103, 6432
Ito, M., 2506, 8763
Ito, T., 5691, 6320
Ito, Y., 6651
Itoh, F., 6432, 8606
Itoh, H., 3729
Itoh, K., 854, 2829
Itoh, M., 6090, 8338
Itoh, S., 1371
Itoh, T., 1555, 5041
Itoh, Y., 7920
Ittmann, M., 5754, 6237, 8256
Ittmann, M. M., 8784
Iturria, S. J., 3877
Iuliano, R., 882
Ivanova, M., 5203
Ivarsson, L., 7641
Ivie, S. E., 6405
Iwadate, M., 7791
Iwai, T., 5564
Iwakiri, D., 7062
Iwamoto, M., 2506
Iwamura, T., 4945, 6265
Iwanari, H., 8629
Iwao, Y., 3747
Iwata, K., 8278
Iwata, K. K., 4450
Iyer, A., 6802
Iyer, M., 4552
Iyer, N., 1138
Izbicka, E., 3247
Izeradjene, K., 5118
Izumi, H., 3729, 8592
Izumi, Y., 747
Izzotti, A., 793
- J**
- Jäättelä, M., 8233
Jablons, D. M., 4547
Jackman, A. L., 3612
Jacks, T., 752
Jackson, D., 1920, 8556
Jackson, E. M., 3211
Jackson, R. D., 6096
Jackson, R. J., 3021
Jacob, S., 5738
Jacobetz, M. A., 5198
Jacobs, R. S., 1214
Jacobson, D. R., 2067
Jacobson, J., 1818
Jacquemin-Sablon, A., 164
Jaeger, U., 1723
Jaffe, R., 2923
Jager, P. L., 8558
Jagirdar, J., 1615
Jagmohan-Changur, S., 154
Jain, A., 2872, 5266
Jain, R. K., 747, 5188, 8556
Jaishankar, S., 3464
Jaiswal, A. K., 929, 6016
Jakate, A. S., 7314
Jakowlew, S. B., 5889
Jakse, G., 6200
Jakubczak, J. L., 1490
Jalkanen, S., 1920, 4671, 8556
Jallal, B., 3356
James, C. D., 723
James, S. Y., 3531
Jamieson, A. C., 8968
Janda, K., 2957
Jang, Y., 6458
Jani, J. P., 4450, 7301
Jänicke, F., 5679, 6523
Janin, A., 6084
Janjic, B., 6506
Jankowski, K., 7926
Janowska-Wieczorek, A., 7926
Jansen, B., 8735
Jansen, G., 3612
Jansen, L., 2062
Jansen, M. J. H., 5595
Janz, S., 8656
Janzer, R. C., 6613
Jardine, L., 8443
Jarrard, D. F., 4614
Järvinen, H., 154
Jasin, M., 8181
Jass, J. R., 4577
Jauma, S., 8784
Jaurand, M-C., 8108
Javed, A., 2631
Jayaraman, M., 7428
Jayatilake, H., 8596
Jazaeri, A., 6
Jeanson, L., 2513
Jeffery, R., 3819
Jeffries, B. A., 2596
Jen, J., 2351
Jeng, M-H., 3425
Jenkins, M. A., 3325
Jenkins, R., 5266
Jenkins, W. T., 8813
Jenne, J., 4766
Jensen, H. L., 4232
Jensen, P., 5428
Jensen, R. M., 7167
Jensen, R. T., 817
Jeon, K., 621
Jeong, S. W., 621
Jeong, S-Y., 7051
Jerry, D. J., 2364
Jeruss, J. S., 3783
Jettz, A., 6697
Jeunemaitre, X., 5615
Jhiang, S. M., 2864
Ji, Y-L., 3743, 6206
Ji, Z-L., 3257
Jia, L-T., 3257
Jia, Y., 214
Jiang, C., 8763
Jiang, F., 4698
Jiang, J., 4819, 7410
Jiang, P., 4239, 7785
Jiang, R., 6357
Jiang, S., 4037, 5021, 5203
Jiang, S. H., 7724
Jiang, W., 1228
Jiang, W. W., 7694
Jiang, X., 2589
Jiang, X. H., 7724
Jiang, Y., 3899, 4750
Jimenez, A. I., 1382
Jiménez, M., 1615, 4188
Jimenez, X., 8912
Jimeno, J., 5902
Jin, C., 4936, 8784
Jin, D-Y., 7646
Jin, F., 3980, 5727
Jin, H., 2802
Jin, L., 2251
Jin, M., 3257
Jin, S., 4204
Jin, W., 6154
Jin, Z., 980
Jing, Y., 1853
Jinquan, T., 6469
Jinshen, H., 6469
Jirincy, J., 8113, 8158

- Jisaka, M., 2256
 Joba, W., 1333
 Jochum, M., 337
 Jöckel, K.-H., 2578
 Jodrell, D. I., 8443
 Joenje, H., 2688, 6998
 Joensuu, H., 4671, 5005
 Jögi, A., 1441
 Joh, T., 5785
 Johannsdottir, H. K., 2024
 Johansson, B., 1202
 Johansson, M., 6909
 John, S., 9048
 Johnson, B. E., 6272
 Johnson, D., 3162, 6697, 8912
 Johnson, D. E., 4003
 Johnson, L., 1583, 6900
 Johnson, M., 4552
 Johnson, M. A., 6056
 Johnson, M. J., 4181
 Johnson, M. S., 468
 Johnson, R. L., 1636
 Johnson, V., 7595
 Johnston, J., 579, 824
 Johnston, P. G., 4602, 6221
 Johnston, S. R. D., 6516
 Johnstone, R. W., 4460
 Jolliffe, L., 6162
 Jonas, S., 1083
 Jones, A., 7595
 Jones, C. D., 6056
 Jones, C. J., 4854
 Jones, G. D. D., 3107
 Jones, G. E., 1667
 Jones, S. J., 8827
 Jones, T., 2409
 Jones-Bolin, S., 5559, 5978
 Jongmans, W., 1994, 8717
 Jonker, J. W., 6447
 Joos, S., 1179
 Jordan, M. A., 2794, 6026
 Jordan, V. C., 7490
 Joseph, L., 3517, 8749
 Josephson, L., 1936, 6838, 8122
 Jost, E., 8414
 Joste, N., 4620
 Joubert, A., 3221
 Jouvenot, Y., 8968
 Jove, R., 93, 1270, 5126, 8523
 Joyce, P. L., 7959
 Joynes, C. J., 250
 Ju, R., 2891
 Juang, J., 2393
 Jung, K., 6543
 Jung, Y., 8248
 Jung, Y. D., 3632
 Jung, Y. J., 7777
 Jungbluth, A. A., 6076
 Junttila, M. R., 3473
 Junyan, L., 6469
 Junying, J., 2338
 Jupe, E. R., 5251
 Jurisica, I., 2416
- K**
- Kabbinavar, F. F., 196
 Kabickova, H., 1508
 Kadhim, S., 2072
 Kadota, M., 4174
 Kadouri, L., 6340
 Kagan, B. L., 1696
 Kaganoi, J., 6320
 Kagawa, S., 8302
 Kähäri, V.-M., 3473
 Kahn, A., 541
 Kahn, C. R., 5850
 Kahnoski, K., 4583
 Kaiser, L. R., 878, 3352, 7845
 Kajdacsy-Balla, A., 1359
 Kajiyama, H., 2278
 Kakinuma, H., 7840
 Kakiuchi, Y., 6726
 Kakizawa, T., 7545
 Kalluri, R., 8312
 Kaloss, M., 1490
 Kaluz, S., 917
 Kaluzová, M., 917
 Kamal, M. H., 2631
 Kamano, Y., 8869
 Kamataki, T., 7581
 Kamath, K., 6026
 Kamijo, T., 2096
 Kamiryo, T., 6962
 Kamm, Y. J. L., 7609
 Kammertens, T., 4095
 Kamoto, T., 4407
 Kamsteeg, M., 5573
 Kamura, T., 4607
 Kan, B., 600
 Kan, T., 6320
 Kanai, F., 8132
 Kanai, T., 3747
 Kanamori, M., 1962
 Kanashiro, C. A., 7913
 Kanazawa, S., 4547
 Kandasamy, K., 1059, 1712
 Kaneko, C., 2762
 Kanerva, A., 847
 Kanety, H., 2470
 Kaneuchi, M., 3101, 3913
 Kang, D., 3729
 Kang, H. J., 2188
 Kang, H.-Y., 4888, 7106
 Kang, J. Y., 1101
 Kang, K., 5203
 Kang, M.-J., 7068
 Kang, T., 4842
 Kankova, K., 8827
 Kannan, K., 5352
 Kannan, R., 4082
 Kannengiesser, C., 3061
 Kanomata, N., 2096
 Kantoff, P. W., 4781
 Kanzaki, N., 149
 Kanzawa, T., 2103
 Kaplan, R., 1475
 Kapoor, V., 7845
 Karacay, H., 354
 Karashima, T., 4017
 Kardias, S. L. R., 2913
 Kargman, S., 586
 Karhu, A., 154
 Karhu, R., 8861
 Kari, C., 1
 Karim, B. O., 8188
 Karin, M., 7689
 Karjalainen, A., 8623
 Karlan, B. Y., 196, 1413
 Karlsson, A., 6909
 Kartvelishvili, Y., 1657
 Kasahara, A., 6282
 Kasai, M., 4927
 Kasaoka, T., 119
 Kashfi, K., 7613
 Kashuba, V., 404
 Kasperbauer, J. L., 6501
 Kassan, H., 4275
 Kassaei, K., 3966
 Kassiss, J., 5629
 Kassner, A., 5838
 Kast, W. M., 3478
 Kastens, E., 4389
 Kasuya, Y., 7876
 Katagiri, T., 7038
 Kataja, V., 2610
 Kataoka, H., 5785, 8674
 Kataoka, K., 8977
 Katayama, K., 4420
 Katayama, M., 222
 Kath, J. C., 4450
 Kato, J., 8948
 Kato, K., 1555
 Kato, M., 801
 Kato, T., 3043, 4407
 Kato, Y., 8977
 Katoh, F., 6942
 Katoh, H., 1555
 Katsaros, D., 807, 2223, 3403, 4225, 9032
 Katsuki, M., 2404
 Katsuoka, Y., 8090
 Kattan, M. W., 4662, 5874
 Katz, D. R., 5143
 Katz, M. H., 5521
 Katze, M. G., 859
 Kaucic, K., 7270
 Kaufman-Francis, K., 2470
 Kaufmann, M., 5329
 Kaul, S., 1359
 Kauppinen, R. A., 3195, 7571
 Kaur, A. P., 455
 Kaur, G., 2812
 Kaushal, A., 3413, 8984
 Kawabe, A., 1470
 Kawabe, T., 8132
 Kawaguchi, M., 3370
 Kawaguchi, N., 4253
 Kawai, M., 7861
 Kawai, N., 6726
 Kawai, Y., 2688
 Kawakami, K., 6004
 Kawakami, T., 8132
 Kawakami, Y., 1262, 2688, 5564
 Kawamori, T., 7704
 Kawamoto, J.-k., 5281
 Kawamoto, S., 271
 Kawano, K., 2829, 6282
 Kawano, S., 6726
 Kawano, Y., 6791
 Kawarada, Y., 1555
 Kawasaki, H., 119, 6809
 Kay, L. S., 8014
 Kay, R. A., 8827
 Kazanietz, M. G., 2284
 Kazansky, A. V., 8757
 Kazmin, D., 8029
 Ke, S., 7870
 Kee, K., 3619
 Keezer, S. M., 6405
 Kehlen, A., 8500
 Keilholz, U., 3483, 5582
 Keisari, Y., 8241
 Keitz, B., 6076
 Kejian, Z., 6469
 Keller, E. T., 7883
 Keller, J. A., 214
 Kelley, K. M. M., 2820
 Kelley, M. R., 549, 608
 Kelling, J., 2794
 Kellum, M. J., 6424
 Kelly, B., 1138, 2330
 Kelly, C. R., 586
 Kelly, D. L., 5011
 Kelly, T., 8749
 Kelly, V. P., 4287
 Kelton, K. R., 5636
 Kemp, P. R., 2610
 Kench, J. G., 4196
 Kennedy, K. B., 4829
 Kennedy, R., 3281
 Kennedy, R. C., 1040
 Kennedy, R. D., 6221
 Kennedy, W., 7652
 Kenney, M. E., 5194
 Kenter, G., 636
 Kenyon, L. C., 250
 Kerbel, R. S., 4342
 Kern, S. E., 994, 2585, 6999, 8614
 Kernohan, N. M., 4656
 Keshelava, N., 1520
 Kessler, O., 1657
 Kessler, T., 7241
 Kettunen, A. S. L., 5136
 Kettunen, H. L., 5136
 Kettunen, M. I., 3195, 7571
 Keum, Y.-S., 7520
 Khabie, N., 2596
 Khafizova, G., 1838
 Khaled, G., 3567
 Khan, N., 1192
 Khare, S., 3517
 Khatib, A.-M., 1458
 Khatua, S., 1865
 Khavari, P. A., 319
 Khawli, L. A., 5046, 8384
 Khin, E. E., 2278
 Kho, Y.-H., 3430
 Khoo, S. K., 4583
 Khuri, F., 4796
 Kibel, A. S., 2033
 Kiehlhorn, E., 8103
 Kienast, J., 7241
 Kiener, P. A., 7907
 Kiessling, F., 8264
 Kiessling, R., 8006
 Kifle, G., 7907
 Kiguchi, K., 4819
 Kijima, T., 6272
 Kikkawa, F., 2278
 Kikuchi, E., 107
 Kikuchi, T., 7038, 8606
 Kilger, E., 2982
 Kim, A., 2425
 Kim, B., 8248
 Kim, B.-R., 7520
 Kim, C.-H., 3453
 Kim, C.-S., 760
 Kim, D., 3268
 Kim, D. S., 6458
 Kim, D.-H., 3743, 6206
 Kim, D.-M., 621
 Kim, G., 9016
 Kim, H., 2188, 2188, 3743, 6135
 Kim, H. O., 2188
 Kim, H. S., 6458
 Kim, H.-R., 7068
 Kim, H.-R. C., 5454, 8302
 Kim, J., 386, 5496
 Kim, J. H., 7497
 Kim, J. J., 2188
 Kim, J. S., 3743, 6206, 8656
 Kim, K., 1789, 7384
 Kim, K. K., 7247
 Kim, K. S., 6458
 Kim, K.-C., 7619

- Kim, K.-Y., 4648
 Kim, L. S., 1345
 Kim, M., 7694
 Kim, M. H., 621
 Kim, M. S., 7291
 Kim, M.-S., 5454, 8700
 Kim, M.-Y., 3247
 Kim, N.-G., 2188
 Kim, S., 60, 4792, 5243, 8248
 Kim, S. I., 6458
 Kim, S. J., 2940
 Kim, S.-S., 8248
 Kim, S.-Y., 7384
 Kim, Y., 1242
 Kim, Y. J., 7247
 Kim, Y.-H., 3430
 Kim, Y.-J., 1583, 4648
 Kim, Y.-S., 8248
 Kimura, A., 6726
 Kimura, E. T., 1454
 Kimura, M., 2762
 Kinch, M. S., 3425, 4481, 7907
 King, B. L., 1445
 King, D. J., 5526
 King, P. H., 4181
 King, R. S., 8122
 Kinoshita, A., 2688
 Kinoshita, H., 4407
 Kinoshita, Y., 3546
 Kinsella, T. J., 838, 3049, 5490
 Kinzler, K. W., 5234, 8578
 Kinzy, T. G., 6894
 Kipling, D., 4854
 Kipps, T. J., 4128
 Kircher, M. F., 6838, 8122
 Kirkels, W. J., 7674
 Kirkin, V., 713
 Kirkpatrick, J. P., 6162
 Kirkwood, J. M., 6506
 Kirn, D. H., 1317, 8556
 Kirpotin, D. B., 3154
 Kirsch, I. R., 1000, 8634
 Kirschenlohr, H. L., 2610
 Kirschner, L. S., 5308
 Kishi, M., 737
 Kishi, T., 2771
 Kiesel, D. G., 2020
 Kisselev, P., 8062
 Kitada, S., 1242, 8118, 8138
 Kitada, T., 6282
 Kitagawa, M., 4607
 Kitahama-Shiseki, M., 2373
 Kitajima, S., 5011
 Kitamura, T., 4516, 6090
 Kitayama, J., 1706
 Kitayama, T., 6894
 Kitchen, S. M., 8330
 Kitchener, H. C., 400, 6032
 Kittas, C., 2977, 7185
 Kittrell, F. S., 1067, 6140
 Kiyama, S., 3575, 8090
 Klages, N., 534
 Kleihues, P., 6643
 Klein, E. A., 6795
 Klein, G., 404, 8656
 Klein, R. S., 527
 Klein-Cabral, M., 8051
 Kleinman, H. K., 5060, 8821
 Klein-Szanto, A., 2172, 4997, 5978
 Klenke, F., 8890
 Klijn, J. G. M., 337, 8153
 Klimczak, E., 4310
 Kline, K., 2483
 Klinge, D. M., 4842, 7089
 Klingebiel, T., 1508
 Klomp, D. W. J., 7609
 Klug, S. J., 7515
 Kluger, H. M., 8103
 Kluij, L., 1449
 Knapp, R., 4583
 Knauf, J. A., 1454
 Knauth, E., 7301
 Knowles, H. J., 1764
 Knowles, M. A., 7652, 7657
 Knudsen, K. E., 4903
 Ko, J.-H., 3453
 Ko, T. C., 3340, 4731
 Kobayashi, G., 394
 Kobayashi, H., 271, 6613
 Kobayashi, M., 8338
 Kobayashi, T., 60, 2477
 Koble, J. J., 1860
 Koch, P., 3904
 Kochi, M., 6962
 Kodama, J., 7834
 Kodama, S., 936
 Kodama, T., 8629
 Koelbl, H., 3066
 Koeneman, K. S., 5917
 Koeppen, H., 1020
 Koga, M., 2829
 Kogai, T., 5065
 Kogan, S., 5257
 Kogner, P., 8006
 Koh, E., 2042, 5446
 Koh, V., 2716
 Koh, W.-P., 573
 Kohgo, T., 8338
 Köhler, S., 3234
 Kohlgraf, K. G., 5011
 Kohlhausen, G., 7291, 7428, 8203
 Kohn, E. A., 31
 Kohn, K. W., 1000, 2782, 7428
 Kohn, K., 3729, 8592
 Kohn, S., 2506
 Kohn, T., 5091
 Koide, Y., 7920
 Koike, K., 854
 Koistinen, R., 6258
 Kojima, T., 8606
 Kolesnick, R., 4232, 4338
 Kölgen, W., 4101
 Kolls, J. K., 7936
 Kolluri, S. K., 3531
 Kolman, B. D., 5808
 Kolodner, R. D., 154
 Kolodney, M. S., 5669
 Colonel, L. N., 6984
 Komarova, N. L., 6635
 Komazawa, N., 674
 Komori, K., 6942
 Komori, M., 6726
 Komori, T., 5357
 Komoro, K., 4287
 Komurasaki, T., 1743
 Kon, O. L., 3309
 Kondo, E., 3302
 Kondo, M., 7791
 Kondo, S., 1555, 2103
 Kondo, T., 895, 4641
 Kondo, Y., 2103
 Kong, A.-N. T., 7520
 Kong, D., 2812
 Konishi, C., 2404
 Konishi, N., 737
 Kononen, J., 2244
 Konopleva, M., 5926
 Kontani, K., 7920
 Kontny, U., 1122
 Koo, H., 8912
 Koo, H.-M., 8330
 Koo, S.-Y., 621
 Koo, T. H., 4648
 Kopeček, J., 7876
 Kopečková, P., 7876
 Kopelovich, L., 923, 1914, 7613
 Korkola, J. E., 2872, 7167
 Korn, W. M., 2088
 Kormeyer, S. J., 1712, 8664
 Kosanke, S. D., 2425
 Kosaras, B., 5335
 Kosmatopoulos, K., 8476
 Kosmehl, H., 3202
 Kostakis, P., 5438
 Kostourou, V., 4960
 Kotchetkov, R., 1508
 Kottenko, S., 5105
 Kothare, M., 8922
 Kottke, T., 3173
 Kou, K., 7301
 Koukourakis, M. I., 5376
 Kouros-Mehr, H., 1000
 Koutcher, J. A., 9042
 Kouvarakis, M. A., 2977
 Kouyoumdjian, J. C., 8108
 Kovacs, G., 455
 Kovacs, K., 2251
 Kovalchuk, A. L., 8656
 Kow, Y. W., 549
 Kowalewski, J., 4351, 4899
 Koyanagi, S., 7277
 Kozlowski, J. M., 4698
 Kraan, J., 8153
 Kraft, A., 8079
 Kramar, A., 4809
 Kramer, D. L., 3619
 Kramer, J., 7241
 Krammer, P. H., 3112
 Krams, S. M., 4472
 Krasnykh, V., 1262
 Krassenstein, R., 8695
 Kratz, F., 4062
 Kraus, J., 8578
 Krause, U., 2864
 Kreiss, M., 8212
 Krempien, R., 3755
 Krieg, A. M., 394
 Krimpenfort, P., 7042
 Krishna, U. S., 951
 Krishnamachary, B., 1138
 Krishnan, J., 713
 Krishnan, L., 2526
 Krishnan, V., 6056
 Kriwacki, R. W., 3840
 Krix, M., 8264, 8890
 Kroemer, G., 541, 8233
 Kroemer, R. T., 8233
 Kroeze-Jansema, K., 8153
 Krohn, R., 8414
 Kroiss, R., 3325
 Kromhout, D., 1249
 Kronblad, A., 1441
 Krooshoop, D. J. E. B., 12
 Krop, I., 2024
 Krouse, R. S., 3891
 Kruger, E. A., 3189
 Kruh, G. D., 4048
 Krukutis, R., 7845
 Krumm, K., 8763
 Krupitza, G., 5745
 Kruse, E., 2578
 Kruskal, J. B., 6327
 Kruttsch, H. C., 6405
 Kruyt, F. A. E., 6566
 Krynetskaia, N. F., 100
 Krynetski, E. Y., 100
 Krysan, K., 766
 Krysiak, E., 4533
 Krystal, G., 1822, 2118
 Kubicka, S., 3181
 Kubonishi, I., 304
 Kucia, M., 7926
 Kudo, D., 1676
 Kudoh, S., 4641
 Kufe, D., 5551
 Kuhajda, F. P., 7330
 Kühnel, F., 3181
 Kuick, R., 2913
 Kuijpers, M. J. E., 2322
 Kulangara, K., 534
 Kumar, C. C., 6697
 Kumar, R., 2977
 Kumar-Sinha, C., 132
 Kume, A., 5091
 Kummer, J. A., 1727
 Kung, H. F., 7724
 Kunisato, A., 4516
 Kuo, C., 441
 Kuo, H.-P., 7630
 Kuo, M.-L., 1046
 Kuo, W.-L., 2872
 Kupfer, D., 7490
 Küppers, R., 1644
 Kuramoto, H., 7834
 Kuramoto, Y., 7277
 Kuratsu, J.-i., 6962
 Kuriyama, H., 1589
 Kuriyama, N., 1589
 Kurman, R. J., 7215
 Kuroda, K., 107
 Kuroda, N., 455
 Kurokawa, T., 1555
 Kuroki, T., 878, 2404, 3352, 3724
 Kurt, R. A., 1860
 Kuruganti, P., 7345
 Kusaka, H., 3931
 Kusaka, M., 149, 5622
 Kusaka, N., 7853
 Kusano, M., 8606
 Kusmartsev, S., 4441
 Kussie, P., 8749, 8912
 Küsters, B., 5408
 Kuzmin, I., 1888
 Kuzushita, N., 4739
 Kvam, E., 1464
 Kwabi-Addo, B., 5754
 Kwappenberg, K. M. C., 636
 Kwiatkowski, D. J., 5173
 Kwok, W. W., 3675
 Kwon, I., 2194
 Kwon, T. K., 3430
 Kwon, Y. M., 6206
 Kwong, E., 586
 Kyle, A. H., 5707
 Kyo, S., 8338

L

Laakso, N., 3716
 Lababidi, S., 1000, 5243, 8634
 Labato, M. I., 6370
 Labelle, Y., 449
 Labrecque, P., 7679
 Labrie, C., 277
 Labrie, F., 6442
 Laco, G., 7428

- Lacy, E. K., 5838
 Ladanyi, M., 449, 1759
 Ladd, C., 1351, 1602
 Lade, S., 2569
 Ladenson, P. W., 2312, 2316
 Ladisch, S., 3654, 7270
 Ladjimi, M., 3682
 Ladner, R. D., 2898
 Laflamme, C., 449
 LaFleur, B., 1748, 1865
 Lahaye, J-B., 8108
 Lahortiga, I., 3079
 Lahti-Domenici, J., 2024
 Lai, B., 1776
 Lai, Y-J., 8680
 Laiho, M., 5005
 Laine, J-P., 7136
 Laing, M. A., 4920
 Lajos, G., 7674
 Lake, R. A., 4490
 Lakka, S. S., 2454
 Lal, A., 4773
 Lally, C. A., 6556
 Lam, A., 296
 Lam, E. C., 586
 Lam, J. T., 1262
 Lam, M., 5194
 Lam, S. K., 7724
 Lam, V., 2802
 Lam, W. L., 8582
 Lamarre, L., 4588
 Lambert, J. R., 5879
 Lambert, P. F., 4862, 8173
 Lamendola, D. E., 2200
 Lance, P., 522
 Land, S., 3539
 Landazuri, M. O., 6877
 Landberg, G., 1441, 1737
 Landi, S., 3560
 Landini, M. P., 7256
 Landuzzi, L., 2728
 Lane, W. S., 2665
 Laneville, P., 4895
 Lange, E. M., 3486
 Langenbach, R., 4872
 Langermann, S., 7907
 Langford, C. F., 3940
 Langley, R. R., 2971
 Langner, J., 8500
 Lanham, I. S., 250
 Lanson, N. A., Jr., 7936
 Lanza, E., 1752
 Lanza, G. M., 5838
 Lanzavecchia, A., 3005
 Lanzen, J., 4705
 Laouari, D., 7284
 Lapillonne, H., 5926
 Lapointe, E., 7679
 Lapointe, R., 2836
 Laposa, R. R., 3909
 Lapushin, R., 1073
 Laroocca, L. M., 3750
 LaRose, J., 2782
 Laquet, E., 541
 Larrayoz, M. J., 3079
 Larriba, M. J., 7799
 Larsen, M., 5859
 LaRue, D. M., 1914
 Larue, L., 2172
 LaRusch, J., 1138
 Lassalle, P., 6084
 Lassen, C., 1202
 Lassus, H., 6258, 7591
 Laterra, J., 2990
 Latham, V. M., Jr., 7410
 Lathion, S., 8687
 Latif, F., 1054, 5344
 Latif, T., 4602
 Lattime, E. C., 2150, 6956
 Lau, C. C., 3866
 Lau, C. P-Y., 3121
 Lau, N., 1106
 Laud, K., 3061
 Laudet, V., 7545
 Lauer, U. M., 2369
 Lauffenburger, D., 1130, 4632
 Launonen, V., 154
 LaVallee, T. M., 468
 Laverge, E., 7468
 Lavia, P., 1430
 Lavie, G., 8241
 Lavigne, J. A., 1752
 LaVoie, E. J., 8400
 Lavon, I., 25
 Law, D. A., 6387
 Law, G. R., 4327
 Law, M. E., 5266
 Lawlor, C., 1865
 Lawrence, E., 1568
 Lawrence, T. S., 658
 Laxmi, Y. R. S., 4402
 Laye, J., 7657
 Lazaro, C. A., 859
 Lazo, J. S., 771
 Le, K. H., 4552
 Le, P., 7345
 Le, X., 3855
 Leal, R. M., 1538, 3211
 Lebailly, P., 1722
 LeBaron, R. G., 4786
 Le Bas, J-F., 3221
 Lebecque, P., 6607
 Lebedeva, I. V., 8138
 Lebioda, A. M., 5060
 Lecerf, L., 8108
 Lechpammer, M., 4781
 Lécluse, Y., 7475
 Le Dai, J., 4724
 Ledbetter, J. A., 3695
 Leder, G., 4945, 6265
 Ledoux, S., 7284
 Lee, A. J., 6532
 Lee, A. V., 5203
 Lee, B. D., 5962
 Lee, C., 3646, 6914, 8248
 Lee, C. H., 3309
 Lee, C-C. R., 2216, 2351
 Lee, C-T., 6432
 Lee, D. H., 4648
 Lee, E-J., 5454
 Lee, H. W., 1093
 Lee, H-J., 3430
 Lee, H-P., 573
 Lee, H-W., 742, 3395
 Lee, H-Y., 4796
 Lee, I., 3356, 8248
 Lee, I. K., 3430
 Lee, J., 621, 3447, 4792, 5723, 7760, 8877
 Lee, J. H., 6885, 7247
 Lee, J. J., 4648
 Lee, J. K., 5243
 Lee, J. M-F., 7646
 Lee, J. W., 22
 Lee, J-E., 6135
 Lee, J-H., 4648
 Lee, K., 8248
 Lee, K. S., 7384
 Lee, K-H., 8700
 Lee, M. P., 655, 6996
 Lee, M-G., 7068
 Lee, N., 8726
 Lee, P. W. K., 348, 3162
 Lee, R. M., 1153
 Lee, S., 8248
 Lee, S. B., 5218
 Lee, S. H., 3145
 Lee, S. J., 1093, 4648
 Lee, S. K., 6206
 Lee, S-D., 6229
 Lee, S-G., 8248
 Lee, S-H., 3430, 3430
 Lee, S-S., 1093
 Lee, T-C., 6680
 Lee, W. M. F., 742, 8073
 Lee, W-H., 2589
 Lee, W-P., 6229
 Lee, Y., 2802, 5428, 8248
 Lee, Y. H., 4648
 Lee, Y-C., 3453
 Lee, Y-S., 7051
 Leeb-Lundberg, L. M. F., 2037
 Lee-Kwon, W., 2172
 Leemans, C. R., 1727
 Leemons, C. R., 5167
 Leenders, W. P. J., 5408
 Leggatt, G. R., 3058
 Leggett, B., 4577
 Legnini, D., 1776
 Lehr, H-A., 7221
 Lehtimäki, K. K., 3195, 7571
 Lei, H., 5299
 Lei, K. I. K., 2028
 Leibel, S. A., 3268
 Leisser, C., 5745
 Leithäuser, F., 2681
 Leitzmann, M. F., 8542
 Lejeune, F. J., 5712
 Lele, S., 6076
 Leman, E. S., 4927
 Lemieux, B., 7679
 Leminen, A., 6258
 Lemmon, M., 6900
 Lemon, W. J., 3317
 Lemonnier, F. A., 8476
 Lendeckel, U., 8500
 Lengauer, C., 8578
 Lenoir, G. M., 3061
 Lenormand, J-L., 3701
 Lenz, H-J., 2898
 Lenz-Bauer, C., 3904
 Lenzi, M. L., 527
 Leo, E., 4507
 Leodolter, S., 3066
 Leonard, J., 1906
 Leonard, W. J., 9016
 Leone, B. E., 7451
 Leone, M., 8118
 Leong, A., 6658
 Leong, S. H., 3309
 Le Pera, I., 882
 Lerch, M. M., 6265
 Lerman, C. E., 5649
 Lerman, M. I., 404, 1888
 Lerner, A., 6802
 Lerner, M. R., 5251
 LeRoith, D., 4384
 Leskow, F. C., 2284
 Leslie, A., 4656
 Lesniewski, R., 7861
 Lesser, M., 8791
 Lesterhuis, W. J., 12
 Letarte, M., 2416
 Letsch, A., 5582
 Leu, Y-W., 2164, 6110, 6178
 Leung, B. M., 7081
 Leung, S. Y., 4878
 Leung, S-F., 2028
 Levi, A., 3750
 Levick, J. R., 3969
 Levin, A. M., 2913
 Levine, L., 3495
 Levitskaya, J., 8006
 Levitsky, H. I., 9007
 Levitsky, V., 8006
 LeVoyer, T., 4594
 Levy, J., 1325
 Lewis, A. M., Jr., 3435
 Lewis, J. S., 5496
 Lewis, M. R., 6864
 Lewis, R. C., 8549
 Lewis, V., 6847
 Leygue, E., 1954
 Li, B., 6166, 7443
 Li, C., 4781, 7870
 Li, G., 756, 6174, 6488, 7122
 Li, G. C., 3268
 Li, H., 1262, 2569
 Li, J., 600, 2716, 8384
 Li, K., 3593, 4547
 Li, L., 2733, 3073, 3413, 7384
 Li, M., 6116, 6791
 Li, N., 8103
 Li, Q., 1254, 2546, 8466
 Li, R., 6244
 Li, S., 658, 2624, 3931, 5114, 8377
 Li, S-L., 627
 Li, S-P., 3473
 Li, T., 1900
 Li, T-K., 8400
 Li, W., 1780, 6395
 Li, X., 4037
 Li, X-M., 4239
 Li, X-N., 3866
 Li, Y., 1527, 7530
 Li, Y. F., 6735
 Li, Y. M., 7630
 Li, Y-Q., 5950
 Li, Z., 6488, 7689
 Lian, F., 3138
 Lian, J. B., 2631, 5357
 Liang, C., 5462, 7356
 Liang, G., 3987
 Liang, X-J., 3084, 5909
 Liang, Y., 923
 Liang, Z., 1470
 Liao, W. S-L., 4315
 Liao, L. M., 8487
 Libermann, T. A., 2206
 Libutti, S. K., 6405, 8022
 Lich, J. D., 6928
 Lichter, P., 1179
 Lichtman, A. H., 6838
 Lieber, M. M., 7840
 Lieberfarb, M. E., 4781
 Lieberman, H. B., 5291
 Lien, H-C., 6537
 Liénard, D., 5712
 Lichtenberg, M. J. L., 8153
 Lim, D., 3309
 Limoli, C. L., 3107
 Lin, C-T., 2393
 Lin, C-Y., 1101
 Lin, D., 3987, 8057
 Lin, F., 3531
 Lin, H-H., 6537

- Lin, H-K., 7106
 Lin, J., 484
 Lin, L., 4136
 Lin, M., 4781
 Lin, M. C. M., 7724
 Lin, S-H., 386
 Lin, S-Y., 3593
 Lin, T. K., 4136
 Lin, W., 6501
 Lin, W-J., 7106
 Lin, X., 498, 3413, 5230
 Lin, Y., 642
 Lin, Y-M., 6116
 Linardic, C. M., 8451
 Lindblom, A., 1894, 2024
 Lindemann, D., 8212
 Lindholm, P. F., 1359
 Lindmark, G., 1894
 Lindner, H., 7507
 Lindvall, C., 1743
 Ling, C. C., 3268
 Ling, L. L., 5793
 Ling, M., 2393
 Ling, X., 298
 Lingen, M. W., 555
 Lingner, J., 689
 Link, C. J., Jr., 987
 Linke, S. P., 2596
 Linnekin, D., 4412
 Liotta, L. A., 2042, 5243, 5446
 Lippman, M. E., 132
 Lippman, S. M., 1470, 5649
 Lipscomb, E. A., 5230
 Lipson, K. E., 3755, 7345, 8890
 Lipton, L., 7595
 Lissauer, D., 2338
 Liston, B. W., 2399
 Litman, E., 6716
 Little, J. B., 7128
 Litwack, G., 172, 4521
 Liu, A., 7606
 Liu, A. A., 8400
 Liu, B., 847, 2425
 Liu, C., 2802, 2957, 3138
 Liu, D., 1684
 Liu, E., 1000
 Liu, F., 600
 Liu, G., 3317
 Liu, H., 7490
 Liu, H-X., 1894
 Liu, J., 298, 664, 1153, 2569, 3899, 5513
 Liu, J. C., 2164, 6110, 6178
 Liu, J. O., 6135
 Liu, J-q., 6051
 Liu, J-Y., 600
 Liu, K. J., 7825
 Liu, L., 1888, 2665
 Liu, L. F., 8400
 Liu, L-T., 3069
 Liu, M. Y., 2675
 Liu, N., 2425
 Liu, S., 236, 6299, 8323
 Liu, T., 1894, 5034
 Liu, T. F., 1834
 Liu, W., 2079, 3370, 3632
 Liu, X., 980, 6583, 7760
 Liu, Y., 3995, 6051
 Liu, Y. E., 3899
 Liu, Z., 4450
 Lively, J. C., 8312
 Ljungman, M., 6935
 Llombart-Cussac, A., 6523
 Lloyd, R. V., 2251
 Lo, H. S., 655
 Lo, Y. M. D., 2028
 Loar, A., 6096
 Lobb, R. R., 2020
 Lobe, C. G., 5320
 Loda, M., 4781
 Lodeiro, G., 2024
 Loewen, G. M., 1806
 Logan, T., 6069
 Loganzo, F., 1838
 Logsdon, C. D., 2649
 Loh, T., 5490
 Lohmann, D. R., 2578
 Löhr, K., 3904
 Löhr, M., 6265
 Lohse, C. M., 7638
 Loison, G., 4809
 Lokeswar, V. B., 2638
 Lokshin, A., 8768
 Lollini, P-L., 2158, 2518, 2728
 Lombardo, C., 2535, 6948
 London, W. T., 4594
 Long, B. J., 8037
 Longhi, R., 7400, 8481
 Longley, D. B., 4602
 Longnecker, D. S., 2016
 Lonser, R. R., 7051
 Looijenga, L. H. J., 2244, 7674
 Look, M. P., 337
 Lopez De Cicco, R., 4997
 Lopez-Guajardo, C. C., 5808
 Lopez-Lazaro, L., 5902
 Lorang, D., 8022
 Lotan, R., 1999, 3826, 4796
 Lotem, M., 6340
 Lou, M. A., 2440
 Lou, P., 7861
 Lou, S., 1860
 Lou, Y., 9016
 Lou, Y-Y., 600
 Loughran, T., 8523
 Louhelainen, J., 7657
 Louis, D. N., 413, 1602
 Lovat, P. E., 3860, 7310
 Love, V., 6838
 Lovering, A. L., 5532
 Lowe, S. W., 5703
 Lowe, X. R., 44
 Lowell, A. M., 7410
 Löwer, R., 8735
 Lowther, W., 2179
 Lozano, G., 8664
 Lozano, J., 4232
 Lozonschi, I., 4990
 Lu, A. P., 664, 3899
 Lu, D., 8912
 Lu, F., 7056
 Lu, H., 7563
 Lu, J., 256, 6413
 Lu, K. H., 6195
 Lu, K. P., 6244
 Lu, M., 3425, 7497
 Lu, S. L., 1568
 Lu, W., 1345, 3987
 Lu, Y., 600, 7883
 Luan, Z., 3775
 Luben, R. N., 2610
 Lubet, R. A., 793, 4389
 Luboldt, H., 4107
 Lucas, J., 375
 Lucci, J. A., III, 3495
 Luceri, C., 2388
 Lucia, M. S., 5879
 Lucini, V., 2499
 Ludlow, J., 4583
 Ludwig, D. L., 8912
 Lueth, M., 3866
 Luettich, K., 1475
 Luh, F., 6583
 Luk, P., 586
 Luker, G. D., 1780
 Lukes, L., 2179
 Luksch, R., 6948
 Lukyanov, A., 6327
 Lum, C. T., 7724
 Lundberg, M., 6909
 Lundin, J., 5005
 Lundin, M., 5005
 Lunedei, V., 787
 Lunn, J. A., 2379
 Luo, J., 642, 7365
 Luo, J-H., 4632
 Luo, L., 6166
 Luo, L-Y., 807
 Luo, R. Z., 4174
 Luo, W., 386, 3356
 Luo, Y., 1280
 Luo, Z., 6802
 Luoh, S-M., 5781
 Luong, Q. T., 505
 Lush, R., 4441
 Lustgarten, J., 5895
 Luthra, S. K., 2409, 3791
 Lutterbaugh, J. D., 1568
 Lutz, S. Z., 8996
 Luukkaa, M., 1920, 8556
 Luu-The, V., 6442
 Luzzio, F. A., 3189
 Lv, P., 6488
 Ly, C., 5716
 Lydiatt, W. M., 7769
 Lydon, J., 1067
 Lynch, C., 6847
 Lynch, D. K., 4322
 Lynch, M., 4602
 Lynch, P. M., 4805
 Lynch, R., 6056
 Lyons, J. F., 196
 Lyons, S. K., 7042
 Lyu, M-S., 2179

M

- Ma, G., 298
 Ma, J., 5114
 Ma, L., 7575
 Ma, P., 5462
 Ma, P. C., 6272
 Ma, W., 5320
 Ma, W-Y., 4396
 Maass, C., 5408
 Maccalli, C., 6735
 MacDonald, D. G., 458
 MacDonald, T. J., 1865
 Machemer, T., 4003
 Machluf, M., 8345
 Macino, B., 2158
 Mack, B., 6478
 Mack, D., 1568
 Mack, D. H., 4196
 Mackall, C. L., 1122
 MacKeigan, J. P., 5095, 6928
 Maclean, K. H., 140
 MacLeod, R. A. F., 5329
 MacLeod, V., 8749
 Macpherson, J. S., 8443
 MacRobert, A. J., 1818
 Macura, S. I., 2462
 Madachi, A., 4253
 Madari, H., 1214
 Madden, J., 2127
 Madden, J. F., 2037
 Madden, S. L., 5866, 8939
 Madden, T., 5926
 Maeda, H., 3567
 Maeda, Y., 854
 Maemura, K., 8090
 Maeta, H., 7581
 Maeurer, M. J., 1560
 Maggiano, N., 3750
 Maggiorella, L., 2513
 Magin-Lachmann, C., 8735
 Magnani, M., 4028
 Maguire, P., 2024
 Mah, K., 1242
 Maher, E. R., 1054, 5344
 Maher, G. W., 5320
 Mahloogi, H., 4997
 Mahmood, U., 8122
 Maho, M., 7468
 Mai, V., 1752
 Mailänder, V., 5582
 Maillere, B., 6506
 Maitra, A., 994, 3735, 4158, 7032, 8614
 Maity, A., 236
 Maity, S. N., 8167
 Maizel, A. L., 6772
 Maj, J. G., 4338
 Major, S. M., 5243
 Majumdar, S., 4375
 Mak, T. W., 674
 Makarem, M., 4299
 Makino, K., 6962
 Makonnen, S., 8073
 Malinowski, R., 2194
 Malkinson, A. M., 3317, 5889
 Mallamo, J., 5978
 Maloney, E. K., 5073
 Malott, C., 7270
 Malpica, A., 1999
 Malquori, L., 1430
 Malugin, A., 7876
 Malumbres, M., 1615
 Malur, S., 3066
 Mami-Chouaib, F., 3682
 Mamot, C., 3154
 Mamoune, A., 4632
 Man, H-W., 593, 8073
 Manabe, M., 674
 Mancini, B., 342
 Mancini, R., 4244
 Mancuso, A., 8813
 Mancuso, M. T., 1871
 Mancuso, P., 4342
 Mandarino, A., 5829
 Mandel, M., 8241
 Mandelboim, O., 6340
 Mandelin, E., 6258
 Mandic, M., 6506
 Mandir, N., 3819
 Mandola, M. V., 2898
 Manenti, L., 5224
 Mangiacasale, R., 1430
 Mangiarotti, F., 696
 Mani, D. R., 1602
 Manjeshwar, S., 5251
 Manjili, M. H., 2553
 Mannermay, A., 2610
 Manning, S., 2256
 Manns, M., 3181
 Manor, D., 4426

- Manser, E., 2716
 Mansour, A. M., 4062
 Mantei, K., 2347
 Mantovani, V., 787
 Mantyh, P., 6847
 Manzanares, I., 7392
 Mao, H., 4204
 Mao, J.-H., 4849
 Mao, X., 7979
 Mao, Y., 1527, 6488
 March, T. H., 7089
 Marchal, J., 1405
 Marchan, R., 929
 Marchesi, F., 7451
 Marchini, S., 5224
 Marchionni, M., 4281
 Marcinkiewicz, C., 2020
 Marcuello, E., 7206
 Margaryan, N. V., 5381
 Margolis, R. U., 1192
 Mariadason, J. M., 5401, 8791
 Mariani-Costantini, R., 342
 Mariatos, G., 7185
 Marimpietri, D., 86, 7400
 Marini, F. C., III, 5213
 Marinov, A., 1490
 Maris, J. M., 1631, 7861
 Marjanovic, N., 2067
 Mark, G. P., 214
 Mark, W., 4232
 Markovina, S., 8984
 Markowitz, S., 994, 1568
 Marks, J. D., 3154
 Marks, J. W., III, 3995
 Maron, D. J., 5299
 Marques, M. M., 5999
 Marra, G., 8113, 8158
 Marriott, J. B., 593
 Marsh, S., 6170
 Marshall, B., 6069
 Marshall, L. T., 6252
 Marshall, T. W., 4903
 Marshall, V. R., 4786
 Marsters, J., 1020
 Martayan, A., 4119
 Martel, C., 6442
 Martelli, F., 7410
 Martello, L. A., 1207
 Märtén, A., 8962
 Marth, C., 7507, 7641
 Martin, A.-M., 8051
 Martin, E. A., 8461
 Martin, F., 2145
 Martin, K. J., 290
 Martín, P., 8226
 Martinelli, G. N., 787
 Martinelli, M., 1534, 3539
 Martínez, M. E., 3891
 Martínez, N., 8226
 Martínez, O., 8768
 Martínez, O. M., 4472
 Martínez, S., 6149
 Martínez-Climent, J. A., 8226
 Martín-Puig, S., 6877
 Maruki, H., 424
 Marx, A., 3708
 Marx, M. A., 7301
 Marx, S. J., 8022
 Masala, G., 342
 Mashima, T., 831, 6568
 Mason, K. A., 3263
 Mason, R. J., 5889
 Mason, T. L., 2425
 Massie, C. E., 8648
 Massion, P. P., 7113
 Massobrio, M., 807
 Masson, R., 5844
 Massoudi, N., 2606
 Masterson, A. J., 4101
 Masuda, H., 8090
 Masuho, Y., 6651
 Masumori, N., 2256
 Mateo-Lozano, S., 6290
 Mathelin, C., 5844
 Mathew, R., 1046
 Mathiesen, B., 4055
 Matias-Guiu, X., 5697
 Matranga, C. B., 7410
 Matrisian, L. M., 6105
 Matsubara, A., 7717
 Matsubayashi, H., 3735, 4158
 Matsuki, H., 8278
 Matsumoto, N., 6158
 Matsumoto, S.-i., 6651
 Matsumoto, T., 4819
 Matsumura, M., 8132
 Matsumura, Y., 8977
 Matsunaga, T., 8948
 Matsushima, M., 5159
 Matsushita, K., 3511
 Matsushita, M., 2688
 Matsushita, T., 5091
 Matsuura, N., 4253
 Matsuyama, A., 3352, 3724
 Matsuyama, S., 7791
 Mattes, M. J., 111
 Mattock, E., 8461
 Mattson, D., 8984
 Matushansky, I., 6363
 Matusik, R. J., 2256
 Matute, R., 2067
 Matyakhina, L., 5308
 Mauceri, H. J., 308
 Maula, S.-M., 1920, 8556, 8558
 Maulik, G., 6272
 Maunakea, A. K., 1000
 Mauriac, L., 6253
 Maurichi, A., 1871, 2535
 Mauro, F. R., 4497
 Maxwell, C. A., 6689
 Maxwell, E., 6697
 Maxwell, G. L., 6
 Maxwell, P. J., 4602
 May, K. F., Jr., 6051
 Mayaud, C., 1405
 Mayer, A., 7634
 Mayer, R. J., 1608
 Mayne, K., 4786
 Mayo, K. H., 382
 Mayo, L. D., 3585
 Mayumi, T., 4420
 Mazo, A., 5544
 Mazurchuk, R., 2477
 Mazuru, D. G., 4082
 Mazzanti, C., 8022
 Mazzi, M., 696
 Mazzon, E., 5829
 McAlhany, S. J., 5859
 McAlister, C., 290
 McBride, B. J., 111
 McBride, S., 2610
 McBride, W. J., 354
 McCarty, M. F., 3370
 McCaul, J. A., 458
 McConkey, C., 2338
 McConkey, D., 760, 7338
 McCord, J. M., 159
 McCormick, F., 2088, 4547
 McDermott, U., 4602
 McDevitt, M. R., 5084
 McDonald, S. S., 4295
 McDonnell, D. P., 8029
 McDonnell, S. K., 5209
 McElgunn, C. J., 1449
 McFadden, J. M., 7330
 McGinn, C. J., 8466
 McGlynn, K. A., 4594
 McGowan, L., 7215
 McGrath, M. S., 72
 McGuffog, L., 8596
 McHowat, J., 5992
 McIntosh, M., 3695
 McIvor, R. S., 1304
 McKeehan, K., 8784
 McKeehan, W. L., 4936, 8784
 McKenna, W. G., 5656, 7443
 McKenzie, P. P., 3840
 McKinnon, P. J., 5428
 McLaughlin, J. L., 5073
 McLaughlin, M. E., 752, 1602
 McLaughlin, S., 2561
 McLellan, D. L., 484
 McLeod, D. G., 4299
 McLeod, H. L., 6170
 McMahon, G., 4009
 McMahon, M., 2088
 McMaster, K. M., 3073
 McMullan, D. J., 4568
 McNulty, A. M., 6056
 McQueen, T., 5926
 McTiernan, A., 6096
 McTyne, N., 8634
 McVey, R. J., 6032
 Mecklin, J.-P., 154
 Meco, D., 5902
 Medghalchi, S. M., 7330
 Medina, D., 1067, 6140
 Medrano, E. E., 6626
 Meerson, A., 7147
 Mehew, J. W., 6666
 Mehrotra, S., 5607
 Meijers, C., 8153
 Meijers-Heijboer, H., 8153
 Meistrich, M. L., 44
 Melief, C. J. M., 636
 Melillo, G., 2812
 Melino, G., 7310
 Mellon, J. K., 484
 Mellor, R. H., 3969
 Melo, J. V., 5716
 Meltzer, P., 5274, 7158
 Meltzer, S. J., 4577
 Ménard, C., 1990
 Menárguez, J., 1814, 8226
 Menashi, S., 7575
 Mendel, D., 4009, 7345
 Mendez, R., 4724
 Mendoza, L., 491
 Mendoza, N., 1020
 Menez, J., 3682
 Meng, A., 5414
 Menigatti, M., 8158
 Menke, A., 6265
 Menko, F. H., 1449
 Menna, P. L., 2284
 Menon, C., 7232
 Menon, S. G., 2109
 Merbs, S. L., 8507
 Merchant, M. S., 1122
 Mercurio, A. M., 5230
 Meredith, M. J., 5636
 Merle, C., 3919
 Merlino, G., 1576
 Meruelo, D., 8241
 Messina, S. A., 8877
 Mestdagt, M., 2658
 Mesters, R. M., 7241
 Metcalfe, J. C., 2610
 Metzinger, D. S., 4067
 Meunier, C., 5420
 Meuwissen, R., 7042
 Meyer, A. M., 5889
 Meyer, F., 8511
 Meyer, L. A., 6864
 Meyer, R., 1927
 Meyermann, R., 7462
 Meyers, D. A., 3486
 Meyers, P., 1759, 9042
 Meyerson, M., 4781
 Meza, J. L., 5011
 Mezzananza, D., 4507
 Mhashikar, A. M., 5105
 Mian, A., 8366
 Miao, H.-Q., 7733, 8749
 Miao, X., 3987, 8057
 Miao, Z.-H., 4527
 Michael, B. D., 8437
 Michaelis, M., 1508
 Michaud, D. S., 8542
 Micheletti, G., 1534
 Michielli, R. A., 4594
 Michiels, A., 5587
 Michigami, T., 5028
 Michl, P., 6265
 Mick, R., 8051
 Miconnet, I., 8476
 Miederer, M., 5084
 Miele, M. E., 432
 Mihalic, K., 2046
 Mihich, E., 3005
 Miki, Y., 2762
 Milan, G., 2158
 Milas, L., 3263
 Mileo, A. M., 1430
 Miller, C., 1927
 Miller, C. T., 4136
 Miller, D. C., 3486
 Miller, E. P., 8648
 Miller, G. J., 5879
 Miller, H. L., 5428, 5879
 Miller, J. C., 6387
 Miller, J. S., 627
 Miller, K. D., 3425
 Miller, L., 1000
 Miller, M., 8022
 Miller, M. A., 394
 Miller, P. E., 4450
 Miller, W. R., 6523
 Miller, W. T., 6395
 Milleron, B., 1405
 Milliat, F., 2513
 Millo, E., 3490, 6144
 Mills, G. B., 1073, 5446
 Milner, J., 4295, 6674
 Milshteyn, N., 1589
 Milysavsky, M., 7147, 8777
 Mimori, K., 6575
 Min, C., 7384
 Min, Y., 6432
 Minami, S., 8948
 Minato, Y., 424
 Minchinton, A. I., 5707
 Minden, M. D., 1242
 Mingzhen, Y., 6469
 Minna, J. D., 5344
 Minotti, M., 2499

- Minowa, O., 4287
 Miotti, S., 696
 Miquel, C., 5738
 Miró, R., 5731
 Mischel, P. S., 2742
 Misk, D. E., 2649, 2913
 Mishima, H. K., 7791
 Mishra, P. K., 2462
 Miska, S., 2596
 Mistry, K., 7530
 Mita, H., 8145, 8606
 Mita, K., 7717
 Mitchell, C. A., 4275
 Mitchell, J. B., 8984
 Mitchell, T. J., 9048
 Mitchell, T. M., 5165
 Mitelman, F., 1202, 3378, 7094
 Mitsdoerffer, M., 7462
 Mitsiades, C., 18, 5850, 6689, 8428
 Mitsiades, N., 18, 5850, 6689, 8428
 Mitsumori, K., 4407
 Mitsushima, K., 8377
 Miura, K., 728, 1731, 2373
 Miura, T. A., 3435
 Miura, Y., 5785
 Miwa, N., 6116
 Miyagi, Y., 5381
 Miyahara, R., 6791
 Miyake, H., 3575
 Miyamori, H., 2335, 3364
 Miyamoto, H., 4888
 Miyamoto, M., 149, 1555, 8977
 Miyata, K., 6651
 Miyazaki, J.-i., 149
 Miyazaki, K., 4167
 Miyazaki, M., 4167, 7581
 Miyazato, H., 7606
 Miyazawa, K., 7791
 Miyazono, K., 801, 1371, 7791
 Miyoshi, E., 6282
 Miyoshi, I., 304
 Miyoshi, K., 4384
 Mizuguchi, H., 4420
 Mizukami, H., 5091
 Mizumatsu, S., 4021
 Mizuno, H., 4253
 Mizutani, S., 2278
 Mo, X., 6583
 Mo, Y., 579
 Moase, E. H., 86
 Mochan, T. A., 8586
 Mochizuki, M., 831, 5060
 Moeschberger, M., 965
 Mohapatra, S., 8523
 Mohla, S., 6105, 6571
 Möhler, T., 3483
 Mohrenweiser, H. W., 8536
 Mohsin, S. K., 2434
 Mok, H., 5213
 Molla, A., 2535
 Mollejo, M., 8226
 Möller, A., 4310
 Möller, P., 154
 Molling, J. W., 4101
 Mondellini, P., 2234
 Mondesert, G., 4809
 Mondino, A., 3688
 Monestiroli, S., 4342
 Monje, M. L., 4021
 Monken, C. E., 6956
 Monske, M. L., 7825
 Monsky, W. E., 6327
 Monson, D. M., 5808
 Montagna, C., 2179, 2855
 Montalto, G., 5041
 Montano, M. M., 5151
 Montes de Oca Luna, R., 8664
 Montó, P., 7451
 Montie, J. E., 3486
 Mooberry, S. L., 1538, 3211
 Moody, J., 2361
 Moon, A., 5454
 Moon, C.-s., 2351
 Moore, D. H., 2347
 Moore, J., 6130
 Moore, J. T., 2434
 Moore, R. E., 8516
 Moore, S., 2338
 Moossa, A. R., 80, 5521, 7785
 Mor, G., 5573
 Mora, J., 4538
 Morales, M. C., 8233
 Moreno, V., 3560, 5731, 7206
 Moreno-Bueno, G., 5697
 Moretti, S., 4119
 Morgan, G. J., 4327
 Morgan, J. I., 2733
 Morgan, S. J., 7861
 Morgan, W. F., 324, 3107
 Morgenbesser, S., 8939
 Morhardt, D. R., 4021
 Mori, M., 3724, 6575
 Mori, N., 2723
 Mori, S., 4253
 Mori, Y., 895, 4577, 4641
 Morikawa, J., 60
 Morimoto, I., 8145
 Morin, P. J., 4144
 Morita, I., 1623
 Moritake, K., 4044
 Moriya, T., 2762
 Morjani, H., 6149
 Morowitz, M., 7861
 Morreau, H., 1148, 8153
 Morris, A. J., 1073
 Morris, J. C., 7840
 Morris, R. L., 5194
 Morrison, C. D., 2864
 Morrison, K., 3575
 Morrison, L. E., 1235
 Morrissey, M., 1927
 Morrow, J. D., 906, 1748, 6920
 Mortarini, R., 2535
 Mortel, R., 7215
 Mortensen, S., 1943
 Mortimer, P. S., 3969
 Morton, C. C., 1351
 Morton, D., 441, 1054
 Moscinski, L., 5126, 7900
 Moser, A. R., 8085
 Moses, M. A., 1990
 Mosher, R., 1927
 Moss, S. F., 4739
 Mosse, Y., 1631
 Mossine, V. V., 3805
 Mossman, B. T., 3539
 Motegi, K., 8827
 Mottolese, M., 4119
 Moul, J. W., 4299
 Moullan, N., 8717
 Mountford, J. C., 505
 Mourah, S., 7575
 Mouraviev, V., 7853
 Mousa, S. A., 2020
 Moyer, J. D., 4450
 Muegge, K., 4677
 Mueller, M. M., 8264
 Mueller, T., 513
 Mueller-Holzner, E., 7507
 Mufson, R. A., 7539
 Mufti, G. J., 1798
 Muhr, D., 3325
 Mukherji, B., 5607
 Mulders, P. F. A., 1994
 Mullan, P. B., 6221
 Muller, G. W., 593, 8073
 Müller, H. M., 7641
 Müller, I., 1772, 8869
 Müller, M. G., 3556
 Muller, M. T., 2891
 Muller, W. J., 3395, 4920
 Müller-Hermelink, H.-K., 2052, 3708, 7995
 Muller-Weeks, S., 2898
 Multani, A. S., 760, 3503
 Mumm, J. B., 5105
 Mundt, B., 3181
 Mundy, G. R., 5028
 Münger, K., 476, 4862
 Munn, L. L., 5188
 Muñoz, A., 7799
 Munro, N. P., 6971
 Munshi, N., 18, 5850, 6187, 6689, 8428
 Munson, P. J., 2782, 5243
 Munyon, K., 7907
 Munzert, G., 2681
 Murai, M., 107
 Murakami, J., 6795
 Murakami, K., 8948
 Murakami, S., 1555
 Murakami, T., 6751, 8948
 Murakami, Y., 6320, 7979
 Murata, H., 6726
 Murata, T., 4434
 Muravenko, O. V., 404
 Murnane, M. J., 1789
 Murphy, K. J., 2416
 Murphy, K. M., 994
 Murphy, L. C., 1954
 Murphy, L. M., 7638
 Murphy, P. M., 7468
 Murray, P. G., 2338
 Murray, R., 6387
 Murthy, S., 2425
 Muschel, R. J., 4750, 5656
 Musgrove, E. A., 4322
 Musiani, P., 2518, 2728
 Musio, A., 2855
 Muster, T., 8735
 Musto, S., 1838
 Mutaguchi, K., 7717
 Muzik, H., 3162
 Myoui, A., 5028
 Mysliwiec, M., 2771
- N
- Naasani, I., 824
 Naber, S. P., 2364
 Nabholz, M., 689
 Nabi, I. R., 242
 Nabors, L. B., 4181
 Nachmias, B., 6340
 Nadaf, S., 6432
 Nadel, B., 1723
 Naeve, D., 1046
 Nagai, A., 5054
 Nagai, K., 2096
 Nagar, S., 324
 Nagase, H., 4849
 Nagashima, K., 7256
 Nagashima, M., 728, 2373
 Nagata, T., 7920
 Nagawa, H., 1706
 Nagel, S., 5329
 Nagle, R. B., 2292
 Nagy, A., 1106
 Nahta, R., 3626
 Nair, S. K., 7483
 Nair, S. S., 7520
 Naishiro, Y., 895
 Nakabayashi, H., 5785
 Nakabeppu, Y., 902
 Nakada, K., 5159
 Nakada, M., 2335, 3364
 Nakagawa, H., 4244, 7277
 Nakagawa, M., 2829
 Nakagawa, S., 4420
 Nakagawara, A., 1876, 4167
 Nakahara, S., 4112, 6282
 Nakajima, K., 8338
 Nakajima, T., 5159
 Nakajima, Y., 3043
 Nakakubo, Y., 1555
 Nakamoto, Y., 6252
 Nakamura, A., 4407
 Nakamura, H., 6962, 8278
 Nakamura, K., 2404, 5622, 7834
 Nakamura, M., 737
 Nakamura, T., 6543
 Nakamura, Y., 3043, 6116, 7038, 7834, 8145
 Nakano, T., 674
 Nakao, K., 2404
 Nakase, H., 737
 Nakashima, J., 107
 Nakata, E., 3263
 Nakata, T., 2762
 Nakatsuka, S.-i., 7606
 Nakatsura, T., 854
 Nakayama, K., 1623, 4607
 Nakayama, K. I., 4607
 Nakayama, K.-I., 1623
 Nakayama, T., 4420
 Nakazawa, K., 8848
 Nam, S. W., 5446
 Nanni, P., 2728
 Naranjo-Suárez, S., 6877
 Narayanan, B. A., 972
 Narayanan, N. K., 972
 Nardin, D., 375
 Narko, K., 3032
 Narod, S. A., 1769
 Nassirpour, R., 80
 Natali, P. G., 2447
 Nath, N., 7613
 Natkunam, Y., 4472
 Natrajan, R., 7657
 Nau, V., 5615
 Naumann, U., 8996
 Nava, H., 1806
 Navarro, E., 8749
 Navarro, M., 3560
 Nawrocki-Raby, B., 2658
 Naz, R. K., 329
 Near, R. I., 6802
 Neckers, L., 7777, 8984
 Nederlof, P. M., 1449
 Neeman, M., 1657
 Neebe, A., 4945
 Nefedova, Y., 4441
 Negassa, A., 3395
 Neill, G. W., 4692
 Neilson, E. G., 3386
 Nelkin, B. D., 2948, 5559

- Nelson, D. S., 8813
 Nelson, W. G., 498, 1550
 Nemoto, K., 771
 Nephew, K. P., 2164
 Nepomuceno, R. R., 4472
 Neri, D., 3202
 Neskey, D. M., 1351
 Nesland, J. M., 7674
 Ness, K. J., 3037, 6547
 Nesslinger, N. J., 2228
 Neubauer, B. L., 6056
 Neufeld, G., 1657
 Neuhaus, P., 1083
 Neuhiel, B., 2982
 Neumaier, B., 2681
 Neureiter, D., 6496
 Nevanlinna, H., 2024
 Nevins, J. R., 3716
 Newbold, R. F., 689
 Newkirk, K., 312, 8097
 Newlands, E., 2409
 Newman, R. A., 1073
 Newsome, G., 111
 Newton, D. L., 2812
 Ng, I. O.-I., 7646
 Ng, S. S. W., 3189
 Nguyen, C., 4662
 Nguyen, L., 5420
 Nguyen, Q., 1696
 Nguyen, T., 5526
 Nguyen, V. T., 186
 Nicholas, C., 4990, 8791
 Nicholson, J., 4568
 Nicholson, J. K., 3195
 Nicke, B., 5344
 Nickel, B., 5745
 Nickols, M. A., 2079
 Nicoletti, G., 2728
 Nicotra, M. R., 2447
 Nie, J., 6758
 Nieder, M. H., 5526
 Niederberger, E., 1846
 Niedre, M. J., 7986
 Niedzwiecki, D., 1608, 2127
 Nielsen, L. D., 5889
 Nieman, J. A., 1838
 Nieminen, A.-L., 5194
 Niethammer, D., 1772
 Nieuwint, A. W. M., 2688
 Niho, N., 6090
 Niitsu, Y., 8948
 Nikiforov, Y. E., 1454
 Nikiforova, M. N., 1454
 Nikitin, A. Y., 1389, 3459, 4426
 Nilsson, E., 1441
 Nilsson, K., 1737
 Nilsson, L. M., 5420
 Nilsson, M. B., 2971
 Nilsson, P.-G., 1202
 Nimbalkar, D., 1034
 Nimmagadda, K., 3517
 Nimmanapalli, R., 93, 5126, 7950
 Nines, R., 2399, 3556
 Ningaraj, N. S., 8899
 Nishi, N., 4101
 Nishida, T., 6726
 Nishikawa, S. G., 348
 Nishimura, K., 4882, 4888
 Nishimura, K., 5028
 Nishimura, S., 4287
 Nishio, K., 8977
 Nishioka, D., 3247
 Nishiyama, N., 7876, 8977
 Nishizuka, S., 5243
 Nistér, M., 4305
 Niu, T., 600
 Niu, Y., 1954
 Noble, J., 6971
 Noci, I., 4281
 Noda, K., 6282
 Noda, T., 801, 4287, 6090
 Noe, M. C., 7301
 Noh, H.-L., 1583
 Nojima, K., 4253
 Nomi, M., 8345
 Nomizu, M., 5060
 Nomoto, S., 2351
 Nomura, F., 3511
 Nomura, S., 7606
 Nonaka, Y., 854
 Nonomura, N., 4888
 Nordeen, S. K., 5879
 Nordenskjöld, M., 1743, 4583
 Nori, A., 7876
 Norman, K. L., 348
 Normanno, N., 1192
 Norris, D. A., 6716
 Nosrati, A., 1568
 Notario, V., 6290
 Novelli, M., 3819, 7595
 Nowak, A. K., 4490
 Nowak, N. J., 5266
 Nowlin, P. S., 2016
 Noy, N., 4426
 Nozaki, M., 6613
 Nuovo, G. J., 965, 1596
 Nurminen, T., 8623
 Nutt, C. L., 413, 1602
 Nyati, M. K., 658
 Nyberg, P., 8312
 Nzula, S., 3275
- O**
- Obata, K., 8278
 Oberley, L. W., 1297, 5513
 Oberley, T. D., 3037, 6547
 O'Brien, H. P., 6563
 O'Brien-Jenkins, A., 3403
 O'Bryan, E., 7950
 Ocal, I. T., 1101
 Ochiai, A., 2096
 Ochiai, T., 3511
 O'Connor, D., 1235
 O'Connor, D. S., 230
 O'Connor, P. J., 7699
 O'Connor, S., 8022
 Otero, M. D., 3079
 Odesa, S. K., 8487
 O'Donnell, M., 1280
 Odunsi, K., 6076
 O'Dwyer, P. J., 3241, 8600
 Oefner, P. J., 3325
 Oesch, F., 7221
 Oesterreich, S., 5203
 Offringa, R., 636
 Ogasawara, K., 7920
 Ogata, H., 3747
 Ogata, T., 4253
 Ogawa, O., 4407
 Ogawa, S., 60
 Ogawa, Y., 2096
 Ogi, K., 8606
 Oguri, T., 771
 Oh, J., 2033
 O'Hagan, R. C., 5352
 O'Hara, J. A., 1025
 O'Hare, M. J., 1667
 Ohdo, S., 7277
 Ohgaki, H., 6643
 Ohh, M., 7076
 Oh-hara, T., 824, 831
 Oh-hash, F., 824
 Ohigashi, T., 107
 Ohishi, M., 674
 Ohkanda, J., 8922
 Ohkawa, K., 5159
 Ohki, M., 4882
 Ohkubo, I., 7920
 Ohno, T., 8338
 Ohshima, N., 6942
 Ohta, M., 8132
 Ohta, S., 923
 Ohtake, Y., 6174
 Ohshima, C., 4407
 Oike, Y., 6651
 Oka, K., 6962
 Okabe, H., 3043
 Okabe, S., 5564
 Okada, H., 6378
 Okada, M., 2506
 Okada, T., 5091
 Okada, Y., 413, 8278
 Okaji, Y., 1706
 Okamoto, I., 250
 Okamoto, T., 6894
 Okamoto, Y., 4167
 Okamura, S., 728, 2373
 Okayasu, I., 6158
 Okazaki, S., 8977
 Okazaki, Y., 1871
 Okegawa, T., 8680
 Okkenhaug, K., 1818
 Okouoyo, S., 3112
 Okushiba, S., 1555
 Okuyama, A., 4888
 Olah, E., 7674
 Olaru, A., 4577
 Old, L. J., 6076, 6948
 Oldenburg, R. A., 8153
 Oldfield, E. H., 7051
 Oleinick, N. L., 5194
 Oliński, R., 4351, 4899
 Olive, P. L., 4347
 Oliverio, S., 7310
 Olivero, W. C., 2454
 Olivier, K., 5505
 Olivier, M., 6643
 Olshen, A. B., 2139, 2872
 Olson, D. J. H., 7975
 Olson, L. E., 6602
 Olson, S. J., 2256
 Olson, W. C., 4481
 Omata, M., 8132
 O'Neill, E. B., 4218
 Ong, S. T., 5716
 Onogi, H., 2373
 Oo, M. L., 6334
 Oohashi, T., 3511
 Oosterhuis, J. W., 2244, 7674
 Oosterwijk, E., 1994
 Oostra, A. B., 2688
 Opipari, A. W., Jr., 6870
 Opresko, L. K., 1130
 Opresko, P. L., 7136
 Orchard, P., 6847
 Ordóñez-Morán, P., 7799
 O'Regan, P., 8181
 O'Reilly, L. A., 4460
 O'Reilly, M. S., 1990
 Oren, M., 25
 Orgel, A., 8821
 Orłowski, R. Z., 5166
 Orntoft, T. F., 154
 O'Rourke, D. M., 236
 Orr, G. A., 1207
 Orringer, M. B., 4136
 Orsini, E., 2561, 4497
 Ortega, S., 5754
 Ortiz, K. L., 8984
 Ortiz, P. A., 6894
 Osada, M., 2351
 Osago, H., 4044
 Osaka Lymphoma Study Group, 7606
 Osborne, C. K., 2434
 Osborne, H. E., 6056
 Oseroff, A. R., 1806, 3812
 Oshikiri, T., 1555
 Oshima, H., 4872
 Oshima, J., 3289
 Oshima, K., 6809
 Oshima, M., 4872
 Oshima, Y., 3931
 Oshimura, M., 4174
 Osieka, R., 8414
 Osman, I., 3955
 Osman, S., 2409, 3791
 Osogawa, K., 5266
 Ossowski, L., 1684
 Ostland, M., 5781
 Ostroff, G. R., 9023
 Oswald, K. A., 7377
 Otake, Y., 6791
 Otero, J., 1759
 Otis, C. N., 2364
 Ott, H. W., 7507
 Ottini, L., 342
 oude Egbrink, M. G. A., 2322
 Owen, N. K., 4082
 Oya, M., 107
 Oyanagi, H., 6791
 Oyew, W. J. G., 12
 Oyesiku, N. M., 4218
 Ozaki, K., 9016
 Ozaki, T., 4167
 Ozaki, Y., 7920
 Ozawa, K., 5091
 Ozen, M., 5754, 6237
 Ozturk, M., 6707
- P**
- Pabo, C. O., 8968
 Pacioret, T., 4899
 Pack, S., 5320
 Packham, G., 4150
 Padera, T. P., 8556
 Padró, T., 7241
 Paganoni, P., 5224
 Page, R., 4426
 Paggi, M. G., 1430, 6350
 Paglierani, M., 342
 Pahlman, S., 1441
 Pai, S. K., 1731
 Paiardini, M., 4028
 Paielli, D., 7497
 Paik, Y.-K., 2188
 Paillerets, B. B.-d., 3061
 Painter, J., 7900
 Pairen, J.-C., 8108
 Pak, B., 1138
 Pak, J., 179
 Pakuts, B., 1198
 Palacios, J., 5697
 Palanca-Wessels, C., 4211

- Palazzo, A. F., 6825
 Palena, A., 1430
 Pallante, P., 7423
 Pallen, C. J., 2716
 Palli, D., 342
 Pallini, R., 3750
 Pálmer, H. G., 7799
 Palmer, T. D., 4021
 Palmisano, W. A., 4620
 Palmowski, M. J., 8408
 Palomba, C., 534
 Palotie, A., 2742
 Pals, G., 1449, 6998
 Pan, B., 5438
 Pan, C., 5526
 Pan, W., 6847
 Pan, Y., 4174
 Pance, A., 8233
 Panda, D., 1214
 Pandey, R. K., 1806
 Panicek, D. M., 9042
 Pankurst, S., 5034
 Pannacci, M., 2499
 Pantazis, P., 1000
 Pantel, K., 5679
 Pantuck, A. J., 4952
 Pao, W., 5889
 Papadopoulos, T., 2268
 Papageorgiou, T., 5308
 Papathanassiou, A., 2997
 Pappas, S., 7490
 Paquette-Straub, C., 432
 Parada, L. F., 8573
 Parant, J. M., 8664
 Parcellier, A., 8233
 Pardee, A. B., 290
 Pariali, M., 7256
 Parikh, A. A., 2079, 3370, 3632
 Parikh, N. U., 2990
 Paris, F., 4338
 Pariselli, F., 541
 Park, C., 7861
 Park, J., 3743, 4792, 6206
 Park, J. I., 2948
 Park, J. W., 3154
 Park, J-H., 6206
 Park, J-I., 5559
 Park, J-W., 3403, 3430, 4225, 6885, 8700
 Park, K-S., 2188
 Park, S., 723
 Park, S. R., 7247
 Park, Y. S., 6458
 Parkinson, E. K., 458
 Parkinson, H., 929
 Parks, W. T., 8284
 Parl, F. F., 3127, 8492
 Parmiani, G., 1560, 2535, 4507, 6948
 Parodi, M. C., 6350
 Parra, I., 2434
 Parrella, P., 8507
 Parrinello, S., 7098
 Parrott, M. B., 5213
 Parsels, J., 658
 Pasha, M. K., 7975
 Pasquale, L., 6350
 Pasquali, C., 7451
 Pastorino, F., 86, 7400
 Patel, G. B., 2526
 Patel, R., 3969
 Patel, V., 2948
 Pathak, S., 760, 3503, 6121
 Pathmanathan, R., 8293
 Patry, C., 7679
 Patterson, A. V., 6914
 Patterson, M. S., 7986
 Patterson, T., 6
 Patti, M., 6784
 Patz, E. F., Jr., 1652
 Paul, A., 6971
 Paul, S., 4342
 Pavlova, I., 1999
 Pawelek, J. M., 5363
 Pawlita, M., 3483, 6032
 Payvandi, F., 8073
 Paz, M. F., 1114
 Pazdrak, B., 3495
 Pazzaglia, S., 1871
 Peabody, J., 7497
 Pearce, S. T., 7490
 Pearce, V. P., 1914
 Peart, M. J., 4460
 Pecha, J., 8763
 Pedersen, I. M., 1242
 Pedersen, M. W., 1943
 Pedersen, N., 1943
 Pedoux, R., 2373, 2596
 Peek, R. M., Jr., 951
 Pegg, A. E., 3945
 Pegg, J., 7497
 Pehamberger, H., 8735
 Pei, D., 1046, 6758
 Peinado, M. A., 5731, 7206
 Peiper, S., 7926
 Peissel, B., 1871
 Pejavar, S., 2872
 Pellagatti, A., 3940
 Pellecchia, M., 8118
 Pelley, R. P., 3503
 Pellicer, A., 1615, 4188
 Peng, K-W., 2462
 Peng, R., 965
 Penninger, J. M., 8233
 Pentimalli, F., 7423
 Pera, P., 2477
 Perego, C., 2234
 Pereira, D. S., 8912
 Peretz, T., 6340, 8821
 Perez, C., 7392
 Perez-Atayde, A. R., 304
 Pérez de Castro, I., 1615
 Perez-Equiza, K., 3079
 Perin, N., 6900
 Perkins, S. N., 1752
 Perkmann, E., 7641
 Perlemonne, K., 5308
 Perlman, E. J., 2244
 Perry, A., 8573
 Persad, S., 2306
 Pervin, S., 5470, 8853
 Peschel, C., 6395
 Pessi, F., 7451
 Pestell, R. G., 3395, 6802
 Peterit, D. G., 8173
 Peterlin, B. M., 4547
 Peters, J. M., 5767
 Peters, M., 1083
 Petersen, I., 1188
 Peterson, E. J., 6579
 Peterson, K. M., 1865
 Peterson, L. E., 5754
 Pettilo, D., 4583
 Petit, P. X., 541
 Petraki, C. D., 9032
 Petre-Draviam, C. E., 4903
 Petricoin, E. F., III, 5243
 Petrovan, R. J., 5381
 Petrovics, G., 4299
 Petrovsky, A., 1936
 Petruzzelli, G. J., 555
 Petrylak, D. P., 1527
 Pettit, G. R., 8869
 Pfeifer, G. P., 1639, 1888, 8708
 Pfeiffer, R., 1752
 Pfister, S. M., 1772
 Phan, V., 2145
 Pharoah, P. D. P., 417, 2610
 Phelps, M., 2616
 Phelps, R. G., 3883
 Phillips, M. R., 72
 Phillips, D. H., 2752
 Phillips, D. R., 1776
 Phillips, M. J., 8014
 Philopena, J., 4003
 Philpott, M. P., 4692
 Phipps, S., 1490
 Phung, S., 8516
 Phuong, L. K., 2462
 Piacentini, M., 3860, 7310
 Piasentin, E., 4258
 Piatyszek, M., 3931
 Piboonniyom, S-o., 476
 Pica, C. M., 1780
 Picherit, C., 6607
 Pichierri, P., 3289
 Pickford, L. B., 5526
 Picus, J., 2033
 Pidgeon, G. P., 4258
 Piek, E., 8284
 Piemonti, L., 7451
 Pienta, K. J., 3805
 Pieper, R. O., 1962
 Pierantoni, G. M., 7423
 Pierconti, F., 3750
 Pierotti, M. A., 2234
 Pierron, A., 6413
 Pietenpol, J. A., 7113
 Pihan, G. A., 1398
 Pikarsky, E., 25
 Pilarski, L., 6689
 Pilčik, T., 4533
 Pili, R., 5978
 Pilla, L., 1560
 Pillmann, A., 7742
 Piloti, S., 1871
 Pinder, K. E., 6424
 Pinedo, H. M., 4101
 Pingpank, J. F., 7232
 Pinkel, D., 2872, 5266
 Pinkstaff, A., 1490
 Pinn, M. L., 7330
 Pins, M., 4698
 Pinthus, J. H., 2470
 Pinto, J. T., 6825
 Pinto, R., 1242
 Pipkorn, R., 4766
 Pirani, P., 1969
 Pircher, H., 4095
 Piris, A., 2535
 Piris, M. A., 8226
 Pisani, P., 8717
 Pisarcik, D. A., 1311
 Piskorska, J., 4533
 Pissard, S., 8108
 Pitha, P. M., 6424
 Pitiphat, W., 296
 Pitkanen, A., 3195
 Pitot, H. C., 1724
 Pittaluga, S., 5243
 Pittman, P., 7321
 Piver, M. S., 417
 Piwnica-Worms, D., 1780
 Place, A. E., 1371
 Planey, S. L., 172
 Plass, C., 2864
 Platten, M., 8996
 Platz, E. A., 8542
 Platzer, P., 1568
 Pledger, W. J., 3021, 8523
 Plénat, F., 6084
 Plentz, R., 3181
 Plescia, J., 230
 Plieth, D., 3386
 Plouin, P-F., 5615
 Pluderi, M., 2499
 Plummer, S., 6795
 Pluta, L. J., 929
 Podar, K., 5462, 5850, 6174, 8428
 Poderoso, J. J., 6370
 Poellinger, L., 2675
 Poerschke, D., 8890
 Pogue, B. W., 1025
 Pohl, U., 1602
 Pohle, T., 7995
 Poikonen, T., 154
 Poirier, D., 6442
 Poirier, M. C., 4402, 5999
 Polavarapu, R., 3092
 Pold, M., 642
 Polette, M., 2658
 Poli, M., 1534
 Polin, G. M., 7232
 Polito, L., 5041
 Pollack, H., 3026
 Pollak, M., 3991
 Pollan, M., 1114, 1814
 Pollara, G., 5143
 Pollock, J. R. A., 2358
 Polnaszek, N., 5754
 Polsky, D., 3955
 Polvinen, K., 6716
 Polyak, K., 2024, 4144
 Polymeris, M-E., 2223, 3958
 Polymeropoulos, M. H., 2194
 Pomeroy, S. L., 1602
 Pommier, Y., 230, 1000, 2782, 7291, 7428, 8203
 Ponce, M. L., 5060
 Ponder, B. A. J., 417, 2610, 4777
 Pong, M., 6387
 Pong, R-C., 8680
 Pongracz, K., 3931
 Ponzanelli, A., 6144
 Ponzoni, M., 86, 7400
 Poole, D. J., 7942
 Poole, T. W., 1389
 Poon, R. T-P., 3121
 Popalis, C., 2223
 Pope, L., 1198
 Pope, R. M., 6928
 Popkie, A. P., 2864
 Poptani, H., 8813
 Porcelli, S. A., 4101
 Porcile, C., 1969
 Porcu, P., 965
 Pore, N., 236
 Porosnicu, M., 8366
 Porteous, D. J., 8648
 Porter, C. W., 3619
 Porter, L. A., 3701
 Poruchynsky, M. S., 1838
 Posey, J. T., 2638
 Postenka, C. O., 4763
 Potter, M., 7002
 Potter, P. M., 6900

- Pouliot, F., 277
 Poulsen, H. S., 1943
 Poulson, R., 3819
 Poutahidis, T., 6042
 Povirk, L. F., 22
 Powers, R., 6387
 Pozzato, P., 787
 Prabhakaran, I., 7232
 Prabhakar, B. S., 8768
 Prabhu, V. V., 2782
 Pradera, F., 4095
 Pradhan, D. G., 7497
 Praha, C., 5745
 Prasmickaite, L., 3490
 Prat, E., 5731
 Prat, J., 5697
 Pratap, J., 5357
 Pratt, N. R., 4656
 Prawitt, D., 7221
 Praz, F., 5738, 6935
 Preston, S. L., 3819
 Pretlow, T. P., 6166
 Prévost, M.-C., 541
 Prewett, M., 8912
 Pribluda, V. S., 468, 2997
 Price, J. E., 2940
 Price, P., 2409, 8558, 8560
 Price, P. M., 3791
 Pride, Y. B., 5462
 Primo, L., 1500
 Primrose, J. N., 2616
 Primus, F. J., 2844
 Pring, D. W., 8461
 Prins, R. M., 8487
 Prinz, R. A., 4561
 Prior, J. L., 1780
 Prise, K. M., 8437
 Pritchard, D., 4211
 Prochownik, E. V., 2923
 Proffitt, J. H., 36
 Protopopov, A., 404
 Protti, M. P., 8481
 Proudfoot, A. E. I., 8360
 Provoncha, K., 4450
 Pruijn, F. B., 5970
 Pruitt, S., 2127
 Pruntel, R., 1449
 Pruzan, R., 3931
 Przybytkowski, E., 4588
 Ptaszynska, M. M., 5446
 Puhlmann, M., 5957
 Pulling, L. C., 4842
 Punt, C. J. A., 12, 7609
 Pustilnik, L. R., 4450
 Pützer, B. M., 2737
 Pye, C., 417
 Pysniak, K., 4533
- Q**
- Qi, D., 3980
 Qi, H., 7076
 Qi, L., 8188
 Qi, R., 8323
 Qian, D., 3356
 Qian, F., 6076
 Qian, X., 2251
 Qiao, R., 3883
 Qin, C., 958
 Qin, J., 4538
 Qin, Z., 4095
 Qingping, G., 6469
 Qiu, C., 5674
 Qiu, W., 980, 6583
- Qiu, X., 6488
 Qiuping, Z., 6469
 Quackenbush, J., 4368
 Quada, J. C., Jr., 3211
 Quade, B. J., 1351
 Quaglino, E., 2518
 Quebe-Fehling, E., 6523
 Quelle, F. W., 1034
 Quijano, E., 4003
 Quinn, A. G., 4692
 Quinn, D. I., 4196
 Quinn, J. E., 6221
 Quinn, T. P., 3805
 Quinlan, L. A., 5462
 Quintero, J., 7815
 Quiros, R. M., 4561
 Qun, L., 6469
- R**
- Raab-Traub, N., 8293
 Rabbani, S. A., 2072
 Rabbe, N., 1405
 Rabiasz, G. J., 8648
 Rabinovitch, P. S., 4211
 Race, P. R., 5532
 Rad, A. N., 5143
 Rademaker, A. W., 3783
 Radinsky, R., 2990
 Radivoyevitch, T., 838
 Radjabi-Rahat, A. R., 3066
 Radjendirane, V., 67
 Radke, C., 1083
 Radparvar, F., 6363
 Radvanyi, F., 8108
 Raffeld, M., 5243
 Raffo, A. J., 1527
 Raffoul, J. J., 5799
 Rahman, A., 7032
 Rahman, M. M., 7106
 Rahman, N., 8596
 Rahman, S. M. J., 7113
 Rahmani, M., 1822, 2118, 8420
 Rahmatpanah, F., 2164, 6110, 6178
 Rainone, S., 1776
 Raj, K., 8687
 Rajasekaran, A. K., 2645
 Rajasekaran, S. A., 2645
 Rajendra, R., 3228
 Rajewsky, K., 1644
 Rajjayabun, P. H., 484
 Raju, J., 6595
 Raju, U., 3263
 Rakitina, T. V., 3241, 8600
 Ralph, S., 812
 Ralston, R., 4003
 Ramachandra, M., 4003
 Ramage, J. G., 1834
 Ramakrishnan, S., 382
 Ramakrishnan, V., 6387
 Ramanan, S., 6658
 Ramanathanpuram, L. V., 1860
 Ramani, P., 4568
 Ramdas, L., 4315
 Ramesh, R., 5105
 Ramirez, K. M., 2971
 Ramji, S., 6914
 Rammensee, H.-G., 8996
 Ramnaraine, M., 6847
 Ramon, J., 2470
 Ramos-Nino, M. E., 3539
 Ramphal, J., 7345
 Ramus, S. J., 417
 Ranalli, M., 7310
- Randall, T. C., 3403
 Randall-Hlubek, D. A., 1538, 3211
 Randazzo, F., 3145
 Ranicar, A. S. O., 2409
 Ranieri, E., 4481
 Ranzani, T., 6948
 Rao, C. V., 5239
 Rao, J. S., 2454
 Rao, M. K., 8899
 Rao, N., 4952
 Rao, P. N., 1538
 Rao, V. P., 6042
 Rao, X.-M., 3073
 Rapp, U. R., 2268
 Rappaport, E., 1631
 Rashid, A., 4805
 Rasiah, K. K., 4196
 Rassidakis, G. Z., 2977
 Rassoul, F. V., 1798
 Rastinejad, F., 7301
 Ratajczak, J., 7926
 Ratajczak, M. Z., 7926
 Ratcliffe, P. J., 1764, 6130
 Ratnam, M., 2820
 Ratovitski, E., 2351
 Raufman, J.-P., 6744
 Rautonen, N. E., 5136
 Ravagnani, F., 2535
 Raval, R., 1764, 6130
 Ravetch, J. V., 6453
 Ravetti, J. L., 1969
 Ravetto, P. F., 6563
 Ravi, R., 2723
 Ravid, K., 6413
 Ray, D. W., 812
 Ray, P., 1160
 Ray, R., 8085
 Ray, S., 4713
 Raycraft, J., 3695
 Rayman, P., 1676
 Raz, A., 242, 2251, 8302
 Rdzanek, M., 6125
 Re, D., 2606
 Rebar, E. J., 8968
 Rebmman, V., 4107
 Recca, R., 7926
 Rechthand, P., 2351
 Recio, J. A., 1576
 Recio, L., 929
 Reddy, A. N., 7694
 Reddy, B. S., 972
 Reddy, G., 838
 Reddy, P., 4218
 Redfern, C. P. F., 7310
 Redston, M., 1769
 Reed, H., 2913
 Reed, J. C., 263, 1242, 8118, 8138
 Reed, K., 5114
 Reed, L., 111
 Reeder, J. A., 887
 Reese, E., 8420
 Reeves, R. H., 6602
 Reffey, S. B., 1371
 Regli, L., 6613
 Regnerus, R., 1449
 Rehmtulla, A., 658
 Rehg, J. E., 5420
 Rehman, A., 1192
 Reid, B. J., 4211
 Reilly, R. M., 5950
 Reinartz, S., 3234
 Reinhold, W. C., 1000, 2782, 5243
 Reinmuth, N., 2079, 2990, 3370, 3632
- Reis, A., 6565
 Reischbach, G., 2982
 Reisman, D. N., 560
 Rekhtman, N., 6363
 Remaley, A., 8022
 Rempel, R., 3716
 Ren, W., 7321
 Ren, X.-Q., 4048
 Renaud, A., 6149
 Renauld, J.-C., 5105
 Renier, M., 3221
 Renkvist, N., 1560
 Rennstam, K., 8861
 Renoir, J.-M., 4322
 Renou, J.-P., 7668
 Renwick, A., 8596
 Repasky, E., 2553
 Reppert, T., 2179
 Rerko, R. M., 1568
 Resing, K. A., 6716
 Reske, S. N., 2681
 Resnick, M., 1657
 Ressler, S. J., 5859
 Retzinger, G. S., 7314
 Retzlaff, S., 7241
 Reutens, A. T., 3395
 Rewcastle, N. B., 3162
 Reynolds, C. P., 1520, 3026
 Reynolds, G. M., 2338
 Rhoades, B., 2005
 Riabowol, K., 5785
 Ribas, M., 7206
 Ribatti, D., 7400
 Riccardi, R., 5902
 Ricciardelli, C., 4786
 Ricciardiello, L., 787, 1608, 7256
 Ricci-Vitiani, L., 6784
 Rice, P. L., 616
 Richard, S., 4583
 Richards-Kortum, R., 1999
 Richardson, A., 2024, 5799
 Richardson, C. J., 6008
 Richardson, E. L., 3855
 Richardson, P., 18, 5850, 6187
 Richardson, P. G., 8428
 Richon, S., 3682
 Ridder, R., 3112
 Riddick, D. S., 6914
 Riddler, S., 6516
 Ride, J. P., 505
 Ried, T., 2179, 2855
 Riegel, A. T., 1696, 8085
 Rieger, R., 4128
 Rieneck, K., 1943
 Ries, C., 337
 Riethdorf, L., 5679
 Rieubland, C., 5615
 Rigas, B., 7613
 Rigault de la Longrais, I. A., 4225
 Riggins, G. J., 4773
 Riley, R., 4862, 5257
 Rimm, D. L., 1101, 1445, 8103
 Rimoldi, D., 5601, 5712
 Ringberg, A., 1737
 Ringert, R.-H., 6200
 Ringnér, M., 7158
 Rini, F., 4507
 Rio, M.-C., 3032, 5844
 Riou, J.-F., 6149
 Ripalti, A., 7256
 Risinger, J. L., 6
 Risingsong, R., 1371
 Risques, R.-A., 5731, 7206
 Riss, D., 2251

AUTHOR INDEX TO VOLUME 63

- Ristamäki, R., 1920, 8556
Ristimäki, A., 3032, 5005, 7591
Ritchie, J., 1297
Ritter, G., 6076
Ritz, J., 2561
Rivoltini, L., 1560, 4507, 6948
Rizzuto, R., 541
Robbins, P. D., 6378
Robbins, P. F., 6735
Roberts, A. B., 1371, 8284
Roberts, D. D., 6405
Roberts, J. R., 7113
Roberts, K., 929
Roberts, M., 458
Roberts, P., 4568
Roberts, R. L., 2256
Roberts, T., 1589
Roberts, W. G., 7301
Robertson, G. P., 2881, 5198
Robertson, J. D., 5838
Robertson, N. M., 172, 4521
Robey, R. W., 4048
Robinson, B. W., 4490, 6935
Robinson, C., 5978
Robinson, J. A., 5357
Robinson, S. C., 8360
Robinson, S. P., 4960
Robledo, M., 1814
Roca, C., 1500
Rocha de Quadros, M., 1
Roda, E., 787, 7256
Rodabough, R. J., 6096
Roddam, P. L., 4327
Rodeck, U., 1
Roden, R., 3966
Rodgers, G., 7051
Rödicker, F., 2737
Rodolfo, C., 7310
Rodolfo, M., 6948
Rodríguez, A., 8226
Rodríguez, C., 1280
Rodríguez, C. O., Jr., 7968
Rodríguez-Perales, S., 5697
Roeder, R. G., 8763
Roemen, G. M. J. M., 3133
Rofstad, E. K., 4055
Rogers, A. B., 942, 6042
Rogers, M. A., 6971
Rogler, C. E., 7753
Roh, M., 8079
Rojas, J. M., 1814
Rokhlin, O. W., 2905
Rola, R., 4021
Roland, I. H., 4967
Rolke, M., 6265
Rollins, L., 7321
Rollinson, S., 4327
Romero, M. E., 1122
Romero, P., 5601
Romestaing, P., 8717
Romirer, I., 8735
Ronai, Z., 3883, 8103
Roncari, L., 1106
Ronnella, S., 6144
Rone, J. D., 8097
Roninson, I. B., 2705
Ronnott, G. V., 7330
Roodi, N., 3127, 8492
Roos, E., 3833
Roots, I., 8062
Rosania, G. R., 4331
Rosano, L., 2447
Rosato, A., 2158
Rosato, R. R., 3637
Roschke, A., 1000, 8634
Roscoe, W., 5526
Rosen, B., 2416
Rosen, J. M., 1067, 6237, 8256
Rosen, M., 5559
Rosen, N., 2139, 7777, 8393
Rosenberg, G. B., 859
Rosenberg, M. P., 4819
Rosenberg, S. A., 6735
Rosenblum, M. G., 72, 3995
Rosewicz, S., 1083
Rosin, M. P., 5168, 8582
Ross, A. R. S., 7975
Ross, D. D., 3228, 4048
Ross, G. D., 9023
Rosser, C. J., 760
Rossi, A. M., 7301
Rossi, A. M. K., 4450
Rosty, C., 4158
Rote, W. E., 2997
Roth, A., 8890
Roth, J., 3904
Roth, M. J., 3872
Rothenfusser, S., 6478
Rotilio, G., 5940
Rotter, V., 7147, 8777
Roudier, M. P., 4662
Roufail, W. M., 8549
Roulland, S., 1722
Roush, J., 4594
Roussel, M. F., 1046, 5420, 5428
Routes, J. M., 3435
Rovida, E., 8955
Rowan, B. G., 2820
Rowlands, D., 2338
Rowley, D. R., 5859
Roxas, A., 3325
Roy, R., 7704
Roychowdhury, S., 965
Roysam, B., 8073
Rozalski, R., 4899
Rozengurt, E., 2379
Rubin, B. P., 5761
Rubin, E. H., 3228
Rubin, S. C., 3403, 4225
Rubinstein, E., 2665
Ruchatz, A., 3173
Ruchelman, A. L., 8400
Rudin, C. M., 312
Rudolph, K. L., 3181, 5021
Rudzinski, J., 6125
Ruebhen, H., 4107
Rueffer, S., 4310
Ruefli, A. A., 4460
Ruers, T. J., 12
Ruf, W., 5381
Ruffino, L., 4819
Ruggeri, B., 5559, 5978
Ruggeri, P., 2658
Ruiter, D. J., 5408
Ruiz, S., 1814
Ruiz-Ballesteros, E., 8226
Ruoff, N., 7995
Rusconi, C., 7483
Ruslim, L., 7345
Russell, J. S., 7377
Russell, P. J., 5034
Russell, R. G., 3395
Russell, R. M., 3138
Russell, S. J., 2462
Russo, P., 6350
Rustgi, A. K., 2005, 4244
Rustin, P., 5615
Rutherford, T. J., 5573
Rutka, J., 3162
Ryan, P., 1490
Rybak, S. M., 2812
Rynkiewicz, S., 8466
Ryu, B.-K., 7068

S

Saadatmandi, N., 3646
Sabichi, A. L., 5649
Sabo, E., 1657
Sabourin, J.-C., 5738
Sachdev, D., 627
Sad, S., 2526
Sadacharan, S., 2306
Sadat, A., 7595
Sadovnikova, N. Y., 859
Saetta, A., 5041
Safe, S., 958
Safer, H. M., 6996
Saga, Y., 5091
Sagalowsky, A., 8680
Sage, E. H., 5376
Saha, A., 2844
Saha, D., 6920
Saha, S., 4144
Sahin, A., 4724
Sahin, A. A., 4174
Sahoo, S. K., 3567
Said, J. W., 4952
Said-Al-Naief, N., 8079
Saieva, C., 342
Saika, T., 7853
Saisho, H., 8674
Saito, H., 5159
Saito, K., 1731
Saito, Y., 5105
Saitoh, M., 7791
Saito-Ohara, F., 1876
Sajithlal, G., 7263
Sakai, M., 6116
Sakaki, T., 737
Sakamoto, H., 831
Sakamoto, M., 4641
Sakamoto, T., 8090
Sakko, A. J., 4786
Sakumi, K., 902
Sakuragi, N., 3101, 3913
Sala, F., 3079
Salado, C., 491
Salani, D., 2447
Saleem, A., 2409, 3228
Sales, M., 4656, 8827
Salgia, R., 5462, 6272
Säll, T., 3378
Salles, A., 5526
Salloum, R. M., 308
Salnikow, K., 3524
Salomao, D., 6501
Salomon, D. S., 1192
Salter, J., 6516
Salvadori, M., 2388
Salvi, S., 5712
Salwen, H. R., 6299
Samà, I., 882
Samanta, M., 8670
Samia, A. C. S., 5194
Samuelson, D. J., 5808
Sánchez-Carbayo, M., 7799
Sanchez-Céspedes, M., 1382
Sánchez-Estévez, C., 5697
Sandberg, M. L., 2982
Sanders, B. G., 2483
Sanders, S., 6290
Sanderson, R. D., 8749
Sandgren, E. P., 2016
Sandler, A. D., 394
Sandrini, F., 5308
Sänger, J., 6395
Sanger, L. J., 6154
Sanicola, M., 1192
Sano, H., 8338
Sanovich, E., 2812
Santa, S. D., 2158
Santi, M. R., 1865
Santiago, D., 6076
Santinami, M., 2535
Santini, V., 8955
Santiskulvong, C., 2379
Santorio, M., 882, 7423
Santulli, M., 4747
Santulli-Marotto, S., 7483
Sanzen, N., 222
Saoo, K., 7581
Saporta, S., 7900
Sapra, P., 86
Saran, A., 1871
Sarcevic, B., 4322
Sareth, S., 8118
Sarg, B., 7507
Sarkar, D., 8138
Sarman, A. V., 3486
Sarman, S., 6051
Sarsour, E. H., 2109
Sarti, M., 1183
Sartor, C. L., 7807
Sarvazyan, N., 5992
Sasaki, M., 3101, 3913
Sasaki, M. S., 2688
Sasaki, T., 674, 801
Sasaki, Y., 6726, 8145, 8606
Sasano, H., 2762
Sasi, S., 5636
Sasisekharan, R., 8351
Sassa, T., 3659
Satagopan, J. M., 1759
Sathya, G., 8029
Sato, F., 4577
Sato, H., 2335, 3364
Sato, I., 5091
Sato, K., 4407
Sato, M., 4552
Sato, N., 3735, 4158
Sato, S., 831
Satoh, A., 8606
Satoh, S., 3043
Satoh, T., 7853
Sattler, M., 5462, 6272
Satyamoorthy, K., 756
Sauerbruch, T., 8962
Saukkonen, K., 3032
Sausville, E. A., 2812, 5243, 8069
Sauter, G., 2244, 5679
Savelyeva, L., 7742
Savontaus, M. J., 3605
Sawa, H., 7256
Sawa, T., 3567
Sawai, S., 7920
Sawyer, C., 1667
Sawyers, C. L., 2742
Saya, H., 6962
Sayers, T. J., 207
Sbarba, P. D., 8955
Scadeng, M., 3026
Scaltrini, F., 7451
Scaltriti, M., 3469
Scanlan, M. J., 6076
Scapoli, L., 3539

AUTHOR INDEX TO VOLUME 63

- Scaravilli, F., 3708
 Scardino, P. T., 4662
 Scarfi, S., 6144
 Scarselli, G. F., 4281
 Schaber, S., 6496
 Schaeffer, P., 5978
 Schaeffer, T., 7301
 Schafer, C. A., 4684
 Schäfer, G., 1083
 Schafer, P., 593
 Schaid, D. J., 5209
 Schalken, J. A., 4748
 Schally, A. V., 7913
 Schanab, O., 8735
 Schaper, J., 8687
 Scharenborg, N. M., 12
 Schatzkin, A., 1752
 Schreckenbach, K., 1188
 Scheibenbogen, C., 3483, 5582
 Scheinberg, D. A., 72, 5084
 Scheithauer, B. W., 2251
 Schellenberger, E., 1936
 Schellens, J. H. M., 3228, 6447
 Schellhammer, P. F., 2701
 Schemaında, I., 7436
 Schenk, M., 2369
 Schep, R. J., 4101
 Schepis, F., 882
 Scher, H. I., 2139, 4196, 8393
 Scherf, U., 5243
 Scherpereel, A., 6084
 Scherthan, H., 5745
 Schettini, G., 1969
 Schiestl, R. H., 5335
 Schiff, R., 2434, 5203
 Schiffer, I. B., 7221
 Schiffmann, E., 2042, 5446
 Schild, L. J., 4402, 5999
 Schild-Poulter, C., 7197
 Schilling, H., 2578
 Schimmer, A. D., 1242
 Schindler, D. G., 2470
 Schinkel, A. H., 1339, 6447
 Schipper, M. L., 1333
 Schirripa, O., 5879
 Schlebusch, H., 3234
 Schlegel, R., 1927
 Schleman, S., 616
 Schlom, J., 7942
 Schlossman, R., 2561
 Schmalbrock, P., 965
 Schmalfeldt, B., 2771, 3958
 Schmeiser, H. H., 2752
 Schmid, G., 7263
 Schmidt, E. V., 3626
 Schmidt, H., 1172, 1333, 1846
 Schmidt, L. S., 5320
 Schmidt, T., 8962
 Schmidtko, A., 1846
 Schmidt-Wolf, I. G. H., 8962
 Schmitt, E., 8233
 Schmitt, M., 2771, 3958
 Schmitz, M. L., 4310, 8271
 Schmitz, V., 8962
 Schmoll, H.-J., 513
 Schneider, C., 8962
 Schneider, D., 7462
 Schneider, D. T., 2244
 Schneider, E., 5538
 Schnepf, R. W., 4204
 Schnitzer, J. E., 6571
 Schoenberg, M., 2216, 5723
 Scholich, K., 1846
 Schor, A. M., 8827
 Schor, S. L., 8827
 Schouten, J. P., 1449
 Schrecengost, R. S., 5962
 Schreck, R., 7345
 Schreiber, F. S., 2005
 Schreiber, W. G., 7221
 Schreiner, B., 7462
 Schroeder, A., 5761
 Schroeder, J. C., 7530
 Schuch, G., 8345
 Schueneman, A. J., 4009
 Schulte, B., 3181
 Schultheiß, S., 2681
 Schumaker, L. M., 312, 8097
 Schummer, M., 3695
 Schupp, J. E., 838
 Schuppan, D., 6496
 Schwab, M., 7742
 Schwaerzler, P., 7507
 Schwall, R., 1020
 Schwartz, A. G., 4842
 Schwartz, D. R., 2913
 Schwartz, E. L., 527, 8791
 Schwartz, P. E., 5573, 7215
 Schwartz, P. S., 8563
 Schwartzkopf, J., 4095
 Schwarz, D., 8062
 Schwarz, S., 3708
 Schwarze, S. R., 4614
 Schwarzenberger, P., 7936
 Sciarrotta, J., 560
 Sckell, A., 8890
 Scolnick, D. M., 7185
 Scorigas, A., 807, 2223, 2771, 3958, 6543
 Scott, D. L., 394
 Scott, K. A., 8360
 Scott, S. L., 7190
 Scudiero, D. A., 5243, 8634
 Seal, S., 8596
 Searle, P. F., 5532
 Sebo, T. J., 7638
 Sebt, S. M., 1270, 8922
 Secomb, T. W., 4705
 Secord, A. J., 7986
 Sedelies, K. A., 4460
 Sedivy, J. M., 1743
 Seeger, K., 6565
 Seetharam, S., 308
 Seftor, E. A., 4757, 5381
 Seftor, R. E. B., 4757, 5381
 Segawa, N., 8090
 Sehgal, C. S., 7232
 Sehr, P., 6032
 Seidah, N. G., 1458
 Seiden, M. V., 2200
 Seidlitz, E., 7979
 Seifried, H. E., 4295
 Seike, M., 4641
 Seiki, M., 8278
 Seitz, U., 2681
 Sekhar, K. R., 5636, 6920
 Sekharam, M., 7708
 Sekhon, H. S., 214
 Seki, N., 207
 Sekiguchi, K., 222
 Sekiguchi, M., 902
 Selaru, F. M., 4577
 Selby, P. J., 6971
 Seliger, B., 4095, 4107, 7221
 Seligson, D., 2742
 Sell, S., 7553
 Sellar, G. C., 8648
 Sellers, L. A., 8351
 Sellers, W. R., 4781
 Selvakumar, P., 7975
 Selvakumaran, M., 1311
 Semac, I., 534
 Sementchenko, V. I., 4626
 Semenza, G. L., 1138, 2330
 Senderovich, S., 7147
 Sénéchal, S., 6084
 Seneviratne, K., 8827
 Senga, T., 6334
 Senger, D., 3162
 Sengupta, P. K., 1789
 Sengupta, S., 2596, 7591, 8351
 Senoo, H., 674
 Senter, P., 6387
 Seo, E., 4434
 Seo, Y. R., 608
 Seo, Y.-W., 7247
 Seong, Y.-S., 7384
 Seow, A., 573
 Seppälä, M., 6258
 Seppel, H., 8735
 Sergina, N., 4731
 Serova, M., 7575
 Session, N. N., 838
 Sesterhenn, I. A., 4299
 Setser, J., 4384
 Settleman, J., 4089
 Seu, P., 3593
 Severino, A., 1430
 Sevic-Muraca, E. M., 7870
 Sevnigani, C., 1183
 Sforzini, S., 696
 Sgouros, G., 8393
 Shabram, P., 4003
 Shah, M., 7321
 Shain, K. H., 4368, 7900
 Shaked, Y., 4342
 Shammass, M. A., 6187
 Shan, L., 5674
 Shankar, S., 5390
 Shanmugam, S., 2881
 Shannon, P., 1106
 Shao, C., 8437
 Shao, H., 3923
 Shao, J., 5218
 Shao, X., 3268
 Shapiro, E., 179
 Shapiro, G. I., 7410
 Shappell, S. B., 2256
 Shariat, S. F., 4662, 5874
 Sharifi, J., 5046
 Sharkey, R. M., 354, 8069
 Sharma, A., 2881
 Sharma, N., 5320
 Sharma, R. K., 7975
 Sharma, S., 642, 766, 1280, 5065
 Sharma, V., 1780
 Sharoni, Y., 1325
 Sharp, A., 4150
 Sharpless, N. E., 5352
 Shats, I., 7147, 8777
 Shaughnessy, J., 8749
 Shay, J. W., 760, 1914, 5813
 Shchavaleva, I., 4048
 Sheard, M. A., 7176
 Shearer, M. H., 1040
 Shedden, K., 2913, 4331
 Shelby, M. D., 44
 Shellman, Y. G., 6716
 Shen, C.-Y., 2440
 Shen, D.-W., 5909
 Shen, F.-M., 4594
 Shen, G., 7520
 Shen, H.-J., 1207
 Shen, L., 3268, 7321
 Shen, M. M., 3886
 Shen, W., 4315
 Sheng, H., 5218
 Shen-Ong, G. L., 3296, 8614
 Shepard, A., 1067
 Shepel, L. A., 5808
 Sheppard, G. S., 7861
 Sherr, C. J., 1046, 5420
 Sheu, B.-C., 6537
 Shewach, D. S., 6935
 Shi, H., 2164, 6110, 6178, 7825
 Shi, Q., 8791
 Shi, X., 7689
 Shi, X.-B., 2228
 Shi, Y., 4299
 Shi, Y. E., 3899
 Shi, Z. Q., 3162
 Shibata, D., 4577
 Shibata, K., 2278
 Shibutani, S., 4402
 Shichijo, S., 854
 Shichinohe, T., 1555
 Shida, D., 1706
 Shih, A., 7197
 Shih, I.-M., 3966, 4144
 Shih, J., 3872, 6583
 Shih, Y.-P., 647
 Shiina, H., 7717
 Shiku, H., 60
 Shim, E.-H., 1583
 Shim, J., 4781
 Shim, V., 2347
 Shim, Y. M., 3743, 6206
 Shima, Y., 107
 Shimada, H., 3026, 3511
 Shimada, K., 737
 Shimada, Y., 1470, 5691, 6320
 Shimeno, H., 7277
 Shimizu, K., 7791
 Shimizu, N., 5281
 Shimokawa, T., 6116
 Shimo, M., 5091
 Shin, M., 4888
 Shin, S. M., 4648
 Shindoh, M., 8338
 Shing, D. C., 4568
 Shingaki, K., 5281
 Shingu, T., 4044
 Shinohara, T., 1555
 Shinohara, Y., 8090
 Shinojima, N., 6962
 Shinozaki, K., 3605
 Shintaku, P., 4952
 Shin-ya, K., 6149
 Shipman, C., 287, 912
 Shiraishi, S., 6962
 Shirakata, Y., 2506
 Shirazian, S., 5462
 Shirin, H., 6825
 Shirley, P., 1490
 Shirwan, H., 4067
 Shiseki, M., 728, 2373
 Shishodia, S., 4375
 Shivakrupa, R., 4412
 Shmidt, E. N., 3459, 4426
 Shmulevich, I., 60
 Shockley, K., 4583
 Shoji, Y., 6090
 Shokat, K. M., 8930
 Shook, M. F., 2256
 Shringarpure, R., 5850, 6174
 Shrivastav, A., 7975

- Shu, H-K. G., 7443
 Shu, S., 1884
 Shu, X-O., 3980, 5727, 7624
 Shukeir, N., 2072
 Shukla-Dave, A., 9042
 Shultz, K. L., 8197
 Shusterman, S., 1631, 7861
 Shyr, Y., 7113
 Sibilio, L., 4119
 Sibley, K., 4327
 Sidhu, G. S., 2067
 Sidman, R. L., 5335
 Sidransky, D., 2216, 2312, 2316, 2351, 5723, 6575, 7694, 8507
 Sieber, O., 7595
 Sieck, L. K., 8984
 Sieckman, G. L., 4082
 Siedlecki, J. A., 4351
 Siegal, G. P., 847
 Siegel, P. M., 4920
 Sieger, K., 5105
 Siegfried, G., 1458
 Sigal, Y. J., 1073
 Sikes, R. A., 1981
 Silberg, D. G., 2005
 Silva, A. C., 4204
 Silva, S., 8656
 Silver, A., 2361
 Silverman, G. A., 1871
 Silverman, R. H., 6795
 Simeone, D. M., 2649
 Simi, B., 972
 Simms, L. A., 4577
 Simon, B., 1333
 Simon, H., 513
 Simons, B., 5866
 Simony-Lafontaine, J., 4809
 Simpson, P. J., 7330
 Singanallore, T., 1838
 Singer, F. R., 1884
 Singer, J. W., 8428
 Singh, B., 1101, 6523
 Singh, G., 2306
 Singh, J., 5978, 7098
 Singh, N. P., 4067
 Singh, R., 5073, 5470, 8853
 Singh, S., 2306
 Singh, S. K., 5821
 Singh, S. V., 771
 Singh, T. R., 5390
 Sinko, P., 3228
 Siomek, A., 4899
 Sirma, H., 4310
 Sitarz, M., 4533
 Sitrin, M. D., 3517
 Siu, I-M., 4773
 Sivridis, E., 5376
 Sivula, A., 7591
 Skelton, L. A., 3612
 Skepper, J., 8351
 Skibola, C. F., 4327
 Skilton, G., 2284
 Skoultschi, A. I., 6363
 Skripchenko, Y., 1490
 Slagboom, P. E., 1249
 Slamon, D. J., 196
 Slawin, K. M., 4662, 5874
 Sledge, G. W., Jr., 6105
 Sleeman, J. P., 713
 Slomovitz, B. M., 6195
 Slonim, D. K., 6069
 Slusher, L. B., 3092
 Smetsers, T. F. C. M., 2965
 Smeyne, R. J., 5420
 Smirnow, I., 2369
 Smit, F., 4748
 Smit, L. A., 3894
 Smith, A., 4538
 Smith, A. G., 4327
 Smith, B. A., 4239
 Smith, B. D., 1789
 Smith, B. L., 2742
 Smith, C., 5126
 Smith, C. D., 5962
 Smith, C. J., 4082
 Smith, C. L., 8877
 Smith, D. E., 3138
 Smith, E. M., 1789
 Smith, G., 4656
 Smith, G. C. M., 6008
 Smith, J. R., 5727
 Smith, K., 4568
 Smith, L., 36
 Smith, L. E., 324
 Smith, L. L., 8461
 Smith, L. M., 1235
 Smith, M. L., 608
 Smith, M. T., 4327
 Smith, M. W., 859
 Smith, P., 3654, 8596
 Smith, R., 958, 7051
 Smith, S. N., 5962
 Smithgall, T. E., 6763
 Smith-McCune, K., 1927
 Smyth, J. F., 8443, 8648
 Smyth, M. J., 207, 3058
 Snow, A. L., 4472
 Snow, B. E., 196
 Snowden, A. W., 8968
 Snyder, J. W., 8126
 Snyder, S. A., 6162
 Snyderwine, E. G., 5674
 Sobel, E., 1235
 Sobol, R. W., 5799
 Soda, Y., 6809
 Soden, J., 812
 Soderstrom, C., 7301
 Sodha, N., 6643
 Soeda, S., 7277
 Sofer, M., 2638
 Soff, G. A., 4275
 Soh, J-W., 6825
 Sohaib, S. M. A., 5143
 Sohara, Y., 3026
 Soker, S., 8345
 Sokoll, L. J., 3966
 Sokolov, K., 1999
 Solano, F., 8226
 Soler, P., 1405
 Solit, D. B., 2139, 8393
 Soloway, M. S., 2638
 Somsouk, L., 6666
 Sonar, V. N., 5636
 Song, C., 8079
 Song, C-Z., 4801
 Song, D. J., 3764
 Song, J., 5629
 Song, K., 4358, 8248
 Song, K. S., 4648
 Song, P., 214
 Song, S. H., 579
 Song, W., 5874
 Sonntag, D., 5745
 Sonoda, I., 5691
 Sonoda, Y., 1962
 Sonoshita, M., 4872
 Sonveaux, P., 1012
 Soo, K. C., 3309
 Sood, A., 6076
 Soosaipillai, A., 2223, 2771, 3958, 6543, 9032
 Sorek, R., 6996
 Sørensen, S. B., 1943
 Soret, J., 8203
 Sotomayor, E., 4441, 9007
 Soubeyrand, S., 1198
 Southon, E., 5320
 Sowadski, J., 6244
 Sowers, A., 8984
 Sowter, H. M., 6130
 Spaan, W. J. M., 2695
 Spangenberg, C., 7221
 Spaziente, R., 1969
 Specht, K. M., 8930
 Speicher, M. R., 8578
 Speina, E., 4351, 4899
 Speirs, V., 9055
 Speiser, D., 5601, 5712
 Spence, S., 5320
 Spencer, D. M., 6237, 8256, 8757
 Sperling, K., 6565
 Sperryak, J., 2477
 Sperti, C., 7451
 Spiegel, A. M., 8022
 Spiegelman, D., 8536
 Spiess, P. J., 5957
 Spindel, E. R., 214
 Spinella, F., 2447
 Spinola, M., 1871
 Spitz, D., 1297, 2109, 3413
 Spitz, F. R., 5299
 Spitz, M. R., 1157, 8531
 Spitzweg, C., 7840
 Spivack, D., 5521
 Spolski, R., 9016
 Sporn, M., 1371, 5551
 Spring, H., 4766
 Sprott, G. D., 2526
 Sproull, M., 1990
 Spugnardi, M., 1639
 Squarcina, P., 1560
 Squire, J., 5821
 Srinivasula, S. M., 1712
 Sriurapong, V., 2948
 Srivastava, R. K., 1059, 1712, 5390
 Srivastava, S., 4299
 St. C. Roberts, J., 6032
 St. Croix, B., 4144
 St. J. Whitley, G., 4960
 Stadler, W., 6069
 Stadtmayer, E., 8051
 Staff, S., 4978
 Staffend, N. A., 8330
 Stahl, J. M., 2881
 Stahl, M., 3395
 Stalle, L. R-V., 3833
 Stamatoyannopoulos, G., 4801
 Stampfl, A. P. J., 1776
 Stanbridge, E. J., 917, 1888
 Stancu, A., 7515
 Stanley, P., 7753
 Stanston, J., 3675
 Stanton, A. W. B., 3969
 Star, R. A., 271
 Staratschek-Jox, A., 2606
 Stark, G. R., 4074
 Starnes, J. H., 5636
 Starostik, P., 2606, 3708
 Stassi, G., 6784
 Stattin, P., 2701
 Stavnezer, E., 6626
 Steege, J. C. A. B-t., 2322
 Steeghs, K., 458
 Steele, R. J. C., 4656
 Steele, V. E., 3556
 Steffen, A., 713
 Stein, G. S., 2631, 5357
 Stein, J. L., 5357
 Stein, R., 111
 Steinle, A., 8996
 Steinman, A., 1769
 Steins, M., 7241
 Stellrecht, C. M., 7968
 Stenman, U-H., 807
 Stenner-Liewen, F., 263
 Stephan, C., 6543
 Stephan, D. A., 1865
 Stephens, K. C., 1389
 Stergiopoulos, S., 5308
 Sterling, J. C., 400
 Sterman, D. H., 7845
 Stern, P. L., 400, 6032
 Stévenin, J., 8203
 Stevens, A., 812
 Stevens, M. F. G., 2409
 Stevens, R., 5607
 Stevens, V. L., 4218
 Stewart, A. L., 5105
 Stewart, D., 1490
 Stewart, J., 958
 Stewart, T. J., 3058
 Stewart, V., 8437
 Stiborova, M., 2752
 Stidley, C. A., 7089
 Stigliano, A., 4747
 Stirling, D. I., 593
 Stöcker, M., 8414
 Stockert, E., 6076, 6948
 Stockett, D., 6387
 Stoehlmacher, J., 2898
 Stoeltzing, O., 2079, 2990, 3370, 3632
 Stoffers, D. A., 2005
 Stoiber, D., 3517
 Stoica, G. E., 1696
 Stojic, L., 8158
 Stoll, I., 5844
 Stollberg, N., 8271
 Stoner, G. D., 2399, 3556
 Stoop, H., 2244, 7674
 Stoppa-Lyonnet, D., 3061
 Storchova, Z., 8113
 Storkus, W. J., 4481, 6378
 Stott, D. I., 3275
 Stover, J. A., 6069
 Stover, K., 1000
 Stracke, M., 2042, 5446
 Strahs, A., 5352
 Strain, K., 5257
 Straszewski, S. L., 5573
 Stratakis, C. A., 5308
 Stratton, M. R., 8596
 Stricker, H., 7497
 Stricker, P. D., 4196
 Strickland, F. M., 3503
 Strijk, S. P., 12
 Strizzi, L., 1192
 Strobel, D., 6496
 Ströbel, P., 3708
 Strock, C. J., 5559
 Strome, S. E., 6501
 Stronach, E. A., 8648
 Strong, M. A., 8188
 Strube, R., 7321
 Struijk, L., 2695
 Stuart, K. E., 6327

- Stubdal, H., 6900
 Studzinski, G. P., 1325
 Stupp, R., 6613
 Sturge, J., 1667
 Sturgis, C. D., 3783
 Sturm, M., 2109
 Sturman, J. R., 5970
 Stürzbecher, H.-W., 2596
 Styblo, M., 1853
 Su, H., 3872
 Su, J., 1345
 Su, J. D., 3585
 Su, J.-M., 600
 Su, M.-w., 7122
 Su, S., 2306
 Su, W., 3524
 Su, Z., 2127
 Su, Z.-Z., 8138
 Suarez, B. K., 2033
 Subject, J. R., 2553
 Subler, M., 2118
 Suchiman, H. E. D., 1249
 Suda, T., 6651
 Sudilovsky, D., 2347
 Sugano, S., 6651
 Sugihara, K.-i., 4872
 Sugimoto, T., 1876
 Sugimoto, Y., 4048
 Sugimura, J., 4583
 Sugimura, T., 6090
 Suginaka, A., 8377
 Sugita, K., 4882
 Sugiyama, Y., 8977
 Suh, E., 60
 Suh, N., 1371
 Suh, W. S., 1242
 Suit, H. D., 747
 Sükösd, F., 455
 Sullenger, B., 7483
 Sullivan, K., 2794
 Sultan, M., 2416
 Sumida, T., 7098
 Sumitomo, M., 1365
 Summar, S. R., 5636
 Summers, M. K., 7185
 Sun, C., 2957, 4299
 Sun, C.-L., 573
 Sun, F.-X., 80
 Sun, H., 1583
 Sun, J., 1270, 8922
 Sun, L., 4299
 Sun, M., 7708
 Sun, T., 298
 Sun, T.-T., 179
 Sun, X., 3886, 6488, 8377
 Sun, Y., 1192, 7563
 Sung, M., 4037
 Sung, V., 3356
 Susa, S., 801
 Suswam, E., 4181
 Sutherland, R. L., 4196, 4322, 5926, 6387
 Sutter, G., 4107
 Suwihat, S., 4786
 Suyama, E., 119
 Suzuki, A., 674
 Suzuki, C., 7038
 Suzuki, H., 801, 3302, 5054, 5274, 8606
 Suzuki, K., 936, 6282
 Suzuki, M., 5091
 Suzuki, N., 4402, 6334
 Suzuki, T., 2762
 Suzuki, Y., 5159, 5564
 Suzuoki, M., 1555
 Suzuoke, H., 5669
 Svensson, S., 1737
 Swain, G., 2005
 Swamy, M. V., 5239
 Swarbrick, A., 4322
 Swarts, S. G., 3107
 Swartz, G., 468
 Swartz, G. M., 2997
 Swartz, H. M., 1025
 Swartz, M. J., 1550
 Sweeney, C. J., 6063
 Sweeney, C. L., 1304
 Sweeney, P., 4017
 Sweep, F., 5408
 Swift, L., 5992
 Swift, R. I., 6855
 Swilling, N. W., 476
 Swinler, S., 1568
 Swinnen, J. V., 3799
 Sykes, S. M., 4204
 Symmans, W. F., 4724
 Szepeshazi, K., 7913
 Szereday, Z., 7913
 Szucs, K. S., 5118
 Szutorisz, H., 689
- T**
- Tabach, Y., 7147
 Taback, B., 1884
 Tabor, M. P., 1727
 Tada, K., 6962
 Tada, M., 8674
 Taddei, G. L., 4281
 Taflan, P. M., 7113
 Tagawa, M., 2506
 Tagaya, Y., 271
 Taghavi, P., 1138
 Taguchi, O., 7920
 Tahara, H., 4112
 Tai, D.-I., 6229
 Tai, Y.-T., 18, 5850, 6187
 Tainton, K. M., 4460
 Taira, K., 119, 6809
 Taira, T., 8338
 Tait, D. M., 6855
 Takada, K., 7062, 8948
 Takada, M., 895
 Takahara, K., 8090
 Takahashi, A., 8338
 Takahashi, H., 3054
 Takahashi, M., 6090, 8948
 Takahashi, N., 107
 Takahashi, S., 5213
 Takahashi, T., 4516
 Takahashi, Y., 4253
 Takakuwa, T., 7606
 Takamori, S., 2829
 Takata, M., 432
 Takayama, T., 8948
 Takebayashi, H., 1106
 Takeda, A., 3632
 Takeda, H., 4872
 Takeda, J., 674
 Takeda, K., 5889
 Takehara, T., 3054
 Takei, Y., 5091
 Takenaka, K., 6791
 Takenaka, Y., 8302
 Taketani, T., 4882
 Taketo, M. M., 4872
 Takeuchi, H., 441, 7581
 Taki, T., 4882
 Takimoto, A., 8377
 Takimoto, R., 8948
 Takimoto, S., 5521
 Takino, T., 2335
 Takuwa, Y., 1706
 Talarico, T., 1776
 Tallini, G., 2316
 Tamada, K., 6501
 Tamayo, P., 1602
 Tamimi, R. M., 8536
 Tammela, J., 6076
 Tamura, D., 5028
 Tamura, H., 6501
 Tan, H.-X., 2716
 Tan, J., 4009, 7663
 Tan, P., 3309
 Tan, S., 8968
 Tan, S. Y., 3309
 Tan, W., 3987, 8057
 Tan, X., 1838
 Tan, Y., 8377
 Tanabe, M., 8592
 Tanaka, F., 5105, 6791
 Tanaka, H., 6942
 Tanaka, N., 4434
 Tanaka, T., 5257, 7845, 8145
 Tanaka, Y., 3913, 8132
 Tandle, A., 6405
 Tanenbaum, D. M., 4781
 Tang, B., 8284
 Tang, J., 7753
 Tang, K., 4258
 Tang, P., 6488
 Tang, X., 7147
 Tang, Y., 1166
 Tangrea, J. A., 3991
 Tani, K., 6809
 Tani, Y., 4420
 Taniguchi, H., 8629
 Taniguchi, N., 6262
 Tanihara, H., 6651
 Tannenbaum, C., 1676
 Tanner, B., 7221
 Tanner, J. E., 207
 Tanner, M., 4978, 8861
 Tannock, I. F., 2134
 Tanuma, J.-i., 1871
 Tanyi, J. L., 1073
 Tao, H.-Q., 4684
 Tao, J., 5126
 Tao, Y., 6523
 Tapang, P., 7861
 Taraboletti, G., 1534, 5224
 Tarafa, G., 5731
 Tardy, C., 7392
 Tarutani, M., 319
 Tashiro, E., 424
 Tateishi, K., 8132
 Tatsumi, M., 6252
 Tatsumi, T., 4481, 6378
 Taub, J. S., 2037
 Taupin, D., 2569
 Taverna, P., 838
 Taxman, D. J., 5095
 Tay, S. T., 3309
 Taylor, B., 3084
 Taylor, D. D., 4067
 Taylor, G. M., 6563
 Taylor, J. A., 7530
 Taylor, J. M., 4577
 Taylor, J. M. G., 2913
 Taylor, K. J., 8648
 Taylor, N. S., 942
 Taylor, P. R., 3872, 3991
 Taylor, R., 7694
 Taylor, R. N., 3145
 Taylor, S. M., 6579
 Taylor, W. R., 4074
 Tazi, J., 6149, 8203
 Teeling, J. L., 5480
 Tegeder, I., 1846
 Teh, B. T., 1743, 4583
 Teicher, B. A., 5866, 8939
 Teitz-Tennenbaum, S., 2546, 8466
 Tejada, L. V., 906
 Telleria, N., 491
 Tellez, C., 3632
 Tempfer, C. B., 3066
 ten Dam, G. B., 2965
 ten Dijke, P., 1371
 TenEyck, C. J., 2462
 Terada, K., 2300
 Terai, M., 7215
 Teramoto, K., 7920
 Terasaki, M., 5821
 Terasima, M., 4044
 te Riele, H., 2062
 Terry, E., 1748
 ter Schegget, J., 2695
 Terui, T., 8948
 Teshima, T., 4253
 Tessorollo, L., 5320
 Têtu, B., 8511
 Teubert, U., 3189
 Tezuka, N., 7920
 Thacker, J., 8181
 Thaker, H. M., 5291
 Thaler, H. T., 9042
 Thelen, M., 7221
 Theodossiou, T., 1818
 Thepen, T., 8414
 Theti, D. S., 3612
 Thiantanawat, A., 8037
 Thibodeau, J. B., 2836
 Thibodeau, S. N., 5209
 Thiel, E., 3483, 5582
 Thiele, C. J., 1122
 Thielemans, K., 5587
 Thiery, J., 3682, 8108
 Thilly, W. G., 5793
 Thimmaiah, K. N., 364
 Thomas, H. J. W., 7595
 Thomas, R. K., 2606
 Thomas, S. M., 5629
 Thomas, T. Z., 2256
 Thompson, B. G., 348
 Thompson, C. B., 1712, 8451
 Thompson, H. J., 1228
 Thompson, J., 3173, 5505
 Thompson, R. G., 8360
 Thompson, T. C., 3073, 7853
 Thor, A. D., 2425
 Thornburn, A. M., 1834
 Thornburg, N. J., 8293
 Thornton, A., 6195
 Thornton, M., 1676
 Thorpe, P. E., 1144
 Thorstenson, Y. R., 3325
 Thun, M. J., 6556
 Tian, F., 8284
 Tian, L., 600, 2977
 Tian, Y., 6299
 Tice, D., 7907
 Tidow, N., 1172
 Tiemann, K., 8962
 Tiemessen, D. M., 1994
 Tien, E. S., 5767
 Tikhomirov, O., 39

- Tilley, W. D., 4786
 Tilli, M. T., 7668
 Tillman, D. M., 5118
 Tillman, R. M., 4568
 Timme, T. L., 7853
 Timms, J., 2338
 Tindall, D. J., 7638
 Ting, H.-J., 4888
 Ting, J. P.-Y., 5095, 6928
 Tinley, T. L., 1538, 3211
 Tirado, O. M., 6290
 Tirkkonen, M., 8861
 Titley, J., 3612
 Tlsty, T. D., 1596, 2347
 Tnani, M., 250
 To, L. B., 5438
 Todaro, M., 6784
 Todisco, A., 6350
 Todoroki, T., 4434
 Tofilon, P. J., 7377
 Tognon, M., 7256
 Tohgo, A., 80
 Tokino, T., 8145, 8606
 Tokizane, T., 4888
 Tokumaru, Y., 2312, 2316
 Tokunaga, M., 7062
 Tollenaar, R. A. E. M., 1148
 Tomarev, S., 713
 Tomasetto, C., 3032, 5844
 Tomassetti, A., 696
 Tomczak, M., 6042
 Tomei, G., 2499
 Tomes, L., 1954
 Tominaga, Y., 902
 Tomita, K., 7785
 Tomita-Mitchell, A., 5793
 Tomlinson, A. E., 6032
 Tomlinson, I. P., 3819, 7595
 Tommasi, S., 1639
 Tomonaga, T., 3511
 Tonetti, M., 6282
 Tong, B. C., 2316
 Tong, B. J., 906
 Tong, W.-M., 4836, 7263
 Tonnel, A.-B., 6084
 Tonon, G., 8634
 Tops, C., 154
 Torchia, E. C., 3464
 Torchilin, V. P., 6327
 Torigoe, T., 3729
 Torres, K., 1207
 Toscano, V., 4747
 Tosello, V., 2158
 Tousson, A., 8079
 Toutant, J., 7679
 Town, A., 5761
 Townsend, C. A., 7330
 Townsend, C. M., Jr., 3495
 Townsend, P. A., 4150
 Toyota, M., 4620, 8145, 8606
 Tracy, E., 3812
 Tran, A., 1527
 Tran, H., 1413
 Trapani, J. A., 4460
 Trapasso, F., 878, 882, 1183, 3352, 3724
 Traugher, B., 6252
 Traverso, G., 8578
 Trempus, C., 4232
 Trent, J., 7926
 Trent, J. M., 6795
 Trent, S., 3626
 Trentesaux, C., 6149
 Treon, S. P., 6689
 Trepel, J., 7777
 Trepicchio, W. L., 6069
 Tretiakova, M., 3517
 Triano, E. A., 3092
 Triebel, F., 2518
 Trinh, T., 3755
 Trink, B., 2351
 Tripodis, N., 125
 Trivedi, N. R., 2881
 Trosko, J. E., 1724
 Trost, T., 7221
 Trott, D. A., 689
 Troyer, D. A., 3296
 Trudel, D., 8511
 Trzyna, E., 7926
 Tsai, C.-H., 256
 Tsai, K. K. C., 3418
 Tsai, M.-Y., 7106
 Tsai, S.-L., 6229
 Tsai, V., 4003
 Tsan, R. Z., 2971
 Tsang, B. K., 7081
 Tsao, T., 5926
 Tschentscher, F., 2578
 Tschoi, M., 9016
 Tseng, C.-C., 7526
 Tseng, T.-L., 647
 Tseng, Y.-H., 5850
 Tschlis, P. N., 2172
 Tsiopoulos, A., 6084
 Tsokos, M., 1122
 Tsuchida, T., 1806
 Tsuchiya, H., 7785
 Tsuchiya, M., 4044
 Tsuchiya, N., 4407
 Tsuda, Y., 4420
 Tsui, H., 250
 Tsui, M., 8090
 Tsui, S., 6726
 Tsui, M., 6726
 Tsuno, N. H., 1706
 Tsunoda, T., 4112
 Tsuruo, T., 824, 831, 6568
 Tsutsumi, S., 242, 4882
 Tsutsumi, Y., 4420
 Tsuzuki, T., 902
 Tu, S. P., 7724
 Tu, Z., 7356
 Tucker-Garcia, L., 7861
 Tudek, B., 4351, 4899
 Tunstead, J., 386
 Tuominen, P., 8623
 Tur, M. K., 8414
 Turk, J. R., 3805
 Turkson, J., 1270
 Turner, E., 5957, 8022
 Turteltaub, K. W., 8461
 Tuszyński, G. P., 2020
 Tutt, A. L., 5480
 Tuveson, D. A., 5198
 Tuxhorn, J. A., 5859
 Tuyaerts, S., 5587
 Twardzik, T., 2268
 Twardy, D. J., 3923
 Twine, N. C., 6069
 Tyler, T., 3646
 Tyminski, E., 2300
 Tyrsin, O. Y., 2268
 U
 Ubai, T., 8090
 Ucur, E., 3112
 Udayakumar, T. S., 2292
 Udelsman, R., 2316
 Uematsu, K., 4547
 Uemura, T., 4044
 Ueno, S., 60
 Ugai, H., 4434
 Uhrbom, L., 4305
 Ulaner, G. A., 1759
 Ulbright, T. M., 6063
 Uldrian, S., 7176
 Ulivi, M., 6144
 Um, H.-D., 1093
 Umezawa, K., 107
 Umphress, S. M., 5889
 Underhill, C. B., 5685
 Underwood, S., 4275
 Unfer, R. C., 987
 Unger, C., 4062
 Uochi, T.-a., 3931
 Upson, J., 2172
 Urano, M., 3268
 Urasaki, Y., 1000
 Urashima, M., 5159
 Urban, N., 3695
 Urnov, F., 8968
 Usadel, H., 2316
 Ushio, Y., 6962
 Usui, T., 7717
 Utsumi, R., 6894
 Uzzo, R. G., 8695
 V
 Vadasz, Z., 1657
 Vader, V., 2256
 Vadlamudi, A., 7330
 Väisänen, T. H., 7571
 Valcárcel, M., 491
 Valdembri, D., 1500
 Validire, P., 3682
 Valk, P., 7674
 Vallina, L. A., 3173
 Valmori, D., 5601
 Valonen, P. K., 3195, 7571
 Vanaja, D. K., 3877
 Van Arsdall, M., 2971
 van Asperen, C. J., 8153
 van Belle, P., 756
 van Bokhoven, A., 5879
 VanBrocklin, M. W., 8330
 Van Camp, B., 287, 3019
 VandeBerg, J. L., 6121
 Vandecasteele, G., 541
 van Dekken, H., 2244
 van den Berg, D., 573, 7526
 van den Brandt, P. A., 3133
 van den Eeden, S. J. F., 636
 van den Eertwegh, A. J. M., 4101
 Vanden Heuvel, J. P., 5767
 van der Bruggen, P., 5587
 van der Burg, S. H., 636
 van der Heijden, M. S., 2585, 6999
 van der Hulst, J. M., 636
 Vanderhyden, B. C., 1389
 Vanderkerken, K., 287, 3019
 van der Meijden, E., 2695
 van der Niet, S. T., 2322
 Vanderveer, L., 664, 4967
 van der Vliet, H. J. J., 4101
 VanderWaal, R. P., 6864
 van der Wal, A., 2062
 VanderWeele, D. J., 312
 van der Zee, A. G. J., 807
 van de Westerloo, E. M. A., 2965
 van de Winkel, J. G., 5595, 8414
 van Diest, P., 5679
 van Dijk, T., 7674
 van Dort, S. C., 1339
 van Echten-Decker, G., 534
 van Engeland, M., 3133
 van Geloof, W. L., 2965
 van Grambergen, M., 807
 van Gurp, R. J. H. L. M., 7674
 Vanhaesebroeck, B., 1667
 van Heek, N. T., 4158
 van Herwaarden, A. E., 6447
 Van Hummelen, P., 44
 Vanin, E. F., 505
 Van Kien, P. K., 5615
 Van Kuppevelt, T. H., 2965
 van Laarhoven, H. W. M., 7609
 Van Meir, E. G., 8670
 van Muijen, G. N. P., 12, 2965
 Vanni, R., 1351
 van Noessel, C. J. M., 3894
 van Ojik, H. H., 5595
 van Oorschot, M., 7674
 van Puijenbroek, M., 1148
 Van Riet, I., 3019
 van Roozendaal, K. E. P., 2244
 van Roy, F., 2172
 van Spaendonck, R., 1449
 van Tellingen, O., 1339
 van't Veer, L. J., 1449
 Vantuyghem, S. A., 4763
 van Vugt, M. J., 5595
 van Waarde, A., 8558
 van Welsom, T., 1449
 van Wijnen, A. J., 2631, 5357
 Van Zant, G., 5414
 van Zoelen, E. J. J., 2244
 Varani, J., 67
 Varga, J. L., 7913
 Varon, R., 6565
 Varro, A., 942
 Varticovski, L., 2118
 Vasen, H., 154, 1148, 8153
 Vasilevskaya, I. A., 3241, 8600
 Vassilakos, A., 2802
 Vaughan, A. T. M., 1377
 Vaughan, L., 8126
 Vaught, J., 5978
 Vaupel, P., 7634
 Vaziri, H., 5785
 Vázquez, I., 3079
 Veach, D. R., 6395
 Vecchione, A., 186, 1183
 Veerkamp, J. H., 2965
 Veith, J., 2477
 Velculescu, V. E., 4144
 Velicescu, M., 5813
 Vella, V., 5829
 Veltman, J. A., 2872
 Veneri, M., 8586
 Venkatasubbarao, K., 2624
 Venkatraman, E., 4338
 Venkov, C., 3386
 Venturo, I., 4119
 Venuti, A., 2447
 Verdier-Pinard, P., 1207
 Verfaillie, C. M., 1304
 Vergnon, I., 3682
 Vergote, I., 807
 Verhaegh, G. W., 4748
 Verhoef, S., 1449
 Verhoeven, G., 3799
 Verlaan, B. P. J., 2695
 Verma, A. K., 3037, 6547
 Verrier, F., 541

AUTHOR INDEX TO VOLUME 63

- Verrijp, K., 5408
Verschoyle, R. D., 5902
Versteeg, E. M. M., 2965
Vertuani, S., 8006
Vessella, R. L., 4662
Vetrie, D., 3940
Veuger, S. J., 6008
Veverka, K. A., 364
Vezzani, C., 4225
Vezzoni, P., 2855
Vezzosi, V., 342
Viel, S., 6506
Vidal, H., 4809
Vidal, S., 2251
Vidal-Vanaclocha, F., 491
Vieira, H. L. A., 541
Vieweg, J., 2127
Vieyra, D., 5785
Viglietto, G., 882, 7423
Vigneri, P., 5829
Vigneri, R., 5829
Vignot, S., 7575
Viguier, J., 5738
Vijayachandra, K., 3447
Vile, R., 2145, 3173, 5505
Vilki, S., 154
Villa, A., 2855
Villa, R., 3490
Villalobos, M. J., 1377
Villani, M. E., 3202
Villani, R., 2499
Villar-Garea, A., 4984
Villemure, J-F., 3334
Vincent, T. L., 6212
Vincent-Dejean, C., 5308
Virador, V., 5257
Virtamo, J., 3991
Viscofsky, N., 4805
Vishwanatha, J. K., 7769
Vissac-Sabatier, C., 6607
Visvanathan, J., 3309
Vizmanos, J. L., 3079
Vlasuk, G. P., 2997
Vlodavsky, I., 7733, 8821
Vo, K. T., 250
Vogel, H., 3866
Vogel, J-U., 1508
Vogel, S., 8414
Vogelstein, B., 994, 5234, 8578
Voigt, W., 513
Vojtesek, B., 7176, 8827
Volk, E. L., 5538
Volkert, W. A., 4082
Voll, R., 6496
Vollmar, A. M., 8869
Vollmers, H. P., 2052, 7995
Volpe, P., 756
von Blomberg, B. M. E., 4101
von Bredow, D. C., 2292
von Bubnoff, N., 6395
von Deimling, A., 1602
von der Lieth, C-W., 4766
von Freeden-Jeffry, U., 6387
von Heydebreck, A., 6200
von Knebel Doeberitz, M., 3112
von Kobbe, C., 7136
von Lindern, M., 7674
von Lintig, F. C., 3517
von Marschall, Z., 1083
von Willebrand, M., 1420
Vortmeyer, A., 817, 5320, 7051
Voss, N., 7122
Voss, S. G., 6501
Vosseler, S., 8264
Vourganti, S., 965
Vradii, D., 5357
Vu, T. H., 1900
Vuillaume, M., 8717
Vujanovic, N. L., 6378
Vujcic, S., 3619

W
Wacker, H-H., 1644
Wada, H., 6791
Wagenaar, E., 6447
Wagner, K., 1083
Wagner, M., 2681, 4945, 6478
Wagner, T. M. U., 3325
Wagner, U., 3234
Wagstaff, J., 2322
Wahl, R. L., 6252
Wainscoat, J. S., 3940
Waisfisz, Q., 2688, 6998
Waisman, D. M., 348
Wakabayashi, K., 6090
Wakayama, M., 4434
Wakefield, L. M., 8284
Wakimoto, H., 2300
Waks, T., 2470
Waldeck, W., 4766
Walden, P. D., 2067
Waldman, F. M., 179, 2872, 7167
Waldman, T., 5370, 8085
Waldmann, T. A., 271, 6453
Wali, R. K., 3517
Walker, C. L., 1221, 2675
Walker, E. A., 505
Walker, R. L., 7158
Walker, V., 5173
Wall, N. R., 230
Wall, S. J., 4750
Wallace, J., 1398
Wallace, S., 7870
Waller, J. L., 5808
Waller, S. M., 2631
Wallerand, H., 8108
Wallwiener, D., 3234
Walsh, C. M., 5716
Walsh, M. D., 887
Walshe, C. A., 5480
Waltenberger, A., 8735
Walter, L., 8212
Walter-Yohrling, J., 5866, 8939
Waltham, M., 5243
Walton, F., 1853
Walz, T. M., 2194
Wanders, R. J., 7365
Wang, B. G., 3966
Wang, C., 3872, 5866, 8939
Wang, C-J., 3257
Wang, C-K., 647
Wang, D., 6244
Wang, F., 4936, 8784
Wang, G., 7936, 9016
Wang, H., 4315, 4315, 8057, 9007
Wang, H. G., 93, 4368
Wang, H-G., 1483
Wang, H-J., 441
Wang, J., 7853, 7861
Wang, L., 2775, 3855, 4174, 4407, 4724, 5209
Wang, L. H., 2046
Wang, M., 847, 2802, 3317, 6864
Wang, M. Z., 1652
Wang, N., 5151
Wang, Q., 1325, 1631, 2425
Wang, Q-H., 3872
Wang, R., 7699
Wang, S., 2645, 4577
Wang, T., 3764
Wang, T. C., 942
Wang, T-L., 4144
Wang, W., 560, 4037
Wang, X., 1325, 5291, 7345, 8377
Wang, X. W., 2596
Wang, X-D., 3138
Wang, X-Y., 2553
Wang, Y., 600, 793, 2206, 3317, 4389, 5414, 7563
Wang, Y-C., 7861
Wang, Y-H., 5526
Wang, Z., 655, 4698, 5234, 6121, 6795, 6996
Wang, Z-Q., 4836, 7263
Wanner, G., 8869
Ward, J. M., 8022
Wardman, P., 776
Wargovich, M. J., 8549
Waring, P., 2569
Warren, R. S., 3145
Waseda, S., 936
Washington, M., 616
Wasserman, L., 1608
Watabe, K., 1731
Watabe, M., 1731
Watanabe, A., 8629
Watanabe, C., 5781
Watanabe, G., 6004, 6320
Watanabe, M., 936, 3747, 8090
Watanabe, O., 1906
Watanabe, T., 1706
Waterhouse, N. J., 4460
Watkins, S. C., 6378
Watring, N., 4412
Watson, D. K., 4626
Watson, P. H., 1954
Watts, K. T., 5808
Watts, M., 1040
Wawra, E., 2681
Wax, A., 3556
Waxman, D. J., 8563
Waxman, S., 1853, 8138
Wayne, T. L., 3325
Weaver, Z., 2179
Weber, A., 1333
Weber, B., 8051
Weber, B. L., 756
Weber, K. J., 3755
Weber, K. L., 2940
Weber, M. J., 1975, 1981
Weber, R. F. A., 2244, 7674
Weber, W., 5866, 8939
Webster, L. K., 1776
Webster, R., 2033
Wechselberger, C., 1192
Wehner, S., 7032
Wei, D., 3855
Wei, H., 4037
Wei, S., 8523
Wei, S. H., 2164, 6110
Wei, Y-Q., 600
Weichselbaum, R. R., 308
Weih, D., 713
Weijnenberg, M. P., 3133
Weil, M. M., 2361
Wein, L. M., 1317, 8555, 8556
Weinberg, R., 1853
Weiner, G. J., 5595
Weinreb, P. H., 2020
Weinreich, D. M., 5957
Weinstein, I. B., 424, 6825
Weinstein, J., 6299
Weinstein, J. N., 1000, 2782, 5243, 8634
Weinstein, M. H., 484
Weiss, M., 3189, 3654
Weiss, R. M., 5381
Weiss, T. S., 2369
Weiss, W., 3001
Weiss, W. A., 1589, 5266, 8930
Weissleder, R., 1936, 6838, 8122
Weissman, B. E., 560
Weisz, J., 3092
Welch, D. R., 432
Welch, M. J., 5496
Weller, M., 7462, 8996
Wellinger, R., 7679
Wellisch, D., 6478
Wells, A., 4632, 5629
Wells, D., 417
Wellstein, A., 1696, 8085
Weim, B. E., 6237, 8256
Welsh, W., 7563
Welters, M. J. P., 636
Welzel, N., 1723
Wen, S. F., 4003
Wen, W., 5727
Wen, W-H., 3257
Wen, X., 7870
Wen, Y., 7630
Wen, Y-J., 600
Wendland, M. F., 1589
Wendt, M. A., 5230
Werahera, P. N., 5879
Werelius, B., 1894
Weremowicz, S., 1351
Werness, B., 417
Wesemann, D. R., 8670
Wesseling, P., 5408
West, K. A., 780
West, M., 3716
Westendorp, R. G. J., 1249, 2695
Westermann, F., 7742
Westermarck, J., 3473
Westermarck, B., 4305
Westfall, M. D., 7113
Westlin, W. F., 2079
Westra, W. B., 2312, 2316
Westra, W. H., 5723
Wetherill, Y. B., 4903
Wetmore, C., 2733, 3162, 5428
Wexler, L. H., 1122
Wey, J. S., 3370
Weydert, C., 1297, 5513
Whalen, P. M., 7301
Wharton, W., 3021
Whary, M. T., 942
Wheeler, D. L., 3037, 6547
Wheeler, T. M., 4662, 5874, 6244
Whisenhunt, T. R., 8670
White, E., 6096
White, I. N. H., 8461
White, M., 3395
White, S. A., 5532
Whitehead, R. H., 994, 1748
Whitesell, L. J., 1860
Whiteside, T. L., 3675
Whittaker, S. J., 9048
Whittemore, A. S., 417
Wickline, S. A., 5838
Wickramasinghe, D., 1020
Widschwendter, A., 7641
Widschwendter, M., 7641
Wiedemeyer, R., 7742
Wiedenmann, B., 1083

- Wiehle, S., 4017
 Wiendl, H., 7462
 Wientjes, M. G., 579
 Wiesmann, M., 3145
 Wijnen, J., 154
 Wikman, F., 154
 Wilcox, G. E., 4662
 Wilczynski, S. P., 1888, 7515
 Wiley, H. S., 1130
 Wilfert, F., 5745
 Wilkens, L. R., 1538
 Will, H., 4310, 8271
 Wilcox, N., 3708
 Willems, A., 287, 3019
 Willett, W. C., 8542
 Willhauck, M., 3483
 Willhite, D., 4196, 6387
 Williams, C. R., 1371
 Williams, D., 8516
 Williams, J. L., 7613
 Williams, K., 1192
 Williams, M. S., 468
 Williams, N. N., 878, 3352
 Williams, P. J., 5028
 Williams, S., 3632, 7657
 Williams, S. A., 7338
 Williamson, B., 6076
 Willingham, M. C., 1834, 5274
 Willis, J., 1568
 Willson, J. K. V., 994, 1568, 4731
 Wilmot, C. M., 1025
 Wilson, A. J., 5401, 6311, 8791
 Wilson, B. C., 7986
 Wilson, D., 4705, 5761
 Wilson, D. M., III, 549
 Wilson, J. L., 8360
 Wilson, J. M., 5299
 Wilson, K., 1568
 Wilson, L., 1214, 2794
 Wilson, S. H., 5799
 Wilson, W. R., 5970
 Wilting, J., 713
 Wiltrout, R. H., 207
 Wine, J., 207
 Winter, C. L., 1631
 Winter, P. M., 5838
 Winters, J. L., 5209
 Winters, S. A., 4620
 Winterle, S., 7462
 Wirth, T., 3181
 Wise, P., 4594
 Wislez, M., 1405
 Wisiowski, T. T., 6496
 Witte, L., 8912
 Wittke, I., 7742
 Wittmann, B. M., 5151
 Wittmann, S., 93
 Wittrup, K. D., 1288
 Wodarz, D., 6635, 8554
 Woelfle, U., 5679
 Wolf, C. R., 4656
 Wolf, J., 2606
 Wolf, J. K., 1073
 Wolfe, M. M., 586
 Wolff, J., 3162
 Wolff, K., 8735
 Wolffe, A. P., 8968
 Wolffenbuttel, K. P., 2244
 Wollenberg, B., 6478
 Wollscheid, U., 7221
 Wong, A. J., 250
 Wong, B. C.-Y., 7724
 Wong, C. A., 4275
 Wong, C. S., 5950
 Wong, C.-M., 7646
 Wong, H., 6658
 Wong, K., 3309
 Wong, L.-J. C., 3866
 Wong, T.-W., 3812
 Wong, V. A., 929
 Wong, W. H., 5352
 Wong, W. K., 3309
 Wong, W. M., 7724
 Wong, W.-M., 3819
 Woo, J.-H., 3430
 Woo, S. L. C., 3605
 Wood, J. T., 2364
 Wood, W. C., 6815
 Wood, W. L., 5781
 Woodhouse, E. C., 2042
 Woodruff, T. K., 3783
 Woods, E. A., 1818
 Woods, R., 7907
 Woods, W., 7270
 Woods, W. G., 6357
 Woodson, K., 3991
 Workman, P., 6855
 Wormke, M., 958
 Wozniak, E., 7995
 Wray, L., 8051
 Wright, G. L., Jr., 2701
 Wright, J., 2802
 Wright, N. A., 3819
 Wright, R. L., 4781
 Wright, W. E., 1914
 Wrighton, C. J., 5532
 Wu, A. H., 7526
 Wu, A. M., 1160
 Wu, C.-Y., 2440
 Wu, E. F., 4805
 Wu, F., 8318
 Wu, G., 2312, 2351, 2589
 Wu, H., 1515
 Wu, H.-S., 2440
 Wu, J., 4037, 5126, 7950
 Wu, J. T., 1317
 Wu, K., 3395
 Wu, L., 2134, 4552, 6488
 Wu, M., 2477
 Wu, P.-E., 2440
 Wu, Q., 8318
 Wu, R., 2913
 Wu, R. S., 1860
 Wu, T., 296, 3775
 Wu, T. D., 5781
 Wu, T.-C., 2393
 Wu, W., 6195, 7356
 Wu, X., 865, 1106, 1157, 3775, 4936
 Wu, X.-R., 179
 Wu, Y., 600, 4384
 Wu, Y. L., 2933
 Wulf, G., 6244
 Wunder, E., 3931
 Wyllie, F. S., 4854
 Wynford-Thomas, D., 4854
 Wyrobek, A. J., 44
 Wyszczynski, M., 7926
 Xi, D., 8877
 Xi, L., 4805
 Xi, S., 6763
 Xia, X., 7497
 Xiang, Y., 6795
 Xiao, D., 6825
 Xiao, F., 600
 Xiao, H., 8763
 Xiao, W., 2046, 4698
 Xiao, X., 579
 Xiaolian, Z., 6469
 Xie, D., 8549
 Xie, H., 2802
 Xie, K., 3855
 Xie, T.-X., 6154
 Xie, X., 3073
 Xie, X. T., 4331
 Xie, Z., 5370
 Xing, M., 2312, 2316
 Xing, R., 4232
 Xing, Z., 3775
 Xiong, K., 2802
 Xiong, P., 3987
 Xu, C., 3386
 Xu, D., 1743
 Xu, H., 8323
 Xu, J., 3486, 7624
 Xu, J.-P., 8869
 Xu, L. L., 4299
 Xu, M., 7785
 Xu, P., 902
 Xu, W., 6626, 7777
 Xu, X., 4561
 Xu, X.-c., 1470
 Xu, X.-M., 5685
 Xu, X.-X., 4967
 Xu, Y., 4577
 Xu, Y.-M., 3257
 Xu, Z., 4547
 Xue, C., 3386
 Xue, L., 980, 4037, 6583
 Xuejun, Z., 6469
 Y
 Yacoub, G. M., 2223
 Yafal, A. G., 7942
 Yagi, K., 801
 Yagi, S., 80, 8377
 Yagita, H., 207
 Yakar, S., 4384
 Yamada, A., 2829
 Yamada, K., 4044
 Yamada, K. M., 2335
 Yamada, S., 3026
 Yamada, T., 895, 4641
 Yamagata, T., 4967
 Yamaguchi, H., 93, 1483, 1706
 Yamaguchi, M., 60
 Yamaguchi, S., 3511
 Yamamoto, H., 6432
 Yamamoto, N., 7785
 Yamamoto, T., 1046, 5159
 Yamamoto, Y., 3931
 Yamamoto-Yamaguchi, Y., 3659
 Yamane, K., 3049
 Yamaoka, M., 149, 5622
 Yamaoka, Y., 3043
 Yamasaki, K., 2506
 Yamasaki, T., 4044
 Yamashita, J., 2335, 3364
 Yamashita, K., 5723, 6575
 Yamashita, M., 4017
 Yamashita, T., 8145, 8606
 Yamashita, Y., 3931
 Yamazaki, H., 7581
 Yamori, T., 831, 8592
 Yan, H., 6815
 Yan, J., 5046, 9023
 Yan, P. S., 2164, 6110, 6178
 Yan, Q., 4677
 Yan, T., 5490
 Yan, X., 7081
 Yanaga, K., 5159
 Yanagihara, K., 6791
 Yanamandra, N., 2454
 Yancey, D., 2127
 Yang, A. S., 2150, 6956
 Yang, A.-G., 3257
 Yang, B., 1520
 Yang, C., 3556, 3626, 8312
 Yang, C. S., 4396, 7563
 Yang, C.-P. H., 7891
 Yang, D., 1927
 Yang, F., 5859
 Yang, G., 7853
 Yang, H., 655, 4731
 Yang, I., 4368
 Yang, J. Y., 7384
 Yang, J.-L., 600
 Yang, J.-M., 1515, 2492, 6894
 Yang, L., 600, 831, 6568, 6815, 7106
 Yang, M., 4239, 7785
 Yang, N., 3403, 4225
 Yang, Q., 2596
 Yang, Q.-W., 6299
 Yang, R., 7284
 Yang, S., 5685
 Yang, W., 965
 Yang, W. C., 4990
 Yang, W. Q., 3162
 Yang, W.-H., 8393
 Yang, X., 1122, 4181, 7753
 Yang, X. H., 2425
 Yang, X. Y., 2046
 Yang, Y., 4648, 7724, 7777, 8749
 Yang, Z., 312, 8377
 Yannone, S. M., 22
 Yao, M., 586
 Yao, R., 801
 Yao, S., 3883
 Yao, W., 4225
 Yao, Z., 7883
 Yarranton, G. T., 5526
 Yarymowich, N. C., 7197
 Yashiro, M., 8629, 8848
 Yasumaru, M., 6726
 Yasumoto, H., 7717
 Yasumoto, K., 8592
 Yasunaga, K., 6651
 Ye, F., 375, 4037
 Ye, J. J., 8516
 Ye, W., 3026
 Yeatman, T. J., 4368
 Yee, D., 627
 Yeh, C.-T., 6229
 Yeh, K.-T., 647
 Yeh, S., 4888, 7106
 Yen, L., 3764
 Yen, Y., 980, 6583
 Yendamuri, S., 878, 1183, 3352, 3724
 Yeo, C. J., 994, 2585, 3735, 7032, 8614
 Yeo, E.-J., 8700
 Yeom, Y.-I., 8248
 Yeung, A. T., 1311
 Yi, F., 2923
 Yi, J., 4037
 Yih, L.-H., 6680
 Yildiz, P., 7113
 Yin, H., 8922
 Yin, J., 4577
 Yin, J. J., 3084

AUTHOR INDEX TO VOLUME 63

- Yin, Z., 6697
Ying, H., 5274
Ylä-Herttua, S., 3195, 7571
Yochim, J. M., 3891
Yoda, K., 3511
Yodh, A. G., 7232
Yokohira, M., 7581
Yokohori, N., 5054
Yokose, T., 2096
Yokosuka, O., 8674
Yokota, H., 2506
Yokota, J., 2373
Yokoyama, K. K., 4434
Yokoyama, S., 936
Yokoyama, Y., 382
Yolcu, E. S., 4067
Yoneda, T., 5028
Yonezawa, K., 8278
Yonou, H., 2096
Yoo, C. J., 31
Yoo, H-S., 8248
Yoo, P. B., 3667
Yoo, S., 8284
Yoon, C-S., 348
Yoon, J-T., 6825
Yoshida, K., 8338
Yoshida, T., 6158
Yoshida, Y., 3729
Yoshie, O., 4420
Yoshihara, H., 6282
Yoshii, T., 8302
Yoshikawa, K., 6282
Yoshioka, T., 8377
You, L., 4547
You, M., 793, 3317, 4389
Youn, H-D., 6135
Young, A., 2802
Young, C. Y. F., 3877
Young, D., 36
Young, J., 4577
Young, K. J., 8014
Young, L., 2782, 5243
Young, L. S., 2338
Young, M. F., 2631
Young, M. K., 8516
Young, W. F., Jr., 2251
Yousef, G. M., 2223, 3958, 9032
Yu, A., 5021
Yu, B., 4441, 5041
Yu, C., 1822, 2118, 3987, 4936, 8420
Yu, C-J., 3257
Yu, D., 3575, 4705
Yu, H., 7624
Yu, J., 5813, 6170
Yu, J-C., 2440
Yu, K., 3309
Yu, K. M., 3325
Yu, M., 5674
Yu, M. C., 573, 2898, 7526
Yu, Q., 2782
Yu, W., 2483
Yu, W-C., 3121
Yu, Y., 4174, 8323
Yuan, J., 4174
Yuan, J-M., 573
Yuan, K., 7051
Yuan, M., 7443
Yuan, R. R., 5084
Yuan, X., 7777
Yuan, Z., 7708
Yuan, Z-M., 3418
Yuasa, Y., 5564
Yue, Z. N., 859
Yuen, M. F., 7724
Yuen, S. T., 4878
Yuki, Y., 5691
Yu-Lee, L-Y., 386
Yun, J. K., 5962
Yun, W., 1776
Yuspa, S. H., 5257, 7384
Yusuf, R. Z., 2200
- Z**
- Zabarovska, V. I., 404
Zabarovsky, E. R., 404
Zabel, B., 7221
Zacharatos, P., 7185
Zacksenhaus, E., 1420
Zaffaroni, D., 1871
Zaffaroni, M., 5902
Zaffaroni, N., 3490, 4028
Zagari, R. M., 787
Zaidi, S. K., 5357
Zakian, K. L., 9042
Zambroni, D., 2855
Zangari, M., 8749
Zannettino, A. C. W., 5438
Zanovello, P., 2158
Zapf, J. W., 7490
Zardi, L., 3202
Zarling, D. A., 838
Zarour, H. M., 6506
Zask, A., 1838
Zaunders, J., 5034
Zavras, A. I., 296
Zbar, B., 5320
Zborowska, E., 4731
Zcharia, E., 8821
Zeelenberg, I. S., 3833
Zeillinger, R., 3066
Zeimet, A., 7507
Zeisberg, M., 8312
Zeiss, C., 1583
Zellweger, T., 3575
Zembala, M., 7926
Zender, L., 3181
Zeng, Q., 2716
Zeng, X., 5370
Zengou, R., 5607
Zerbi, A., 7451
Zerbini, L. F., 2206
Zerilli, M., 6784
Zeschnick, M., 2578
Zetser, A., 7733
Zettl, A., 3708
Zgola, M., 4426
Zha, S., 7365
Zhai, D., 8118
Zhai, Y., 2913
Zhan, F., 8749
Zhan, X. H., 468
Zhang, C., 8930
Zhang, C. X., 4836
Zhang, C-y., 6666
Zhang, D., 1166
Zhang, D. Y., 4037
Zhang, F., 3413, 5005, 5496, 5889
Zhang, H., 52, 1583, 2109, 5173, 5838
Zhang, H. S., 8968
Zhang, J., 2028, 6488, 6658, 7883
Zhang, L., 994, 3403, 4225, 4552, 5065, 5685, 5889, 6488, 8014, 8582, 8968
Zhang, L-H., 3257
Zhang, M., 658, 6453, 8323
Zhang, N., 8377
Zhang, P. S., 4724
Zhang, Q., 3524, 4698, 6763, 7708
Zhang, R., 7704
Zhang, S., 6063, 6488
Zhang, W., 60, 1769, 4037, 4299, 4315
Zhang, X., 760, 2046, 5352, 7410, 8763
Zhang, X. A., 2665
Zhang, X-k., 3531
Zhang, Y., 5587, 5781, 6488, 7106
Zhang, Y. P., 5513
Zhang, Y-W., 1623
Zhang, Z., 793, 4144, 4389, 5781, 6453, 8167
Zhao, D., 7926
Zhao, H., 1631, 7708
Zhao, J., 3257, 8763
Zhao, L., 5274
Zhao, S., 2624
Zhao, T., 3073
Zhao, W., 4878
Zhao, X., 600, 1927
Zhao, Z., 1759
Zheng, C., 1743
Zheng, J., 6488
Zheng, P., 6051
Zheng, S. L., 3486, 7624
Zheng, W., 3980, 5727, 7624
Zheng, X., 6909
Zheng, Y., 586
Zhimin, S., 6469
Zhong, X., 8968
Zhou, B., 980, 6583
Zhou, B. P., 7630
Zhou, D., 5414
Zhou, F., 865, 5526
Zhou, G., 8057
Zhou, H. S., 3073
Zhou, J-H., 760
Zhou, L., 1636, 1853
Zhou, M., 6357
Zhou, W., 7330
Zhou, X-L., 1894
Zhou, X-M., 5073
Zhou, Y., 1398, 5781, 7122
Zhou, Y-H., 4315
Zhu, B. T., 6532
Zhu, B-P., 6556
Zhu, G. H., 527
Zhu, K., 3855
Zhu, L., 766
Zhu, L. X., 5065
Zhu, X., 394, 6488
Zhu, Y., 522, 1157, 8573
Zhu, Y. B., 7724
Zhu, Z., 1228, 1454, 8912
Zhuang, Y., 5962
Zhuang, Z., 817, 7051
Zieher, H., 8890
Zielińska, M., 4351, 4899
Zimniak, P., 6744
Zindy, F., 5420, 5428
Ziober, B., 4731
Zipper, L. M., 8085
Zischler, H., 1756
Ziske, C., 8962
Zisman, A., 4952
Zografos, L., 5712
Zolfaghari, R., 3092
Zolla-Pazner, S., 2067
Zona, G. L., 1969
Zong, J., 4805
Zoso, A., 2158
Zou, B., 7724
Zu, K., 6988
Zucchetti, M., 5902
Zuhowski, E. G., 312
Zurakowski, D., 484
Zweigner, J., 1772

SUBJECT INDEX

Volume 63

A

- A1/A2 proteins**
cancer targets, 7679
- A12**
tumor growth inhibition, 8912
- A-357300**
tumor inhibition, 7861
- Aberrant crypt foci**
DNA alterations, polymerase chain reaction, 6166
modulation, Zucker obese rats, 6595
- Abl**
Bcr interactions, 298
- Abl-interactor-1**
oligomerization, 873
- Acetylcholine**
autocrine growth factor effects, small cell lung cancer, 214
- N-Acetylglucosaminyltransferase III**
and liver tumor progression, mice, 7753
- Actinium-225**
targeted *in vivo* generators, ovarian cancer therapy, 5084
- Activating transcription factor 2**
melanoma, 8103
- Activating transcription factor 4 (ATF4/CREB2)**
and cisplatin resistance, cancer, 8592
- Activation-induced cytidine deaminase**
expression, B-cell non-Hodgkin's lymphoma, 3894
- Activin**
signaling components, breast cancer, 3783
- Activin A type II receptor (ACVR2)**
mutations, gastrointestinal cancer, 994
- Adducin 3 gene**
NUP98 fusion, biphenotypic acute leukemia, 3079
- Adenine nucleotide translocase**
modulation by Bcl-2 and Bax, 541
- Adenocarcinoma**
colon
diagnostic markers, identification by omic profiling, 5243
esophageal
DYRK2 gene amplification, 4136
gastric
Bcl-w expression and function, 1093
XIAP-associated factor 1 hypermethylation, 7068
gastric cardia
MMP-2 polymorphism and, 3987
lung
etheno-DNA adduct repair activity, 4351, 6103, 6570
MGMT methylation, 4842
neutrophil-derived HGF, 1405
risk
CYP2A13 polymorphism and, 8057
morphine antitumor activity, 1846
ovarian
diagnostic markers, identification by omic profiling, 5243
HPV16/18 distribution, 7215
platinum uptake, direct mapping, 1776
pancreatic
gene hypomethylation, 4158
growth inhibition by MnSOD, 1297
molecular profiling, 2649
pancreatic ductal
gene expression analysis, 8614
prostate
invasive, *Nkx3.1*; *Pten* mice, 3886
metastasis to lymph nodes, *Nkx3.1*; *Pten* mice, 3886
- TS/A**
tumor-immunodominant antigen, 2158
- Adenoma**
colorectal
COX expression and, 3891
origins, 3819
risk
CCND1 and, 8549
gastric
COX-2 and celecoxib effects, 3032
microsatellite instability, single first-degree relative with colorectal cancer, 787
multiplicity, irradiated *Apc^{Min}* mice, 2361
pituitary
folate receptor expression, 4218
seriated
BRAF and KRAS mutations, 4878
- Adenomatous polyposis**
familial
genetic instability, 5731
- Adenomatous polyposis coli (APC) gene**
Apc-deficient mice
hyperlipidemia, 6090
Apc^{Min} mice
dietary prevention, 1752
irradiated
adenoma multiplicity, 2361
Apc^{Min/+} mice
intestinal immune responses and tumorigenesis, 5136
Apc^{Min} mutation modifiers
opposite effects, 4533
caspase expression and apoptosis regulation, 4368
Mdr1^{-/-} Apc^{Min/+} mice
intestinal polyposis inhibition, 895
mutations
colorectal adenocarcinoma, 4656
- Adenovirus**
AdE3-*IAI.3B*, ovarian cancer therapy, 2506
Ad-RB94
growth inhibition, bladder cancer, 760
antitumor replication-selective vector, 7936
bicistronic p14ARF/p53, 3646, 5171
CD154 gene transfer
and CpG ODNs, B-cell lymphoma, 4128
E1A
centrosome deregulation, 1430
gemcitabine sensitization, hepatocellular carcinoma, 6229
insertion-mutated, hepatocellular carcinoma, 3073
E1 double-restricted, gallbladder cancer gene therapy, 4434
hTERT-Ad, cancer treatment, 3181
oncolytic, Rb pathway-defective tumors, 1490
renal cell carcinoma gene therapy, 1994
replicative
HIF-positive tumor treatment, 6877
ONYX-015-based
carboxylesterase delivery, 6900
r-PTP η
cell growth inhibition, thyroid carcinoma, 882
serotype 5 (Ad5)
knob substitution
and oncolytic replication, 1262
suicide gene therapy, prostate cancer, 7497
TRAIL gene transfer
hepatocyte toxicity, 2369
transgene expression modulation, 847
- 9101
- VAI, mutant
Ras-dependent oncolysis, 5544
- Adrenocortical tumors**
PRKARIA gene, 5308
- Adriamycin sensitivity**
LANC-like 2-induced, 723
- Advanced intercross lines**
candidate *PAS1* gene mapping and identification, 3317
- AF9 gene**
MLL-AF9 translocations
apoptotic effectors and, 1371
- Aflatoxin B₁**
-related hepatocellular carcinoma susceptibility, 4594
- African-American men**
MSR1 mutations and prostate cancer risk, 3486
- AG14361**
combined with NU7026
radiosensitization and DNA repair inhibition, 6008
- Aggressive carcinoma**
BRD4-NUT, 304
transitional cell
nuclear HB-EGF, 484
- Airway epithelium**
smoking-induced H19 upregulation, 1475
- Akt**
activation
vascular endothelium resistance to radiation-induced apoptosis, 7663
dephosphorylation promotion by PPI, breast cancer, 7777
E-cadherin downregulation
invasion induction, squamous cell carcinoma, 2172
kinase-dead mutant
apoptosis induction, tumor cells, 6697
-mediated chemoresistance
p53, 7081
PI3K/Akt pathway
CDK inhibitors and, leukemia, 1822
- AKT2/protein kinase B β**
cell invasion, breast and ovarian cancer, 196
- Albumin**
-binding doxorubicin prodrug
MMP-2-cleaved, 4062
- Alcohol dehydrogenase**
class I, mammary epithelium, 3092
- Alcohol intake**
and promoter methylation, colorectal cancer, 3133
- Aldo-keto reductase AKR1C3**
differentiation inhibition, 505
- Alkylpurine-DNA-N-glycosylase**
APNG knockout mice
etheno DNA adducts, 7699
- Allelic losses: See Deletions**
- 17-Allylamino-17-demethoxygeldanamycin**
and cervical tumor radiosensitization, 8984
combined with radiation
growth inhibition, prostate cancer, 8393
combined with suberoylanilide hydroxamic acid
apoptosis induction, leukemia, 8420
oxaliplatin sensitization, colon cancer, 8600
Taxol sensitization, 2139
- S-Allylmercaptocysteine**
apoptosis induction, 6825
- Alpha particle generators**
ovarian cancer therapy, 5084
- Alternative lengthening of telomeres**
-associated promyelocytic leukemia bodies assembly, 2589

- γ -Aminobutyric acid**
prostate cancer metastasis, 8090
- 9-Aminocamptothecin**
BCRP effects, 3228
- 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine**
exposure
restriction by Bcrp1, 6447
mammary cancer
cyclin D1/Cdk4, rat, 5674
- 4-Amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo-d-3,4-pyrimidine**
RETMEN2A and RETMEN2B degradation
induction, 2234
- Aminopeptidase N/CD13**
biological significance, thyroid carcinoma, 8500
- Amphiregulin**
induction by prostaglandin E₂, colon cancer, 5218
- Amyloid precursor protein**
pancreatic cancer, 7032
- AND-34/BCAR3**
Rac and Cdc42 signaling activation, 6802
- Androgen**
-refractory prostate cancer
androgen receptor signaling, MDA PCa
2b-hr cells, 5622
regulation, ovarian epithelial cells, 2416
sensitivity
restoration by Ras signaling attenuation, 1975
- Androgen receptor**
coactivation by paxillin, prostate cancer, 4927
-mediated prostate cancer transcription/proliferation
uncoupling, 8029
mutations
bicalutamide withdrawal syndrome, 149
NF- κ B signaling interruption, prostate cancer, 7106
promotion by gelsolin, prostate cancer, 4888
recurrent prostate cancer, imaging, 4552
regulation by cyclin D1, 4903
signaling, androgen-refractory MDA PCa
2b-hr prostate cancer, 5622
- Anemia**
Fanconi
and familial breast cancer predisposition, 8596
- Aneuploidy**
NOVP chemotherapy-induced, Hodgkin's disease, 44
- Anginex**
tumor growth inhibition, 382
- Angioblastic lineage**
developmental arrest, 7051
- Angiogenesis**
DDAH and, 4960
gene profiling, childhood astrocytoma, 1865
inhibition
angiopoietin-1, colon cancer, 3370
anti-VEGF siRNA, 3919
heavy ion irradiation, 4253
hyperthermia, 1500
IL-10-mediated, ovarian cancer, 5091
NSAIDs, 8351
PTEN, glioma, 2300
PTEN and LY294002, 3585
selective cytokine inhibitory drugs, 8073
TF/FVIIa inhibitors, 2997
tumor vessel-targeted liposomal chemotherapy, 7400
irradiation-induced, 1012
and leukocyte adhesion, 2322
molecular imaging, MRI, 5838
promotion by PI3KCA, ovarian cancer, 4225
promotion by ps20, prostate cancer, 5859
regulation by MDA-7/IL-24, 5105
and thalidomide analogues, 3189
- Angiogenesis inhibitors**
cytoskeletal alterations, 6405
- Angiogenic factors**
upregulation by TNF- α , malignant glioma, 4181
- Angiography**
fluorescein video
microcirculation *in vivo*, basal cell carcinoma, 3969
- Angiopoietin-1**
expression
tumor angiogenesis inhibition, colon cancer, 3370
- Angiopoietin-2**
upregulation by tumor-derived VEGF, epithelium, 3403
- Angiopoietin-related protein 4**
antiangiogenic activity, 6651
- Angiostasis**
CD8⁺ T cell-mediated tumor rejection, 4095
- Angiostatin**
metastasis inhibition, radiation therapy, 308
- Angiotensin I-converting enzyme gene (ACE)**
polymorphisms
and breast cancer risk, 573, 6984
- Angiotensin II**
growth effects, colon cancer, 6726
- Angiotensin**
inhibition by angiopoietin-related protein 4, 6651
- 4-Anilino-3-quinolinecarbonitrile SKI-606**
antiproliferative effects, chronic myelogenous leukemia, 375
- Animal models: See also Mouse models**
opossum xenograft model, 6121
- Ansamycin**
cisplatin interactions, colon cancer, 3241
- Anthracyclines**
phospholipase A₂ inhibition, 5992
- Antiangiogenic therapy**
combined with immunotherapy, solid tumors, 5895
sonographic monitoring, 8264
spontaneous autochthonous tumor response, 747
- Antibodies: See also Monoclonal antibodies**
anti-EGFR
conjugated to gold nanoparticles, real-time vital optical imaging, 1999
anti-Id-IL-6 fusion protein, ovarian cancer immunotherapy, 3234
anti-idiotypic antibody-pulsed dendritic cells
antitumor immunity, 2844
anti-IGF-I EM164
cancer cell proliferation inhibition, 5073
anti-IGF1R scFv-Fc
IGF-I inhibition, breast cancer, 627
bispecific
cancer pretargeting system, 354
cancer therapy, meeting report, 8069
IGF-I receptor antagonist A12, 8912
natural IgM
and immunosurveillance, epithelial cancer, 7995
tumor spheroid targeting, 1288
- Anticancer drugs**
cytotoxicity
HDAC inhibitors and, 7291
novel TOP1-targeting ARC-111, 8400
- Antiestrogens**
apoptosis signaling pathway, 8037
- Antigen**
cancer-testis
targets, epithelial ovarian cancer, 6076
human lymphocyte
polymorphisms, HPV-16-positive vulval intraepithelial neoplasia, 400
lung cancer, newly defined, 2829
melanoma-associated
mRNA levels, prognostic value, 441
shared
targeting, murine glioma model, 8487
- MHC class I**
presentation
enhancement, 2393
retinoids and, neuroblastoma, 8006
- MSI+ colorectal cancer**
identification by SEREX, 5564
shared, 6051
simian virus 40 large tumor
CD4+ T lymphocytes and, 1040
squamous cell carcinoma 2 SCCA2-like serpins, skin tumors, 1871
tumor
vaccinia-expressed
combined with GM-CSF, intratumoral vaccination, 6956
tumor-immunodominant, TS/A adenocarcinoma, 2158
tumor rejection, 6051
EphA2, 8476
- Antigen-presenting cells**
CD40-activated B cells, tumor lysate-pulsed, 2836
- Antioxidant response element**
-mediated gene expression
glutathione and, 7520
- Antioxidants**
conundrum, 4295
and differentiation, leukemia, 1325
- Antiproliferative genes**
induction by Arf, 1046
- Antiviral therapy**
EBV⁺ primary CNS lymphoma, 965
- Antizyme**
forestomach carcinogenesis inhibition, 3945
- Apo-2 ligand (Apo-2L/TRAIL)**
adenoviral gene transfer
hepatocyte toxicity, 2369
apoptosis
Bax and Bak effects, 1712
inhibition by IL-8, ovarian cancer, 4521
regulation by NF- κ B, 1059
chemotherapeutic drug interactions, breast cancer, 5390
combined with CPT-11
apoptosis induction, prostate cancer, 4713
combined with flavopiridol
apoptosis induction, 621
liver metastases, murine renal cancer, 207
promoter activity induction by IFN- β , 5299
receptor
caspase 8/TR2
restoration, and TRAIL sensitivity, neuroblastoma, 1122
sensitivity, neuroblastoma
caspase 8/TR2 restoration and, 1122
sensitization by paclitaxel, renal cancer, 1365
sensitization by rottlerin, colon cancer, 5118
- Apoptosis**
angiostatin_{4,5}-mediated, vascular endothelial cells, 4275
antiestrogen-induced, signaling pathway, 8037
aromatase inhibitor-induced, signaling pathway, 8037
camptothecin resistance and, 1000
and cancer, meeting report, 263
CDDO effects, breast cancer, 5926

CD20-induced, lymphoma, 5480
 cephalostatin 1-induced, 8869
 chemotherapeutic drugs and TRAIL/Apo-2
 ligand interactions, 5390
 drug-induced
 inhibition by curcumin, breast cancer,
 5165
 modulation by *BRCA1*, 6221
 proteomic profiling, non-small cell lung
 cancer, 6928
 endothelial
 and blood-brain barrier disruption, 5950
 epothilone B-induced
 inhibition by flavopiridol, breast cancer,
 93
 Fas-mediated
 and p53 status, 1527
 fatty acid synthase inhibition and, cancer,
 7330
 fenretinide-induced
 mediation by Bak, neuroblastoma, 7310
 flavopiridol-induced, 7410
 galectin-3-induced, T cells, 8302
 glucocorticoid-induced, pre-B leukemic
 cells, 172
 IFN- γ -induced
SOXN, neuroblastoma, 7742
 induction
 Ad-RB94, bladder cancer, 760
 Akt kinase-dead mutant, tumor cells, 6697
 S-allylmercaptocysteine, 6825
 arsenic trioxide, leukemia, 7950
 caffeine, JB6 C141 cells, 4396
 CDDO, 5551
 chlorophyllin, colon cancer, 1254
 combination 17-AAG and SAHA, leuke-
 mia, 8420
 combination flavopiridol and TNF- α or
 TRAIL, 621
 combination TRAIL/Apo-2L and CPT-11,
 prostate cancer, 4713
 GGT1-2154, breast cancer, 8922
H. pylori VacA, gastric epithelial cells,
 951
 histone deacetylase inhibitors, 8948
 histone deacetylase inhibitors, mecha-
 nisms, 4460
 hyaluronan-binding peptide, 5685
 IGF1BP-rP1, prostate cancer, 7717
 initiation protein silencing, 7356
 LAQ824, chronic myelogenous leukemia,
 5126
mda-7/IL-24, prostate cancer, 8138
 MEK1,2 dephosphorylation, 3469
 MIC-1, prostate cancer, 5034
 nonradioactive iodide, lung cancer, 5065
 As₂O₃ methylated metabolites, leukemia,
 1853
 roscovitine, HTLV type 1 MT-2 cells,
 8523
 SCH66336, head and neck squamous cell
 carcinoma, 4796
 selenium and vitamin E, prostate cancer,
 6988
 SHetA2, head and neck squamous cell
 carcinoma, 3826
 small molecule Met inhibitor, 5462
 tumor gangliosides, T cells, 1676
 inhibition by stromal prostacyclin, colonic
 epithelial cells, 1748
 lymphocyte, tumor supernatant, 642
 2-methoxyestradiol-induced, mechanism of
 action, 468
 and *MLL-AF9* translocations, 1371
 near-infrared fluorescent imaging, 1936
 proapoptotic secreted tumor-targeted
 caspase-3, 3257

proapoptotic therapy, ER-negative breast
 cancer, 290
 proapoptotic UBP41 activity, 682
 radiation-induced
 PCPH and mTOR, fibroblasts, 6290
 vascular endothelium resistance, 7663
 RANKL effects, 1772
 rapamycin-induced
 IGF-1 protection against, 364
 regulation by *APC*, 4368
 resistance
 AMF/PGI overexpression, fibroblasts, 242
 induction by glucocorticoid cotreatment,
 3112
 RNase L, prostate cancer, 6795
 ST1571-mediated
 promotion by histone deacetylase inhibi-
 tors, 2118
 stress-induced
 Bax role, endoplasmic reticulum, 1483
 SUAP induction, myeloid cells, 705
 sulforaphane-induced
 glutathione and, 7520
 TGF- β -induced
 regulation by HIPK2, hepatoma, 8271
 TRAIL/Apo-2L-induced
 Bax and Bak effects, 1712
 inhibition by IL-8, ovarian cancer, 4521
 regulation by NF- κ B, 1059
 TR3/Nur77, colon cancer, 5401
 VES-induced
 mitochondrial events, 2483
Apoptosis-inducing factor
 chemosensitizing derivative, 8233
Apoptosome
 inhibition by IAP, non-small cell lung can-
 cer, 831, 6566
Apoptotic factors
 and gene therapy, 8563
AP20-region gene 1 *APRG1*
 isolation, 404
Arachidonic acid
 metabolism, prostate cancer, 2256
ARC-111
 novel TOP1-targeting anticancer drug, 8400
Archaeosomes
 tumor protection, 2526
Arf
 induction
 transcriptional response, 1046
ARH1 gene
 aberrant methylation and silencing, breast
 cancer, 4174
Aromatase
 induction, breast cancer, 3546
 inhibition by procyanidin dimers, 8516
Aromatase inhibitors
 apoptosis signaling pathway, 8037
Arsenic trioxide
 autophagic cell death, malignant glioma,
 2103
bcr-abl translation inhibition, leukemia,
 7950
 methylated metabolites
 apoptosis, leukemia, 1853
Arzoxifene (LY353381)
 tumor growth effects, breast cancer xe-
 nograft model, 6516
Ascorbate
 effects on hypoxia-inducible factor, 1764
Asian-American women
 tea intake, *COMT* genotype, and breast can-
 cer, 7526
Aspirin
 NO-releasing, molecular targets, 7613
Astrocytic glioma
 classification by gene expression profiles,
 9103

6613
Astrocytoma
 childhood
 angiogenesis gene profiling, 1865
 transgenic mouse model, 1106
Ataxia telangiectasia-mutated gene (*ATM*)
 activation by 53BP1 and NFB1/MDC1,
 double-strand breaks, 8573
 and breast cancer risk and clinical radiosensi-
 tivity, 8717
 deficiency
 and telomere dysfunction, 8188
 histone deacetylase and, 2891
 mutations, familial breast and ovarian can-
 cer, 3325
 recombination and, mice, 5335
ATP-binding cassette gene *ABCP/ABCG2*:
See Breast cancer resistance protein
Atrial natriuretic peptide
 production
 corin effects, small cell lung cancer, 8318
Autochthonous tumors
 spontaneous
 antiangiogenic treatment response, 747
Autocrine motility factor/phosphoglucose
isomerase
 overexpression
 transformation and resistance to apoptosis,
 fibroblasts, 242
Autocrine signaling
 and radioresistance, RIE-1 cells, 7807
Autotaxin
 phosphosphingolipid hydrolyzation, 5446
5-Aza-2'-deoxycytidine
 combined with phenylbutyrate
 lung cancer prevention, 7089

B

B7-H1
 expression, glioma, 7462
 squamous cell carcinoma, 6501
Bacillus Calmette-Guérin
 breast cancer vaccine BCG-hIL2MUC1, de-
 velopment and preclinical evaluation,
 1270
Bad
 EGF-induced phosphorylation
 inhibition by sulindac sulfide, colon can-
 cer, 616
 inactivation by MAPK, melanoma, 8330
BAG-1
 effects, breast cancer, 4150
Bak
 fenretinide-induced apoptosis mediation,
 neuroblastoma, 7310
 TRAIL-induced apoptosis, 1712
Barrett's esophagus
 4N (G₂-tetraploid) cells, 4211
Basal cell carcinoma
 Gli1 regulation by PKC α , 4692
 invasion and proliferation
 regulation by p16^{INK4a}, 1737
 microcirculation *in vivo*, fluorescein video
 angiography, 3969
Base excision repair
 inhibition
 and IdUrd sensitization, 838
 oxidative DNA damage
 alterations, hepatocellular carcinoma, 7704
 yeast vs mammals, 549
Base excision repair deficiency
 β -pol haploinsufficient mice, 5799
Bax
 adenine nucleotide translocase modulation,
 541
 stress-induced apoptosis, endoplasmic reticu-
 lum, 1483

- TRAIL-induced apoptosis, 1712
- BCAR3**
Rac and Cdc42 signaling activation, 6802
- Bcl-2**
adenine nucleotide translocase modulation, 541
expression deregulation, 6666
homology 3 (BH3)-only proteins
Bim splice variant Bim_y, identification and characterization, 736
inhibition by tea polyphenols, 8118
transgenic plasmacytoma, 8656
- Bcl-2 homology 3-only proteins**
Bim splice variant Bim_y, identification and characterization, 736
- Bcl-3**
NF- κ B p50 homodimer/Bcl-3 complexes, nasopharyngeal carcinoma, 8293
- BCL11B gene**
juxtaposition
NKX2-5 deregulation, pediatric T-ALL, 5329
- Bcl-w**
expression and function, gastric adenocarcinoma, 1093
- Bcl-xL**
deamidation inhibition, hepatocellular carcinoma, 3054
- Bcr**
Abl interactions, 298
- Bcr-Abl**
inhibition by pyrido-pyrimidine-type small molecule kinase inhibitors, 6395
preleukemic P190^{Bcr/Abl} transgenic mice, genomic instability, 4895
translation inhibition by arsenic trioxide, leukemia, 7950
- Benign prostatic hyperplasia**
hK11, 6543
- Benzene toxicity**
NQO1 role, 929
- Benzo(a)pyrene diol epoxide**
Cdc25B expression induction, lung cancer, 771
mutagenicity
ultraviolet A radiation and, 8708
- Benzo(a)pyrene diol epoxide-binding DNA fragments**
identification, immunoprecipitation technique, 1470
- Benzo(a)pyrene quinones**
EGFR pathway activation, 7825
- Benzodiazepine Bz-423**
sensitivity, Burkitt's lymphoma, 6870
- β -cell tumorigenesis**
MEN1, mice, 4836
- BH3 (Bcl-2 homology 3)-only proteins**
Bim splice variant Bim_y, identification and characterization, 736
- Bicalutamide withdrawal syndrome**
androgen receptor mutations, 149
- Bik gene**
mutations, antitumor effects, 7630
- Bim_y**
BH3-only Bim splice variant, 736
- Bioluminescence imaging**
novel reporter mouse, 7042
- Birt-Hogg-Dubé syndrome (BHD)**
gene inactivation, renal tumors, 4583
- BK virus infection**
susceptibility, mesothelioma, 6125
- Bladder cancer**
array-based comparative genomic hybridization, 2872
gene therapy
novel PEI/DNA vector, 4017
genome-wide genetic characterization, 2216
growth inhibition
Ad-RB94, 760
HuSNP chip assay, urinary, 5723
nuclear HB-EGF, 484
PCR-based microsatellite analysis, 2216
p53 mutations, 7530
risk
death receptor 4 and, 1157
single nucleotide polymorphism arrays, 2216
transitional cell
chromosome 15q loss of heterozygosity, 7657
TSC1 mutations, 7652
urothelial cell
FGFR3 and TP53 mutations, 8108
- Bladder carcinoma in situ**
genetic alterations, 179
- BLM^{AsH} gene**
heterozygosity
and cancer risk, 1769
- Blood-brain barrier**
disruption
endothelial cell death and, 5950
- Blood vessels**
ZD6126 antivascular activity, 1534
- Bloom syndrome**
BLM^{AsH} heterozygosity
and cancer risk, 1769
- Bloom syndrome gene (BLM) deficiency**
hyper-recombination and genetic instability, epithelial cells, 8578
- B lymphocytes**
CD40-activated, tumor lysate-pulsed antigen-presenting cell effects, 2836
growth transformation by LMPI1, 2982
lymphoma
CpD ODNs and Ad-CD154 gene transfer, 4128
Epstein-Barr virus
growth inhibition by rapamycin, 4472
non-Hodgkin's lymphoma
activation-induced cytidine deaminase expression, 3894
pre-B cells
glucocorticoid-induced apoptosis, 172
selection, ductal breast carcinoma, 3275
- BMI-1026**
characterization, 7384
- Bombesin**
IL-8 and VEGF expression stimulation, prostate cancer, 3495
Tc(1)-radiolabeled carbonyl conjugates, prostate cancer diagnosis, 4082
- Bone**
breast cancer metastasis
c-Src activity and, 5028
invasion
osteoclasts, neuroblastoma, 3026
prostate cancer progression
inhibition by OPG/OCIF, mice, 2096
inhibition by sRANK-Fc, 7883
renal cell carcinoma growth inhibition, 2940
- Bone marrow**
breast cancer micrometastasis, molecular signature, 5679
genetic markers, early-stage breast cancer, 1884
hematopoietic cell senescence
ionizing radiation and busulfan-induced, murine cells, 5414
melanoma-reactive T cells, 5582
microenvironment
and hematological malignancy, meeting report, 7539
neural stem-like cells, characterization, 8877
stromal cells
differentiation blockade by Ewing tumor fusion proteins, 3464
- Bone morphogenetic protein receptor**
dominant-negative type II
growth inhibition, breast cancer, 277
- Bone sarcoma**
prognostic markers, identification, 8680, 9042
- Bortezomib (PS-341, Velcade)**
p53 stabilization, prostate cancer, 7338
resistance
Hsp27, lymphoma, 6174
- 53BP1**
ATM activation, double-strand breaks, 8586
- BP75**
Wnt signaling enhancement, 4792
- Bradykinin receptor**
subtype 1, prostate cancer, 2037
- BRAF gene**
melanoma susceptibility candidate, 3061
mutations
absence, uveal melanoma, 5761
colon cancer, 5209
colorectal hyperplastic polyps, 4878
melanoma, 3883
metastatic melanoma, 3955
papillary thyroid cancer, 1454, 4561
thyroid tumors, 4561
uveal melanoma, 5712
- B-Raf gene**
kinase activation segment mutations, colorectal tumors, 8132
- BRAF^{V599E}**
inhibition effects, melanoma, 5198
- Brain metastasis**
immunotherapy, 1345
VEGF-A isoform effects, melanoma, 5408
- Brain tumors**
cancer stem cells, identification, 5821
cloned mouse embryos, 2733
optical delineation, pre- and intraoperative, 8122
paclitaxel distribution, mice, 5114
- Brassica (Chinese cabbage)**
and breast cancer, 3980
- BRCA1 gene**
chemotherapy-induced apoptosis modulation, 6221
expression
phytoestrogen effects, mammary glands, 6607
genomic rearrangements, novel screening method, 1449
G₂-M checkpoint regulation, 3049
haplo-insufficiency, breast cancer, 4978
-linked breast tumors
HIN-1 methylation patterns, 2024
mutations
familial versus sporadic ovarian tumors, 417
male breast cancer, 342
- BRCA2 gene**
expression
phytoestrogen effects, mammary glands, 6607
mutations
familial versus sporadic ovarian tumors, 417
male breast cancer, 342
- BRD4-NUT fusion gene**
aggressive carcinoma, 304
- Breast cancer**
activin signaling components, 3783
AKT dephosphorylation
promotion by PP1, 7777
AKT2-induced cell invasion, 196
apoptosis
CDDO effects, 5926
induction by GGTI-2154, mice, 8922

inhibition by curcumin, 5165
ARHI methylation and silencing, 4174
 BAG-1 effects, 4150
 bone marrow micrometastasis, molecular signature, 5679
BRCA1 haplo-insufficiency, 4978
 chemotaxis regulation by PI3K p110 δ , 1667
 chemotherapeutic drugs and TRAIL/Apo-2 ligand interactions, 5390
 chromosomal imbalance patterns, comparative genomic hybridization, 8861
 combination trastuzumab and flavopiridol treatment
 EGFR target, 3626
 CXCR4 downregulation by RNAi, 4801
 CYP19 expression induction, 3546
DAPK gene methylation, 5171
 doxorubicin cytotoxicity
 NADPH-cytochrome P450 reductase and, 6914
 ductal
 B-cell selection, 3275
 early-stage
 bone marrow genetic markers, detection, 1884
 EGFR
 near-infrared optical imaging, xenografts, 7870
egfr gene, 1172
 EMMPRN regulation by EGFR, 7575
 Epstein-Barr virus absence, 2338
ER β expression, 2434, 9055
ESR and estrogen interactions, Chinese women, 7624
 estrogen-mediated E-cadherin downregulation, 5203
 estrogen receptor-negative
 proapoptotic therapy, 290
 estrogen sulfotransferase, 2762
 extracellular signal-regulated kinase
 MKP-1-induced dephosphorylation, 8853
 familial
 ATM mutations, 3325
 Fanconi anemia genes and, 8596
 FGF-BP regulation by EGF and C/EBP β , 1696
FHIT expression, 1183
 gene amplification, gene expression profiling, 2194
 gene expression to growth regulators, 7158
 genomic instability, 4588
 glutathione peroxidase 1, 3347
 growth arrest
 antiestrogen-induced
 p27^{Kip1} and, 4322
 CDDO-induced, 5926
 growth inhibition
 dominant-negative BMPRII, 277
 estrogen response element decoy, 2046
 IB-MECA, 6413
 novel I3C tetrameric derivative, 4028
 growth promotion by VEGF, 4684
 hdm2 regulation, 2616
 heparanase gene expression regulation by estrogen, 8821
 hereditary nonpolyposis colorectal cancer
 tumor exclusion, 1148
 HER2 expression, prognostic value, 1445
 hK5 biomarker, 3958, 5647, 7544
 hK14 biomarker, 9032
 IGF-1 inhibition, 627
 IL-6 gene polymorphisms, 8051
 inhibition by G129R-endostatin fusion protein, 3598
 inhibition by *prohibitin* 3'UTR, 5251
 invasion
 inhibition

Syk nuclear localization and, 7004
 invasive
 inhibition
 Syk nuclear localization and, 4724
 TGF β -1 variant and, 2610
 JAB1 and p27^{Kip1} expression, 2977
 lobular versus ductal expression, 7167
 male
 BRCA1 and *BRCA2* mutations, 342
 metastasis
 regulation by epithelial-mesenchymal transition, 3386
 metastasis to bone and lung
 c-Src activity and, 5028
 methyl-CpG-binding domain protein-2, MCF-7 cells, 498
 node-negative, tissue microarray analysis, 1101
 nonhomologous end-joining genes, 2440
 and NSAIDs, 6096
 nuclear PTEN, MCF-7 cells, 282
 oxygenation
 hemoglobin level and, 7634
 Pdef expression effects, 4626
 phenotype
 Id-2 and, 7098
 polymorphonuclear leukocyte elastase, prognostic value, 337
 radiosensitivity
 ATM haplotype and, 8717
RASSF1A CpG island methylation, 6178
 risk
 ACE polymorphisms and, 573, 6984
 ATM haplotype and, 8717
 ER- α polymorphism and, 5727
 modification by *CHEK2*, 8153
 PGR polymorphisms and, 5236
 XRCC1 and, 8536
 roscovitine-induced radiosensitization, 2513
 Runx2 expression, 2631
Sepr9 amplification, 2179
 serum DNA methylation, prognostic value, 7641
 Shc protein, prognostic value, 6772, 8562
 signaling, microarrays, 7158
 Smad2/3 signaling, 8284
 SnoN expression, 5005
 steroid sulfatase, 2762
synuclein γ demethylation, 664
 tissue microarray analysis, quantitative, 1445
 tumor growth
 arzoifene effects, xenograft model, 6516
 inhibition by GGTI-2154, mice, 8922
 urinary isothiocyanate levels, 3980
 vaccine BCG-hIL2MUC1, development and preclinical evaluation, 1270
 vimentin transactivation by β -catenin, 2658
Breast cancer resistance protein (Bcrp1/Abcg2)
 and 9-AC vs. 9-NC, 3228
 etoposide resistance mediation, 1339
 methotrexate and E₂17BG transport, 4048
 PhIP exposure restriction, 6447
 wild-type
 methotrexate polyglutamate transport, 5538
Breast carcinoma in situ
 ductal
 hypoxia-induced dedifferentiation, 1441
Breast epithelial cells
 immortalization
 chemopreventive agent effects, 1914
 MAPK regulation by H-ras vs N-ras, 5454
Breast tumors
 BRCA1-linked
 HIN-1 methylation patterns, 2024
 chemotherapy
 repopulation, 2134

growth inhibition
 chemokine receptor antagonist, 8360
 EDG1, identification, 5151
BRG1/BRM
 expression loss, non-small cell lung cancer, 560
Bromodeoxyuridine
 distribution, tumors, 5707
(E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU, RP101)
 chemoresistance inhibition, 5745
BUB1 gene
 inhibition
 genomic instability effects, 2855
Budesonide
 chemopreventive effects, lung tumorigenesis, 4389
Burkitt's lymphoma
 Bz-423 sensitivity, 6870
 c-Myc inhibition, 6144
Busulfan
 hematopoietic cell senescence, murine bone marrow, 5414
Buthionine sulfoximine
 and tirapazamine and hypoxia, neuroblastoma, 1520
Butyrate
 granulocytic maturation, acute myeloid leukemia, 8955
Butyrate sensitivity
 $\Delta\psi_m$, mitochondrial activity, and, 6311
BVDU: See (E)-5-(2-Bromovinyl)-2'-deoxyuridine
Bystander effects
 cytosine deaminase fusion gene *NGFR-CD*, sarcoma, 6847
 NO-mediated, glioma, 8437
Bz-423 sensitivity
 Burkitt's lymphoma, 6870

C

c-Abl
 kinase oligomerization, 873
 p73 stabilization, tyrosine phosphorylation-dependent, 3418
E-Cadherin
 downregulation
 Akt
 invasion induction, squamous cell carcinoma, 2172
 estrogen-mediated, breast cancer, 5203
 promotion by calcium, colon cancer, 67
 upregulation by DPPIV, ovarian cancer, 2278
Caffeine
 apoptosis induction, JB6 C141 cells, 4396
Caga
 cell proliferation induction, gastric epithelial cells, 6350
Calcium
 E-cadherin promotion, colon cancer, 67
 β -catenin/TCF inhibition, colon cancer, 67
Calgranulins
 ovarian cancer, 7507
Calpain-2
 prostate cancer invasion, 4632
Campath-1H
 adult T-cell leukemia therapy, murine model, 6453
Campothecin resistance
 and apoptosis, 1000
Campothecin sensitivity
 gene profiling-based prediction, colon cancer, 8791
Cancer: See also specific cells, sites, types
 aggressive
 BRD4-NUT, 304

- alternative RNA splicing, 655, 6996
 CD95 expression and function regulation by p53, 7176
 chromosome aberrations, power law distribution, 7094
 circadian control, 7545
 cyclin D1b expression, 7056
 DNA methylation, systematic profile, 1114
 hypericin-induced mitotic cell death, 8241
 migration stimulating factor expression, 8827
 modifier genes, mouse, 3011
 mutator phenotypes, 6635
 non-basal cell carcinoma
 hedgehog signaling, 923
 opossum xenograft model, 6121
 plasma DNA integrity, 3966
 pre-invasive
 centrosome abnormalities, 1398
 progression
 trypsin tumor-suppressive role, 6575
 risk
 BLM^{Δh} heterozygosity and, 1769
 MTHFR gene variant and, 1249
 shed vesicles
 small molecule expulsion, 4331
 stem cells
 identification, brain tumors, 5821
- Cancer prevention:** *See also Chemoprevention*
 research frontiers, meeting report, 5649
- Cancer Prevention Study II**
 lung cancer mortality and smoking duration/intensity, 6556
- Cancer-testis antigens**
 targets, epithelial ovarian cancer, 6076
- Cancer treatment:** *See also Chemotherapy*
 hTERT-Ad, 3181
 tumor cell senescence, review, 2705
- Capecitabine**
 metabolism, ¹⁹F MRS, 7609
- Carbonic anhydrase IX**
 expression
 metastatic renal cell carcinoma tumor model, 4952
 SP1 activity and, 917
- Carbonyl reductase 1**
Cbr1 +/- mice
 protection against doxorubicin cardiac toxicity, 6602
- Carboxylesterase**
 ONYX-015-based replicating adenovirus delivery, 6900
- Carcinoembryonic antigen**
 -specific dominant CD4 epitope, colon cancer, 8481
- Carcinogenesis**
 chemical, K14-survivin mice, 567
 evolutionary model, 6212
 glycolytic phenotype, mathematical models, 3847
 MYH-associated
 genetic pathways, 7595
 Stat5b activation, 6763
 UC-associated
 epithelial and stromal microsatellite instability, 6158
- Carcinoma in situ**
 bladder
 genetic alterations, 179
 centrosome abnormalities, 1398
 ductal
 COX-2 expression, 2347
 hypoxia-induced dedifferentiation, 1441
- Cardiac toxicity**
 doxorubicin
 protection against, *Cbr1* +/- mice, 6602
- Cardiolipin probe**
 energy transfer to phthalocyanine 4, 5194
- Caspase**
 activation, acute myeloid leukemia, 1242
 expression regulation by *APC*, 4368
 livin cleavage mediation, 6340
- Caspase 3**
 activation failure
 and cisplatin resistance, testicular cancer, 513
 tumor-targeted, secreted
 proapoptosis, 3257
- Caspase 8/TR2**
 restoration
 and TRAIL sensitivity, neuroblastoma, 1122
- Catechol-O-methyltransferase gene (COMT)**
 genotype
 and breast cancer, Asian-American women, 7526
 methylation, endometrial cancer, 3101
- β-Catenin**
 FGF-BP upregulation, colon carcinogenesis, 8085
 inhibition by calcium, colon cancer, 67
 intestinal epithelial cells expressing, proteomic analysis, 4641
 phosphorylation, colon cancer, 5234
 signaling activation by SKI, melanoma, 6626
 target genes, ovarian cancer, 2913
 transformation
 TIP49, 8726
 VEGF regulation, colon cancer, 3145
 vimentin transactivation, breast cancer, 2658
- Caveolae**
 cancer role, workshop summary, 6571
- Caveolin-1**
 thyroid cancer, 2864
- Caveolin-2**
 thyroid cancer, 2864
- CB1954**
 sensitization
 enhanced mutant *E. coli* nitroreductase and, 5532
- CB300638**
 α-folate receptor-targeted delivery, 3612
- C57BR/cdJ/C57BL/6J chimeric mice**
 hepatocarcinogenesis, 4914
- CCAAT/enhancer binding protein β**
 FGF-BP regulation, breast cancer, 1696
- CCAAT motif-binding factor CBF/NF-Y**
 early mouse development, 8167
- CCL2**
 effects in pancreatic cancer progression, 7451
- CCL5 (RANTES)**
 Met-CCL5
 growth inhibition, breast tumors, 8360
- CCL6 gene**
 regulation by c-Myc and L-Myc, 2923
- CD4**
 CEA-specific dominant epitope, colon cancer, 8481
 esophageal squamous cell carcinoma, immunohistochemical analysis, 1555
 T cells
 CCR9 overexpression effects, T-ALL, 6469
 COA-1 identification, 6735
 natural killer T-cell inhibition, 4516
 p53₁₁₀₋₁₂₄-specific, 3675
 and simian virus 40 large tumor antigen, 1040
 stimulation by dendritic cells
 IL-10 and, 2150
- CD5**
 gene expression, diffuse large B-cell lymphoma, 60
- CD8**
 esophageal squamous cell carcinoma, immunohistochemical analysis, 1555
 T cells
 differentiation, metastatic metastasis, 2535
 stimulation by dendritic cells
 IL-10 and, 2150
 tumor rejection, 4095
- CD10**
 peptide-conjugated doxorubicin prodrug cleavage, 5526
- CD13**
 biological significance, thyroid carcinoma, 8500
- CD20**
 apoptosis, lymphoma cells, 5480
- CD25**
 T cells
 depletion
 LEC/chTNT-3 and, solid tumors, 8384
 natural killer T-cell inhibition, 4516
- CD40**
 -activated B cells, tumor lysate-pulsed antigen-presenting cell effects, 2836
- CD44**
fra-1 and, mesothelioma, 3539
 head and neck squamous cell carcinoma, 1920, 8555
 tumor-specific glycosylation pattern, detection, 8278
- CD44v2-10**
 metastatic phenotype, 887
- CD44v6**
 upregulation by HGF/SF, melanoma cells, 1576
- CD45**
 myeloma cells, prognostic value, 3019
- CD57**
 esophageal squamous cell carcinoma, immunohistochemical analysis, 1555
- CD64**
 recombinant immunotoxin, acute myeloid leukemia treatment, 8414
- CD80**
 -decorated tumor cells, cancer immunotherapy, 4067
- CD95**
 expression and function regulation by p53, carcinoma, 7176
- CD158 receptor**
 and CTL survival, 7475
- Cdc25B**
 expression
 endometrial cancer, 6195
 induction by BPDE, lung cancer, 771
- Cdc37**
 overexpression
 proliferation enhancement, prostate epithelial cells, 4614
- Cdc42**
 signaling activation by AND-34/BCAR3, 6802
- CDDO: See 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid**
- Celecoxib**
 COX-2 inhibition
 gastric adenoma, 3032
 p53 activation, colon cancer, 5239
- Cell adhesion**
 B16 tumor cells to endothelial cells
 CXCR4 and, 6751
 and drug resistance, multiple myeloma, 7900
 IGF-1-induced, multiple myeloma, 5850, 7543
 inhibition by MIC-1, prostate cancer, 5034
 inhibition by versican, prostate cancer, 4786

- intravascular, 3805
malignant, lymphatic vessel endothelium
MR and CLEVER-1, 4671
- Cell cycle**
c-anaphase
induction by sodium arsenite, fibroblasts, 6680
decatenation checkpoint, Werner syndrome, 3289
G₂ checkpoint
control by p53, 4074
DNA damage-induced
inhibition by G66976, 31
G₂-M checkpoint
regulation by TopBP1 and BRCA1, 3049
growth inhibition by flavopiridol, breast cancer, 93
regulation by redox, fibroblasts, 2109
S checkpoint
DNA damage-induced
inhibition by G66976, 31
- Cell-cycle-checkpoint kinase 2 gene (CHEK2)**
breast cancer risk modification, 8153
- Cell death: See also Apoptosis**
autophagic
induction by As₂O₃, malignant glioma, 2103
cisplatin-induced
sensitization by PI3K, 1034
DNA damage
dendritic cell effects, 5143
endothelial
and blood-brain barrier disruption, 5950
¹H NMR-visible lipids, glioma, 3195
mitotic
hypericin-induced, cancer cells, 8241
p53 downstream target deletions and, 8664
- Cell differentiation**
antioxidants and, leukemia, 1325
dedifferentiation
GATA-6 inactivation, ovarian tumors, 4967
hypoxia-induced dedifferentiation, ductal carcinoma *in situ*, 1441
inhibition by AKR1C3, 505
inhibition by Ewing tumor fusion proteins, marrow stromal cells, 3464
inhibition by Twist, 1906
- Cell growth: See also Tumor growth**
androgen-independent
mediation by mutant p53, prostate cancer, 2228
antiestrogen-induced arrest
p27^{Kip1} and, breast cancer, 4322
arrest
selenium-induced, prostate cancer, 52
autocrine, EBV-positive gastric carcinoma, 7062
CDDO effects, breast cancer, 5926
eEF-2 kinase inhibitors and, 6894
estrogen-independent
promotion by VEGF, breast cancer, 4684
inhibition
adenoviral AD-r-PTP η , thyroid carcinoma, 882
Ad-RB94, bladder cancer, 760
bone, renal cell carcinoma, 2940
CEP-701 and CEP-751, medullary thyroid carcinoma, 5559
c-Met downregulation, colorectal cancer, 2990
combination 17AAG and radiation, prostate cancer, 8393
dominant-negative BMPRII, breast cancer, 277
EDG1, identification, 5151
- estrogen response element decoy, breast cancer, 2046
FASE siRNA, prostate cancer, 3799
GAP43, glioma, 2933
hLPP-3, ovarian cancer, 1073
intracerebral endogenous inhibitors, glioma, 2499
IRF-5, 6424
MnSOD, pancreatic adenocarcinoma, 1297
Notch1, hepatocellular carcinoma, 8323
novel I3C tetrameric derivative, breast cancer, 4028
PMEPA1, prostate cancer, 4299
procaine, cancer, 4984
proline-rich acidic protein, 6658
rapamycin, EBV B-cell lymphoma, 4472
SKI-606, chronic myelogenous leukemia, 375
modification by α -methylacyl-CoA race-mase, prostate cancer, 7365
PPAR α -dependent regulatory genes, 5767
regulation
Runx2, preosteoblasts, 5357
stimulation
prostaglandin E₂, colon cancer, 5218
transformation by LMP1, B cells, 2982
visinin-like protein-1 effects, squamous cell carcinoma, 4997
- Cell migration**
dendritic cell
maturation state and, melanoma, 12
endothelial
thymidine phosphorylase and, 527
genes, library identification, 119
IGF-1-induced, multiple myeloma, 5850, 7543
induction by MT1-MMP, prostate cancer, 2292
inhibition by EW1/PGRL, prostate cancer, 2665
modulation by Crkl adapter protein, glioblastoma, 2335
promotion by PRL-3 and PRL-1, 2716
- Cell proliferation: See also Cell growth**
antiproliferative genes
induction by Arf, 1046
AR-mediated transcription/proliferation uncoupling, prostate cancer, 8029
enhancement by Cdc37 overexpression, prostate, 4614
glomeruloid microvascular
prognostic value, non-small cell lung cancer, 6791
induction by *H. pylori* proteins, gastric epithelial cells, 6350
inhibition
EM164, cancer, 5073
GH-RH antagonists, non-small cell lung cancer, 7913
IB-MECA, breast cancer, 6413
PPAR γ ligands, leiomyoma, 1221
Scutellaria baicalensis, 4037
telomerase inhibitors, 5917
mutation enhancement
8-OH-G and, 4287
p300, prostate cancer, 7638
regulation
p16^{INK4a}, basal cell carcinoma, 1737
Runx2, osteoblasts, 5357
TGF- β -induced, osteosarcoma, 7791
- Cell survival**
 γ H2AX and, 4347
- Cell transformation**
AMF/PGI overexpression, fibroblasts, 242
 β -catenin-mediated
TIP49, 8726
- Kaposi's sarcoma-associated herpes virus G protein-coupled receptor
p21-activated kinase 1, 8837
- Cellular retinoic acid-binding protein II**
mammary carcinoma inhibition, 4426
- Central nervous system lymphoma**
primary
EBV-associated
antiviral therapy, 965
novel 6q22-23 tumor suppressor loci, 737
- Central nervous system tumors**
mouse models, meeting report, 3001
- Centromere protein-A**
overexpression, colorectal cancer, 3511
- Centromeres**
inhibition by Taxol, osteosarcoma, 2794
- Centrosome abnormalities**
carcinoma *in situ*, 1398
pRB and, 476
- Centrosome cycle**
deregulation by E1A, 1430
- CEP-701**
RET inhibition, 5559
- CEP-751**
RET inhibition, 5559
- CEP-7055**
antiangiogenic activity, 5978, 7543
- Cephalostatin 1**
apoptosis, 8869
- Cervical cancer**
gelatinolytic MMP expression, 6537
markers, identification by cDNA and tissue microarrays, 1927
MCM7 biomarker, 8173
radiosensitization
geldanamycin and 17-AAG effects, 8984
RASSF1A and human papillomavirus, 1888
- Cervical carcinogenesis**
E6 and E7, transgenic mouse models, 4862
- Chaperone complexes**
hsp110-gp100 vaccine
antitumor immunity, 2553
- Chemical carcinogenesis**
K14-survivin mice, 567
- Chemiluminescence photodynamic therapy**
1818
- Chemokine receptor CCR1**
antagonist Met-CCL5
growth inhibition, breast tumors, 8360
- Chemokine receptor CCR5**
antagonist Met-CCL5
growth inhibition, breast tumors, 8360
- Chemokine receptor CCR9**
overexpression effects, T-ALL CD4⁺ T cells, 6469
- Chemokine receptor CXCR4**
colon carcinoma micrometastasis outgrowth, 3833
CXCR4-B16 arrest, flow conditions, 6751
CXCR4-SDF-1, rhabdomyosarcoma, 7926
downregulation by RNAi, breast cancer, 4801
glioblastoma tumor proliferation, 1969
- Chemoprevention**
budesonide effects, lung tumorigenesis, 4389
enzyme induction and dietary chemicals, 7005
perillyl alcohol, esophageal tumorigenesis, 2399
selenium, prostate cancer, 52
selenium and vitamin E, prostate cancer, 6988
- Chemoresistance**
inhibition by BVDU, 5745
Xiap/Akt-mediated
p53, 7081
- Chemosensitivity**
gene profiling-based prediction, colon can-

- cer, 8791
- Chemotaxis**
regulation by autocrine NP1 ligands, cancer, 5230
regulation by PI3K p110 δ , breast cancer, 1667
- Chemotherapy**
apoptosis
inhibition by curcumin, breast cancer, 5165
modulation by *BRCA1*, 6221
damage
prevention by NF- κ B, 25
DNA-modifying
HMGB1-HMGB2-HSC70-ERp60-glycer-aldehyde 3-phosphate dehydrogenase complex sensor, 100
endothelial progenitor cell effects, 4342
repopulation, breast tumors, 2134
synergy with immunotherapy, solid tumors, 4490
TRAIL/Apo-2 ligand interactions, breast cancer, 5390
tumor vessel-targeted liposomal anti-angiogenic effects, 7400
- CHFR**
methylation, gastric cancer, 8606
- CHFR gene**
mutations, lung cancer, 7185
- Childhood astrocytoma**
angiogenesis gene profiling, 1865
- Childhood leukemia, acute lymphoblastic**
gene expression profiling, 4882
NBS1 mutations, 6563
T-cell
NKX2-5 deregulation by *BCL11B* juxtaposition, 5329
- β 2-Chimaerin**
and metastasis, mammary carcinoma, 2284
- Chinese women**
ESR and estrogen interactions, breast cancer, 7624
- 8-Chloro-adenosine**
RNA-directed actions, multiple myeloma, 7968
- Chlorophyllin**
apoptosis induction, colon cancer cells, 1254
- Cholangiocellular carcinoma**
VEGF gene transcription, 1083
- Chromatin remodeling**
hTERT regulation, 689
- Chromosome 1q**
loss of heterozygosity, gastrinoma, 817
- Chromosome 3**
fine mapping, uveal melanoma, 8507
- Chromosome 3p**
copy number alterations, oral squamous cell carcinoma, 8582
tumor suppressor genes, esophageal squamous cell carcinoma, 3724
- Chromosome 3p14.2-p25**
deletion, renal cell carcinoma, 455
- Chromosome 3p21.3**
AP20 region, physical and gene map, 404
loss of heterozygosity, non-small cell lung cancer, 3352
- Chromosome 3p25.1-p25.2**
deletions, uveal melanoma, 8507
- Chromosome 3q26**
ZASC1 amplification, esophageal squamous cell carcinoma, 5691
- Chromosome 6**
genetic alterations, colorectal cancer, 3747
metastasis inhibition, melanoma, 432
- Chromosome 6q22-23**
novel tumor suppressor loci, primary central nervous system lymphoma, 737
- Chromosome 6q25**
allelic losses, Hodgkin and Reed Sternberg cells, 2606
- Chromosome 11**
ovarian cancer inhibition, 8648
- Chromosome 12q15**
rearrangements
HMG A2 fusion transcripts, uterine leiomyomata, 1351
- Chromosome 15q**
loss of heterozygosity, transitional cell carcinoma of the bladder, 7657
- Chromosomes**
aberrations
power law distribution, 7094
crisis
Ad-RB94, bladder cancer, 760
diplochromosomes
induction by sodium arsenite, fibroblasts, 6680
imbalance patterns, breast cancer, 8861
increased tumor expression regions, transcriptome analysis, 5781
instability
carcinoma *in situ*, 1398
induction by JC virus, colonic cells, 7256
translocation t(11;14) junctions
T-nucleotide additions, mantle cell lymphoma, 1722
- Cigarette smoke**
H19 upregulation, 1475
p53-mutant mice, 793
- Circadian rhythms**
cancer control, 7545
VEGF expression, tumor cells, 7277
- cis decoy**
estrogen response element
growth inhibition, breast cancer, 2046
- Cisplatin**
ansamycin interactions, colon cancer, 3241
-loaded micelles
solid tumor eradication, mice, 8977
synchrotron photoactivation, 3221
- Cisplatin-induced death**
sensitization by phosphatidylinositol 3-kinase, 1034
- Cisplatin resistance**
ATF4/CREB2 and, cancer, 8592
caspase-3 activation failure and, testicular cancer, 513
GST- π amplification and, head and neck squamous cell carcinoma, 8097
increase by glutathione, 312
membrane protein mislocalization, 5909
platinum sensitivity, ovarian cancer, 1311
- c-Jun**
MDR-1 expression inhibition, 4527
- c-Jun NH₂-terminal kinase**
constitutively active, glial tumors, 250
IKK β deficiency and, 7689
signaling pathway, diallyl disulfide cytotoxicity, 5940
TGF- β -induced activation
regulation by HIPK2, hepatoma, 8271
- c-Jun NH₂-terminal kinase 1**
activation by S-allylmercaptocysteine, 6825
- c-KIT**
mutations
and bilateral testicular germ-cell tumors, 7674
- Classification mapping**
gene expression-based
tumor origin, 4144
- Claudin-4**
effects, pancreatic cancer, 6265
- Clonality**
metastasis
determination by color-coded fluorescent-protein imaging, 7785
- Cloning**
mouse embryos, brain tumors, 2733
- c-Met**
c-MET-HGF, rhabdomyosarcoma, 7926
downregulation
tumor growth inhibition, colorectal cancer, 2990
fra-1 and, mesothelioma, 3539
juxtamembrane domain mutations, small cell lung cancer, 6272
small molecule inhibitor
antitumor activity, 7345
- c-Myc**
activation, medulloblastoma, 4773
CCL6 regulation, 2923
inhibition, Burkitt's lymphoma, 6144
- Coarse vesicles**
 β 1,6-branched oligosaccharides and, 5363
- Cofilin**
altered regulation by angiogenesis inhibitors, 6405
- Collagen α 2(I) gene COL1A2**
hypermethylation, colorectal cancer, 1789
- Colon**
aberrant crypt foci
DNA alterations, polymerase chain reaction, 6166
modulation, Zucker obese rats, 6595
chromosomal instability induction by JC virus, 7256
epithelial cells
butyrate sensitivity
 $\Delta\psi_m$, mitochondrial activity, and, 6311
stromal prostacyclin antiapoptotic effects, 1748
- Colon adenocarcinoma**
diagnostic markers, identification by omic profiling, 5243
- Colon cancer**
 α (1.3)galactosyl epitope immunity, 987
ansamycin and cisplatin interactions, 3241
Apc^{Min/+} mouse model
intestinal immune responses, 5136
apoptosis
induction by chlorophyllin, 1254
TR3/Nur77, 5401
BRAF mutations, 5209
E-cadherin promotion by calcium, 67
 β -catenin phosphorylation, 5234
 β -catenin/TCF inhibition by calcium, 67
CEA-specific dominant CD4 epitope, 8481
chemosensitivity
gene profiling-based prediction, 8791
DNA alterations, polymerase chain reaction, 6166
drug resistance reversal by food additives, 8443
EGF-induced ERK 1/2 and Bad phosphorylation inhibition by sulindac sulfide, 616
EGFR transactivation, 6744
genomic instability, 1608
growth inhibition by prostaglandin E₂ and angiotensin II, 6726
growth stimulation by prostaglandin E₂, 5218
IGF-1 receptor overexpression, 7708
intrahepatic
yCD gene therapy, 658
invasion regulation by HIF-1, 1138
metastasis
inhibition by S247, 2079
lysophosphatidic acid effects, 1706
micrometastasis outgrowth
CXCR4, 3833
oxaliplatin sensitization by 17-AAG, 8600

- p53 activation by COX-2 inhibition, 5239
p53 and topotecan treatment, pharmacogenomics, 2782
PGE₂-induced VEGF expression mediation by HIF-1, 2330
PMEPA1 expression, 1568
proinflammatory gene modulation by omega-3 fatty acids, 972
Ras and COX-2 inhibition by ursodeoxycholic acid, 3517
TGF- β 1 and p21^{Waf1/Cip1} stability, 3340
TRAIL sensitization by rottlerin, 5118
tumor angiogenesis inhibition by angiopoietin-1, 3370
VEGF expression regulation by β -catenin, 3145
vitamin D₃ target genes, 7799
- Colon carcinogenesis**
FGF-BP upregulation by β -catenin, 8085
interruption by regulatory cells, 6042
mucin-depleted foci, 2388
- Colon tumors**
inhibition by *Ink4a/Arf*, 742
- Color-coded fluorescent-protein imaging**
metastasis clonality determination, 7785
- Colorectal adenocarcinoma**
5-fluorouracil anabolism, modeling, 3667
genetic abnormalities, 4656
- Colorectal adenoma**
COX expression and, 3891
origins, 3819
risk
 CCND1 and, 8549
- Colorectal cancer**
advanced
 microsatellite instability and irinotecan response, 5738
centromere protein-A overexpression, 3511
COL1A2 hypermethylation, 1789
COX-2 upregulation by IL-1 β , 3632
familial
 hMLH3 mutations, 1894
 methylator phenotype and, 4805
ferredoxin reductase pharmacogenomics, 6170
folate and alcohol intake and promoter methylation, 3133
gene expression profiling, 6855
genetic pathways, 7206
growth inhibition by c-Met downregulation, 2990
inflammatory gene SNPs and, 3560
microsatellite instability
 antigens, identification by SEREX, 5564
single first-degree relative
 adenoma
 microsatellite instability, 787
 SLIT2 methylation status, 1054
treatment
 COX-2 inhibition by rofecoxib, 586
tumor-specific T-cell induction by survivin, 4507
UC-associated
 chromosome 6 genetic alterations, 3747
- Colorectal cancer, hereditary nonpolyposis**
breast cancer tumor exclusion, 1148
EXO1 role, 154
- Colorectal carcinogenesis**
FGF18 involvement, 6116
- Colorectal fibroblasts**
phenotype
 and COX-2 expression, 522
- Colorectal hyperplastic polyps**
BRAF and *KRAS* mutations, 4878
- Colorectal tumor-associated antigen COA-1**
identification by CD4⁺ T cells, 6735
- Colorectal tumors**
B-Raf gene kinase activation segment mutations, 8132
microsatellite instability and phenotype, 4577
- Common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1**
malignant cell adhesion to lymphatic vessel endothelium, 4671
- Comparative genomic hybridization**
array-based
 bladder cancer, 2872
 tumor classification, mouse models of malignant melanoma, 5352
chromosomal imbalance patterns, breast cancer, 8861
combined with microarray analysis, gastric cancer, 3309
complete coverage array
 chromosome 3p copy number alterations, oral squamous cell carcinoma, 8582
familial versus sporadic ovarian tumors, 417
genome-wide array analysis, murine neuroblastoma, 5266
- Complementary DNA microarrays**
cervical cancer marker identification, 1927
endometrial cancer, 6
5-FU-inducible target genes, 4602
polycythemia vera gene expression profiling, 3940
- Computed tomography**
small animal FDG-PET/CT imaging, 6252
- Connexin 43**
Skp2 inhibition, 1623
upregulation by ionizing radiation, 7128
- Contrast agents**
dendrimer-based
 micro-magnetic lymphangiography, mice, 271
molecular imaging, 1999
- Copper(II)diacetyl-bis(*N*⁴-methylthiosemicarbazone)**
targeted radiotherapy
 deoxyglucose-enhanced, 5496
- Corin**
atrial natriuretic peptide production, small cell lung cancer, 8318
- Cotlenin A**
combined with IFN- α , non-small cell lung cancer, 3659
- Coxsackie-adenovirus receptor**
adenoviral transgene expression modulation, 847
upregulation by Raf/MEK/ERK pathway inhibition, 2088
- CP-31398**
chemopreventive effects, breast epithelial cells, 1914
- CP-547632**
pharmacological characterization, 7301
- CP-654577**
biological and biochemical effects, breast cancer, 4450
- CpG island methylator phenotype**
and family history, colorectal cancer, 4805
- CpG oligodeoxynucleotides**
and Ad-CD154 gene transfer, B-cell lymphoma, 4128
adjuvant, peptide-based vaccines, 3281
combined with GM-CSF, neuroblastoma immunotherapy, 394
combined with MAbs, antitumor activity, 5595
- CPI-0004Na**
activation, 5526
- CPT-11: See Irinotecan**
- craf**
-induced lung adenoma
 p53, 2268
- Cripto-1**
signaling pathways, 1192
- Crkl adapter protein**
glioblastoma, 2335
- CRSP3/DRIP130**
metastasis inhibition, melanoma, 432
- CS-682**
antimetastatic activity, orthotopic pancreatic cancer model, 5521
liver metastasis inhibition, nude mouse model, 2477
- c-Src**
and metastasis, breast cancer, 5028
skin carcinogenesis, transgenic mice, 4819
- Cucurbitacin I**
JAK/STAT3 inhibition and antitumor activity, 1270
- Curcumin**
chemotherapy-induced apoptosis inhibition, breast cancer, 5165
- Cutaneous melanoma**
malignant
 RASSF1A inactivation, 1639
- CXC chemokine receptor CXCR4**
colon carcinoma micrometastasis outgrowth, 3833
CXCR4-B16 arrest, flow conditions, 6751
CXCR4-SDF-1, rhabdomyosarcoma, 7926
downregulation by RNAi, breast cancer, 4801
glioblastoma tumor proliferation, 1969
- 1-[2-C-Cyano-2-deoxy- β -D-arabino-pentofuranosyl]-N⁴-palmitoyl cytosine: See CS-682**
- 2-Cyano-3,12-dioxoleana-1,9-dien-28-oic acid**
apoptosis and oxidative stress induction, 5551
growth and apoptosis effects, breast cancer, 5926
and TGF- β /Smad signaling, 1371
- 1-(2-Cyano-3,12-dioxoleana-1,9-dien-28-oyl)imidazole**
and TGF- β /Smad signaling, 1371
- Cyclic AMP response element binding protein 2 (ATF4)**
and cisplatin resistance, cancer, 8592
- Cyclin D1**
androgen receptor regulation specificity, 4903
degradation induction by PPAR γ agonists, 958
overexpression
 combined with zinc deficiency, forestomach carcinogenesis, 4244
 FGFR-1 upregulation, 424
 PhIP-induced rat mammary gland cancer, 5674
- Cyclin D1 gene (CCND1)**
and colorectal adenoma risk, 8549
- Cyclin D1b**
expression, cancer-derived cells, 7056
- Cyclin-dependent kinase inhibitors**
and PI3K/Akt pathway, leukemia, 1822
- Cyclin-dependent kinase 1 gene CDKN1A**
polymorphisms
 and prostate cancer, 2033
- Cyclin-dependent kinase 1 gene CDKN1B**
polymorphisms
 and prostate cancer, 2033
- Cyclin-dependent kinase 1 inhibitor**
BMI-1026, characterization, 7384
- Cyclin-dependent kinase 2/cyclin A antagonists**
selective inhibitors, 1020
- Cyclin-dependent kinase 4**
PhIP-induced rat mammary gland cancer,

5674
Cyclin E
 expression, ovarian cancer, 1235
Cyclooxygenase gene COX
 expression
 and colorectal adenoma, 3891
Cyclooxygenase 1
 cooperation, intestinal polyposis, 4872
 overexpression, ovarian cancer, 906
Cyclooxygenase 2
 and celecoxib effects, gastric adenoma, 3032
 cooperation, intestinal polyposis, 4872
 expression
 colonic fibroblast phenotype and, 522
 ductal carcinoma *in situ* and surrounding
 epithelium, 2347
 non-small cell lung cancer, 766
 prostate cancer, 2256
 regulation by Wnt and Ras, 728
 inhibition
 combined with immunotherapy, antitumor
 effects, 7845
 p53 activation, colon cancer, 5239
 rofecoxib, colorectal cancer treatment, 586
 ursodeoxycholic acid, colon cancer, 3517
 regulation by SU5416, lung cancer, 6920
 upregulation by IL-1 β , colorectal cancer,
 3632
Cyclooxygenase 17
 nove non-small cell lung cancer treatment
 target, 7038
Cyclophilin A
 non-small cell lung cancer, 1652
Cyclophosphamide
 endothelial progenitor cell effects, 4342
 metronomic
 combined with immunotherapy, murine
 melanoma, 8408
 repopulation, breast tumors, 2134
 and tumor glycolysis, ^{13}C NMR spectroscopy, 8813
**CYPRED: See NADPH:cytochrome P450
 reductase**
**Cysteine-rich fibroblast growth factor recep-
 tor 1**
 precancerous marker, 2052
Cytochrome c
 release
 NO-induced, 5470
Cytochrome P450 1A1
 feedback inhibition by methoxyestrogens,
 3127
 inhibition by St. John's wort, 8062
 promoter methylation, 8623
Cytochrome P450 2A13
 gene polymorphisms
 and lung cancer risk, 8057
Cytochrome P450 3A7
 estrone 16 α -hydroxylation, 6532
Cytochrome P450 1B1
 activity, mammary estrogen metabolism,
 8492
 endometrial cancer, 3913
 feedback inhibition by methoxyestrogens,
 3127
Cytokine inhibitory drugs
 selective
 antiangiogenic activity and tumor growth
 inhibition, 8073
Cytokine therapy
 T-cell receptor repertoire, melanoma metas-
 tases, 3483
Cytolysis
 E1A-induced susceptibility, 3435
Cytosine deaminase
 fusion gene CD/UPRT
 vesicular stomatitis virus vector, 8366

fusion gene *NGFR-CD*
 sarcoma killing, 6847
 yeast yCD
 gene therapy, intrahepatic colon cancer,
 658
Cytoskeletal alterations
 angiogenesis inhibitors, 6405
Cytotoxicity
 anticancer drug
 HDAC inhibitors and, 7291
 2DG-induced, 3413
 diallyl disulfide
 JNK/c-Jun pathway, 5940
 doxorubicin
 NADPH-cytochrome P450 reductase and,
 breast cancer, 6914
 ionizing radiation effects, 324
 TNF- α -induced
 sensitization by pVHL, renal cell carci-
 noma, 7076
Cytotoxic T lymphocyte antigen-4
 aptamers, 7483
 blockade, peptide-based vaccines, 3281
Cytotoxic T lymphocytes
 activation
 tumor architecture and, 3682
 lysability
 Hsp70 effects, tumor cells, 8212
 melanoma epitope-specific
 response regulation by dendritic cells,
 5607
 peptide SSX-2 $_{41-49}$ responses, melanoma,
 5601
 recruitment to tumors
 tracking by MRI, 6838
 sensitization
 retinoids and, neuroblastoma, 8006
 survival
 KIR2DL1/CD158 receptor and, 7475

D

DAD: See 5-Aza-2'-deoxycytidine
dChipSNP
 genome-wide loss of heterozygosity map-
 ping, prostate cancer, 4781
**DDAH: See Dimethylarginine dimethylamin-
 ohydrolase**
DD3 gene
 prostate tumor marker, 4747
Death-associated protein kinase
 hypermethylation, lymphocytes, 7694
 methylation, breast cancer, 5171
Death-inducing effects
 ionizing radiation, 324
Death receptor 4
 and bladder cancer risk, 1157
Death receptor 5
 upregulation by 2-methoxyestradiol, 468
Decorin
 expression, oral dysplasia and squamous cell
 carcinoma, 7769
Dehydroxymethylperoxyquinomicin DHMEQ
 prostate cancer inhibition, 107
Deleted in liver cancer DLC-1 gene
 alterations, hepatocellular carcinoma, 7646
Deletions
 chromosome 1q, gastrinoma, 817
 chromosome 3p, esophageal squamous cell
 carcinoma, 3724
 chromosome 3p14.2-p25, renal cell carci-
 noma, 455
 chromosome 3p21.3, non-small cell lung
 cancer, 3352
 chromosome 3p14.2-p25, renal cell carci-
 noma, 455
 chromosome 3p25.1-p25.2, uveal melanoma,
 8507

chromosome 6q25, Hodgkin and Reed
 Sternberg cells, 2606
 chromosome 15q, transitional cell carcinoma
 of the bladder, 7657
Ink4a-Arf
 PDGF-B and, glioma, 4305
p53
 PDGF-B and, glioma, 4305
Dendrimer-based contrast agent
 micro-magnetic lymphangiography, mice,
 271
Dendritic cells
 anti-idiotypic antibody-pulsed
 antitumor immunity, 2844
 CD4 and CD8 T-cell response stimulation
 IL-10 and, 2150
 circulating
 compartment defects, chronic lymphocytic
 leukemia, 4497
 combined with radiotherapy, 8466
 DNA damage tumor cell death effects, 5143
 HPV virus-like particle uptake and cross-
 presentation, 3478
 IL-12 and IL-18 gene-transduced, immuno-
 therapy, 6378
 intratumoral, pancreatic cancer, 8962
 melanoma epitope-specific CTL response
 regulation, 5607
 migration to lymph nodes
 maturation state and, melanoma, 12
 OK-432-stimulated, 4112
 plasmacytoid, head and neck squamous cell
 carcinoma, 6478
 recently activated
 and IL-12, 3688
 recombinant invariant chain-electroporated,
 5587
 recruitment and loading, 5505
 renal tumor RNA-transfected, 2127
 vaccines
 combined with TGF- β -neutralizing mAb
 2G7, 1860
2-Deoxy-d-glucose
 cytotoxicity and radiosensitization, 3413
Deoxyglucose
 targeted ^{64}Cu -ATSM radiotherapy, 5496
Dexamethasone
 protection against yonelis hepatotoxicity,
 rat, 5902
Diallyl disulfide
 cytotoxicity
 JNK/c-Jun pathway, 5940
Dicoumarol
 Taxol synergy, 1214
Dietary chemicals
 enzyme induction and, cancer chemopreven-
 tion, 7005
Dietary curcumin
 chemotherapy-induced apoptosis inhibition,
 breast cancer, 5165
Dietary folate
 and promoter methylation, colorectal cancer,
 3133
Dietary polyphenols
 telomerase inhibition, 824
1 α ,25-Dihydroxyvitamin D $_3$
 antioxidant and prodifferentiation effects,
 leukemia, 1325
 target genes, colon cancer, 7799
**8,9-Dimethoxy-5-(2-N,N-dimethylamin-
 oethyl)-2,3-methylenedioxy-5H-
 dibenzo[c,h][1,6] naphthyridin-6-one:**
 See ARC-111
Dimethylarginine dimethylaminohydrolase
 and tumor angiogenesis, 4960
5,6-Dimethylxanthone-4-acetic acid
 combined with photodynamic therapy, anti-

tumor effects, 7584
Dipeptidyl peptidase IV
 E-cadherin upregulation, ovarian cancer, 2278
Diphtheria toxin-human epidermal growth factor fusion protein DAB₃₈₉EGF
 glioblastoma multiforme therapy, 1834
Diplochromosomes
 induction by sodium arsenite, fibroblasts, 6680
Disaccharides
 and tumor metastasis, 2775
Dishevelled-1
 BP75 binding, 4792
Disintegrins
 obtustatin
 $\alpha 1 \beta 1$ integrin inhibition, 2020
DNA
 alterations
 aberrant crypt foci, polymerase chain reaction, 6166
 BPDE-binding fragments
 identification, immunoprecipitation technique, 1470
 complementary
 microarrays
 endometrial cancer, 6
 endometrial
 tamoxifen binding, irreversible, 8461
 hypermethylation
 COL1A2, colorectal cancer, 1789
 iododeoxyuridine recognition
 MutS α , 5490
 methylation
 cancer cells, 1114
 inhibition
 lung cancer prevention, 7089
 RNA interference and, 6110
 serum, bcx, 7641
 methylation damage
 transcriptional response, 8158
 Pan-IA
 tumor growth inhibition augmentation, 7920
 plasma integrity, 3966
DNA adducts
 etheno
 APNG knockout mice, 7699
 repair activity, lung adenocarcinoma, 4351, 6103, 6570
 tamoxifen, monkeys, 4402, 5999
DNA damage
 cell cycle checkpoints
 inhibition by G6976, 31
 cell death
 dendritic cell effects, 5143
 cell sensitivity
 control by PRMT, 164
 double-strand breaks
 aberrant repair, MSH2 deficiency, 3334
 ATM activation, 8586
 repair, myeloid leukemia, 1798
 TopBP1 focus formation
 hRad9, 4829
 histone H2B downregulation by DNA-dependent protein kinase, 7197
 lung cancer, 4899
 MMC-induced cross-linking
 GRP58, 6016
 Oct-1 targeting by Ku/DNA-PK, 7197
 oxidative
 base excision repair alterations, hepatocellular carcinoma, 7704
 tamoxifen, endometrium, 8461
 transcriptional response, 8158
DNA damaging agents
 cell sensitization by *N*-methylpurine DNA

glycosylase, 608
DNA-dependent protein kinase
 histone H2B downregulation after DNA damage, 7197
 and ionizing radiation resistance, 1198
DNA-dependent protein kinase inhibitors
 combined with PARP-1 inhibitors
 radiosensitization and DNA repair inhibition, 6008
DNA ligase IV
 gap filling, 22
DNA methyltransferase
 inhibition by EGCG, cancer cells, 7563
DNA methyltransferase I
 expression
 p53-mediated inhibition, 6579
DNA polymerase β haploinsufficiency
 base excision repair deficiency, 5799
DNA polymerase H
 small interfering siRNA, 3909
DNA repair
 base excision
 inhibition
 and IdUrd sensitization, 838
 oxidative DNA damage
 alterations, hepatocellular carcinoma, 7704
 yeast vs mammals, 549
 double-strand break
 MSH2 deficiency, 3334
 myeloid leukemia, 1798
 etheno-DNA adduct activity, lung adenocarcinoma, 4351, 6103, 6570
 gap filling
 XRCC4/DNA ligase IV, 22
 hRRM2 response, 6583
 inhibition
 combination DNA-PK and PARP-1 inhibitors, 6008
 lung cancer, 4899
DNA repair factors
 silencing by siRNAs, 1550
DNA replication-initiation proteins
 inhibition
 apoptosis induction, 7356
DNA vaccine immunotherapy
 combined with Pan-IA DNA
 tumor growth inhibition, 7920
 and LAG-3, mammary carcinogenesis prevention, 2518
Docetaxel
 fibrinogen-coated olive oil droplet delivery, solid malignancies, 7314
Docosahexaenoic acid
 proinflammatory gene modulation, colon cancer, 972
Donor lymphocyte infusion
 myeloma-specific T cells, 2561
Doppler sonography
 antiangiogenic therapy monitoring, 8264
Double-negative T lymphocytes
 antitumor activity, 8014
Doxorubicin
 cardiac toxicity
 protection against, *Cbr1* +/- mice, 6602
 cytotoxicity
 NADPH-cytochrome P450 reductase and, breast cancer, 6914
 immunoliposomal
 antitumor activity, neuroblastoma, 86
 liposomal
 combined with radiofrequency tumor ablation, 6327
 MMP-2-cleaved albumin-binding prodrugs, 4062
 peptide-conjugated prodrugs
 cleavage by CD10, 5526

DP-1
 phosphorylation
 and dysplasia, mouse model, 7668
Drg-1 gene
 expression, prostate cancer, 1731
Drug delivery
 photodynamic therapy, 8126
Drug-induced apoptosis
 proteomic profiling, non-small cell lung cancer, 6928
Drug resistance: See also Multidrug resistance
 and apoptosis, 1000
 cell adhesion and, multiple myeloma, 7900
 reversal by food additives, colon cancer, 8443
Drug sensitivity
 LANC-like 2-induced, 723
Drug sensitivity genes
 identification with genetic suppressor elements, 164
Dual-specific tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene
 amplification, esophageal adenocarcinoma, 4136
Ductal adenocarcinoma
 pancreatic
 gene hypomethylation, 4158
Ductal breast carcinoma
 B-cell selection, 3275
 expression microarray analysis, 7167
Ductal carcinoma in situ
 COX-2 expression, 2347
 hypoxia-induced dedifferentiation, 1441
Ductal cell neoplasia
 pancreatic
 preinvasive, mice, 2016
DX-8951f (exatecan mesylate)
 efficacy, pancreatic cancer, 80
Dykellic acid
 PMA-induced MMP-9 activity inhibition, 3430
Dysplasia
 DP-1 phosphorylation and, mouse model, 7668
 epidermodysplasia verruciformis-related human papillomavirus
 seroreactivity, nonmelanoma skin cancer, 2695
 oral
 decorin expression, 7769

E

E1 gene
 Ad5-hTERT-E1 vector, antitumor replication-selective, 7936
E1A gene
 cytolytic susceptibility, 3435
E2
 cancer-related UbcH10, 4167
E2F1
 and flavopiridol-induced apoptosis, 7410
Eck: See EphA2
Egr-1
 CD44v6 upregulation by HGF/SF, melanoma, 1576
Elongation factor 2
 eukaryotic eEF-2 kinase inhibitors, 6894
Endocan
 tumor growth promotion, 6084
Endogenous inhibitors
 intracerebral
 growth inhibition, glioma, 2499
Endometrial cancer
 cdc25B and Er- α expression, 6195
 cDNA microarray analysis, 6
 cell invasiveness
 LH/hCG and, 4281

- COMT* methylation, 3101
 CYP1B1, 3913
 gene expression profile, 5697
STK15 expression and amplification, 5697
- Endometrial DNA**
 tamoxifen binding, irreversible, 8461
- Endoplasmic reticulum**
 stress-induced apoptosis
 Bax role, 1483
- Endostatin**
 combined with SU5416, antitumor activity, 8890
 endothelial progenitor cell inhibition, 8345
 G129R-endostatin fusion protein
 breast cancer inhibition, 3598
- Endothelial cells**
 apoptosis
 and blood-brain barrier disruption, 5950
 B16 tumor cell adhesion
 CXCR4 and, 6751
 migration
 thymidine phosphorylase and, 527
 organ-derived lines, 2971
 radiation effects
 SU5416 and SU6668 and, 3755
 vascular
 angiotensin₁₋₄-mediated apoptosis, 4275
 GBM-mediated telomerase reactivation, 3750
- Endothelial precursor cells**
 tumor endothelium model, 5866
- Endothelial progenitor cells**
 circulating
 chemotherapy effects, 4342
 inhibition by endostatin, 8345
- Endothelin A receptor**
 ovarian tumor growth, 2447
- Endothelium**
 intravascular cell adhesion, 3805
 lymphatic vessel
 malignant cell adhesion
 MR and CLEVER-1, 4671
 tumor
 endothelial precursor cell model, 5866
 vascular
 resistance to radiation-induced apoptosis, 7663
- Energy intake**
 and prostate cancer risk, 8542
- Energy restriction**
 mechanisms, 1228
- Enolase**
N-myristoyltransferase inhibition, 7975
- EphA2**
 epitope display, malignant cells, 7907
 immunotherapy target, 8476
 overexpression effects, 3425
 T-cell responses, renal cell carcinoma, 4481
 tumor antigen, 8476
- Epidermal growth factor**
 DAB₃₈₀EGF fusion protein
 glioblastoma multiforme therapy, 1834
 ERK 1/2 and Bad phosphorylation
 inhibition by sulindac sulfide, colon cancer, 616
 FGF-BP regulation, breast cancer, 1696
 receptor
 anti-EGFR antibodies
 conjugated to gold nanoparticles, real-time vital optical imaging, 1999
 autocrine signaling
 and radioresistance, RIE-1 cells, 7807
 coregulation with HER2, 1130
 -dependent tumor cell survival, 1
 EMMPRN regulation, breast cancer, 7575
 flavopiridol-trastuzumab target, breast cancer, 3626
- inhibitors
 combinatorial efficacy with PI3 inhibitors, 8899
 combined with phosphatidylinositol 3-kinase inhibitors, 8930
 inhibitors, small molecule
 resistance, malignant glioma, 7443
 invasion promotion, head and neck squamous cell carcinoma, 5629
 near-infrared optical imaging, breast cancer xenografts, 7870
 prognostic value, glioblastoma multiforme, 6962
 PTEN mutation and
 VEGF mRNA expression regulation, glioblastoma, 236
 Stat3 recruitment sites, 3923
 -targeted immunoliposomes, targeted therapy, 3154
 transactivation
 benzo(a)pyrene quinones, 7825
 colon cancer, 6744
 receptor 2
 human: See **HER-2/neu**
 receptor gene *EGFR*
 selection pressures, glioblastoma, 413
v-erbB transgenic mice
 oligodendroglioma, 1589
 receptor gene *egfr*, breast cancer, 1172
- Epidermis**
 Ras and Raf regulation, 319
- Epidermodysplasia verruciformis-related human papillomavirus**
 seroreactivity, nonmelanoma skin cancer, 2695
- (-)-Epigallocatechin-3-gallate**
 DNA methyltransferase inhibition, cancer cells, 7563
- Epigenetic mechanisms**
 oligodendroglioma, 7600
- Epigenome**
 triple analysis, 2164
- Epiregulin gene**
 activation, hTERT-BJ cells, 1743
- Epithelial carcinoma**
 IgG expression, 6488
 invasion
 circulating laminin-5 fragment marker, 222
 natural IgM antibodies and immunosurveillance, 7995
 ovarian
 functional FasL secretion, 5573
 NY-ESO-1 and LAGE-1 target antigens, 6076
 transgenic mouse model, 1389
- Epithelial cells**
 autocrine-mediated radioresistance, 7807
 Barrett's
 4N (G₂-tetraploid), 4211
 BLM-deficient
 hyper-recombination and genetic instability, 8578
 breast
 immortalization
 chemopreventive agent effects, 1914
 MAPK regulation by H-ras vs N-ras, 5454
 colonic
 butyrate sensitivity
 $\Delta\psi_m$, mitochondrial activity, and, 6311
 stromal prostacyclin antiapoptotic effects, 1748
 gastric
 apoptosis induction by *H. pylori* VacA, 951
 cell proliferation induction by *H. pylori* proteins, 6350
- H. pylori* and p27 degradation, 4739
 intestinal
 β -catenin-expressing, proteomic analysis, 4641
 mammary
 immortalization
 chemopreventive agent effects, 1914
 PDK1 transformation signaling pathway, 5370
 ovarian
 androgen regulation, 2416
 prostate
 proliferation enhancement by Cdc37 overexpression, 4614
 stromal cross-talk
 stromal cell heterogeneity, prostate tumors, 4936
 SV40-transformed
 determinants of crisis, 5813
- Epithelial-mesenchymal transition**
 gatekeeper effects
 breast cancer metastasis regulation, 3386
- Epithelial thyroid tumors**
TSHR methylation, 2316
- Epithelium**
 airway
 smoking-induced *H19* upregulation, 1475
 Ang-2 upregulation by tumor-derived VEGF, 3403
 mammary
 class I alcohol dehydrogenase, 3092
p16^{INK4a} hypermethylation, 1596
 microsatellite instability, UC-associated carcinogenesis, 6158
 normal adjacent
 COX-2 expression, ductal carcinoma *in situ*, 2347
- Epothilone B**
 apoptosis
 inhibition by flavopiridol, breast cancer, 93
 mechanism of action, 6026
- Epstein-Barr virus**
 absence, breast cancer, 2338
 B-cell lymphoma
 growth inhibition by rapamycin, 4472
 circulating DNA
 molecular characterization, nasopharyngeal carcinoma and lymphoma, 2028
 EBV⁺ primary CNS lymphoma
 antiviral therapy, 965
 gastric carcinoma
 autocrine growth, 7062
 MMP-1 regulation, 256
- erbB-2: See HER-2/neu**
- ErbB receptors**
 tumor microenvironment regulation, 3764
- ERG gene**
FUS/ERG gene fusions, Ewing's tumors, 4568
- Erythroleukemia**
 tumorigenicity reversal by GATA-1, 6363
- Erythropoietin**
 and tumor oxygenation, 6162
- Escherichia coli nitroreductase**
 mutations, 5532
- Esophageal adenocarcinoma**
DYRK2 gene amplification, 4136
- Esophageal/forestomach carcinogenesis**
 mice, 186
- Esophageal squamous cell carcinoma**
 CD4, CD8, and CD57 analyses, 1555
 chromosome 3p tumor suppressor genes, 3724
 gene expression profiling, 3872
 gene expression ratios, predictive value, 5159

- progression
 TSLC1, 6320
 ZASC1 amplification, 5691
- Esophageal tumorigenesis**
 perillyl alcohol chemopreventive effects, 2399
- Esophagus, Barrett's**
 4N (G₂-tetraploid) cells, 4211
- Estradiol**
 erbB-2-associated mammary cancer modulation, 2425
- 17 β -Estradiol 17-(β -d-glucuronide)**
 transport by ABCG2, 4048
- Estrogen**
 E-Cadherin downregulation, breast cancer, 5203
 ESR interactions, breast cancer, 7624
 formation by liver tissues and cells, 5041
 heparanase gene expression regulation, breast cancer, 8821
 mammary metabolism
 enzyme activity, 8492
 receptor
 folate receptor α modulation, 2820
 HMGB1-HMGB2-HSC70-ERp60-glycer-aldehyde 3-phosphate dehydrogenase complex
 chemically modified DNA sensor, 100
 stimulation by γ Synuclein, 3899
 receptor α
 conformations, 7490
 degradation induction by PPAR γ agonists, 958
 downregulation by IB-MECA, 6413
 expression, endometrial cancer, 6195
 receptor α gene (ER- α)
 polymorphisms
 and breast cancer risk, 5727
 receptor β
 expression, breast cancer, 2434, 9055
 receptor β gene (ESR)
 estrogen interactions, breast cancer, 7624
- Estrogen down-regulated gene 1 (EDG1)**
 identification, 5151
- Estrogen response element decoy**
 growth inhibition, breast cancer, 2046
- Estrogen sulfotransferase**
 breast cancer, 2762
- Estrone**
 16 α -hydroxylation by CYP3A7, 6532
- Estrone sulfate**
 uterine growth
 inhibition by potent steroid sulfatase inhibitors, 6442
- Estrous cycle**
 and organ-specific metastasis, melanoma, 4763
- ET-743: See Yondelis**
- 1,N⁶-Ethenoadenine**
 DNA adducts, APNG knockout mice, 7699
 repair activity, lung adenocarcinoma, 4351, 6103, 6570
- 3,N⁴-Ethenocytosine**
 repair activity, lung adenocarcinoma, 4351, 6103, 6570
- N-Ethyl-N-nitrosourea**
 mutagenesis and lymphomagenesis
 MSH2 deficiency and, 2062
- Estoposide resistance**
 Bcrp1-mediated, 1339
- Ewing's sarcoma gene EWS**
 EWS/ETS fusion
 telomerase activation, Ewing's tumors, 8338
 uridine phosphorylase target, functional analysis, 4268
 EWS/NOR-1 fusion
 transcriptional regulation by Six3, extraskeletal myxoid chondrosarcoma, 449
- Ewing's tumors**
 FUS/ERG gene fusions, 4568
 fusion proteins
 differentiation blockade, marrow stromal cells, 3464
 telomerase activation by EWS/ETS fusions, 8338
- EWI2/PGRL**
 KAI1/CD82 association, prostate cancer, 2665
- Exatecan mesylate (DX-8951f)**
 efficacy, pancreatic cancer, 80
- EXO1 gene**
 hereditary nonpolyposis colorectal cancer, 154
- Exonic splicing enhancer**
 splicing
 Topo 1 and, 8203
- Expressed sequence tags**
 analysis and validation, 6996
- Expression microarray analysis**
 lobular versus ductal breast carcinoma, 7167
- Extracellular matrix**
 production
 SERPINE2 and, pancreatic cancer, 4945
 and proteases, meeting report, 4750
- Extracellular matrix metalloproteinase inducer**
 regulation by EGFR, breast cancer, 7575
- Extracellular proteolysis**
 and cancer, meeting report, 6105
- Extracellular signal-regulated kinase**
 ERK^{MAPK}/p38^{SAPK} activity ratio, tumor growth and dormancy, 1684
 MKP-1-induced dephosphorylation, breast cancer, 8853
 Raf/MEK/ERK pathway
 inhibition
 CAR upregulation, 2088
- Extracellular signal-regulated kinase 1/2**
 EGF-induced phosphorylation
 inhibition by sulindac sulfide, colon cancer, 616
- Extracutaneous tumors**
 hedgehog signaling, 923
- Extraskeletal myxoid chondrosarcoma**
 EWS/NOR-1 regulation by Six3, 449
- F**
- Familial adenomatous polyposis tumors**
 genetic instability, 5731
- Familial aggregation**
 smoking-related cancer, 8531
- Familial breast cancer**
 ATM mutations, 3325
 Fanconi anemia genes and, 8596
- Familial colorectal cancer**
 hMLH3 mutations, 1894
 methylator phenotype and, 4805
- Familial ovarian cancer**
 ATM mutations, 3325
 BRCA1/2 mutations, 417
- FANCD2**
 menin interactions, 4204
- Fanconi anemia**
 acute myeloid leukemia cell line, 2688
 gene mutations, young-onset pancreatic cancer, 2585, 6998
- Fanconi anemia genes**
 and familial breast cancer, 8596
- Farnesyltransferase inhibitors**
 investigation results, 5656
- Fas gene**
 apoptosis
 and p53 status, 1527
- resistance
 p53 mutants and, prostate cancer, 2905
- Fas ligand**
 microvesicle-derived
 immune privilege mediation, epithelial ovarian cancer, 5573
- FAS promoter**
 polymorphisms
 and acute myeloid leukemia risk, 4327
- Fatty acid synthase**
 inhibition
 and apoptosis, cancer, 7330
- Fatty acid synthesis**
 HER2 cross-talk, 132
 siRNA
 cell growth inhibition, prostate cancer, 3799
- Fenretinide**
 apoptosis
 mediation by Bak, neuroblastoma, 7310
- Ferredoxin reductase**
 pharmacogenomics, colorectal cancer, 6170
- Fibrinogen-coated olive oil droplets**
 docetaxel delivery, solid malignancies, 7314
- Fibroblast growth factor**
 basic
 overexpression, acute myeloid leukemia, 7241
 receptor 1
 cysteine-rich CFR-1, precancerous marker, 2052
 inducible
 activation effects, prostate cancer, 6237
 inducible transgenic mice, 8256
 prostatic intraepithelial neoplasia induction, mouse, 8784
 upregulation by cyclin D1 overexpression, 424
 receptor 1 gene (FGFR1)
 alternative splicing
 regulation by polypyrimidine tract-binding protein, 6154
 receptor 2
 prostatic intraepithelial neoplasia induction, mouse, 8784
 receptor 3 gene (FGFR3)
 mutations, urothelial cell carcinoma of the bladder, 8108
 receptor-specific signaling, prostate tumorigenesis, 8784
- Fibroblast growth factor 2**
 tumor progression promotion, prostate cancer, 5754
- Fibroblast growth factor 18 gene (FGF18)**
 colorectal carcinogenesis, 6116
- Fibroblast growth factor-binding protein**
 regulation by EGF and C/EBP β , breast cancer, 1696
 upregulation by β -catenin, colon carcinogenesis, 8085
- Fibroblasts**
 c-anaphase and diplochromosome induction
 by sodium arsenite, 6680
 cell cycle regulation by redox, 2109
 colonic phenotype
 and COX-2 expression, 522
 gastric
 keratinocyte growth factor, scirrhous gastric cancer, 8848
 hTERT-immobilized hTERT-BJ cells
 Epiregulin activation, 1743
 hTERT-immortalized
 premalignant phenotype, 7147
 UV-induced genomic instability, 1464
- Fibrosarcoma**
 radiation-induced
 glycolysis, ¹³C NMR spectroscopy, 8813

- Fibrosis**
pulmonary
augmentation by ZD1839, 5054
tumor
induction by LOR-1, 1657
- Fibrotic matrix**
invasion mediation, hepatocellular carcinoma, 8312
- Field cancerization**
genetic explanation, 1727
- Filamin**
PSMA association, 2645
- Fingerprinting, molecular**
medulloblastoma, 5428
- Firefly luciferin-activated rose bengal**
chemiluminescence photodynamic therapy, 1818
- FK866**
cellular effects, 7436
- Flavopiridol**
apoptosis, 7410
cell cycle growth-inhibitory and apoptotic effects, breast cancer, 93
combined with TNF- α or TRAIL
apoptosis induction, 621
combined with trastuzumab
EGFR target, breast cancer, 3626
and radiosensitivity, ovarian cancer, 3263
survivin expression regulation, 230
- Fluorescein video angiography**
microcirculation *in vivo*, basal cell carcinoma, 3969
- Fluorescent imaging**
color-coded, metastasis clonality determination, 7785
multiple myeloma, SCID/NOD *in vivo* model, 6689
near-infrared, tumor apoptosis, 1936
- 2-[F-18]Fluoro-2-deoxy-d-glucose**
small animal FDG-PET/CT imaging, 6252
- 3'-[F-18]Fluoro-3'-deoxythymidine**
anticancer therapy monitoring marker, positron emission tomography, 3791, 8558
proliferation imaging, non-Hodgkin's lymphoma, 2681
- 5-Fluorouracil**
anabolism, modeling, 3667
-inducible target genes, cDNA microarray profiling, 4602
repopulation, breast tumors, 2134
sensitivity
gene profiling-based prediction, colon cancer, 8791
- Flutamide**
transport
MRP1 and, 2492
- Folate**
dietary
and promoter methylation, colorectal cancer, 3133
receptor
expression, pituitary adenoma, 4218
- α -Folate**
receptor
CB300638 delivery, 3612
modulation by estrogen receptor, 2820
P1 promoter regulation by vHNF1, ovarian cancer, 696
- Food additives**
drug resistance reversal, colon cancer, 8443
- Forestomach carcinogenesis**
cyclin D1 overexpression and zinc deficiency effects, 4244
inhibition by antizyme overexpression, 3945 mice, 186
- 4-1BB**
tumor-reactive T-cell costimulation, 2546
- 4N (G_2 -tetraploid) cells**
Barrett's esophagus, 4211
- Fowlpox**
combined with MVA prime, antitumor therapy, 7942
- fra-1***
and motility genes, mesothelioma, 3539
- Fractalkine**
NK-dependent antitumor responses, 7468
- Fragile histidine triad (*FHIT*) gene**
expression, breast cancer, 1183
methylation status and loss of heterozygosity, esophageal squamous cell carcinoma, 3724
- Functional proteomic analysis**
melanoma progression, 6716
- FUS/ERG* gene fusions**
Ewing's tumors, 4568
- Fusion constructs**
antimelanoma sFv-rGel, 3995
- Fusion genes**
ADD3-NUP98, biphenotypic acute leukemia, 3079
BRD4-NUT, aggressive carcinoma, 304
CD/UPRT
vesicular stomatitis virus vector, 8366
cytosine deaminase *NGFR-CD*
sarcoma killing, 6847
EWS/ETS
telomerase activation, Ewing's tumors, 8338
uridine phosphorylase target, functional analysis, 4268
FUS/ERG, Ewing's tumors, 4568
MLL-AF9
translocations
apoptotic effectors and, 1371
MSI2/HOXA9, chronic myelogenous leukemia blast crisis, 1202
NUP98-ADD3, biphenotypic acute leukemia, 3079
reporter, multimodality imaging, 1160
- Fusion proteins**
anti-Id-IL-6, ovarian cancer immunotherapy, 3234
DAB₃₈₉EGF, glioblastoma multiforme therapy, 1834
Ewing tumor
differentiation blockade, marrow stromal cells, 3464
G129R-endostatin, breast cancer inhibition, 3598
IL-12-L19 and L19-TNF- α combination treatment, therapeutic effects, 3202
LEC/chTNT-3
and CD25⁺ T-cell depletion, solid tumors, 8384
tissue factor, targeted, 5046
- Fusion transcripts**
HMG42
chromosome 12q15 rearrangements, uterine leiomyomata, 1351
- Fv antibody fragment**
single-chain
anti-IGF1R
IGF-1 inhibition, breast cancer, 627
antimelanoma sFv-rGel, 3995
- G**
- G207**
combined with vincristine, rhabdomyosarcoma, 1508
- GABA: See ³c β o λ δ > γ -Aminobutyric acid³c μ e δ >**
- GA-binding protein**
Skp2 promoter regulation, 4607
- Gadd45a**
effects on recombination, mice, 5335
- α (1,3)Galactosyl epitope**
immunity, colon cancer, 987
- Galectin-3**
apoptosis, T cells, 8302
expression, pituitary tumors, 2251
- Gallbladder cancer**
oncolytic gene therapy
E1 double-restricted Ad, 4434
- Gamma-radiation sensitivity**
IG20, 8768
- Gangliosides**
complex B pathway, neuroblastoma, 7270
tumor
apoptosis induction, T cells, 1676
- Gap filling**
XRCC4/DNA ligase IV, 22
- Gastric adenocarcinoma**
Bcl-w expression and function, 1093
XIAP-associated factor 1 hypermethylation, 7068
- Gastric adenoma**
COX-2 and celecoxib effects, 3032
- Gastric cancer**
CHFR methylation, 8606
EBV-positive
autocrine growth, 7062
expression profiling and subtype-specific expression, 8248
gene expression patterns, 2569
H. pylori-associated, INS-GAS mice, 942
invasiveness
induction by MIC-1, 4648
microtubule inhibitor sensitivity, 8606
molecular subtypes, combination CGH and microarray analysis, 3309
scirrhous
gastric fibroblast-secreted KGF, 8848
survival inhibition effects, 7724
XIAP-associated factor 1 inactivation, 7068
- Gastric carcinogenesis**
K-ras, 2005
- Gastric cardia adenocarcinoma**
MMP-2 polymorphism and, 3987
- Gastric epithelial cells**
apoptosis induction by *H. pylori* VacA, 951
cell proliferation induction by *H. pylori* proteins, 6350
H. pylori and p27 degradation, 4739
- Gastric fibroblasts**
keratinocyte growth factor, scirrhous gastric cancer, 8848
- Gastric mucosa**
preinvasive
gene expression patterns, 2569
- Gastrinoma**
chromosome 1q loss of heterozygosity, 817
- Gastrointestinal cancer**
ACVR2 mutations, 994
- Gastrointestinal stromal tumors**
HMGB1 overexpression, 2188
- Gastrointestinal tract**
crypt damage
regulation by microvascular function, 4338
- GATA-1**
tumorigenicity reversal, erythroleukemia, 6363
- GATA-6**
inactivation, ovarian tumor dedifferentiation, 4967
- GCLC gene**
Keap1/Nrf2-mediated induction
NADPH oxidase and, 5636
- GDP-1-fucose**
synthesis levels, hepatocellular carcinoma, 6282
- Geldanamycin**
AKT dephosphorylation promotion, breast

- cancer, 7777
and cervical tumor radiosensitization, 8984
ErbB-2/*neu* degradation, 39
polymer-drug conjugate
 stress response modulation, ovarian cancer, 7876
- Gelonin immunotoxin**
antimelanoma sFv-rGel, 3995
resistance, multidrug-resistant cells, 72
- Gelsolin**
androgen receptor modulation, prostate cancer, 4888
- Gemcitabine**
radiosensitization, MMR-deficient HCT116 cells, 6935
sensitization by E1A, hepatocellular carcinoma, 6229
- Gene amplification**
gene expression profiling, breast cancer, 2194
- Gene expression**
antioxidant response element-mediated glutathione and, 7520
CD5⁺ and CD5⁻ diffuse large B-cell lymphoma, 60
classification mapping
 tumor origin, 4144
and class I HLA antigen processing mechanisms, 4119
endometrial cancer, cDNA microarray analysis, 6
gastric cancer, 2569
genome-wide
 MYCN-associated, neuroblastoma, 4538
growth regulatory response, breast cancer, 7158
malignancy, 8939
and microtubule-stabilizing drugs, 7891
pancreatic ductal adenocarcinoma, 8614
phenotypes
 Rb and Rb family members, 3716
polycythemia vera, cDNA microarray analysis, 3940
profiles
 astrocytic glioma classification, 6613
 colorectal cancer, 6855
 endometrial carcinoma, 5697
 esophageal squamous cell carcinoma, 3872
 gastric cancer, 8248
 gene amplification, breast cancer, 2194
 genome-wide, prostate cancer, 4196
 mantle cell lymphoma, 8226
 Neu-induced mammary tumors, transgenic mice, 4920
 pediatric acute lymphoblastic leukemia, 4882
 peripheral blood mononuclear cells, advanced renal cell carcinoma, 6069
 uvea melanoma classification, 2578
ratios, esophageal squamous cell carcinoma, 5159
regulation by ING1, 5785
transcriptional, small cell lung cancer, 1943
- Gene polymorphisms**
ACE
 and breast cancer risk, 573, 6984
CDKN1A
 and prostate cancer, 2033
CDKN1B
 and prostate cancer, 2033
CYP2A13
 and lung cancer risk, 8057
CYP1B1, endometrial cancer, 3913
ER-α
 and breast cancer risk, 5727
FAS promoter
 and acute myeloid leukemia risk, 4327
GNMT, hepatocellular carcinoma, 647
G691S/S904S
 RET, 1814
human lymphocyte antigen, HPV-16-positive vulval intraepithelial neoplasia, 400
IGFBP-3, prostate cancer, 4407
IL-6, high-risk breast cancer, 8051
MMP-2, gastric cardia adenocarcinoma, 3987
PGR
 and breast cancer risk, 5236
single nucleotide
 bladder cancer, 2216
 genome-wide loss of heterozygosity mapping, prostate cancer, 4781
 inflammatory genes
 and colorectal cancer, 3560
TS double polymorphism, 6004
TS tandem repeats, 2898
- Gene profiling**
chemosensitivity prediction, colon cancer, 8791
prostate cancer recurrence prediction, 3469
- Genes**
cancer modifier, mouse, 3011
growth regulatory
 PPARα-dependent, 5767
tumor-stromal interactions, 8939
X-linked juvenile-type granulosa cell tumor susceptibility, mapping, 8197
- Gene therapy**
Ad-CD154 and CpG ODNs, B-cell lymphoma, 4128
adenoviral, renal cell carcinoma, 1994
apoptotic factors and, 8563
Bik mutant, 7630
h-NIS, prostate cancer, 7840
microsatellite instability tumors, 8113
novel PEI/DNA vector, bladder cancer, 4017
oncolytic
 E1 double-restricted Ad, gallbladder cancer, 4434
 response, MRI contrasts, 7571
 sodium iodide symporter (NIS)
 combined with radioiodide treatment, neuroendocrine tumor cells, 1333
 suicide
 adenovirus-mediated, prostate cancer, 7497
 systemic
 rapalog-regulated, 3173
 yCD, intrahepatic colon cancer, 658
- Genetic instability**
Xrcc2-knockout mice, 8181
- Genetic mechanisms**
oligodendroglioma, 7600
- Genetics**
colorectal cancer pathways, 7206
field cancerization, 1727
TPA promotion susceptibility, skin tumors, 2747
- Genetic suppressor elements**
drug sensitivity gene identification, 164
- Gene transfer**
adenoviral Ad-*TRAIL*
 hepatocyte toxicity, 2369
IL-1ra
 effects, melanoma, 5957
- Genome-wide gene expression analysis**
bladder cancer, 2216
MYCN-associated expression, neuroblastoma, 4538
prostate cancer, 4196
- Genomic instability**
breast cancer, 4588
BUB1 inhibition effects, 2855
- colon cancer, 1608
oxidative stress and, 3107
Pim-1 and, 8079
preleukemic transgenic mice, 4895
radiation-induced
 p53 and, 936
 UV-induced, 1464
- Genotoxic damage**
cellular recovery
 Spy1 and, mammalian cells, 3701
- Genotype**
COMT
 and breast cancer, Asian-American women, 7526
HPV, nonmelanoma skin cancer, 7515
- Geranylgeranyltransferase I inhibitors**
GGTI-2154
 apoptosis and breast tumor inhibition, mice, 8922
 Rac1 and Rac3 targets, 7959
- Germ cell tumors**
pluripotent, identification by POU5F1, 2244
testicular
 bilateral
 c-KIT mutations and, 7674
- GGTI-2154**
apoptosis and breast tumor inhibition, mice, 8922
- Gleevec**
effects on Rad51 levels and radiosensitivity, glioma, 7377
and TGF-β-induced proliferation, osteosarcoma, 7791
- Gli1**
regulation by PKCα, basal cell carcinoma, 4692
- Glial tumors**
constitutively active JNK, 250
- Glioblastoma**
Crkl adapter protein, 2335
EGFR selection pressures, 413
invasion enhancement by IGFBP2, 4315
PI3K signaling pathway, 2742
tumor proliferation
 SDF-1α and CXCR4, 1969
ZFP TF-mediated VEGF-A inhibition, 8968
- Glioblastoma multiforme**
DAB₃₈₉EGF therapy, 1834
EGFR, prognostic value, 6962
measles virus treatment, 2462
telomerase reactivation, HUVECs, 3750
- Glioma**
angiogenesis inhibition by PTEN, 2300
astrocytic
 classification by gene expression profiles, 6613
B7-H1 expression, 7462
bone marrow-derived neural stem-like cells, 8877
combination ZD1839 and LY294002 effects, 8930
growth inhibition
 GAP43, 2933
 intracerebral endogenous inhibitors, 2499
 uPAR and MMP-9, 2454
 heparanase effects, 7733
 ¹H NMR-visible lipids, cell death, 3195
 invasion inhibition by uPAR and MMP-9, 2454
malignant
 angiogenic factor upregulation by TNF-α, 4181
 autophagic cell death by As₂O₃, 2103
 LY294002 and microtubule drug synergy, 4044
 microarray-based classification, 1602
 small molecule *EGFR* inhibitor resistance, 7443

MICA/NGK2D-mediated therapy, 8996
 NO-mediated bystander effects, 8437
 optic nerve, *Nf1* mutant mice, 8573
 p53-dependent proliferative life span barriers, *in vitro* model, 4854
 PDGF-B and *p53* or *Ink4a-Arf* loss, 4305
 Rad51 levels and radiosensitivity
 Gleevec and, 7377
 shared melanoma antigen targeting, murine model, 8487
 wild-type *p53* inactivation, 8670
Gliomagenesis
 VEGF isoform expression, 1962
Glomeruloid microvascular proliferation
 prognostic value, non-small cell lung cancer, 6791
 β -Glucan
 monoclonal antibody therapy adjuvant, 9023
Glucocorticoids
 apoptosis, pre-B leukemic cells, 172
 cotreatment
 apoptosis resistance induction, 3112
Glucose depletion
 and P-glycoprotein expression, hepatoma, 7284
Glucose-regulatory protein GRP58
 MMC-induced DNA cross-linking, 6016
Glucosylceramide synthase
 modulation by RTN-1C, neuroepithelioma, 3860
Glucosylceramide synthase inhibitors
 tumor growth inhibition, melanoma, 3654
Glutathione
 cisplatin resistance increase, 312
 gene activation and apoptosis effects, 7520
Glutathione peroxidase 1
 breast cancer, 3347
Glutathione S-transferase π
 amplification
 and cisplatin resistance, head and neck squamous cell carcinoma, 8097
 GSTP1
 activity, mammary estrogen metabolism, 8492
Glyceraldehyde 3
 HMGB1-HMGB2-HSC70-ERp60-glyceraldehyde 3-phosphate dehydrogenase complex
 chemically modified DNA sensor, 100
Glycine N-methyltransferase (GNMT)
 gene polymorphisms, liver cancer, 647
Glycodelin
 ovarian serous carcinoma, 6258
Glycogen synthase kinase-3 β
 inactivation by BP75, 4792
Glycolysis
 ¹³C NMR spectroscopy, RIF-1 tumors, 8813
Glycolytic phenotype
 carcinogenesis, mathematical models, 3847
Glycosaminoglycans
 melanoma-associated, localization and characterization, 2965
Glycosphingolipids
 metabolism
 and tumor growth, melanoma, 3654
Glycosylation
 tumor-specific
 CD44 pattern, detection, 8278
Gö6976
 DNA damage-induced cell cycle checkpoint inhibition, 31
Gold nanoparticles
 anti-EGFR antibodies-conjugated, real-time vital optical imaging, 1999
Golgi peripheral membrane protein p65 GOLPH5 (GORASP1)
 human homologue, isolation, 404

G protein-coupled receptor
 Kaposi's sarcoma-associated herpes virus cell transformation, 8837
G-quadruplex ligand telomerase inhibitor
 senescence induction resistance, 6149
Granulocyte-macrophage colony-stimulating factor
 combined with CpG ODNs, neuroblastoma immunotherapy, 394
 combined with vaccinia-expressed tumor antigen, intratumoral vaccination, 6956
Granulocytic maturation
 butyrate treatment, acute myeloid leukemia, 8955
Granulosa cell tumors
 X-linked juvenile-type
 susceptibility genes, mapping, 8197
G129R-endostatin fusion protein
 breast cancer inhibition, 3598
GRN163: See Oligonucleotide N3' \rightarrow P5' thio-phosphoramidate
Growth-associated protein GAP43
 growth inhibition, glioma, 2933
Growth factors
 independence
 TGF- α and, 4731
Growth hormone-releasing hormone antagonists
 proliferation inhibition, non-small cell lung cancer, 7913
GTI-2040
 antitumor activity, 2802

H

H19 gene
 smoking-induced upregulation, 1475
Haem
 red meat endogenous intestinal *N*-nitrosation, 2358
Hair follicle morphogenesis
 Pten role, 674
Hair growth
 PKC ϵ and ornithine decarboxylase, 3037
Haplotype analysis
 VEGF gene, 812
hdm2 gene
 regulation, breast cancer, 2616
HEA (WFDC2) protein
 ovarian cancer biomarker, 3695
Head and neck squamous cell carcinoma
 apoptosis induction by SCH66336, 4796
 apoptosis induction by SHetA2, 3826
 EGFR-independent constitutive STAT3 activation, 2948
 GST- π amplification and cisplatin resistance, 8097
 invasion promotion by EGFR, 5629
 lymphatic endothelial markers, 8555
 LYVE-1, VAP-1, and CD44, 1920, 8555
 molecular progression
 PAI-2 biomarker, 555
 p53 and HPV16/18 E6 transcripts, 1188
 plasmacytoid dendritic cells, 6478
 tissue microarray analysis, 1179
Heat-activated antisense Ku70
 radiosensitization, tumor cells, 3268
Heat shock protein
 HMGB1-HMGB2-HSC70-ERp60-glyceraldehyde 3-phosphate dehydrogenase complex
 chemically modified DNA sensor, 100
 mediated oncolytic tumor vaccine, 7321
Heat shock protein 27
 altered regulation by angiogenesis inhibitors, 6405
 PS-341 resistance, lymphoma, 6174
Heat shock protein 70
 chemosensitizing apoptosis-inducing factor derivative binding, 8233
 CTL lysability effects, tumor cells, 8212
Heat shock protein 110
 hsp110-gp100 vaccine
 antitumor immunity, 2553
Hedgehog
 signaling, non-BCC cancer, 923
Helicobacter pylori
 -associated gastric cancer, INS-GAS mice, 942
 and p27 degradation, gastric epithelial cells, 4739
 proteins CagA and HspB
 cell proliferation induction, gastric epithelial cells, 6350
 vacuolating toxin VacA
 gastric epithelial cell apoptosis induction, 951
Hemangiosarcoma
 Ink4c/p53-null mice, 5420
Hematological malignancy
 and marrow microenvironment, meeting report, 7539
Hemiasterlin analogue HTI-286
 multidrug resistance circumvention, 1838
Hemoglobin
 and oxygenation, breast cancer, 7634
Hematopoietic cells
 senescence
 ionizing radiation and busulfan-induced, murine bone marrow, 5414
Heparanase
 activity, multiple myeloma, 8749
 gene expression
 regulation by estrogen, breast cancer, 8821
 glioma cell effects, 7733
Heparin-binding epidermal growth factor-like growth factor
 nuclear, bladder cancer, 484
Hepatitis B virus X protein
 PTEN downregulation, 3453
Hepatitis C virus-associated hepatocellular carcinoma
 novel tumor markers, 859
Hepatocellular carcinogenesis
 chimeric mice, 4914
 PEG10, 3043
 telomere dysfunction and, 5021
Hepatocellular carcinoma
 acquired selenium deficiency tolerance, 6707
 AFB₁-related
 susceptibility, 4594
 Bcl-xL deamidation inhibition, 3054
 DLC-1 alterations, 7646
 GDP-L-fucose synthesis levels, 6282
 gemcitabine sensitization by E1A, 6229
 GNMT polymorphisms, 647
 growth inhibition by Notch1, 8323
 HAI-2/PB hypermethylation, 8674
 HCV-associated
 novel tumor markers, 859
 insertion-mutated E1A adenovirus, 3073
 invasion
 matrix-mediated, 8312
 oxidative DNA damage base excision repair alterations, rats, 7704
 risk factor interactions, mouse models, 7553
 SVH-B upregulation, 3775
 VEGF serum levels and tumor expression, 3121
 vesicular stomatitis virus treatment, 3605
Hepatocyte growth factor
 angiogenesis
 inhibition by NSAIDs, 8351
 CD44v6 upregulation, melanoma cells, 1576
 c-MET-HGF, rhabdomyosarcoma, 7926

- neutrophil-derived, lung adenocarcinoma, 1405
- Hepatocyte growth factor activator inhibitor 1**
node-negative breast cancer, 1101
- Hepatocyte growth factor activator inhibitor 2/placental bikunin gene (HAI-2/PB)**
hypermethylation, hepatocellular carcinoma, 8674
- Hepatocyte nuclear factor 1**
variant vHNF1
P1 α FR promoter regulation, ovarian cancer, 696
- Hepatocyte toxicity**
Ad-TRAIL gene transfer, 2369
- Hepatosoma**
inhibition by RNA interference, 3593
P-glycoprotein expression
glucose depletion and, 7284
TGF- β JNK activation and apoptosis regulation by HIPK2, 8271
tumor-specific T cell activation by radiofrequency ablation, rabbits, 6496, 7543
- Hepatotoxicity**
yondelis
dexamethasone protection against, rat, 5902
- HER-2/neu**
coregulation with EGFR, 1130
downregulation
tumor remission after, mouse model, 7221
erbB-2-associated mammary cancer
hormonal modulation, 2425
expression, breast cancer, 1445
fatty acid synthesis cross-talk, 132
geldanamycin-induced degradation, 39
mammary tumorigenesis
Ink4a/Arf, 3395
prometastatic gene upregulation, medulloblastoma, 140
receptor, magnetic resonance imaging, 2723
transgenic p53 mutant mice
rhabdomyosarcoma, 2728
- Hereditary nonpolyposis colorectal cancer**
breast cancer tumor exclusion, 1148
EXO1 role, 154
- Herpes simplex virus type 1**
multimutated G207
combined with vincristine, rhabdomyosarcoma, 1508
- Herpes virus**
Kaposi's sarcoma-associated
G protein-coupled receptor
cell transformation, 8837
- Heteroarotinoids**
synthetic SHetA2
apoptosis induction, head and neck squamous cell carcinoma, 3826
- 2-[1-Hexyloxyethyl]-2-devinyl prophephorbide-a**
population pharmacokinetics, 1806
- High mobility group A2**
HMGA2 fusion transcripts
chromosome 12q15 rearrangements, uterine leiomyomata, 1351
- High mobility group box 1**
HMGB1-HMGB2-HSC70-ERp60-glyceraldehyde 3-phosphate dehydrogenase complex
chemically modified DNA sensor, 100
overexpression, gastrointestinal stromal tumors, 2188
- High mobility group box 2**
HMGB1-HMGB2-HSC70-ERp60-glyceraldehyde 3-phosphate dehydrogenase complex
chemically modified DNA sensor, 100
- HIN-1 gene**
methylation, BRCA1-linked breast tumors, 2024
- Histone deacetylase**
menin-HDAC complex
JunD inhibition, 6135
T β RII inhibition mechanism, 2624
- Histone deacetylase inhibitors**
and anticancer drug cytotoxicity, 7291
apoptosis induction mechanisms, 4460, 8948
lung cancer prevention, 7089
MS-275
dose-dependent effects, leukemia, 3637
p21^{WAF1} activation, 2891
RECK upregulation, 3069
STI571-mediated apoptosis promotion, 2118
- Histone H3**
modification
site-specific p53 effects, 6674
- Histone H2AX**
serine 139 phosphorylated γ H2AX
and cell survival, 4347
- Histone H2B**
downregulation by DNA-dependent protein kinase, 7197
- Histone methyltransferase**
inactivation by mutations, cancer, 7619
- HMGA2 protein**
inhibition, well-differentiated liposarcoma therapy, 7423
- HMN-176**
multidrug resistance circumvention, 6942
- Hodgkin and Reed Sternberg cells**
chromosome 6q25 allelic losses, 2606
- Hodgkin's disease**
NOVP chemotherapy-induced sperm aneuploidies, 44
- Hodgkin's lymphoma**
lymphocyte-rich classical
single-cell analysis, 1644
- Homeobox gene HOXA9**
MSI2/HOXA9 fusion gene, chronic myelogenous leukemia blast crisis, 1202
- Homeodomain-interacting protein kinase 2**
p53 induction
and promyelocytic leukemia, 4310
TGF- β JNK activation and apoptosis regulation, hepatoma, 8271
- Hormones**
and mammary tumorigenesis, 1067
p53 function and, mammary tumorigenesis, 6140
- Hot spots**
MNNG-induced, 5793
- HOXC gene**
expression, prostate cancer, 5879
- HRAD9 gene**
mammalian paralogue
expression, testicular cancer, 5291
- H-ras**
mitogen-activated protein kinase regulation, breast epithelial cells, 5454
mutations
allele-specific, skin carcinoma, 4849
- H-Ras IDX: See p19**
- HspB**
cell proliferation induction, gastric epithelial cells, 6350
- Human epidermal growth factor receptor 2: See HER-2/neu**
- Human leukemia virus type 1**
apoptosis induction by roscovitine, MT-2 cells, 8523
- Human lymphocyte antigen**
class I
antigen processing mechanisms, 4119
polymorphisms, HPV-16-positive vulval intraepithelial neoplasia, 400
- Human lymphocyte antigen B46**
-restricted tumor-infiltrating lymphocytes
mutated p53 recognition, 854
- Human lymphocyte antigen DR**
-restricted epitopes, promiscuous
LAGE-1 alternative open reading frame, 6506
- Human lymphocyte antigen G**
upregulation, renal cell carcinoma, 4107
- Human mammary epithelial cells**
immortalization
chemopreventive agent effects, 1914
- Human papillomavirus**
epidermodysplasia verruciformis-related
seroreactivity, nonmelanoma skin cancer, 2695
genotypes, nonmelanoma skin cancer, 7515
keratinocyte transformation
Notch1 and, 8687
RASSF1A and, cervical carcinoma, 1888
- Human papillomavirus 16**
distribution, ovarian adenocarcinoma, 7215
E6
cervical carcinogenesis, transgenic mouse models, 4862
immortalization
modulation by culture conditions, keratinocytes, 7815
-specific Th responses, 636
transcripts
p53 and, head and neck squamous cell carcinoma, 1188
E7
cervical carcinogenesis, transgenic mouse models, 4862
immortalization
modulation by culture conditions, keratinocytes, 7815
oncogene vaccination, high-grade vulval intraepithelial neoplasia, 6032
vulval intraepithelial neoplasia
HLA polymorphisms, 400
- Human papillomavirus 18**
distribution, ovarian adenocarcinoma, 7215
E6
cervical carcinogenesis, transgenic mouse models, 4862
transcripts
p53 and, head and neck squamous cell carcinoma, 1188
E7
cervical carcinogenesis, transgenic mouse models, 4862
oncogene vaccination, high-grade vulval intraepithelial neoplasia, 6032
- Human papillomavirus virus-like particles**
uptake and cross-presentation by dendritic cells and Langerhans cells, 3478
- Human prostate-specific gene-1 (HPG-1)**
molecular cloning, 329
- Human umbilical vein endothelial cells**
GBM-mediated telomerase reactivation, 3750
- HuR**
expression, serous ovarian carcinoma, 7591
- Hyaluronan-binding peptide**
antitumor activity, 5685
- Hyaluronic acid**
prognostic value, prostate cancer, 2638
- Hyaluronidase HYAL1**
prognostic value, prostate cancer, 2638
- Hydrogen peroxide**
and tumor proliferation, 6370
- 8-Hydroxyguanine**
and mutation enhancement by cell proliferation, 4287

Hypercalcemia malignancy
inhibition
PSP-94, 2072

Hypercalcemic hyperparathyroidism
mouse model, 8022

Hypericin
mitotic death, cancer cells, 8241

Hyperlipidemia
Apc-deficient mice, 6090

Hyperparathyroidism
hypercalcemic, mouse model, 8022

Hyperplasia, benign prostatic
hK11, 6543

Hyperplastic polyps
BRAF and *KRAS* mutations, 4878

Hyperthermia
angiogenesis inhibition, 1500

Hypoxanthine-guanine-phosphoribosyltransferase gene (HPRT)
mutational spectrum, 5793

Hypoxia
buthionine sulfoximine and tirapazamine, neuroblastoma, 1520
transcriptional response
regulation by HIF-1 α vs HIF-2 α , 6130

Hypoxia-induced dedifferentiation
ductal carcinoma *in situ*, 1441

Hypoxia-inducible factor
ascorbate effects, 1764
tumors
replicative adenoviral treatment, 6877

Hypoxia-inducible factor 1
cell invasion regulation, colon cancer, 1138
nickel carcinogenesis, 3524
PGE₂-induced VEGF expression mediation, 2330

Hypoxia-inducible factor 1 α
gene activation, 6130
inhibition by mPHD1, 8777
PMA-induced, 8700

Hypoxia-inducible factor 2 α
gene activation, 6130
upregulation, renal cell carcinoma, 2675

I

IAI.3B gene
AdE3-*IAI.3B*, ovarian cancer therapy, 2506

IB-MECA
ER α downregulation and breast cancer cell proliferation inhibition, 6413

Id2
expression, neuroblastoma, 1631
and phenotype, breast cancer, 7098

IG20
tumor growth and γ -radiation sensitivity, 8768

Imaging: See also specific modalities
bioluminescence
novel reporter mouse, 7042
fluorescent
color-coded, metastasis clonality determination, 7785
multiple myeloma, SCID/NOD *in vivo* model, 6689
near-infrared, tumor apoptosis, 1936
molecular
angiogenesis, MRI, 5838
contrast agents, 1999
protein-protein interactions, 1780
multimodality
fusion reporter gene, 1160
optical
near-infrared
EGFr, breast cancer xenografts, 7870
pre- and intraoperative delineation, brain tumors, 8122
real-time vital

anti-EGFR antibodies conjugated to gold nanoparticles, 1999

Imatinib resistance
rapamycin and, chronic myelogenous leukemia, 5716

Immortalization
chemopreventive agent effects, beast epithelial cells, 1914
HPV-16 E6 and E7
modulation by culture conditions, keratinocytes, 7815
hTERT-immortalized fibroblasts
premalignant phenotype, 7147

Immune system
privilege
mediation by microvesicle-derived FasL, 5573
tumor interactions, meeting report, 3005

Immunity
 α (1,3)galactosyl epitope, colon cancer, 987
antigen-specific, neuroblastoma, 6948
antitumor
anti-idiotypic antibody-pulsed dendritic cells, 2844
hsp110-gp100 vaccine, 2553
NY-ESO-1, neuroblastoma, 6948

Immunoconjugates
cancer therapy, meeting report, 8069

Immunodiagnostics
ovarian cancer, 3695

Immunogene therapy
MICA/NGK2D-mediated, glioma, 8996
MMP-2, 600
T-body, prostate tumors, 2470

Immunogenicity
intralesional tumor cell injection and, 2145

Immunoglobulin G
expression, epithelial cancer, 6488

Immunoglobulin M
antibodies
natural
and immunosurveillance, epithelial cancer, 7995
prostate infiltration, chronic lymphocytic leukemia, 2067

Immunohistochemistry
RT-PCR, micrometastatic prostate cancer, 4662

Immunoliposomes
EGFR-targeted, targeted therapy, 3154

Immunoprecipitation
BPDE-binding DNA fragment identification, 1470

Immunosurveillance
natural IgM antibodies and, epithelial cancer, 7995

Immunotherapy
adoptive
B7-H1 and, squamous cell carcinoma, 6501
anti-E-selectin, prostate cancer, 6387
anti-Id-IL-6 fusion protein, ovarian cancer, 3234
brain metastasis, 1345
CD80-decorated tumor cells, 4067
CD25⁺ T-cell depletion
LEC/chTNT-3 and, solid tumors, 8384
combined CpG ODNs and GM-CSF, neuroblastoma, 394
combined with antiangiogenic therapy
solid tumor rejection, mice, 5895
combined with COX-2 inhibition, antitumor effects, 7845
combined with metronomic cyclophosphamide, murine melanoma, 8408
DNA vaccine
combined with Pan-IA DNA

tumor growth inhibition, 7920
EphA2 target, 8476
IL-12 and IL-18 gene-transduced dendritic cells, 6378
synergy with chemotherapy, solid tumors, 4490

Immunotoxins
recombinant, acute myeloid leukemia treatment, 8414
resistance
multidrug-resistant cells, 72

Indole acetic acid
combined with photodynamic therapy, 776

Indole-3-carbinol tetrameric derivatives
breast cancer cell growth inhibition, 4028

Infections
polyomavirus
susceptibility, mesothelioma, 6125

Inflammatory chemokines
dendritic cell recruitment and loading, 5505

ING1
gene expression regulation, 5785

Inherited ovarian cancer
BRCA1/2 mutations, 417

Inhibitor of apoptosis protein
apoptosome inhibition, non-small cell lung cancer, 831, 6566
targeting, tumor cells, 6815

Inhibitor of nuclear factor κ B kinase deficiency
and JNK, 7689

Initiation proteins
inhibition
apoptosis induction, 7356

Ink4a/Arf
deletion
PDGF-B and, glioma, 4305
ErbB2 mammary tumorigenesis, 3395
tumor growth inhibition, colon tumors, 742

Ink4c
Ink4c/p53-null mice
tumor spectrum, 5420

Insulin-like growth factor
receptor type 1
anti-IGF1R scFv-Fc antibody
IGF-I inhibition, breast cancer, 627

Insulin-like growth factor-binding protein 2
androgen-independent growth promotion, prostate tumors, 3575
invasion enhancement, glioblastoma, 4315

Insulin-like growth factor-binding protein 3
gene polymorphism, prostate cancer, 4407
upregulation by lycopene supplementation, 3138

Insulin-like growth factor binding protein-related protein 1
antitumor activity, prostate cancer, 7717

Insulin-like growth factor I
cell adhesion and migration induction, multiple myeloma, 5850, 7543
circulating levels, mammary tumor risk factor, 4384
inhibition, breast cancer, 627
protection against rapamycin-induced apoptosis, 364
receptor
antibody A12, 8912
antibody EM164
cancer cell proliferation inhibition, 5073
dominant negative, prostate cancer, 6432
overexpression, colon cancer, 7708
soluble sIGF-IR, ovarian cancer, 7834
VEGF-C regulation, 1166
serum, prostate cancer, 3991

Insulin-like growth factor II gene (IGF2)

- loss of imprinting, Wilms' tumor, 1900
receptor genotype
and oral cancer risk, 296
- α, β_3 Integrin**
antagonist S247
metastasis inhibition, colon cancer, 2079
expression
platelet-type 12-lipoxygenase and, 4258
- α, β_5 Integrin**
expression
platelet-type 12-lipoxygenase and, 4258
- $\alpha 1 \beta 1$ Integrin**
inhibition by obtustatin, 2020
matrix-mediated invasion regulation, hepato-
cellular carcinoma, 8312
- $\alpha 2 \beta 1$ Integrin**
matrix-mediated invasion regulation, hepato-
cellular carcinoma, 8312
- Interferon α**
combined with cotylenin A, non-small cell
lung cancer, 3659
- Interferon β**
TRAIL promoter activity induction, 5299
- Interferon γ**
apoptosis
SOXN, neuroblastoma, 7742
- Interferon regulatory factor 5**
cell growth inhibition, 6424
- Interleukin 1**
receptor antagonist
gene transduction effects, melanoma, 5957
- Interleukin 1 β**
COX-2 upregulation, colorectal cancer, 3632
- Interleukin 2**
breast cancer vaccine BCG-hIL2MUC1, de-
velopment and preclinical evaluation,
1270
- Interleukin 4**
production, thyroid cancer, 6784
receptor α
p73 target, identification, 8145
- Interleukin 6**
anti-Id-IL-6 fusion protein, ovarian cancer
immunotherapy, 3234
gene polymorphisms, high-risk breast can-
cer, 8051
gene promoter polymorphism, ovarian can-
cer, 3066
regulation, prostate cancer, 2206
single nucleotide polymorphisms
and colorectal cancer, 3560
- Interleukin 8**
expression stimulation by bombesin, prostate
cancer, 3495
TRAIL/Apo-2L-induced apoptosis inhibition,
ovarian cancer, 4521
- Interleukin 10**
and CD4 and CD8 T-cell response stimula-
tion by dendritic cells, 2150
and COX-2 expression, non-small cell lung
cancer, 766
production, thyroid cancer, 6784
- Interleukin 11**
receptor α -locus chemokine
antitumor effects, 4420
- Interleukin 12**
IL-12-L19 fusion
combined with L19-TNF- α , therapeutic
effects, 3202
recently activated dendritic cells and, 3688
-transduced dendritic cells, immunotherapy,
6378
-transduced macrophages, metastatic prostate
cancer therapy, 7853
- Interleukin 18**
-transduced dendritic cells, immunotherapy,
6378
- Interleukin 18-binding protein**
liver melanoma metastasis inhibition, 491
- Interleukin 21**
antitumor activity, 9016
- Interleukin 24**
MDA-7/IL-24
angiogenesis regulation, 5105
mda-7/IL-24
apoptosis induction, prostate cancer, 8138
- Intestinal epithelial cells**
 β -catenin-expressing, proteomic analysis,
4641
- Intestinal immune response**
Apc^{Min/+} mouse model, 5136
- Intestinal polyposis**
COX-1 and COX-2 cooperation, 4872
inhibition, *Mdr1^{-/-} Apc^{Min/+}* mice, 895
- Intestinal tumorigenesis**
p27^{Kip1}, mouse, 4990
- Intracellular magnetic resonance imaging**
prostate cancer, 4766
- Intradermal injection**
tumor cell
and immunogenicity, 2145
- Intraepithelial neoplasia, prostate**
inducible, FGFR1 transgenic mice, 8256
induction
FGFR1 and FGFR2, mouse, 8784
- Intraepithelial neoplasia, vulval**
high-grade
HPV oncogene vaccination, 6032
- Intratumoral vaccination**
vaccinia-expressed tumor antigen and GM-
CSF, 6956
- Invasion: See also Cell migration**
AKT2-induced, breast and ovarian cancer,
196
calpain-2, prostate cancer, 4632
circulating laminin-5 fragment marker, epi-
thelial carcinoma, 222
enhancement by IGFBP2, glioblastoma,
4315
induction
Akt E-cadherin downregulation, squamous
cell carcinoma, 2172
MIC-1, gastric cancer, 4648
inhibition
Syk nuclear localization and, breast can-
cer, 4724, 7004
uPAR, glioma, 2454
legumain overexpression, 2957
LH/hCG and, endometrial cancer, 4281
matrix-mediated, hepatocellular carcinoma,
8312
MUC1 contributions, pancreatic cancer,
5011
promotion by PRL-3 and PRL-1, 2716
regulation
Crkl adapter protein, glioblastoma, 2335
HIF-1, colon cancer, 1138
p16^{INK4a}, basal cell carcinoma, 1737
RhoA and NF- κ B, prostate cancer, 1359
SERPINE2 and, pancreatic cancer, 4945
visinin-like protein-1 effects, squamous cell
carcinoma, 4997
- Invasive breast cancer**
TGF β -1 variant and, 2610
- Invasive phenotype**
vimentin overexpression and, prostate can-
cer, 2306
- Invasive prostate adenocarcinoma**
Nkx3.1; *Pten* mice, 3886
- Iodide**
nonradioactive
apoptosis induction, lung cancer, 5065
- Iodine**
monoclonal antibody therapy radiolabels,
111
residualizing
radioimmunotherapy, 111
- N⁶-(3-Iodobenzyl)adenosine-5'-N-methylu-
ronamide*: See IB-MECA**
- Iododeoxyuridine**
recognition
MutSa, DNA, 5490
sensitization
base excision repair inhibition and, 838
- Ionizing radiation: See also Radiation**
adenoma multiplicity, *Apc^{Min}* mice, 2361
connexin43 upregulation, 7128
death-inducing effects, 324
fractionated
survival after
p53 and, prostate cancer, 7190
heavy
in vitro angiogenesis inhibition, 4253
hematopoietic cell senescence, murine bone
marrow, 5414
p21^{Cip1} and metastasis, mice, 3021
PBN protective effects against, U937 cells
and mice, 6885
tumor angiogenesis, 1012
- Irinotecan**
combined with TRAIL/Apo-2L
apoptosis induction, prostate cancer, 4713
tumor response
microsatellite instability and, advanced
colorectal cancer, 5738
- Iron**
haem
red meat endogenous intestinal *N*-nitrosat-
ion, 2358
- Isothiocyanate**
urinary levels, breast cancer, 3980

J

- Jab1**
psoriasis interactions, breast cancer, 1954
- Janus kinase**
JAK/STAT3 pathway
inhibition by JSI-124, 1270
- Japan**
simian virus 40 sequences, malignant lym-
phoma, 7606
- JB6 C141 cells**
apoptosis induction by caffeine, 4396
- JC virus**
chromosomal instability induction, colonic
cells, 7256
infection susceptibility, mesothelioma, 6125
- JSI-124 (cucurbitacin I)**
JAK/STAT3 inhibition and antitumor activ-
ity, 1270
- Jun activation domain-binding protein 1**
and *p27^{Kip1}*, breast cancer, 2977
- JunD**
inhibition by menin-HDAC complex, 6135
- Jurkat cells**
thiol-sensitive SOD2 mutant, 159
- Juvenile-type granulosa cell tumors**
X-linked
susceptibility genes, mapping, 8197
- JV-1-38**
proliferation inhibition, non-small cell lung
cancer, 7913
- JV-1-42**
proliferation inhibition, non-small cell lung
cancer, 7913

K

- KAI1/CD82**
EWI2/PGL association, 2665
splice variant, functional characterization,

- 7247
Kallikrein
 human hK5, breast and ovarian cancer, 3958, 5647, 7544
 human hK8, ovarian cancer, 2771
 human hK10, ovarian cancer, 807
 human hK11, prostate cancer and benign prostatic hyperplasia, 6543
 human hK14, ovarian and breast cancer, 9032
 overexpression, ovarian cancer, 2223
Kaposi's sarcoma
 real-time PCR arrays, 2010
Kaposi's sarcoma-associated herpes virus G protein-coupled receptor
 cell transformation
 p21-activated kinase 1, 8837
Karyotype
 complexity, NCI-60 drug-screening panel, 8634
Keap1/Nrf2
 NADPH oxidase and, 5636
Keratin-14 (K14)-survivin mice
 chemical carcinogenesis, 567
Keratinocyte growth factor
 gastric fibroblast-secreted, scirrhous gastric cancer, 8848
Keratinocytes
 telomerase
 modulation by culture conditions, 7815
 viral-induced transformation
 Notch1 and, 8687
Killer cell immunoglobulin-like receptors
 and CTL survival, 7475
Kinase suppressor of ras Ras1
 deficiency
 Ras/MAPK signaling prevention, 4232
KISS1
 metastasis inhibition, melanoma, 432
Kit^{D814V} mutants
 signaling
 PI3K and, mast cells, 4412
K-ras
 COX-2 expression regulation, 728
 mutations
 colorectal adenocarcinoma, 4656
 colorectal hyperplastic polyps, 4878
 RASSF1A methylation and, non-small cell lung cancer, 6206
 pancreatic and gastric carcinogenesis, 2005
Ku70
 heat-activated antisense
 radiosensitization, tumor cells, 3268

L

- L19**
 combination IL-12-L19 and L19-TNF- α treatment, therapeutic effects, 3202
LAG-3
 and DNA vaccination, mammary carcinogenesis prevention, 2518
LAGE-1
 alternative open reading frame
 promiscuous HLA-DR-restricted epitopes, 6506
 target antigen, epithelial ovarian cancer, 6076
Lamellarin D
 topoisomerase I inhibition, 7392
Laminin-1
 peptide antagonist, 5060
Laminin-5 β 3 chain
 cleavage by MT1-MMP, prostate cancer, 2292
Laminin-5 fragment
 circulating
 epithelial tumor invasion marker, 222
- Langerhans cells**
 HPV virus-like particle uptake and cross-presentation, 3478
Lanthionine synthetase components C-like 2
 P-glycoprotein decrease and drug sensitivity, 723
LAQ824
 chronic myelogenous leukemia effects, 5126
Latent membrane protein 1
 B cell growth transformation, 2982
Law, Lloyd W.
 obituary, 7002
LEC/chTNT-3
 and CD25⁺ T-cell depletion, solid tumors, 8384
Legumain
 overexpression, tumor invasion/metastasis and prodrug therapy, 2957
Leiomyoma
 growth inhibition by PPAR γ ligands, 1221
Leiomyomata
 uterine
 chromosome 12q15 rearrangements
 HMG2 fusion transcripts, 1351
Letrozole
 tumor proliferation inhibition, 6523
Letters to the editor
 re: A. Müller *et al.*, 62: 1014–1019, 1148
 re: B.-L. Adam *et al.*, 62: 3609–3614, 2701
 re: H. Barthel *et al.*, 63: 3791–3798, 8558
 re: J. B. de Kok *et al.*, 62: 2695–2698, 4747
 re: L. M. Wein *et al.*, 63: 1317–1324, 8554
 re: L. Yang *et al.*, 63: 831–837, 6566
 re: M. P. Rosin *et al.*, 62: 6447–6450, 5167
 re: M. S. van der Heijden *et al.*, 63: 2585–2588, 6998
 re: R. Varon *et al.*, 61: 3570–3572, 6563
 re: S. Maula *et al.*, 63: 1920–1926, 8555
 re: SAW Fuqua *et al.*, 63: 2434–2439, 9055
 re: Somasundaram *et al.*, 62: 3868–3875, 5165
 re: Welzel *et al.*, 61: 1629–1636, 1722
 re: Y.S. Haviv *et al.*, 62: 4273–4281, 1994
 re: Z. Wang *et al.*, 63: 655–657, 6996
Leukemia
 ALT-associated promyelocytic bodies, assembly, 2589
 apoptosis
 induction by As₂O₃ methylated metabolites, 1853
 induction by coadministered 17-AAG and SAHA, 8420
 induction by roscovitine, MT-2 cells, 8523
bcr-abl translation inhibition by arsenic trioxide, 7950
 CDK inhibitors and PI3K/Akt pathway, 1822
 differentiation
 antioxidant and, 1325
 gene
 cleavage by maxizymes and shRNAs, 6809
 mixed lineage
 apoptotic effectors and *MLL-AF9* translocations, 1371
 MS-275 dose-dependent effects, 3637
 myeloid
 double-strand break repair, 1798
 pre-B cells
 glucocorticoid-induced apoptosis, 172
 preleukemic P190^{BCR/ABL} transgenic mice
 genomic instability, 4895
 promyelocytic
 HIPK2-mediated p53 induction and, 4310
PMLRARA transgenic mice
 retinoid deficiency, 5257

- T-cell, adult
 campath-1H therapy, murine model, 6453
Leukemia, acute lymphoblastic
 biphenotypic
ADD3-NUP98 and *NUP98-ADD3* fusion transcripts, 3079
 pediatric
 gene expression profiling, 4882
NBS1 mutations, 6563
PTEN interactions with p53 and MDM2, 6357
 T-cell
 CCR9 overexpression effects, CD4⁺ T cells, 6469
 T-cell, pediatric
NKX2-5 deregulation by *BCL11B* juxtaposition, 5329
Leukemia, acute myeloid
 bFGF overexpression, 7241
 butyrate treatment
 granulocytic maturation, 8955
 caspase activation, 1242
 Fanconi anemia cell line, 2688
 recombinant immunotoxin treatment, 8414
 risk
FAS promoter polymorphisms and, 4327
Leukemia, chronic lymphocytic
 binding peptides, selection, 5213
 circulating dendritic cell compartment defects, 4497
 cytogenetic abnormalities
 and rituximab response, 36
 IgM-mediated prostate infiltration, 2067
Leukemia, chronic myelogenous
 blast crisis
 LAQ824 effects, 5126
MSI2/HOXA9 fusion gene, 1202
 growth inhibition by SKI-606, 375
 imatinib resistance
 rapamycin, 5716
Leukemia, chronic myeloid
 inhibition by trimetrexate, 1304
Leukocytes
 adhesion
 tumor angiogenesis and, 2322
Li-Fraumeni syndrome
 germ-line *TP53* mutations and, 6643
Lipid phosphate phosphatase-3
 human hLPP-3
 growth inhibition, ovarian cancer, 1073
Lipid rafts
 cancer role, workshop summary, 6571
Lipids
¹H NMR-visible, glioma cell death, 3195
 protein delivery
 nucleoside kinases, 6909
Lipomatous tumors, atypical
 HMG2 inhibition therapy, 7423
Liposarcoma
 well-differentiated
 HMG2 inhibition therapy, 7423
Liposomes
 doxorubicin
 combined with radiofrequency tumor ablation, 6327
 tumor vessel-targeted chemotherapy
 anti-angiogenic effects, 7400
12-Lipoxygenase
 platelet-type
 and integrin expression, 4258
12/15-Lipoxygenase
 expression, prostate cancer, 2256
Liver
 capecitabine metabolism, ¹⁹F MRS, 7609
 estrogen formation, 5041
 metastasis
 inhibition by CS-682, nude mouse model, 2477

- inhibition by IL-18 binding protein, melanoma, 491
 TRAIL, murine renal cancer, 207
- Liver tumors**
 progression
 GlcNAc-THI and, mice, 7753
- Livin**
 caspase-mediated cleavage, 6340
- LKB1 gene**
 transfection
 growth and molecular profile, lung cancer, 1382
- L-Myc**
 CCL6 regulation, 2923
- Lobular breast carcinoma**
 expression microarray analysis, 7167
- Loss of heterozygosity: See also Deletions**
 genome-wide mapping, prostate cancer, 4781
 and second oral malignancy, oral cancer, 5167
- Loss of imprinting**
 IGF2, Wilms' tumor, 1900
- Low-coherence interferometry**
 angle-resolved, neoplasia detection, 3556
- Lsh gene**
 deficiency
 abnormal mitosis, 4677
- Luciferin**
 firefly, chemiluminescence photodynamic therapy, 1818
- Lung**
 breast cancer metastasis
 c-Src activity and, 5028
- Lung adenocarcinoma**
 etheno-DNA adduct repair activity, 4351, 6103, 6570
 MGMT methylation, 4842
 neutrophil-derived HGF, 1405
 risk
 CYP2A13 polymorphism and, 8057
- Lung adenoma**
 craf-induced
 p53, 2268
- Lung cancer**
 antigen, newly defined, 2829
 apoptosis induction by nonradioactive iodide, 5065
 Cdc25B expression induction by BPDE, 771
chfr mutations, 7185
 COX-2 regulation by SU5416, 6920
 DNA damage and repair, 4899
 familial aggregation, 8531
LKB1-transfected
 growth and molecular profile, 1382
 mortality and smoking duration/intensity, 6556
 prevention by DAC and phenylbutyrate treatment, 7089
- Lung cancer, non-small cell**
 apoptosome inhibition by IAP, 831, 6566
 BRG1/BRM expression loss, 560
 chromosome 3p21.3 loss of heterozygosity, 3352
 combination cotylenin A and IFN- α antitumor effects, 3659
 COX17, novel treatment target, 7038
 COX-2 expression, 766
 drug-induced apoptosis, proteomic profiling, 6928
 glomeruloid microvascular proliferation, prognostic value, 6791
 growth inhibition by GH-RH antagonists, 7913
 migration inhibitory factor and cyclophilin A, 1652
 PKC isoforms, 780
- RASSF1A* methylation and *K-ras* mutation, 6206
RASSF1A promoter hypermethylation and, 3743
RASSF1A target genes, 5344
SEMA3B hypermethylation, 3352
 SPARC/osteonectin expression, 5376
TSLC1 tumor suppressor activity, 7979
 tumor supernatant
 lymphocyte apoptosis, 642
 WWOX expression, 878
- Lung cancer, small cell**
 acetylcholine autocrine growth factor effects, 214
 atrial natriuretic peptide production
 corin effects, 8318
c-Met juxtamembrane domain mutations, 6272
 transcriptional gene expression profiling, 1943
- Lung carcinogenesis**
 inhibition by lycopene supplementation, 3138
- Lung tumorigenesis**
 budenonide chemopreventive effects, 4389
 inhibition by methoxsalen, mouse, 7581
p63 amplification and overexpression, 7113
- Lung tumors**
Ogg1, *Mth1* double knockout mice, 902
 serum surfactant protein D levels, 5889
 shape-determining (*Ltsd*) loci and tumor heterogeneity, mouse, 125
- Luteinizing hormone/human chorionic gonadotropin (LH/hCG)**
 and endometrial cancer cell invasiveness, 4281
- LY133314: See Trioxifene**
- LY294002**
 combined with EGFR inhibitors, glioma, 8930
 combined with PTEN
 p53 upregulation and angiogenesis inhibition, 3585
 microtubule drug synergy, malignant glioma, 4044
- Lycopene supplementation**
 IGFBP-3 upregulation, 3138
- Lymphangiogenic factors**
 tumor expression, 713
- Lymphangiography**
 micro-magnetic
 dendrimer-based contrast agent, mice, 271
- Lymphatic endothelial markers**
 head and neck squamous cell carcinoma, 8555
- Lymphatic vessel endothelial hyaluronan receptor 1**
 head and neck squamous cell carcinoma, 1920, 8555
- Lymphatic vessels**
 endothelium
 malignant cell adhesion
 MR and CLEVER-1, 4671
 and metastasizing malignant cells, 4671
- Lymph nodes**
 dendritic cell migration
 maturation state and, melanoma, 12
 IL-6 gene polymorphisms, breast cancer, 8051
 prostate adenocarcinoma metastasis, *Nkx3.1*; *Pten* mice, 3886
- Lymphocytes**
 apoptosis, tumor supernatant, 642
DAPK hypermethylation, 7694
 donor infusion
 myeloma-specific T cells, 2561
 regulatory
 colon carcinogenesis interruption, 6042
 -rich classical Hodgkin's lymphoma, single-cell analysis, 1644
- Lymphoid enhancer factor 1**
 TGF- β resistance, 801
- Lymphoma**
 B-cell
 CpD ODNs and Ad-CD154 gene transfer, 4128
 diffuse large
 gene expression, 60
 Epstein-Barr virus
 growth inhibition by rapamycin, 4472
 rituximab and rafts/microdomains, 534
 CD20-induced cell death, 5480
 circulating EBV DNA, molecular characterization, 2028
 inhibition by double-negative T lymphocytes, 8014
 malignant
 simian virus 40 sequences, Japan, 7606
 mantle cell
 expression profile, 8226
 T-nucleotide additions, 1722
 PS-341 resistance
 Hsp27, 6174
- Lymphoma, Burkitt's**
 Bz-423 sensitivity, 6870
 c-Myc inhibition, 6144
- Lymphoma, Hodgkin's**
 lymphocyte-rich classical, single-cell analysis, 1644
- Lymphoma, non-Hodgkin's**
 B-cell
 activation-induced cytidine deaminase
 expression, 3894
 proliferation, imaging, 2681
- Lymphomagenesis**
 ENU-induced
 MSH2 deficiency and, 2062
- Lysophosphatidic acid**
 metastatic effects, colon cancer, 1706
- Lysophosphatidic acid acyltransferase- β inhibitors**
 antitumor activity, multiple myeloma, 8428
- Lysophospholipase D**
 reaction mechanism, 2042
- Lysyl oxidase-related protein-1**
 tumor progression and fibrosis induction, 1657

M

- Macrophage inhibitory cytokine-1**
 cell adhesion reduction and apoptosis induction, prostate cancer, 5034
 invasiveness induction, gastric cancer, 4648
- Macrophages**
 IL-12-transduced, metastatic prostate cancer therapy, 7853
- Macrophage scavenger receptor 1 gene (*MSR1*)**
 mutations, germ-line
 and prostate cancer risk, African-American men, 3486
- MAGE-A3 epitopes**
 HLA class II-restricted
 presentation by recombinant invariant chain-electroporated dendritic cells, 5587
- Magnetic resonance imaging**
 angiogenesis, 5838
 contrasts, gene therapy response, 7571
 CTL recruitment to tumors, 6838
 dendrimer-based contrast agent, micro-magnetic lymphangiography, 271
 HER-2/*neu* receptor, 2723
 intracellular, prostate cancer, 4766

- optical brain tumor delineation, pre- and intraoperative, 8122
- Magnetic resonance spectroscopy**
¹⁹fluorine, capecitabine metabolism, 7609
phosphorus, bone sarcoma, 8680, 9042
- Major histocompatibility complex**
class I antigen presentation enhancement, 2393
retinoids and, neuroblastoma, 8006
class I chain-related A
MICA/NKG2D-mediated therapy, glioma, 8996
- Male breast cancer**
BRCA1 and *BRCA2* mutations, 342
- Malignancy**
autophagic cell death by As₂O₃, glioma, 2103
conversion
inhibition by Smad3, skin carcinogenesis, 3447
Smad7 and, mouse squamous cell carcinoma model, 7760
EphA2 epitope display, 7907
gene expression, 8939
genetic determinants, oligodendroglioma, 1589
glioma
angiogenic factor upregulation by TNF- α , 4181
LY294002 and microtubule drug synergy, 4044
small molecule EGFR inhibitor resistance, 7443
hematological
and marrow microenvironment, meeting report, 7539
inhibition by PSP-94, hypercalcemia, 2072
lymphoma
simian virus 40 sequences, Japan, 7606
melanoma
albumin-binding doxorubicin prodrug cleaved by MMP-2 treatment, 4062
tumor classification by array-CGH, mouse models, 5352
metastasizing
lymphatic vessels and, 4671
microarray-based classification, glioma, 1602
phaeochromocytoma
SDHB and *SDHD* mutations, 5615
premalignant phenotype, hTERT-immortalized fibroblasts, 7147
progression
TGF- α , 4731
RASSF1A inactivation, cutaneous melanoma, 1639
second oral
loss of heterozygosity and, 5167
- Mammalian replication initiation region plasmids**
amplification, 5281
- Mammals**
DNA base excision repair, 549
- Mammary carcinogenesis**
prevention
DNA vaccination and LAG-3, 2518
- Mammary carcinoma: See also Breast cancer**
cyclin D1/Cdk4, PhIP-induced rat, 5674
energy restriction mechanisms, 1228
erbB-2-associated
hormonal modulation, 2425
inhibition by CRABP-II, 4426
metastasis
 β 2-chimaerin and, 2284
resistance, congenic *Mcs1* rats, 5808
- Mammary carcinoma susceptibility 1 gene (*Mcs1*)**
congenic rats
mammary carcinoma resistance, 5808
- Mammary epithelial cells**
immortalization
chemopreventive agent effects, 1914
PDK1 transformation signaling pathway, 5370
- Mammary epithelium**
class I alcohol dehydrogenase, 3092
p16^{INK4a} hypermethylation, 1596
- Mammary glands**
BRCA1 and *BRCA2* expression
phytoestrogen effects, Wistar rats, 6607
cell differentiation inhibition by *Twist*, 1906
estrogen metabolism
enzyme activity, 8492
- Mammary tumorigenesis**
ErbB2
Ink4a/Arf, 3395
hormones and, 1067
p53 function and hormones, mouse, 6140
- Mammary tumors**
Neu-induced, transgenic mice
gene expression profiling, 4920
risk factors
circulating IGF-I levels, 4384
- Manganese superoxide dismutase**
growth inhibition, pancreatic adenocarcinoma, 1297
- Mannose receptor**
malignant cell adhesion to lymphatic vessel endothelium, 4671
- Mantle cell lymphoma**
expression profile, 8226
T-nucleotide additions, 1722
- Mast cells**
Kit^{D814Y} mutant signaling
PI3K and, 4412
- Mathematical modeling**
glycolytic phenotype, carcinogenesis, 3847
replication-competent virus, 1317, 8554
- Matriptase**
node-negative breast cancer, 1101
- Matrix metalloproteinase**
gelatinolytic, cervical cancer, 6537
membrane-type
testican family protein interactions, 3364
membrane-type 1
laminin-5 β 3 chain cleavage, prostate cancer, 2292
regulation by PI3K, melanoma, 4757
membrane-type 6
pro-MMP-2 processing, 6758
and tumor formation, melanoma metastases, 8221
- Matrix metalloproteinase 1**
regulation by Epstein-Barr virus proteins, 256
- Matrix metalloproteinase 2**
-cleaved albumin-binding doxorubicin prodrug, 4062
expression, cervical cancer, 6537
expression, prostate cancer, 8511
immunogene therapy, 600
MMP-2 gene polymorphisms, gastric cardia adenocarcinoma, 3987
pro-MMP-2
processing by MT6-MMP, 6758
regulation by PI3K, melanoma, 4757
regulation by SHP-2, 6334
VEGF release induction, ovarian cancer, 5224
- Matrix metalloproteinase 9**
expression, cervical cancer, 6537
invasion and growth inhibition, glioma, 2454
- PMA-induced activity
inhibition by dykellic acid, 3430
VEGF release induction, ovarian cancer, 5224
- Matrix metalloproteinase 25**
pro-MMP-2 processing, 6758
- Maxizymes**
leukemia gene cleavage, 6809
- MCF-7 cells**
methyl-CpG-binding domain protein-2, 498
nuclear PTEN, 282
- MCP-1/CCL2**
effects in pancreatic cancer progression, 7451
- mda-7/interleukin (IL)-24**
angiogenesis regulation, 5105
apoptosis induction, prostate cancer, 8138
- MDM2**
PTEN and p53 interactions, acute lymphoblastic leukemia, 6357
- Mdm2**
splice variants
tumor promotion, 5703
- Measles virus**
glioblastoma multiforme treatment, 2462
oncolysis
neutrophils, 6463
- Medullary thyroid carcinoma**
growth inhibition by CEP-701 and CEP-751, 5559
penetrance
strain effects, *RET* transgenic mouse model, 4777
- Medulloblastoma**
c-Myc promoter activation, 4773
Ink4c/p53-null mice, 5420
mitochondrial DNA mutations, 3866
molecular fingerprint, 5428
prometastatic gene upregulation by ERBB2, 140
reovirus effects, 3162
- Meeting reports**
AACR Special Conference in Cancer Research, 4750
apoptosis and cancer, 263
caveolae and lipid rafts, workshop summary, 6571
First International Conference on Vascular Targeting, 1144
Fourteenth Annual Pezcoller Symposium, 3005
Frontiers in Cancer Prevention Research, 5649
Hematological Malignancies and Marrow Microenvironment workshop, 7539
Mouse Models of Human Cancer Consortium Symposium on Nervous System Tumors, 3001
Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates, 8069
Proteases and Cancer workshop, 6105
- Melanoma**
activating transcription factor 2, 8103
antimelanoma sFv-rGel, 3995
 β 1,6-branched oligosaccharides and coarse vesicles, 5363
BRAF mutations, 3883
BRAF^{V599E} inhibition effects, 5198
CD44v6 upregulation by HGF/SF, 1576
combination immunotherapy and metronomic cyclophosphamide, murine model, 8408
CTL responses to peptide SSX-2₄₁₋₄₉, 5601
CXCR4-B16 arrest, flow conditions, 6751
dendritic cell migration
maturation state and, 12

- epitope-specific CTLs
response regulation by dendritic cells, 5607
- growth inhibition
novel glucosylceramide synthase inhibitor, 3654
salmonin gene transfer, B16BL6 cells, 6458
- IL-1ra gene transduction effects, 5957
- malignant
albumin-binding doxorubicin prodrug
cleaved by MMP-2 treatment, 4062
tumor classification by array-CGH, mouse models, 5352
- malignant cutaneous
RASSF1A inactivation, 1639
- MAPK activation, 756
- metastasis
BRAF mutations, 3955
inhibition by chromosome 6, 432
memory CD8⁺ T-cell differentiation, 2535
N-RAS mutations, 3955
organ-specific
estrous cycle effects, 4763
Ras-Raf-MAPK cascade inhibitor treatment, 5669
T-cell receptor repertoire after cytokine therapy, 3483
tumor formation
MMPs and, 8221
- metastasis to brain
VEGF-A isoform effects, mouse model, 5408
- metastasis to liver
inhibition by IL-18 binding protein, 491
MTI-MMP and MMP-2 regulation by PI3K, 4757
new mouse cell lines, analysis, 3503
polyamine analogues and MAPK activation, 3619
pRB reactivation by tyrphostin, 1420
-presented peptides
T-cell activation, 1560
progression
functional proteomic analysis, 6716
promotion by *P TEN* loss, 2881
radiation response
TSP-1 and, 4055
-reactive T cells, bone marrow, 5582
retrovirus, 8735
survival
MAPK pathway-mediated signaling, 8330
susceptibility candidate gene *BRAF*, 3061
tumor oxygen status measurement, xenograft model, 7232
- uveal
BRAF mutation absence, 5761
BRAF mutations, 5712
chromosome 3, fine mapping, 8507
chromosome 3p25.1-p25.2 deletions, 8507
NRAS mutation absence, 5761
tumor classification, gene expression profiling, 2578
vasculogenic mimicry
TFPIs, 5381
Wnt/ β -catenin signaling activation by SKI, 6626
- Melanoma-associated antigen**
mRNA levels, prognostic value, 441
shared
targeting, murine glioma model, 8487
- Melanoma-associated antigen gp100**
hsp110-gp100 vaccine
antitumor immunity, 2553
- Melanoma-associated glycosaminoglycans**
localization and characterization, 2965
- Melanoma differentiation-associated gene 7, *mda-7/interleukin (IL)-24***
angiogenesis regulation, 5105
apoptosis induction, prostate cancer, 8138
- Melphalan resistance**
cell adhesion and, multiple myeloma, 7900
- Membrane fluidity**
P-glycoprotein effects, 3084
- Membrane potential**
P-glycoprotein effects, 3084
- Membrane proteins**
mislocalization, cisplatin resistance, 5909
- Membrane-type matrix metalloproteinase**
testican family protein interactions, 3364
- Membrane-type 1 matrix metalloproteinase**
laminin-5 β 3 chain cleavage, prostate cancer, 2292
regulation by PI3K, melanoma, 4757
- Membrane-type 6 matrix metalloproteinase**
pro-MMP-2 processing, 6758
- Menin**
FANCD2 interactions, 4204
menin-HDAC complex
JunD inhibition, 6135
- Mesothelioma**
fra-1 and motility genes, microarray analysis, 3539
pemetrexed transporter, novel, 7004
susceptibility to polyomavirus infection, 6125
Wnt pathway activation, 4547
- Met**
node-negative breast cancer, 1101
- Met-CCL5**
growth inhibition, breast tumors, 8360
- Metastasis**
 γ -aminobutyric acid, prostate cancer, 8090
 β 2-chimaerin and, mammary carcinoma, 2284
- brain
immunotherapy, 1345
VEGF-A isoform effects, mouse melanoma model, 5408
circulating cells, prostate cancer, 4239
clonality determination by color-coded fluorescent-protein imaging, 7785
c-Src activity and, breast cancer, 5028
inhibition
angiostatin, radiation therapy, 308
chromosome 6, melanoma, 432
CRSP3/TXNIP/KISS1 pathway, melanoma, 432
CS-682, nude mouse liver model, 2477
CS-682, orthotopic pancreatic cancer model, 5521
IL-18 binding protein, melanoma, 491
IL-12-transduced macrophages, metastatic prostate cancer, 7853
nitric oxide synthase, 3855
S247, colon cancer, 2079
trioxifene, PAIII rat prostate cancer, 6056
intravascular cell adhesion, 3805
lysophosphatidic acid effects, colon cancer, 1706
- malignancy
lymphatic vessels and, 4671
mature teratoma, genetic analysis, 6063
- melanoma
BRAF mutations, 3955
memory CD8⁺ T-cell differentiation, 2535
MMPs and, 8221
N-RAS mutations, 3955
Ras-Raf-MAPK cascade inhibitor treatment, 5669
T-cell receptor repertoire after cytokine therapy, 3483
- melanoma to brain
VEGF-A isoform effects, mouse model, 5408
MUC1 contributions, pancreatic cancer, 5011
organ-specific
estrous cycle effects, melanoma, 4763
outgrowth
CXCR4, colon carcinoma, 3833
p21^{Cip1} and, irradiated mice, 3021
phenotype
CD44v2-10, 887
PKC ϵ and ornithine decarboxylase, squamous cell carcinoma, 3037
PKC ϵ TNF α release signaling, squamous cell carcinoma, 6547
prometastatic genes
upregulation by ERBB2, medulloblastoma, 140
promotion by PRL-3 and PRL-1, 2716
prostate adenocarcinoma to lymph nodes
Nkx3.1; *Pten* mice, 3886
regulation by epithelial-mesenchymal transition, breast cancer, 3386
regulation by HGF and SDF-1, rhabdomyosarcoma, 7926
renal cancer to liver
TRAIL, murine, 207
renal cell carcinoma
CA IX-expressing model LABA21, 4952
stromelysin-3 and, mouse MMTV-ras tumors, 5844
systemic reovirus therapy, mice, 348
tumor
disaccharides and, 2775
legumain overexpression, 2957
MMPs and, melanoma, 8221
- Methioninase**
recombinant rMETase
enhancement by PEGylation and pyridoxal 5'-phosphatase, 8377
- Methionine aminopeptidase-2 inhibitors**
reversible
tumor inhibition, 7861
- Methotrexate**
transport by ABCG2, 4048, 5538
- Methoxsalen**
lung tumorigenesis inhibition, mouse, 7581
(*E*)-4-[[2-*N*-[4-Methoxybenzenesulfonyl] amino] stilbazole]1-oxide:
See HMN-176
- 2-Methoxyestradiol**
apoptosis induction, 468
- 2-Methoxyestradiol analogues**
novel, antitumor activity, 1538
- Methoxyestrogens**
CYP1A1 and 1B1 feedback inhibition, 3127
- 8-Methoxypsoralen**
lung tumorigenesis inhibition, mouse, 7581
- α -Methylacyl-CoA racemase**
alternative splicing, 3296
growth modifier, prostate cancer, 7365
- Methylator phenotype**
and family history, colorectal cancer, 4805
- Methyl-CpG-binding domain protein-2**
MCF-7 cells, 498
- Methylenetetrahydrofolate reductase gene (*MTHFR*)**
Ala/Val variant
and cancer risk, 1249
- O⁶-Methylguanine DNA methyltransferase**
methylation, lung adenocarcinoma, 4842
- N-Methyl-N-nitrosourea hypersensitivity**
and telomere dysfunction, 7047
- N-Methylpurine DNA glycosylase**
sensitization to DNA damaging agents, 608
- Met kinase**
small molecule inhibitor, identification, 5462

Micelles

- CDDP-loaded
- solid tumor eradication, mice, 8977

Microarrays

- breast cancer signaling, 7158
- CD5⁺ and CD5⁻ diffuse large B-cell lymphoma, 60
- cDNA
 - cervical cancer marker identification, 1927
 - endometrial cancer, 6
 - 5-FU-inducible target genes, 4602
 - polycythemia vera gene expression profiling, 3940
- combined with comparative genomic hybridization, gastric cancer, 3309
- expression analysis, lobular *versus* ductal breast carcinoma, 7167
- high-throughput
 - aberrant methylation targets, pancreatic cancer, 3735
- malignant glioma classification, 1602
- mesothelioma, 3539
- tissue
 - cervical cancer marker identification, 1927
 - head and neck squamous cell carcinoma, 1179
 - node-negative breast cancer, 1101
- triple analysis
 - epigenome, 2164

Microcirculation

- in vivo*, basal cell carcinoma, 3969

Micrometastasis

- breast cancer to bone marrow, molecular signature, 5679
- outgrowth
 - CXCR4, colon carcinoma, 3833
- RT-PCR immunohistochemistry, prostate cancer, 4662

Micrometastasis

- breast cancer to bone marrow, molecular signature, 5679
- outgrowth
 - CXCR4, colon carcinoma, 3833
- RT-PCR immunohistochemistry, prostate cancer, 4662

Microsatellite analysis

- PCR-based, bladder cancer, 2216

Microsatellite instability

- adenoma, single first-degree relative with colorectal cancer, 787
- colorectal cancer
 - antigens, identification by SEREX, 5564
- epithelial and stromal, UC-associated carcinogenesis, 6158
- gene therapy, tumors, 8113
- and irinotecan response, advanced colorectal cancer, 5738
- and phenotype, colorectal tumors, 4577

Microtubule drugs

- LY294002 synergy, malignant glioma, 4044

Microtubule inhibitors

- sensitivity, gastric cancer, 8606

Microtubules

- depolymerization by S-allylmercaptocysteine, 6825

Microtubule-stabilizers

- and mitotic exit, 7891
- taccalonolides E and A, 3211

Microvascular endothelial cells

- organ-derived lines, 2971

Microvascular function

- crypt damage regulation, 4338

Microvascular proliferation

- glomeruloid
 - prognostic value, non-small cell lung cancer, 6791

Microvesicles

- derived FasL

- immune privilege mediation, epithelial ovarian cancer, 5573

Microvessel density

- heparanase activity and, multiple myeloma, 8749

Migration inhibitory factor

- non-small cell lung cancer, 1652

Migration stimulating factor

- expression, carcinoma and tumor-associated stromal cells, 8827

Minichromosome maintenance protein 7 gene (MCM7)

- biomarker, cervical cancer, 8173

Mismatch repair deficiency

- gemcitabine radiosensitization, HCT116 cells, 6935

Mitochondrial activity

- $\Delta\psi_m$, butyrate sensitivity, and, 6311

Mitochondrial DNA

- mutations, medulloblastoma, 3866

Mitochondrial membrane potential ($\Delta\psi_m$)

- and mitochondrial activity and butyrate sensitivity, colonic epithelial cells, 6311

Mitochondrial nitric oxide synthase

- and tumor proliferation, 6370

Mitogen-activated protein/extracellular signal-regulated kinase kinase

- Raf/MEK/ERK pathway inhibition
 - CAR upregulation, 2088
- Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)1,2
 - dephosphorylation
 - apoptosis induction, 3469

Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor

- combined with Taxol, transcriptional profiling, 5095

Mitogen-activated protein kinase

- activation, melanoma, 756
 - polyamine analogues and, 3619
- ERK^{MAPK}/p38^{SAPK} activity ratio, tumor growth and dormancy, 1684
- pathway-mediated melanoma survival signaling, 8330
- Ras/MAPK signaling
 - prevention by Ras1 deficiency, 4232
- prostate cancer, 1981
- Ras-Raf-MAPK cascade inhibitor
 - metastatic melanoma treatment, 5669
- regulation by H-ras vs N-ras, breast epithelial cells, 5454

Mitogenic signaling

- neurotensin-induced, pancreatic cancer, 2379

Mitomycin-C

- DNA cross-linking
 - GRP58, 6016

Mitosis

- abnormal, *Lsh* deficiency, 4677

Mitotic exit

- microtubule-stabilizing drugs and, 7891

Mitoxantrone resistance protein MXR: See Breast cancer resistance protein

Mixed lineage leukemia gene (MLL)

- MLL-AF9 translocations
 - apoptotic effectors and, 1371

MJ-III-65 (NSC 706744)

- topoisomerase I inhibition, 7428

MKP-1

- extracellular signal-regulated kinase dephosphorylation, breast cancer, 8853

MMAC1: See Phosphatase and tensin homologue deleted on chromosome 10 (PTEN)

MNNG

- induced hot spots, 5793

Modified vaccinia virus Ankara (MVA)

- prime

- combined with fowlpox boost, antitumor therapy, 7942

Molecular fingerprinting

- medulloblastoma, 5428

Molecular imaging

- angiogenesis, MRI, 5838
- contrast agents, 1999
- protein-protein interactions, 1780

Monoclonal antibodies: See also specific drugs

- adjuvant β -glucan, 9023
- combined with CpG-A and B oligodeoxynucleotides, antitumor activity, 5595
- iodine radiolabels, 111
- TGF- β -neutralizing 2G7
 - combined with dendritic cell-based vaccines, 1860

Monodelphis domestica

- xenograft cancer model, 6121

Mononuclear cells

- peripheral blood
 - gene expression profiling, advanced renal cell carcinoma, 6069

Morphine

- antitumor activity, adenocarcinoma, 1846

Mouse cancer modifier genes

- review, 3011

Mouse development

- early
 - CBF/NF-Y, 8167

Mouse mammary tumor virus-ras tumors

- metastatic development
 - stromelysin-3 and, 5844

Mouse models

- adult T-cell leukemia
 - campath-1H therapy, 6453
- Apc*^{Min/+} mouse model
 - intestinal immune responses, 5136
- Atm-, p53-, and Gadd45a-deficient mice
 - recombination, 5335
- brain metastasis model of melanoma
 - VEGF-A isoform effects, 5408
- hypercalcemic hyperparathyroidism, 8022
- Ink4c/p53*-null mice
 - tumor spectrum, 5420
- malignant melanoma
 - tumor classification by array-CGH, 5352
- nervous system tumors, meeting report, 3001
- novel reporter mouse
 - bioluminescence imaging, 7042
- nude mouse models
 - liver metastasis inhibition by CS-682, 2477
- parathyroid neoplasia, 8022
- PMLRARA* transgenic mice
 - retinoid deficiency, 5257
- preleukemic P190^{BCR/ABL} transgenic mice
 - genomic instability, 4895
- RET* transgenic mouse model
 - strain effects on medullary thyroid carcinoma penetrance, 4777
- risk factor interactions, liver cancer, 7553
- src transgenic mice
 - skin carcinogenesis, 4819
- transgenic mouse models
 - cervical carcinogenesis
 - E6 and E7, 4862
 - epithelial ovarian cancer, 1389
 - oligoastrocytoma, 1106
- VHL* knockout mice
 - vascular lesions and sperm defects, 5320

Mxd9 gene

- mammalian paralogue
 - expression, testicular cancer, 5291

MS-275

- dose-dependent effects, leukemia, 3637

MST4

- prostate cancer progression, 3356

- Mth1**
Ogg1, *Mth1* double knockout mice, 902
- Mucin 1**
 breast cancer vaccine BCG-hIL2MUC1, development and preclinical evaluation, 1270
 invasion and metastasis contributions, pancreatic cancer, 5011
- Mucin-depleted foci**
 colon carcinogenesis, 2388
- Multidrug resistance**
 circumvention by HTI-286, 1838
 circumvention by NF-7 inhibitors, 6942
 gelonin immunotoxin resistance, 72
 membrane protein mislocalization, 5909
- Multidrug resistance gene MDR1**
 expression inhibition by c-Jun, 4527
Mdr1^{-/-} *ApcMin*⁺ mice
 intestinal polyposis inhibition, 895
 modulation by RNA interference, 1515
- Multidrug resistance protein 1**
 and flutamide transport, 2492
- Multimodality imaging**
 fusion reporter gene, 1160
- Multimodal nanoparticles**
 optical brain tumor delineation, pre- and intraoperative, 8122
- Multiple endocrine neoplasia type 1 gene (MEN1)**
 β -cell tumorigenesis, mice, 4836
 parathyroid tissue, 8022
- Multiple myeloma**
 CD45 subsets, prognostic value, 3019
 cell adhesion and drug resistance, 7900
 fluorescence imaging, SCID/NOD *in vivo* model, 6689
 heparanase activity, 8749
 IGF-1-induced cell adhesion and migration, 5850, 7543
 lysophosphatidic acid acyltransferase- β inhibitor effects, 8428
 osteoprotegerin antitumor effects, 5T33MM model, 287
 RNA-directed 8-Cl-Ado actions, 7968
 telomerase RNA-targeting phosphoramidate effects, 6187
- Multivariate analysis**
 ovarian cancer karyotypes, 3378
- Musashi-2 gene (MSI2)**
MSI2/HOX9 fusion gene, chronic myelogenous leukemia blast crisis, 1202
- Mutagenesis**
 ENU-induced
MSH2 deficiency and, 2062
- Mutations**
 ACVR2, gastrointestinal cancer, 994
 adenovirus VAI, Ras-dependent oncolysis, 5544
 Akt kinase-dead mutant
 apoptosis induction, tumor cells, 6697
 androgen receptor, bicalutamide withdrawal syndrome, 149
 APC, colorectal adenocarcinoma, 4656
Apc^{Min}
 modifiers
 opposite effects, 4533
 ATM, familial breast and ovarian cancer, 3325
 Bik, antitumor effects, 7630
BLM^{Ash}
 heterozygosity
 and cancer risk, 1769
 BRAF
 absence, uveal melanoma, 5761
 colon cancer, 5209
 colorectal hyperplastic polyps, 4878
 melanoma, 3883
 metastatic melanoma, 3955
 papillary thyroid cancer, 1454
 papillary thyroid cancer and thyroid tumors, 4561
 uveal melanoma, 5712
- BRCA1**
 familial *versus* sporadic ovarian tumors, 417
 male breast cancer, 342
- BRCA2**
 familial *versus* sporadic ovarian tumors, 417
 male breast cancer, 342
- chfr*, lung cancer, 7185
- c-KIT**
 and bilateral testicular germ-cell tumors, 7674
 c-Met, small cell lung cancer, 6272
E. coli nitroreductase, 5532
 enhancement by cell proliferation
 8-OH-G and, 4287
 Fanconi anemia gene, young-onset pancreatic cancer, 2585, 6998
FGFR3, urothelial cell carcinoma of the bladder, 8108
- germ-line**
hMLH1, yeast two-hybrid assay, 3302
- MSR1**
 and prostate cancer risk, African-American men, 3486
- TP53**
 and Li-Fraumeni syndrome, 6643
 histone methyltransferase inactivation, cancer, 7619
hMLH3, familial colorectal cancer, 1894
HPRT, spectrum, 5793
- Hras**
 allele-specific, skin carcinoma, 4849
- Kit**^{DR14Y}
 signaling
 PI3K and, mast cells, 4412
- K-ras**
 colorectal adenocarcinoma, 4656
 colorectal hyperplastic polyps, 4878
RASSF1A methylation and, non-small cell lung cancer, 6206
- missense**
PATCHED1, 1636
- mitochondrial**, medulloblastoma, 3866
- N-ras**
 absence, uveal melanoma, 5761
 metastatic melanoma, 3955
- p53**
 androgen-independent growth mediation, prostate cancer, 2228
 bladder cancer, 7530
 cigarette smoke, mice, 793
 colorectal adenocarcinoma, 4656
 and Fas resistance, prostate cancer, 2905
 reactivation, 3904
 rhabdomyosarcoma, HER-2/*neu* transgenic *p53* mutant mice, 2728
- PTEN**
 and EGFR
 VEGF mRNA expression regulation, glioblastoma, 236
SDHB and *SDHD*, extra-adrenal or malignant pheochromocytoma, 5615
 thiol-sensitive SOD2, Jurkat cells, 159
 thyroid hormone receptor β
 PPAR γ inhibition, thyroid carcinogenesis, 5274
TSC1, transitional cell carcinoma of the bladder, 7652
- Mutator phenotypes**
 cancer, 6635
- MutL homologue**
 human *hMLH1*
 germ-line mutations, yeast two-hybrid assay, 3302
 human *hMLH3*
 mutations, familial colorectal cancer, 1894
- MutSa**
 iododeoxyuridine recognition, DNA, 5490
- MutS homologue**
 human *hMSH4*
 VBP1 interactions, 865
MSH2 deficiency
 and ENU-induced mutagenesis and lymphomagenesis, 2062
- MYCN gene**
 -associated gene expression, neuroblastoma, 4538
- Myeloid cells**
 apoptosis
 SUAP induction, 705
- Myeloma**
 multiple
 CD45 subsets, prognostic value, 3019
 cell adhesion and drug resistance, 7900
 fluorescence imaging, SCID/NOD *in vivo* model, 6689
 heparanase activity, 8749
 IGF-1-induced cell adhesion and migration, 5850, 7543
 lysophosphatidic acid acyltransferase- β inhibitor effects, 8428
 osteoprotegerin antitumor effects, 5T33MM model, 287
 RNA-directed 8-Cl-Ado actions, 7968
 telomerase RNA-targeting phosphoramidate effects, 6187
 osteoprotegerin paracrine survival factor effects, 912
 RANKL expression, 5438
 T cells, donor lymphocyte infusion, 2561
- MYH-associated polyposis**
 carcinogenesis, genetic pathways, 7595
- N-Myristoyltransferase**
 inhibition by enolase, 7975
- N**
- NADPH:cytochrome P450 reductase**
 and doxorubicin cytotoxicity, breast cancer, 6914
 3-nitrobenzanthrone activation, 2752
- NADPH oxidase**
 and Keap1/Nrf2, 5636
- NADPH:quinone oxidoreductase-1**
 benzene-induced toxicity, 929
 and pancreatic cancer, 5513
- Nanoparticles**
 multimodal, optical brain tumor delineation, 8122
- Nasopharyngeal carcinoma**
 circulating EBV DNA, molecular characterization, 2028
 NF- κ B p50 homodimer/Bcl-3 complexes, 8293
- National Cancer Institute (NCI)**
 NCI-60 drug-screening panel
 karyotypic complexity, 8634
- Natural killer T cells**
 antitumor responses, fractalkine-mediated, 7468
 and IL-21 antitumor activity, 9016
 inhibition by CD4⁺ CD25⁺ regulatory T cells, 4516
 polarization, 4101
 tumor growth, 3058
- Near-infrared imaging**
 fluorescent
 tumor apoptosis, 1936
 optical
 EGFR, breast cancer xenografts, 7870

Neoplasia

- detection by angle-resolved, low-coherence interferometry, 3556
- gene expression patterns and class I HLA antigen processing mechanisms, 4119

Neoplasia, prostate intraepithelial

- inducible, FGFR1 transgenic mice, 8256
- induction

FGFR1 and FGFR2, mouse, 8784

Neoplasia, vulval intraepithelial

- high-grade
- HPV oncogene vaccination, 6032

Neoplastic transformation

- AMF/PGI overexpression, fibroblasts, 242
- β -catenin-mediated
- TIP49, 8726

Nerve growth factor-induced protein-b

- colon cancer cell apoptosis, 5401

Nervous system tumors

- mouse models, meeting report, 3001

Neu-induced mammary tumors

- gene expression profiling, transgenic mice, 4920

Neural-network analysis

- urinary proteins, renal cell carcinoma, 6971

Neural stem-like cells

- bone marrow-derived, characterization, 8877

Neuroblastoma

- antigen-specific immunity, 6948
- caspase 8/TR2 restoration and TRAIL sensitivity, 1122
- combination CpG ODNs and GM-CSF immunotherapy, 394
- complex B pathway gangliosides, 7270
- derived sulphydryl oxidase gene (*SOXN*)
- IFN- γ -induced apoptosis, neuroblastoma, 7742
- fenretinide-induced apoptosis
- mediation by Bak, 7310
- gene expression associated with *MYCN*, genome-wide analysis, 4538
- genome-wide array CGH analysis, murine, 5266
- ID2* expression, 1631
- IFN- γ -induced apoptosis
- SOXN*, 7742
- immunoliposomal doxorubicin antitumor activity, 86
- invasion, bone
- osteoclasts, 3026
- NY-ESO-1 immunity, 6948
- PPM1D*, 1876
- p21^{Waf1/Cip1} dysfunction, 3840
- retinoids and CTL sensitization, 8006
- retinoids and MHC class I antigen presentation, 8006
- TSP-1* methylation, 6299

Neuroendocrine tumors

- radioiodine treatment after NIS gene therapy, 1333

Neuroepithelioma

- glucosylceramide synthase modulation by RTN-1C, 3860

Neurofibromas

- progesterone receptor expression, 752

Neurofibromatosis type 1 gene (*Nf1*)

- Nf1* mutant mice
- optic nerve glioma, 8573

Neurogenesis

- X-irradiation sensitivity, 4021

Neuropilin-1

- autocrine ligands
- chemotaxis regulation, cancer, 5230

Neurotensin

- mitogenic signaling, pancreatic cancer, 2379

Neutrophils

- HGF, lung adenocarcinoma, 1405

- measles virus-mediated oncolysis, 6463

NFBD1/MDC1

- ATM* activation, double-strand breaks, 8586

NF- γ inhibitors

- multidrug resistance circumvention, 6942

NF-Y

- early mouse development, 8167

NGFR-CD fusion gene

- sarcoma killing, 6847

Nickel carcinogenesis

- hypoxia-inducible factor 1, 3524

Nicotinamide phosphoribosyltransferase inhibitors

- noncompetitive FK866

- cellular effects, 7436

Nijmegen breakage syndrome 1

- recombination factors/telomere length maintenance, 2589

Nijmegen breakage syndrome gene (*Nbn*)

- heterozygosity
- and susceptibility to tumor development, mice, 7263

Nijmegen breakage syndrome 1 gene (*NBS1*)

- mutations, childhood acute lymphoblastic leukemia, 6563

Nitric oxide

- induced cytochrome c release, 5470
- mediated bystander effects, glioma, 8437

- releasing aspirin

- molecular targets, 7613

Nitric oxide synthase

- inducible iNOS
- modulation by omega-3 fatty acids, colon cancer, 972

- mitochondrial

- and tumor proliferation, 6370

- tumor growth and metastasis inhibition, 3855

3-Nitrobenzanthrone

- activation by NADPH:P450 reductase, 2752

9-Nitrocampothecin

- BCRP effects, 3228

Nitrogen

- wild-type p53 inactivation, glioma, 8670

NKG2D

- MICA/NKG2D-mediated therapy, glioma, 8996

Nkx3.1; *Pten* mice

- prostate adenocarcinoma and lymph node metastasis, 3886

NKX2-5 gene

- deregulation by *BCL11B* juxtaposition, pediatric T-ALL, 5329

N-nitrosation

- red meat endogenous intestinal, 2358

Non-Hodgkin's lymphoma

- B-cell
- activation-induced cytidine deaminase expression, 3894

- proliferation, imaging, 2681

Nonhomologous end-joining

- genes, breast cancer development, 2440
- myeloid leukemia, 1798

Nonsteroidal anti-inflammatory drugs

- and breast cancer, 6096
- HGF/SF-induced angiogenesis inhibition, 8351

Notch1

- growth inhibition, hepatocellular carcinoma, 8323

- and viral-induced keratinocyte transformation, 8687

Novantrone

- NOVP chemotherapy-induced sperm aneuploidies, Hodgkin's disease, 44

NOVP (Novantrone, Oncovin, Velban, and Prednisone) chemotherapy

- sperm aneuploidies, Hodgkin's disease, 44

N-ras

- mitogen-activated protein kinase regulation, breast epithelial cells, 5454

mutations

- absence, uveal melanoma, 5761

- metastatic melanoma, 3955

- T-cell function and development, 1615

NSC 706744: See MJ-III-65

NU7026

- combined with AG14361
- radiosensitization and DNA repair inhibition, 6008

Nuclear factor- κ B

- activation inhibition by ursolic acid, 4375
- chemotherapy damage prevention, 25

- receptor activator ligand RANKL

- apoptotic effects, 1772

- RhoA and, prostate cancer cell invasion, 1359

- signaling inhibition by 17-AAG, colon cancer, 8600

- signaling interruption by androgen receptor, prostate cancer, 7106

- TRAIL/Apo-2L-induced apoptosis regulation, 1059

Nuclear factor- κ B gene *NFKB1*

- single nucleotide polymorphisms
- and colorectal cancer, 3560

Nuclear factor- κ B inhibitor DHMEQ

- prostate cancer inhibition, 107

Nuclear factor- κ B p50 homodimer/Bcl-3 complexes

- nasopharyngeal carcinoma, 8293

Nuclear factor- κ B p65

- hTERT nuclear translocation mediation, 18

Nuclear magnetic resonance

- ¹³C NMR spectroscopy

- tumor glycolysis, 8813

¹H

- visible lipids, glioma cell death, 3195

Nuclear protein in testis gene (*NUT*)

- BRD4-NUT*, aggressive carcinoma, 304

Nuclear receptor NOR-1 (NR4A3)

- fusion protein EWS/NOR-1

- transcriptional regulation by Six3, extracellular myxoid chondrosarcoma, 449

Nucleoporin 98 gene (*NUP98*)

- ADD3* fusion, biphenotypic acute leukemia, 3079

Nucleoside diphosphate kinase

- Ras inactivation, biochemical, 4089

Nucleoside kinases

- lipid-mediated delivery, 6909

Nucleotides

- T-nucleotide additions, mantle cell lymphoma, 1722

NUT gene

- BRD4-NUT*, aggressive carcinoma, 304

NY-ESO-1

- immunity, neuroblastoma, 6948
- target antigen, epithelial ovarian cancer, 6076

O

Obesity

- aberrant crypt foci modulation, Zucker rats, 6595

Obituaries

- Lloyd W. Law, 7002

- Van Rensselaer Potter II, 1724

Obtustatin

- α 1 β 1 integrin inhibition, 2020

Octamer transcription factor 1

- targeting by Ku/DNA-PK after DNA damage, 7197

OK-432

- dendritic cells, 4112

- Oligoastrocytoma**
transgenic mouse model, 1106
- Oligodendroglioma**
gene silencing mechanisms, 7600
malignancy, genetic determinants, 1589
v-erbB transgenic mice, 1589
- Oligodeoxynucleotides**
CpG
adjuvant, peptide-based vaccines, 3281
combined with GM-CSF, neuroblastoma immunotherapy, 394
CpG-A and B
combined with mAbs, antitumor activity, 5595
- Oligonucleotide N3' → P5' thio-phosphoramidate (GRN163)**
telomerase inhibition, 3931
telomerase RNA-targeting, multiple myeloma, 6187
- Oligosaccharides**
 β 1,6-branched
and coarse vesicles, 5363
- Olive oil**
fibrinogen-coated droplets
docetaxel delivery, solid malignancies, 7314
- Omega-3 fatty acids**
proinflammatory gene modulation, colon cancer, 972
- Omic profiling**
diagnostic marker identification, colon and ovarian adenocarcinoma, 5243
- Oncolysis**
adenovirus
Rb pathway-defective tumors, 1490
gene therapy
E1 double-restricted Ad, gallbladder cancer, 4434
measles virus-mediated
neutrophils, 6463
Ras-dependent
adenovirus VAI mutant, 5544
replication
Ad5 knob substitution and, 1262
replication-competent virus, mathematical modeling, 1317, 8554
tumor vaccine
heat shock protein-mediated, 7321
virotherapy
antitumor efficacy, pharmacologic indicators, 4003
- Oncovin**
NOVP chemotherapy-induced sperm aneuploidies, Hodgkin's disease, 44
- ONYX-015**
carboxylesterase delivery, 6900
- Optical imaging**
near-infrared
EGFR, breast cancer xenografts, 7870
pre- and intraoperative delineation, brain tumors, 8122
real-time vital
anti-EGFR antibodies conjugated to gold nanoparticles, 1999
- Optic nerve glioma**
Nf1 mutant mice, 8573
- Oral carcinoma**
risk
IGF2R genotype and, 296
second malignancy
loss of heterozygosity and, 5167
squamous cell
chromosome 3p copy number alterations, CGH, 8582
decorin expression, 7769
telomere dysfunction, 458
- Oral dysplasia**
decorin expression, 7769
- Ornithine decarboxylase**
PKC ϵ and, metastatic squamous cell carcinoma, 3037
- Osteoblasts**
proliferation regulation by Runx2, 5357
- Osteoclastogenesis inhibitory factor**
prostate cancer burden inhibition, mice, 2096
- Osteoclasts**
bone invasion, neuroblastoma, 3026
- Osteonectin**
expression, non-small cell lung cancer, 5376
- Osteoprotegerin**
antitumor effects, multiple myeloma model, 287
paracrine survival factor effects, myeloma, 912
prostate cancer burden inhibition, mice, 2096
- Osteosarcoma**
centromere dynamic inhibition by Taxol, 2794
proliferation
TGF- β -induced, 7791
telomere maintenance mechanisms, 1759
- Ovarian adenocarcinoma**
diagnostic markers, identification by omic profiling, 5243
HPV16/18 distribution, 7215
platinum uptake, direct mapping, 1776
- Ovarian cancer**
AdE3-*IAI.3B* therapy, 2506
AKT2-induced cell invasion, 196
 α particle generator therapy, 5084
angiogenesis promotion by PI3KCA, 4225
Ang-2 upregulation by tumor-derived VEGF, epithelium, 3403
E-cadherin upregulation by DPPIV, 2278
calgranulins, 7507
 β -catenin/TCF target genes, 2913
COX-1 overexpression, 906
cyclin E expression, 1235
epithelial
functional FasL secretion, 5573
NY-ESO-1 and LAGE-1 target antigens, 6076
transgenic mouse model, 1389
familial or inherited
ATM mutations, 3325
BRCA1/2 mutations, 417
growth inhibition
hLPP-3, 1073
IL-10-mediated, 5091
HEA (WFDC2) protein, 3695
hK5 biomarker, 3958, 5647, 7544
hK8 biomarker, 2771
hK14 biomarker, 9032
IL-6 gene promoter polymorphism, 3066
immunodiagnostics, 3695
immunotherapy
anti-Id-IL-6 fusion protein, 3234
inhibition
expression effects, 8648
karyotypes, multivariate analyses, 3378
paclitaxel resistance, evolution, 2200
P1 α FR promoter regulation by vHNF1, 696
platinum sensitivity and cisplatin resistance, 1311
radiosensitivity
flavopiridol and, 3263
serous
glycodelin, 6258
HuR expression, 7591
serum *hK10* levels, 807
sIGF-IR antitumor effects, 7834
sporadic
BRCA1/2 mutations, 417
- 9127
- squamous cell
HPV16/18 distribution, 7215
stress response modulation by polymer-drug conjugate, 7876
synuclein γ demethylation, 664
targeted actinium-225 *in vivo* generator therapy, 5084
TGF- β /Smad signaling, 1413
TRAIL/Apo-2L-induced apoptosis inhibition by IL-8, OVCAR3 cells, 4521
VEGF release induction by MMP9 and MMP2, 5224
- Ovarian carcinogenesis**
induction by *p53* and *Rb1* inactivation, 3459
- Ovarian epithelial cells**
androgen regulation, 2416
- Ovarian tumors**
dedifferentiation
GATA-6 inactivation, 4967
growth
ET $_A$ receptor, 2447
- Oxaliplatin**
sensitization by 17-AAG, colon cancer, 8600
- Oxidation/reduction (redox)**
intracellular
cell cycle regulation, fibroblasts, 2109
- Oxidative DNA damage**
base excision repair alterations, hepatocellular carcinoma, 7704
- Oxidative stress**
and genomic instability, 3107
induction
CDDO, 5551
- 8-oxoG-DNA glycosylase gene *Ogg1***
Ogg1, *Mth1* double knockout mice, 902
- Oxygen**
gradients
and tumor oxygenation manipulation, 4705
singlet
luminescence, photodynamic therapy, 7986
- Oxygenation**
gain factor, breast cancer, 7634
hemoglobin level and, breast cancer, 7634
tumor
erythropoietin and, 6162
manipulation
oxygen gradients and, 4705
measurement, melanoma xenograft model, 7232
- P**
- p14ARF**
bicistronic p14ARF/p53 adenovirus, 3646, 5171
- p16^{INK4a}**
hypermethylation, mammary epithelia, 1596
invasion and proliferation regulation, basal cell carcinoma, 1737
- p19**
novel Ras family protein, 5178
- p21-activated kinase 1**
Kaposi's sarcoma-associated herpes virus G protein-coupled receptor cell transformation, 8837
- p21^{Waf1/Cip1}**
activation by histone deacetylase inhibitors, 2891
dysfunction, neuroblastoma, 3840
and metastasis, irradiated mice, 3021
polymorphisms
and prostate cancer, 2033
stability
TGF- β 1 and, colon cancer, 3340
- p27^{Kip1}**
and antiestrogen-induced growth arrest,

- breast cancer, 4322
degradation
 H. pylori and, gastric epithelial cells, 4739
JAB1 and, breast cancer, 2977
mouse intestinal tumorigenesis, 4990
polymorphisms
 and prostate cancer, 2033
- p28ING5**
p53 binding, 2373
- p29ING4**
p53 binding, 2373
- p38^{SAPK}**
ERK^{MAPK} activity and, tumor growth and dormancy, 1684
- p50 homodimer/Bcl-3 complexes**
nasopharyngeal carcinoma, 8293
- p53**
acetylation by histone deacetylase inhibitors, 8948
activation by COX-2 inhibition, colon cancer, 5239
bicistronic p14ARF/p53 adenovirus, 3646, 5171
CD95 expression and function regulation, carcinoma, 7176
combination p53 and topotecan treatment, colon cancer, 2782
craf-induced lung adenoma, 2268
deletions
 PDGF-B and, glioma, 4305
DNA methyltransferase I expression inhibition, 6579
downstream targets
 deletion
 phenotype effects, 8664
 and Fas-mediated apoptosis, 1527
 G₂ checkpoint control, 4074
 HIPK2-mediated induction
 and promyelocytic leukemia, 4310
 and hormones, mammary tumorigenesis, 6140
 and HPV16/18 transcripts, head and neck squamous cell carcinoma, 1188
 hRAD51 and hRAD54 interactions, 2596
 hRR subunit interactions, 980
 inactivation, ovarian carcinogenesis, 3459
 Ink4c/p53-null mice
 tumor spectrum, 5420
 mTFA interactions, 3729
 mutations
 androgen-independent growth mediation, prostate cancer, 2228
 bladder cancer, 7530
 cigarette smoke, mice, 793
 colorectal adenocarcinoma, 4656
 and Fas resistance, prostate cancer, 2905
 reactivation, 3904
 recognition by HLA-B46—restricted tumor-infiltrating lymphocytes, 854
 rhabdomyosarcoma, HER-2/*neu* transgenic *p53* mutant mice, 2728
 p29ING4 and p28ING5 protein binding, 2373
 proliferative life span barriers, *in vitro* glioma model, 4854
 PTEN interactions, acute lymphoblastic leukemia, 6357
 radiation abscopal effect mediation, 1990
 and radiation-induced genomic instability, 936
 and recombination, mice, 5335
 site-specific effects on histone H3 modification, 6674
 stabilization by bortezomib, prostate cancer, 7338
 and survival after fractionated ionizing radiation, prostate cancer, 7190
- Trp53^{+/+}* tumors
 modifier genes, 2364
 upregulation by PTEN and LY294002, 3585
 wild-type
 inactivation, glioma, 8670
 XIap/Akt-mediated chemoresistance, 7081
- p53¹¹⁰⁻¹²⁴**
CD4⁺ helper T cells, 3675
- p63**
amplification and overexpression, lung tumorigenesis, 7113
downstream gene targets, 2351
- p65**
NF- κ B
 hTERT nuclear translocation mediation, 18
- p73**
functional impairment, thyroid cancer, 5829
IL-4R α target, identification, 8145
pancreatic cancer, 2737
stabilization by c-Abl, tyrosine phosphorylation-dependent, 3418
- p300**
proliferation and progression, prostate cancer, 7638
- Paclitaxel (Taxol)**
brain tumor distribution, mice, 5114
centromere dynamic inhibition, osteosarcoma, 2794
combined with MEK/Erk inhibitor, transcriptional profiling, 5095
dicoumarol synergy, 1214
resistance
 evolution, ovarian cancer, 2200
 α -tubulin mutations, 1207
sensitization by 17-AAG, 2139
TRAIL sensitization, renal cancer, 1365
- PAK1**
activation by AND-34/BCAR3, 6802
- Pancreatic adenocarcinoma**
gene hypomethylation, 4158
growth inhibition by MnSOD, 1297
molecular profiling, 2649
- Pancreatic β -cell tumorigenesis**
MEN1, mice, 4836
- Pancreatic cancer**
aberrant methylation targets, high-throughput microarrays, 3735
amyloid precursor protein, 7032
claudin-4 effects, 6265
DX-8951f efficacy, 80
intratumoral dendritic cell administration, 8962
invasiveness
 MUC1 contributions, 5011
metastasis
 inhibition by CS-682, orthotopic model, 5521
 MUC1 contributions, 5011
 neurotensin-induced mitogenic signaling, 2379
 NQO₁ and, 5513
 p73, 2737
 progression
 MCP-1/CCL2 effects, 7451
 SERPINE2 and, 4945
 young-onset
 Fanconi anemia gene mutations, 2585, 6998
- Pancreatic carcinogenesis**
K-ras, 2005
- Pancreatic ductal adenocarcinoma**
gene expression analysis, 8614
- Pancreatic neoplasia**
ductal cell
 preinvasive, mice, 2016
- PAN-major histocompatibility complex class II IA peptide DNA**
combined with DNA vaccine immunotherapy
 tumor growth inhibition, 7920
- Papillary carcinoma**
renal cell
 cytogenetic and morphologic typing, 6200
thyroid
 BRAF mutations, 1454, 4561
- Parathyroid neoplasia**
mouse model, 8022
- Parathyroid tissue**
Men1 gene, 8022
- PATCHED1 (PTCH1)**
missense mutations, 1636
- Paternally expressed gene 10 (PEG10)**
hepatocellular carcinogenesis, 3043
- PAX5 α gene**
promoter methylation, cancer, 4620
- PAX5 β gene**
promoter methylation, cancer, 4620
- Paxillin**
androgen receptor coactivation, prostate cancer, 4927
- PCPH oncoprotein**
and mTOR, radiation-induced apoptosis, 6290
- Pdef**
expression effects, breast cancer, 4626
- Pediatric astrocytoma**
angiogenesis gene profiling, 1865
- Pediatric leukemia, acute lymphoblastic**
gene expression profiling, 4882
NBS1 mutations, 6563
T-cell
 NKX2-5 deregulation by *BCL11B* juxtaposition, 5329
- Pegylation**
rMETase enhancement, 8377
zinc protoporphyrin, antitumor activity, 3567
- Pemetrexed**
transporter, mesothelioma, 7004
- Pendred syndrome gene SLC26A4 or PDS**
hypermethylation, thyroid tumorigenesis, 2312
- Peptide nucleic acid**
photochemical internalization, 3490
- Peptides**
chronic lymphocytic leukemia-binding, selection, 5213
doxorubicin prodrugs
 cleavage by CD10, 5526
hyaluronan-binding, antitumor activity, 5685
laminin-1 antagonist, 5060
melanoma-presented
 T-cell activation, 1560
vaccines
 CpG adjuvant and CTLA-4 blockade, 3281
- Peptide SSX-2₄₁₋₄₉**
CTL responses, melanoma, 5601
- Perillyl alcohol**
chemopreventive effects, esophageal tumorigenesis, 2399
- Peripheral blood mononuclear cells**
gene expression profiling, advanced renal cell carcinoma, 6069
- Peroxisome proliferator-activated receptor α**
growth regulatory genes, 5767
- Peroxisome proliferator-activated receptor γ**
agonists
 cyclin D1 and ER α degradation, 958
inhibition by mutant thyroid hormone receptor β , thyroid carcinogenesis, 5274
ligands

- cell proliferation inhibition, leiomyoma, 1221
 RAR β regulation, 3531
 single nucleotide polymorphisms and colorectal cancer, 3560
- P-glycoprotein**
 expression
 glucose depletion and, hepatoma, 7284
 LANC-like 2-induced decrease, 723
 and membrane properties, 3084
 paclitaxel brain and brain tumor distribution effects, mice, 5114
- Phaeochromocytoma**
 extra-adrenal
 SDHB and *SDHD* mutations, 5615
 malignant
 SDHB and *SDHD* mutations, 5615
- Phenotype**
CRAP53 cooperation and, lung adenoma, 2268
 glycolytic
 carcinogenesis, mathematical models, 3847
 Id-2 and, breast cancer, 7098
 invasive
 vimentin overexpression and, prostate cancer, 2306
 metastatic
 CD44v2-10, 887
 microsatellite instability and, colorectal tumors, 4577
 mutator, cancer, 6635
 and *p53* downstream target deletions, 8664
 premalignant, hTERT-immortalized fibroblasts, 7147
- Phenylbutyrate**
 combined with DAC
 lung cancer prevention, 7089
- α -Phenyl-N-t-butyl nitron**
 radioprotective effects, U937 cells and mice, 6885
- Phorbol myristate acetate**
 MMP-9 activity
 inhibition by dykellid acid, 3430
- Phorbol-12-myristate-13-acetate**
 -induced HIF-1 α , 8700
- Phosphatase and tensin homologue deleted on chromosome 10 (PTEN)**
 angiogenesis inhibition, glioma, 2300
 combined with LY294002
 p53 upregulation and angiogenesis inhibition, 3585
 downregulation by HBx, 3453
 loss
 melanoma promotion, 2881
 mutation
 and EGFR
 VEGF mRNA expression regulation, glioblastoma, 236
Nkx3.1; *Pten* mice
 prostate adenocarcinoma and lymph node metastasis, 3886
 nuclear, MCF-7 cells, 282
 p53 and MDM2 interactions, acute lymphoblastic leukemia, 6357
 skin morphogenesis and oncogenesis, 674
- Phosphate dehydrogenase**
 HMGB1-HMGB2-HSC70-ERp60-glyceraldehyde 3-phosphate dehydrogenase complex
 chemically modified DNA sensor, 100
- Phosphate of regenerating liver PRL-1**
 cell migration, invasion, and metastasis promotion, 2716
- Phosphate of regenerating liver PRL-3**
 cell migration, invasion, and metastasis promotion, 2716
- Phosphatidylinositol 3-kinase**
 activation
 vascular endothelium resistance to radiation-induced apoptosis, 7663
 catalytic subunit α
 angiogenesis promotion, ovarian cancer, 4225
 cisplatin-induced death sensitization, 1034
 and Kit^{D814Y} mutant signaling, mast cells, 4412
 MTI-MMP and MMP-2 regulation, melanoma, 4757
 PI3K/Akt pathway
 CDK inhibitors and, leukemia, 1822
 signaling pathway, glioblastoma, 2742
- Phosphatidylinositol 3-kinase inhibitors**
 combinatorial efficacy with EGFR kinases, 8899
 combined with EGFR kinases, 8930
 combined with PTEN
 p53 upregulation and angiogenesis inhibition, 3585
- Phosphatidylinositol 3-kinase p110 δ**
 chemotaxis regulation, breast cancer, 1667
- Phosphodiesterase**
 reaction mechanism, 2042
- 3-Phosphoinositide-dependent kinase-1**
 transformation signaling pathway, mammary epithelial cells, 5370
- Phospholipase A₂**
 inhibition by anthracyclines, 5992
- Phospholipase C γ -1**
 activation by EGFR, head and neck squamous cell carcinoma, 5629
- Phospholipid scramblase 3**
 phosphorylation by PKC- δ , 1153
- Phosphoramidate**
 telomerase inhibition, 3931
 telomerase RNA-targeting, multiple myeloma, 6187
- Phosphosphingolipids**
 hydrolyzation by autotaxin, 5446
- Photoactivation**
 synchrotron
 cisplatin, 3221
- Photochemistry**
 peptide nucleic acid internalization, 3490
- Photodynamic therapy**
 chemiluminescence, 1818
 combined with DMXAA, antitumor effects, 7584
 combined with indole acetic acid, 776
 drug delivery, 8126
 receptor signaling inhibition, 3812
 singlet oxygen luminescence, 7986
 verteporfin, 1025
- Phthalocyanine 4**
 cardiolipin probe energy transfer, 5194
- Phytoestrogens**
BRCA1 and *BRCA2* expression effects, mammary glands, 6607
- PIG3 gene**
 promoter evolution, 1756
- Pim-1**
 and genomic instability, 8079
- Pin1**
 prognostic value, prostate cancer, 6244
- Pituitary adenoma**
 folate receptor expression, 4218
- Pituitary tumors**
 galectin-3 expression, 2251
- Placental bikunin**
 gene hypermethylation, hepatocellular carcinoma, 8674
- Placenta-specific ATP-binding cassette gene ABCP (ABCG2): See Breast cancer resistance protein**
- Plasma**
 DNA integrity, 3966
- Plasmacytoid dendritic cells**
 head and neck squamous cell carcinoma, 6478
- Plasmacytoma**
BCL2 transgenic, 8656
- Plasmids**
 mammalian origin, amplification, 5281
- Plasminogen activator inhibitor-2**
 molecular biomarker, head and neck squamous cell carcinoma, 555
- Platelet-derived growth factor A**
 processing by proprotein convertases, 1458
- Platelet-derived growth factor B**
 and *p53* or *Ink4a-Arf* loss, glioma, 4305
- Platinum**
 sensitivity
 cisplatin resistance, ovarian cancer, 1311
 uptake, direct mapping, 1776
- Pluripotent germ cell tumors**
 identification by POU5F1, 2244
- PMEPA1 gene**
 expression, colon cancer, 1568
 growth inhibition, prostate cancer, 4299
- Poly(ADP-ribose) polymerase-1 inhibitors**
 combined with DNA-PK inhibitors
 radiosensitization and DNA repair inhibition, 6008
- Polyamine analogues**
 and MAPK activation, melanoma, 3619
- Polycythemia vera**
 gene expression profiling, cDNA microarray, 3940
- Polyethylenimine**
 novel PEI/DNA vector, bladder cancer gene therapy, 4017
- Polymerase β haploinsufficiency**
 base excision repair deficiency, 5799
- Polymerase chain reaction**
 DNA alterations, aberrant crypt foci, 6166
 microsatellite analysis, bladder cancer, 2216
 real-time arrays, Kaposi's sarcoma, 2010
 reverse transcription
 immunohistochemistry, micrometastatic prostate cancer, 4662
 RT-PCR-PSA assay, postoperative and prostate cancer progression, 5874
- Polymer-drug conjugates**
 stress response modulation, ovarian cancer, 7876
- Polymeric micelles**
 CDDP-loaded
 solid tumor eradication, mice, 8977
- Polymorphonuclear leukocyte elastase**
 prognostic value, breast cancer, 337
- Polyomavirus infection**
 susceptibility, mesothelioma, 6125
- Polyphenols**
 dietary
 telomerase inhibition, 824
- Polyposis**
 intestinal
 COX-1 and COX-2 cooperation, 4872
 inhibition, *Mdr1*^{-/-} *ApcMin*⁺ mice, 895
 MYH-associated
 carcinogenesis, genetic pathways, 7595
- Polyps**
 hyperplastic
 BRAF and *KRAS* mutations, 4878
- Polypyrimidine tract-binding protein**
FGFR1 alternative splicing regulation, 6154
- Positron emission tomography**
 [¹⁸F]FLT anticancer therapy monitoring,

3791, 8558
 metabolic temozolomide activation, 2409
 proliferation imaging, non-Hodgkin's lymphoma, 2681
 small animal FDG-PET/CT imaging, 6252

Potter, Van Rensselaer II
 obituary, 1724

POU5F1 (OCT3/4)
 and pluripotent germ cell tumors, 2244

Power law distribution
 chromosome aberrations, cancer, 7094

PP1
 AKT dephosphorylation promotion, breast cancer, 7777

PP1 inhibitor
 RETMEN2A and RETMEN2B degradation induction, 2234

PPMID gene
 neuroblastoma, 1876

Precancer
 CFR-1 marker, 2052
 gastric
 gene expression, 2569

Precursor cells
 endothelial
 tumor endothelium model, 5866

Prednisone
 NOV chemotherapy-induced sperm aneuploidies, Hodgkin's disease, 44

Premalignant phenotype
 hTERT-immortalized fibroblasts, 7147

Preosteoblasts
 growth regulation by Runx2, 5357

Prevention
 research
 frontiers, meeting report, 5649

PRKARIA gene
 adrenocortical tumors, 5308

Procaine
 growth-inhibitory effects, cancer, 4984

Procyanidin dimers
 aromatase inhibition, 8516

Prodrug therapy
 legumain overexpression target, 2957

Progesterone receptor
 expression, neurofibromas, 752

Progesterone receptor gene (PGR)
 polymorphisms
 and breast cancer risk, 5236

Prohibitin gene
 3'UTR
 tumor inhibition, breast cancer, 5251

Proinflammatory genes
 modulation by omega-3 fatty acids, colon cancer, 972

Prolactin
 antagonists
 G129R-endostatin fusion protein
 breast cancer inhibition, 3598
 16-kDa fragment
 antitumor activity, prostate cancer, 386

Proliferative life span barriers
 p53-dependent, *in vitro* glioma model, 4854

Proline-rich acidic protein
 growth inhibition, cancer cells, 6658

Prolyl-hydroxylase-1 (PHD1/EGLN2)
 mPHD1
 HIF-1 α and tumor growth inhibition, 8777

Promoter hypermethylation
 urine-based detection, kidney cancer, 8695

Promyelocytic leukemia
 ALT-associated bodies, assembly, 2589
 PMLRARA transgenic mice
 retinoid deficiency, 5257

Proprotein convertases
 PDGF-A processing, 1458

Prostacyclin
 stromal
 antiapoptotic effects, colonic epithelial cells, 1748

Prostaglandin E₂
 growth effects, colon cancer, 6726
 growth stimulation, colon cancer, 5218
 synthesis inhibition by *Scutellaria baicalensis*, 4037
 VEGF expression
 mediation by HIF-1, 2330

Prostate
 DP-153 cells
 tumor inhibition by TGF- β , 4358
 epithelial cells
 proliferation enhancement by Cdc37 overexpression, 4614
 IgM-mediated chronic lymphocytic leukemia infiltration, 2067
 SKP2 oncogenic effects, mouse, 1583

Prostate adenocarcinoma
 invasive, *Nkx3.1*; *Pten* mice, 3886
 metastasis to lymph nodes, *Nkx3.1*; *Pten* mice, 3886

Prostate cancer
 adenovirus-mediated suicide gene therapy, phase I study, 7497
 androgen-independent growth mediation by mutant p53, 2228
 androgen receptor coactivation by paxillin, 4927
 androgen receptor promotion by gelsolin, 4888
 androgen-refractory
 androgen receptor signaling, MDA PCa 2b-hr cells, 5622
 angiogenesis promotion by ps20, 5859
 anti-E-selectin immunotherapy, 6387
 apoptosis induction by combined TRAIL/Apo-2L and CPT-11 treatment, 4713
 apoptosis induction by *mda-7/IL-24*, 8138
 apoptosis induction by MIC-1, 5034
 apoptosis induction by RNase L, 6795
 apoptosis induction by selenium and vitamin E, 6988
 arachidonic acid metabolism, 2256
 AR-mediated transcription/proliferation uncoupling, 8029
 bradykinin receptor subtype 1, 2037
 burden
 inhibition by OPG/OCIF, mice, 2096
 CDKN1A and CDKN1B polymorphisms and, 2033
 cell adhesion
 inhibition by MIC-1, 5034
 inhibition by versican, 4786
 cell migration
 induction by MT1-MMP, 2292
 inhibition by EW12/PGR1, 2665
 cell proliferation
 p300, 7638
 chemoprevention
 selenium and vitamin E, 6988
 COX-2 expression, 2256
 detection by proteomic profiling, 2701
 diagnosis
 Tc(I)-carbonyl conjugates, 4082
 dominant negative IGF-Ir, 6432
 Drg-1 expression, 1731
 genome-wide loss of heterozygosity mapping, 4781
 growth inhibition
 combination 17AAG and radiation, 8393
 FASE siRNA, LNCaP cells, 3799
 NF κ B inhibitor DHMEQ, 107
 PMEPA1, 4299
 16-kDa prolactin fragment, 386

hK11, 6543
h-NIS gene therapy, 7840
HOXC expression, 5879
HYAL1, prognostic value, 2638
 hyaluronic acid, prognostic value, 2638
iGFR1 activation effects, 6237
IGFBP-3 gene polymorphism, 4407
IGFBP-rP1 antitumor activity, 7717
 IL-8 and VEGF expression stimulation by bombesin, 3495
 IL-6 regulation, 2206
 intracellular MRI, 4766
 invasion
 calpain-2, 4632
 RhoA and NF- κ B, 1359
 invasive phenotype
 vimentin overexpression and, 2306
 laminin-5 β 3 chain cleavage by MT1-MMP, 2292
 12/15-lipoxygenase expression, 2256
 metastasis
 γ -aminobutyric acid, 8090
 circulating cells, viable, 4239
 IL-12-transduced macrophage therapy, 7853
 inhibition by trioxifene, PAIII rat, 6056
 α -methylacyl-CoA racemase growth modifier, 7365
 micrometastatic, RT-PCR immunohistochemistry, 4662
 MMP-2 expression, 8511
 MST4, 3356
 NF- κ B signaling interruption by androgen receptor, 7106
 Pin1, prognostic value, 6244
 p53 mutants and Fas resistance, 2905
 progression
 p300, 7638
 postoperative RT-PCR-PSA assay and, 5874
 promotion by FGF2, 5754
 STAT5 activation and, 8757
 progression in bone
 inhibition by sRANK-Fc, 7883
 p53 stabilization by bortezomib, 7338
 Ras/MAP kinase signaling pathway, 1981
 recurrence
 androgen receptor function, imaging, 4552
 prediction by gene profiling, 3469
 relapse
 molecular markers, identification, 4196
 risk
 energy intake and, 8542
 MSR1 mutations and, African-American men, 3486
 serum IGF-I, 3991
 survival after fractionated ionizing radiation p53 and, 7190
 ZNF185 inactivation, 3877

Prostate secretory protein PSP-94
 tumor growth and hypercalcemia malignancy inhibition, 2072

Prostate-specific antigen
 RT-PCR-PSA assay, postoperative and prostate cancer progression, 5874
 secretion
 AR-mediated
 uncoupling, 8029

Prostate-specific membrane antigen
 filamin association, 2645

Prostate tumorigenesis
 receptor-specific FGF signaling, 8784

Prostate tumors
 androgen-independent growth promotion by IGFBP-2, 3575
DD3 gene marker, 4747
 growth inhibition by *U19*, 4698

- inhibition by TGF- β , DP-153 cells, 4358
stromal-epithelial cross-talk
stromal cell heterogeneity, 4936
T-body therapy, 2470
- Prostatic hyperplasia, benign**
hK11, 6543
- Prostatic intraepithelial neoplasia**
inducible, FGFR1 transgenic mice, 8256
induction
FGFR1 and FGFR2, mouse, 8784
- Protease nexin I**
and pancreatic cancer, 4945
- Proteases**
extracellular matrix and, meeting report, 4750
- Protein arginine N-methyltransferase**
DNA damage sensitivity control, 164
- Protein kinase A regulatory-subunit type-I α (RI α ; PRKARIA) gene**
adrenocortical tumors, 5308
- Protein kinase B**
activation
vascular endothelium resistance to radiation-induced apoptosis, 7663
- Protein kinase B β**
cell invasion, breast and ovarian cancer, 196
- Protein kinase C**
isoforms, non-small cell lung cancer, 780
- Protein kinase C α**
Gli1 regulation, basal cell carcinoma, 4692
- Protein kinase C δ**
phospholipid scramblase 3 phosphorylation, 1153
- Protein kinase C ϵ**
and ornithine decarboxylase, metastatic squamous cell carcinoma, 3037
TNF α release signaling, metastatic squamous cell carcinoma, 6547
- Protein kinase C η**
deficiency
skin tumor promotion, mice, 2404
- Protein-protein interactions**
molecular imaging, 1780
- Proteins**
urinary
proteomic profiling, renal cell carcinoma, 6971
- Protein tyrosine phosphatase 2**
SH2 domain-containing
MMP-2 secretion and activation regulation, 6334
- Protein tyrosine phosphatase η**
rat r-PTP η
adenoviral
cell growth inhibition, thyroid carcinoma, 882
- Proteolysis**
extracellular, meeting report, 6105
- Proteomic analysis**
functional, melanoma progression, 6716
- Proteomic profiling**
drug-induced apoptosis, non-small cell lung cancer, 6928
prostate cancer detection, 2701
urinary protein, renal cell carcinoma, 6971
- ps20**
angiogenesis promotion, prostate cancer, 5859
- PS-341: See Bortezomib**
- Psoriasis**
Jab1 interactions, breast cancer, 1954
- Pulmonary adenoma susceptibility 1 gene candidate PASI**
QTL mapping and identification, advanced intercross lines, 3317
- Pulmonary fibrosis**
augmentation by ZD1839, 5054
- Pyrido-pyrimidine-type small molecule kinase inhibitors**
Bcr-Abl inhibition, 6395
- Pyridoxal 5'-phosphatase**
rMETase enhancement, 8377
- R**
- Rac**
signaling activation by AND-34/BCAR3, 6802
- Rac1**
GGTI target, 7959
- Rac3**
GGTI target, 7959
- Rad9**
human hRad9
TopBP1 focus formation, double-strand breaks, 4829
mammalian paralogs, testicular cancer, 5291
- Rad51**
expression
Gleevec effects, glioma, 7377
human hRAD51
p53 interactions, 2596
- Rad54**
human hRAD54
p53 interactions, 2596
- Radiation**
abscopal effect
mediation by p53, 1990
apoptosis
PCPH and mTOR, fibroblasts, 6290
vascular endothelium resistance, 7663
bystander effects
NO-mediated, glioma, 8437
crypt response
regulation by microvascular function, 4338
endothelial cell effects
SU5416 and SU6668 and, 3755
fibrosarcoma
glycolysis, ^{13}C NMR spectroscopy, 8813
 γ -radiation sensitivity
IG20, 8768
genomic instability
p53 and, 936
ionizing
adenoma multiplicity, *Apc*^{Min} mice, 2361
connexin43 upregulation, 7128
death-inducing effects, 324
fractionated
p53 and survival after, prostate cancer, 7190
heavy
in vitro angiogenesis inhibition, 4253
hematopoietic cell senescence, murine bone marrow, 5414
p21^{Cip1} and metastasis, mice, 3021
PBN protective effects against, U937 cells and mice, 6885
tumor angiogenesis, 1012
response
TSP-1 and, melanoma, 4055
ultraviolet A
and benzo(a)pyrene diol epoxide mutagenicity, 8708
- Radiofrequency ablation**
combined with liposomal doxorubicin, 6327
tumor-specific T cell activation, rabbits, 6496, 7543
- Radioimmunotherapy**
residualizing iodine, 111
- Radioiodide treatment**
combined with NIS gene therapy, neuroendocrine tumor cells, 1333
- Radioresistance**
autocrine-mediated, RIE-1 cells, 7807
- DNA-PK and, 1198
HGF and, rhabdomyosarcoma, 7926
- Radiosensitivity**
ATM haplotype and, breast cancer, 8717
flavopiridol and, ovarian cancer, 3263
Gleevec effects, glioma, 7377
- Radiosensitization**
combination DNA-PK and PARP-1 inhibitors, 6008
2DG-induced, 3413
geldanamycin and 17-AAG effects, cervical tumors, 8984
gemcitabine, MMR-deficient HCT116 cells, 6935
heat-activated antisense Ku70, tumor cells, 3268
roscovitine-induced, breast cancer, 2513
- Radiotherapy**
combined with 17AAG, prostate cancer, 8393
combined with dendritic cells, 8466
metastasis inhibition by angiostatin, 308
targeted
 ^{64}Cu -ATSM
deoxyglucose-enhanced, 5496
- Raf**
epidermal regulation, 319
Raf/MEK/ERK pathway
inhibition
coxsackievirus and adenovirus receptor upregulation, 2088
Ras-Raf-MAPK cascade inhibitor
metastatic melanoma treatment, 5669
- Rafts**
lipid
cancer role, workshop summary, 6571
rituximab and, B lymphoma, 534
- Ran**
and centrosome deregulation by E1A, 1430
- RANTES (CCL5)**
Met-CCL5
growth inhibition, breast tumors, 8360
- Rapamycin**
apoptosis
IGF-I protection against, 364
growth inhibition, EBV B-cell lymphoma, 4472
and imatinib resistance, chronic myelogenous leukemia, 5716
mammalian target mTOR
PCPH and, radiation-induced apoptosis, 6290
rapamycin-resistant activity, 8451
mTOR signaling effects, 8451
- Rapamycin analogues**
systemic therapy, 3173
- Ras**
epidermal regulation, 319
inactivation, biochemical, 4089
inhibition by ursodeoxycholic acid, colon cancer, 3517
MMTV-ras tumors
stromelysin-3 and metastatic development, 5844
oncolysis
adenovirus VAI mutant, 5544
Ras/MAPK signaling
prevention by Ras1 deficiency, 4232
prostate cancer, 1981
Ras-Raf-MAPK cascade inhibitor
metastatic melanoma treatment, 5669
signaling attenuation
androgen sensitivity restoration, 1975
- Ras association domain family 1A gene (RASSF1A)**
cervical carcinoma, 1888
CpG island methylation, breast cancer, 6178

inactivation, malignant cutaneous melanoma, 1639
 methylation
 and *K-ras* mutation, non-small cell lung cancer, 6206
 and loss of heterozygosity, esophageal squamous cell carcinoma, 3724
 promoter hypermethylation, non-small cell lung cancer, 3743
 target genes, non-small cell lung cancer, 5344
Ras homologue member 1 gene (*ARHI*)
 aberrant methylation and silencing, breast cancer, 4174
Reactive oxygen species
 and EGFR transactivation by benzo(a)pyrene quinones, 7825
 JNK enhancement by IKK β deficiency and, 7689
 wild-type p53 inactivation, glioma, 8670
Receptor activator of nuclear factor- κ B Fc
 soluble sRANK-Fc
 prostate cancer progression in bone inhibition, 7883
Receptor activator of nuclear factor- κ B ligand
 apoptotic effects, 1772
 expression, myeloma cells, 5438
Receptors
 activin A type II (*ACVR2*)
 mutations, gastrointestinal cancer, 994
 androgen
 coactivation by paullone, prostate cancer, 4927
 mutations, bicalutamide withdrawal syndrome, 149
 NF- κ B signaling interruption, prostate cancer, 7106
 promotion by gelsolin, prostate cancer, 4888
 prostate cancer transcription/proliferation uncoupling, 8029
 recurrent prostate cancer, imaging, 4552
 regulation by cyclin D1, 4903
 bone morphogenetic protein, dominant-negative type II
 growth inhibition, breast cancer, 277
 bradykinin subtype 1, prostate cancer, 2037
 caspase 8/TR2
 restoration
 and TRAIL sensitivity, neuroblastoma, 1122
 CD158
 and CTL survival, 7475
 chemokine CXCR4
 colon carcinoma metastasis outgrowth, 3833
 downregulation by RNAi, breast cancer, 4801
 glioblastoma tumor proliferation, 1969
 CLEVER-1, malignant cell adhesion to lymphatic vessel endothelium, 4671
 coxsackie-adenovirus
 adenoviral transgene expression modulation, 847
 upregulation by Raf/MEK/ERK pathway inhibition, 2088
 death 4
 and bladder cancer risk, 1157
 death 5
 upregulation by 2-methoxyestradiol, 468
 endothelin A, ovarian tumor growth, 2447
 epidermal growth factor
 anti-EGFR antibodies
 conjugated to gold nanoparticles, real-time vital optical imaging, 1999
 autocrine signaling

 and radioresistance, RIE-1 cells, 7807
 coregulation with HER2, 1130
 EMMPRN regulation, breast cancer, 7575
 flavopiridol-trastuzumab target, breast cancer, 3626
 gene, breast cancer, 1172
 gene selection pressures, glioblastoma, 413
 inhibitors
 combinatorial efficacy with PI3 inhibitors, 8899
 combined with phosphatidylinositol 3-kinase inhibitors, 8930
 inhibitors, small molecule
 resistance, malignant glioma, 7443
 invasion promotion, head and neck squamous cell carcinoma, 5629
 near-infrared optical imaging, breast cancer xenografts, 7870
 prognostic value, glioblastoma multiforme, 6962
 Stat3 recruitment sites, 3923
 transactivation
 benzo(a)pyrene quinones, 7825
 colon cancer, 6744
 tumor cell survival, 1
ErbB
 tumor microenvironment regulation, 3764
estrogen
 folate receptor α modulation, 2820
estrogen α
 conformations, 7490
 degradation induction by PPAR γ agonists, 958
 downregulation by IB-MECA, 6413
 expression, endometrial cancer, 6195
estrogen β
 expression, breast cancer, 2434, 9055
 gene-estrogen interactions, breast cancer, 7624
fibroblast growth factor 1
 cysteine-rich CFR-1, precancerous marker, 2052
 inducible transgenic mice, 8256
 prostatic intraepithelial neoplasia induction, mouse, 8784
 upregulation by cyclin D1 overexpression, 424
fibroblast growth factor 1, inducible
 activation effects, prostate cancer, 6237
fibroblast growth factor 2
 prostatic intraepithelial neoplasia induction, mouse, 8784
fibroblast growth factor 3
 mutations, urothelial cell carcinoma of the bladder, 8108
folate
 expression, pituitary adenoma, 4218
 α folate
 CB300638 delivery, 3612
 modulation by estrogen receptor, 2820
 P1 promoter
 regulation by vHNF1, ovarian cancer, 696
G protein-coupled
 Kaposi's sarcoma-associated herpes virus cell transformation, 8837
HER-2/*neu*
 coregulation with EGFR, 1130
 magnetic resonance imaging, 2723
IL-1
 antagonist
 gene transduction effects, melanoma, 5957
IL-11 α -locus chemokine, antitumor effects, 4420
insulin-like growth factor-I
 antibody A12, 8912

antibody EM164
 cancer cell proliferation inhibition, 5073
 anti-IGF1R scFv-Fc antibody
 IGF-I inhibition, breast cancer, 627
 dominant negative, prostate cancer, 6432
 overexpression, colon cancer, 7708
 soluble
 antitumor effects, ovarian cancer, 7834
 VEGF-C regulation, 1166
insulin-like growth factor II
 genotype
 and oral cancer risk, 296
 killer cell immunoglobulin-like
 and CTL survival, 7475
 mannose
 malignant cell adhesion to lymphatic vessel endothelium, 4671
PPAR γ
 agonists, cyclin D1 and ER α degradation, 958
 ligands
 cell proliferation inhibition, leiomyoma, 1221
 RAR β regulation, 3531
 progesterone
 expression, neurofibromas, 752
 retinoic acid
 PMLRARA transgenic mice
 retinoid deficiency, 5257
 retinoic acid β
 regulation by PPAR γ ligands, 3531
 signaling inhibition by photodynamic therapy, 3812
 stem cell factor (c-KIT)
 mutations
 and bilateral testicular germ-cell tumors, 7674
 thyroid hormone β
 mutations
 PPAR γ inhibition, thyroid carcinogenesis, 5274
 thyroid-stimulating hormone
 gene methylation, epithelial thyroid tumors, 2316
 transforming growth factor β type II
 HDAC-mediated inhibition mechanism, 2624
 urokinase plasminogen activator
 invasion and growth inhibition, glioma, 2454
RECK gene
 upregulation by histone deacetylase inhibitor, 3069
Recombination
 Atm-, p53-, and Gadd45a-deficient mice, 5335
Red meat
 endogenous intestinal *N*-nitrosation by haem, 2358
Red wine and grape seeds
 procyanidin dimers
 aromatase inhibition, 8516
Rejection
 tumor
 CD8 $^{+}$ T cell-mediated, 4095
Renal cell carcinoma
 adenoviral gene therapy, 1994
 advanced
 expression profiling, peripheral blood mononuclear cells, 6069
 chromosome 3p14.2-p25 deletion, 455
 gangliosides
 apoptosis induction, T cells, 1676
 growth inhibition, bone, 2940
 HIF2 α upregulation, 2675
 HLA-G upregulation, 4107

- metastasis
CA IX-expressing tumor model LABAZ1, 4952
- metastasis to liver
TRAIL, murine, 207
- papillary
cytogenetic and morphologic typing, 6200
- promoter hypermethylation, urine-based detection, 8695
- T-cell responses to EphA2, 4481
- TNF- α -induced cytotoxicity sensitization by pVHL, 7076
- TRAIL sensitization by paclitaxel, 1365
- urinary proteins, proteomic profiling, 6971
- von Hippel-Lindau-defective
HIF-dependent replicative adenoviral treatment, 6877
- Renal tumors**
BHD inactivation, 4583
- RNA
dendritic cells, 2127
- Reovirus therapy**
medulloblastoma effects, 3162
- systemic, metastatic cancer, 348
- Replication**
oncolytic
Ad5 knob substitution and, 1262
- Replication-competent virus**
mathematical modeling, 1317, 8554
- Reporter genes**
fusion, multimodality imaging, 1160
- Research**
prevention
frontiers, meeting report, 5649
- RET gene**
G691S/S904S polymorphisms, 1814
- inhibition by CEP-701 and CEP-751, 5559
- transgenic mouse model
strain effects on medullary thyroid carcinoma penetrance, 4777
- Reticulon RTN-1C**
glucosylceramide synthase modulation, neuroepithelioma, 3860
- Retinoblastoma**
gene expression phenotype, 3716
- Retinoblastoma 94**
adenoviral-mediated Ad-RB94
telomere erosion, chromosomal crisis, and apoptosis, 760
- Retinoblastoma protein**
and centrosome abnormalities, 476
- pathway defects
oncolytic adenovirus, 1490
- reactivation by tyrphostin, melanoma, 1420
- Retinoblastoma Rb1**
inactivation
ovarian carcinogenesis induction, 3459
- all-trans-Retinoic acid**
and cancer vaccine effects, 4441
- Retinoic acid receptor**
PMLRARA transgenic mice
retinoid deficiency, 5257
- Retinoic acid receptor β**
methylation status and loss of heterozygosity, esophageal squamous cell carcinoma, 3724
- regulation by PPAR γ ligands, 3531
- Retinoids**
deficiency, *PMLRARA* transgenic mice, 5257
- and MHC class I presentation pathway, neuroblastoma, 8006
- RETMEN2A oncoprotein**
degradation induction by PP1 inhibitor, 2234
- RETMEN2B oncoprotein**
degradation induction by PP1 inhibitor, 2234
- Retrovirus**
melanoma-associated, 8735
- rgr gene**
activation by overexpression, 4188
- Rhabdomyosarcoma**
c-MET-HGF and CXCR4-SDF-1 axes, 7926
- combination G207 and vincristine, oncolytic activity, 1508
- HER-2/*neu* transgenic *p53* mutant mice, 2728
- RhoA**
and NF- κ B, prostate cancer cell invasion, 1359
- RhoGDI α**
identification, 6928
- Ribonucleoproteins**
heterogeneous nuclear hnRNP A1/A2 proteins, cancer targets, 7679
- Ribonucleotide reductase**
human hRR subunits
p53 interactions, 980
- subunit hRRM2
DNA repair response, 6583
- Ribozymes**
library
cell migration gene identification, 119
- Rituximab**
and rafts/microdomains, B lymphoma, 534
- response to therapy
cytogenetic CLL abnormalities and, 36
- RNA**
alternative splicing, cancer, 655, 6996
- 8-Cl-Ado actions, multiple myeloma, 7968
- multivalent CTLA-4 aptamers, 7483
- renal tumor
dendritic cells, 2127
- small hairpin-type shRNA
leukemia gene cleavage, 6809
- small interfering siRNA
anti-DNA polymerase H, 3909
- anti-FASE
cell growth inhibition, prostate cancer, 3799
- anti-VEGF
angiogenesis inhibition, 3919
- CXCR4 downregulation, breast cancer, 4801
- and DNA methylation, 6110
- DNA repair factor silencing, 1550
- RNA interference**
and DNA methylation, 6110
- hepatoma inhibition, 3593
- MDR1* modulation, 1515
- RNase L gene**
apoptosis, prostate cancer, 6795
- Rofecoxib**
combined with immunotherapy, antitumor effects, 7845
- COX-2 inhibition, colorectal cancer treatment, 586
- Roscovitin**
apoptosis induction, human leukemia virus type 1 MT-2 cells, 8523
- radiosensitization, breast cancer, 2513
- Rose bengal**
firefly luciferin-activated, chemiluminescence photodynamic therapy, 1818
- Rosiglitazone maleate**
chemopreventive effects, breast epithelial cells, 1914
- Rottlerin**
TRAIL sensitization, colon cancer, 5118
- RPI01: See (E)-5-(2-Bromovinyl)-2'-deoxyuridine**
- RRR- α -tocopheryl succinate (vitamin E succinate, VES)**
apoptosis
mitochondrial events, 2483
- RS/DJ-1**
identification, 6928
- Runx2**
cell growth regulation, preosteoblasts, 5357
- expression, breast cancer, 2631
- S
- S247**
metastasis inhibition, colon cancer, 2079
- S100A4 gene**
upregulation by ERBB2, medulloblastoma, 140
- Salmonella typhimurium**
accumulation, tumors, 5188
- Salmosin gene transfer**
tumor inhibition, melanoma, 6458
- SAMC: See S-Allylmercaptocysteine**
- Sarcoma**
bone
prognostic markers, identification, 8680, 9042
- killing by cytosine deaminase fusion gene *NGFR-CD*, 6847
- Sarcoma, Kaposi's**
-associated herpes virus G protein-coupled receptor
cell transformation
p21-activated kinase 1, 8837
- real-time PCR arrays, 2010
- SB-431542**
and TGF- β -induced proliferation, osteosarcoma, 7791
- SCH66336**
apoptosis induction, head and neck squamous cell carcinoma, 4796
- Scirrhous gastric cancer**
gastric fibroblast-secreted KGF, 8848
- Scutellaria baicalensis**
anticancer activity, 4037
- SELDI: See Surface-enhanced laser desorption/ionization mass spectrometry**
- E-Selectin**
anti-E-selectin immunotherapy, prostate cancer, 6387
- Selective cytokine inhibitory drug SelCID-3**
antitumor effects, 593
- Selenium**
deficiency
acquired tolerance, hepatocellular carcinoma, 6707
- growth arrest, prostate cancer cells, 52
- and vitamin E, prostate cancer chemoprevention, 6988
- Semaphorin 3B (SEMA3B)**
hypermethylation, non-small cell lung cancer, 3352
- Senescence**
hematopoietic cell
ionizing radiation and busulfan-induced, murine bone marrow, 5414
- induction
resistance by telomerase inhibitor, 6149
- modulation by culture conditions, keratinocytes, 7815
- Septin 9 (MSF) gene**
amplification, breast cancer, 2179
- SEREX: See Serological analysis of recombinant cDNA expression cloning**
- Serine 139 phosphorylated histone H2AX (γ H2AX)**
and cell survival, 4347
- Serological analysis of recombinant cDNA expression cloning (SEREX)**
MSI+ colorectal cancer antigen identification, 5564
- Serous carcinoma**
ovarian
glycodelin, 6258
- HuR expression, 7591

- SERPINE2 (protease nexin I)**
and pancreatic cancer, 4945
- Serpins**
SCCA2-like, skin tumors, 1871
- Serum**
DNA methylation, breast cancer, 7641
surfactant protein D levels, lung tumor, 5889
- Sezary cells**
T-plastin expression, 7122
- Sezary syndrome**
STAT5 expression, 9048
- Shc protein**
prognostic value, breast cancer, 6772, 8562
- SH2 domain-containing protein tyrosine phosphatase 2**
MMP-2 secretion and activation regulation, 6334
- Sialyl Lewis X (sLe^x)**
disaccharide precursor
and tumor metastasis, 2775
- Signal transducer and activator of transcription 3**
EGFR-independent constitutive activation, head and neck squamous cell carcinoma, 2948
EGFR recruitment sites, 3923
JAK/STAT3 pathway
inhibition by JSI-124, 1270
- Signal transducer and activator of transcription 5**
activation
and prostate cancer progression, 8757
expression, Sezary syndrome, 9048
inhibition by roscovitine, HTLV type 1 MT-2 cells, 8523
- Signal transducer and activator of transcription 5b**
activation, carcinogenesis, 6763
- Simian virus 40**
malignant lymphoma, Japan, 7606
susceptibility, mesothelioma, 6125
transformation
determinants of crisis, epithelial cells, 5813
- Simian virus 40 large tumor antigen**
CD4+ T lymphocytes and, 1040
- Single nucleotide polymorphisms**
bladder cancer, 2216
genome-wide loss of heterozygosity mapping, prostate cancer, 4781
HuSNP chip assay
urine, bladder cancer detection, 5723
inflammatory genes
and colorectal cancer, 3560
novel
TS tandem repeats, 2898
- Six3**
EWS/NOR-1 regulation, extraskelatal myxoid chondrosarcoma, 449
- SKI**
Wnt/ β -catenin signaling activation, melanoma, 6626
- SKI-606**
antiproliferative effects, chronic myelogenous leukemia, 375
- Skin cancer**
Hras mutations, allele-specific, 4849
nonmelanoma
EV-related HPV seroreactivity, 2695
HPV genotypes, 7515
- Skin carcinogenesis**
malignant conversion
inhibition by Smad3, 3447
src transgenic mice, 4819
- Skin oncogenesis**
Pten role, 674
- Skin tumors**
PKC η -deficient mice, 2404
- SCCA2-like serpins, 1871
TPA promotion susceptibility, genetics, 2747
- Ski-related novel protein N**
expression, breast cancer, 5005
- Skp2 promoter**
regulation by GA-binding protein, 4607
- Slaughter's concept**
genetic explanation, 1727
- SLC26A4**
hypermethylation, thyroid tumorigenesis, 2312
- SLIT2**
methylation status, colorectal cancer, 1054
- Smad**
TGF- β /Smad signaling
ovarian cancer, 1413
synthetic triterpenoids and, 1371
- Smad2/3**
signaling, breast cancer, 8284
- Smad3**
malignant conversion inhibition, skin carcinogenesis, 3447
- Smad7**
and tumor progression, mouse squamous cell carcinoma model, 7760
- Small cell lung cancer**
acetylcholine autocrine growth factor effects, 214
atrial natriuretic peptide production
corin effects, 8318
c-Met juxtamembrane domain mutations, 6272
transcriptional gene expression profiling, 1943
- Small hairpin-type RNA**
leukemia gene cleavage, 6809
- Small interfering RNA**
anti-DNA polymerase H, 3909
anti-FASE
cell growth inhibition, prostate cancer, 3799
anti-VEGF
angiogenesis inhibition, 3919
CXCR4 downregulation, breast cancer, 4801
and DNA methylation, 6110
DNA repair factor silencing, 1550
- Small molecule c-Met kinase inhibitor**
antitumor activity, 7345
- Small molecule EGFR inhibitors**
resistance, malignant glioma, 7443
- Small molecule kinase inhibitors**
pyrido-pyrimidine-type
Bcr-Abl inhibition, 6395
- Small molecules**
expulsion, shed vesicles, 4331
- Small unstable apoptotic protein SUAP**
myeloid cell apoptosis, 705
- Smoking**
duration/intensity
lung cancer mortality and, 6556
H19 upregulation, 1475
- Smoking-related cancer**
familial aggregation, 8531
- SnoN: See Ski-related novel protein N**
- Sodium arsenite**
c-anaphase and diplochromosome induction, fibroblasts, 6680
- Sodium iodide symporter (NIS)**
gene therapy
combined with radioiodide treatment, neuroendocrine tumor cells, 1333
human *h-NIS*
gene therapy, prostate cancer, 7840
- Solid tumors**
CD25⁺ T-cell depletion immunotherapy
LEC/chTNT-3 and, 8384
chemotherapy and immunotherapy synergy, 4490
- docetaxel delivery via fibrinogen-coated olive oil droplets, 7314
eradication by CDDP-loaded micelles, mice, 8977
rejection
cooperative immunotherapy and antiangiogenic therapy, mice, 5895
-specific T-cell tolerance, mechanisms, 9007
- Somatostatin analogues**
subcellular localization, 6864
- Sonography**
antiangiogenic therapy monitoring, 8264
- SP1**
and CAIX expression, 917
- SPARC/osteonectin**
expression, non-small cell lung cancer, 5376
- Speedy Spy1**
and cellular recovery from genotoxic damage, mammalian cells, 3701
- Sperm**
defects, *VHL* knockout mice, 5320
NOVP chemotherapy-induced aneuploidies, Hodgkin's disease, 44
- S-phase kinase-associated Skp2**
inhibition by Cx43, 1623
oncogenic effects, mouse prostate gland, 1583
- Sphingosine kinase inhibitors**
novel, 5962
- Sphingosine-1-phosphate**
production, 5446
- Spleen tyrosine kinase (Syk)**
nuclear localization
and invasion inhibition, breast cancer, 4724, 7004
- Splicing**
exonic splicing enhancer-dependent
Topo I and, 8203
- Squamous cell carcinoma**
B7-H1 role, 6501
cell growth
visinin-like protein-1 effects, 4997
- esophageal
CD4, CD8, and CD57 analyses, 1555
chromosome 3p tumor suppressor genes, 3724
gene expression profiling, 3872
gene expression ratios, predictive value, 5159
progression
TSLC1, 6320
ZASC1 amplification, 5691
- head and neck
apoptosis induction by SCH66336, 4796
apoptosis induction by SHetA2, 3826
cisplatin resistance
GST- π amplification and, 8097
EGFR-independent constitutive STAT3 activation, 2948
invasion promotion by EGFR, 5629
lymphatic endothelial markers, 8555
molecular progression
PAI-2 biomarker, 555
p53 and HPV16/18 E6 transcripts, 1188
plasmacytoid dendritic cells, 6478
tissue microarray analysis, 1179
- invasion
induction by Akt E-cadherin downregulation, 2172
visinin-like protein-1 effects, 4997
- metastatic
PKC ϵ and ornithine decarboxylase, 3037
PKC ϵ TNF α release signaling, 6547
- oral
chromosome 3p copy number alterations, CGH, 8582

decorin expression, 7769
 risk
 IGF2R genotype and, 296
 telomere dysfunction, 458
 ovarian
 HPV16/18 distribution, 7215
 progression
 Smad7 and, mouse model, 7760
Squamous cell carcinoma antigen 2 SCCA2-like serpins
 skin tumors, 1871
SR31747A-binding protein 2
 identification and pharmacological characterization, 4809
St. John's wort
 CYP1A1 inhibition, 8062
Stem cell factor receptor (c-KIT)
 mutations
 and bilateral testicular germ-cell tumors, 7674
Stem cells
 cancer
 identification, brain tumors, 5821
Stem-like cells
 neural
 bone marrow-derived, characterization, 8877
Steroid sulfatase
 breast cancer, 2762
 potent inhibition, 6442
STI2
 isolation, 404
STI571
 apoptosis
 promotion by HDIs, 2118
STK15
 expression and amplification, endometrial carcinoma, 5697
Stress
 apoptosis
 Bax role, endoplasmic reticulum, 1483
Stress, oxidative
 and genomic instability, 3107
 induction by CDDO, 5551
Stress-activated protein kinase
 ERK^{MAPK}/p38^{SAPK} activity ratio, tumor growth and dormancy, 1684
Stress-inducible protein STI2
 isolation, 404
Stress response
 modulation by polymer-drug conjugate, ovarian cancer, 7876
Stroma
 microsatellite instability, UC-associated carcinogenesis, 6158
 prostacyclin
 antiapoptotic effects, colonic epithelial cells, 1748
Stromal cell-derived factor 1
 CXCR4-SDF-1, rhabdomyosarcoma, 7926
Stromal cell-derived factor 1 α
 glioblastoma tumor proliferation, 1969
Stromal cells
 epithelial cross-talk
 stromal cell heterogeneity, prostate tumors, 4936
 heterogeneity, stromal-epithelial cross-talk, 4936
 tumor-associated
 migration stimulating factor expression, 8827
 tumor interactions
 genes, 8939
Stromal tumors
 gastrointestinal
 HMGB1 overexpression, 2188
Stromelysin-3
 and metastatic development, mouse MMTV-

 ras tumors, 5844
SU5416
 combined with endostatin, antitumor activity, 8890
 COX-2 regulation, lung cancer, 6920
 and radiation endothelial cell effects, 3755
SU6668
 and radiation endothelial cell effects, 3755
SU11248
 maintenance therapy
 tumor regrowth prevention, 4009
Suberoylanilide hydroxamic acid
 combined with 17-AAG
 apoptosis induction, leukemia, 8420
Succinate dehydrogenase subunit B gene (SDHB)
 mutations, extra-adrenal or malignant pheochromocytoma, 5615
Succinate dehydrogenase subunit D gene (SDHD)
 mutations, extra-adrenal or malignant pheochromocytoma, 5615
Suicide gene therapy
 adenovirus-mediated, prostate cancer, 7497
 CD/UPRT fusion gene
 vesicular stomatitis virus vector, 8366
Suicide nucleoside kinases
 lipid-mediated delivery, 6909
Sulfhydryl oxidase, neuroblastoma-derived (SOXN)
 IFN- γ -induced apoptosis, neuroblastoma, 7742
Sulforaphane
 gene activation and apoptosis
 glutathione and, 7520
Sulindac sulfide
 EGF-induced ERK 1/2 and Bad phosphorylation inhibition, colon cancer, 616
Superoxide dismutase 2
 thiol-sensitive mutant, Jurkat cells, 159
Surface-enhanced laser desorption/ionization mass spectrometry
 urinary proteins, renal cell carcinoma, 6971
Surfactant protein D
 serum levels, lung tumors, 5889
Surgery
 postoperative RT-PCR-PSA assay
 and prostate cancer progression, 5874
 pre- and intraoperative optimal imaging, brain tumors, 8122
Survivin
 chemical carcinogenesis, K14-survivin mice, 567
 expression
 inhibition effects, gastric cancer, 7724
 regulation by flavopiridol, 230
 tumor-specific T-cell induction, colorectal cancer, 4507
SVH-B
 upregulation, hepatocellular carcinoma, 3775
Synchrotron photoactivation
 cisplatin, 3221
Synthetic heteroarotinoid SHetA2
 apoptosis induction, head and neck squamous cell carcinoma, 3826
Synthetic triterpenoids
 and TGF- β /Smad signaling, 1371
 γ Synuclein
 ER signaling stimulation, 3899
Synuclein γ gene
 demethylation, breast cancer and ovarian cancer, 664

T

Taccalonolide A
 microtubule-stabilizing activity, 3211
Taccalonolide E
 microtubule-stabilizing activity, 3211

Tamoxifen
 DNA adducts, monkeys, 4402, 5999
 endometrial DNA binding, irreversible, 8461
 erbB-2-associated mammary cancer modulation, 2425
 extracellular VEGF inhibition, 8742
 growth arrest
 p27^{Kip1} and, breast cancer, 4322
TATA-binding protein-interacting protein 30 (TIP30)
 and tumorigenesis, 8763
TATA-binding protein-interacting protein 49 (TIP49)
 β -catenin transformation and TCF transcription, 8726
Tat-interacting protein 30 (TIP30/CC3)
 and tumorigenesis, 8763
Taxol: See Paclitaxel
T bodies
 immunogene therapy, prostate tumors, 2470
T-cell factor
 inhibition by calcium, colon cancer, 67
 target genes, ovarian cancer, 2913
 transcription
 TIP49, 8726
Tea intake
 and breast cancer, Asian-American women, 7526
Tea polyphenols
 Bcl-2 protein inhibition, 8118
Technetium-99
 Tc(I)-carbonyl conjugates, prostate cancer diagnosis, 4082
Telomerase
 activation by EWS/ETS fusions, Ewing's tumors, 8338
 hTERT-Ad, cancer treatment, 3181
 human hTERT-immortalized fibroblasts
 premalignant phenotype, 7147
 inhibition by dietary polyphenols, 824
 inhibitors
 antiproliferative effects, 5917
 senescence induction resistance, 6149
 modulation by culture conditions, keratinocytes, 7815
 reactivation
 GBM-mediated, HUVECs, 3750
 simultaneous telomere and telomerase targeting, 579
 template antagonist GRN163, 3931
Telomerase reverse transcriptase
 human hTERT
 activation by EWS/ETS fusions, Ewing's tumors, 8338
 Ad5-hTERT-E1 vector, antitumor replication-selective, 7936
 nuclear translocation mediation by NF- κ B p65, 18
 regulation by chromatin remodeling, 689
 human hTERT-Ad, cancer treatment, 3181
 human hTERT-BJ cells
 EpiRegulin activation, 1743
Telomerase RNA
 phosphoramidate, multiple myeloma, 6187
Telomeres
 dysfunction
 Atm loss and, 8188
 hepatocarcinogenesis, 5021
 MNU hypersensitivity and, 7047
 oral cancer, 458
 erosion
 Ad-RB94, bladder cancer, 760
 length maintenance, 2589
 maintenance mechanisms, osteosarcoma, 1759
 simultaneous telomere and telomerase targeting, 579

- Telomestatin**
biological effects, 3247
- Temozolomide**
metabolic activation, positron emission tomography, 2409
- TEP1: See Phosphatase and tensin homologue deleted on chromosome 10 (PTEN)**
- Teratoma**
metastatic mature, genetic analysis, 6063
- Testican family proteins**
interactions, 3364
- Testicular cancer**
caspase-3 activation failure and cisplatin resistance, 513
mammalian *RAD9* paralogues expression, 5291
- Testicular germ-cell tumors**
bilateral
c-KIT mutations and, 7674
- 12-O-Tetradecanoylphorbol-13-acetate**
skin tumor promotion susceptibility, genetics, 2747
- Thalidomide analogues**
antiangiogenic activity, 3189
novel SelCID-3, antitumor effects, 593
- Thermal ablation**
radiofrequency
combined with liposomal doxorubicin, 6327
- Thiol-sensitive SOD2 mutant**
Jurkat cells, 159
- Thrombosis**
tumor vessel
targeted tissue factor fusion proteins, 5046
- Thrombospondin-1**
and radiation response, melanoma, 4055
- Thrombospondin-1 gene (TSP-1)**
methylation, neuroblastoma, 6299
- Thymidine phosphorylase**
and endothelial cell migration, 527
- Thymidylate synthase (TS) gene**
double polymorphism, 6004
novel tandem repeat SNP, 2898
- Thymoma**
WHO-defined subtypes, allelotyping, 3708
- Thyroid carcinogenesis**
PPAR γ inhibition by mutant thyroid hormone receptor β , 5274
- Thyroid carcinoma**
aminopeptidase N/CD13, biological significance, 8500
caveolin-1 and -2, 2864
growth inhibition by adenoviral AD-r-PTP η , 882
IL-4 and IL-10 production, 6784
medullary
growth inhibition by CEP-701 and CEP-751, 5559
penetrance
strain effects, *RET* transgenic mouse model, 4777
papillary
BRAF mutations, 1454, 4561
p73 functional loss, 5829
- Thyroid hormone receptor β**
mutations
PPAR γ inhibition, thyroid carcinogenesis, 5274
- Thyroid-stimulating hormone receptor gene *TSHR***
methylation, epithelial thyroid tumors, 2316
- Thyroid tumorigenesis**
SLC26A4 hypermethylation, thyroid tumorigenesis, 2312
- Thyroid tumors**
BRAF mutations, 4561
- epithelial
TSHR methylation, 2316
- Tirapazamine**
and buthionine sulfoximine, neuroblastoma, 1520
transport/resistance, three-dimensional cultures, 5970
- Tissue factor**
targeted fusion proteins, 5046
- Tissue factor/factor VIIa inhibitors**
angiogenesis and tumor growth blockade mechanism, 2997
- Tissue factor pathway inhibitor 1**
melanoma vasculogenic mimicry, 5381
- Tissue factor pathway inhibitor 2**
melanoma vasculogenic mimicry, 5381
- Tissue inhibitors of matrix metalloproteinases**
upregulation by DPPIV, ovarian cancer, 2278
- Tissue microarray analysis**
cervical cancer marker identification, 1927
head and neck squamous cell carcinoma, 1179
node-negative breast cancer, 1101
quantitative, breast cancer, 1445
- T lymphocytes**
activation
melanoma-presented peptides, 1560
tumor architecture and, 3682
apoptosis
galectin-3-induced, 8302
induction by tumor gangliosides, 1676
tumor supernatant, 642
CD4+
CCR9 overexpression effects, T-ALL, 6469
CEA-specific dominant epitope, colon cancer, 8481
COA-1 identification, 6735
p53₁₁₀₋₁₂₄-specific, 3675
and simian virus 40 large tumor antigen, 1040
stimulation by dendritic cells
IL-10 and, 2150
CD8+
differentiation, metastatic metastasis, 2535
stimulation by dendritic cells
IL-10 and, 2150
tumor rejection, 4095
CD25+
depletion
LEC/chTNT-3 and, solid tumors, 8384
CD4+ CD25+
natural killer T-cell inhibition, 4516
double-negative
antitumor activity, 8014
EphA2 responses, renal cell carcinoma, 4481
function and development
N-ras, 1615
helper
HPV-16 E6-specific responses, 636
HPRT mutational spectrum, 5793
leukemia
campath-1H therapy, murine model, 6453
leukemia, acute lymphoblastic
CCR9 overexpression effects, CD4+ T cells, 6469
melanoma-reactive, bone marrow, 5582
myeloma-specific, donor lymphocyte infusion, 2561
natural killer
inhibition by CD4+ CD25+ regulatory T cells, 4516
polarization, 4101
tumor growth, 3058
pediatric leukemia, acute lymphoblastic
- NKX2-5* deregulation by *BCL11B* juxtaposition, 5329
recently activated dendritic cells and, 3688
tolerance
solid tumor-specific, mechanisms, 9007
tumor-reactive
costimulation by 4-1BB, 2546
tumor-specific
activation by radiofrequency ablation, rabbits, 6496, 7543
induction by survivin, colorectal cancer, 4507
- TMpPy4**
biological effects, 3247
- Tolerance**
T cell
solid tumor-specific, mechanisms, 9007
- Topoisomerase I**
anticancer drugs targeting
novel ARC-111, 8400
and enhancer-dependent splicing, 8203
inhibition by lamellarin D, 7392
inhibition by MJ-III-65, 7428
Werner protein interactions, 7136
- Topoisomerase II binding protein 1**
G₂-M checkpoint regulation, 3049
- Topoisomerase II β binding protein 1**
focus formation, double-strand breaks
hRad9, 4829
- Topotecan**
combination p53 and topotecan treatment, colon cancer, 2782
- Topovale: See ARC-111**
- Toxicity**
benzene-induced
NQO1 role, 929
doxorubicin
protection against, *Cbr1* +/- mice, 6602
- TP53**
mutations
urothelial cell carcinoma of the bladder, 8108
mutations, germ-line
and Li-Fraumeni syndrome, 6643
- T-plastin**
expression, Sezary cells, 7122
- Transcription**
DNA methylation damage response, 8158
inhibition by ING1, 5785
- Transcription factor A**
mitochondrial
p53 interactions, 3729
- Transcriptome analysis**
increased tumor expression chromosomal regions, 5781
- Transformation**
neoplastic
AMF/PGI overexpression, fibroblasts, 242
 β -catenin-mediated
TIP49, 8726
viral
Notch1 and, keratinocytes, 8687
- Transforming growth factor α**
and growth factor independence, 4731
and malignant progression, 4731
- Transforming growth factor β**
apoptosis
regulation by HIPK2, hepatoma, 8271
-induced *PMEPA1*, colon cancer, 1568
-induced proliferation, osteosarcoma, 7791
JNK activation
regulation by HIPK2, hepatoma, 8271
-neutralizing mAb 2G7
combined with dendritic cell-based vaccines, 1860
resistance
lymphoid enhancer factor 1, 801

- TGF- β /Smad signaling
ovarian cancer, 1413
synthetic triterpenoids and, 1371
tumor inhibition, DP-153 prostate cells, 4358
type II receptor
HDAC-mediated inhibition mechanism, 2624
- Transforming growth factor β 1**
and p21 stability, colon cancer, 3340
secretion and invasive breast cancer, 2610
VEGF gene transcription stimulation, cholangiocellular carcinoma, 1083
- Transgenes**
adenoviral expression, 847
- Transitional cell carcinoma**
aggressive
nuclear HB-EGF, 484
- Transitional cell carcinoma, bladder**
chromosome 15q loss of heterozygosity, 7657
TSC1 mutations, 7652
- Trastuzumab**
combined with flavopiridol
EGFR target, breast cancer, 3626
- Trefoil factor 1**
TFF1^{-/-} mice
COX-2 and celecoxib effects, gastric adenoma, 3032
- Trimetrexate**
growth inhibition, chronic myeloid leukemia, 1304
- Trioxifene (LY133314)**
antimetastatic effects, PAIII rat prostate cancer, 6056
- Triple microarray analysis**
epigenome, 2164
- Triterpenoids**
synthetic
and TGF- β /Smad signaling, 1371
- TR3/Nur77**
colon cancer cell apoptosis, 5401
- Trp53^{+/+} tumors**
modifier genes, 2364
- Trypsin**
tumor-suppressive role, cancer, 6575
- Tuberous sclerosis complex gene *Tsc1***
loss of expression
VEGF production, 5173
mutations, transitional cell carcinoma of the bladder, 7652
- Tuberous sclerosis complex gene *Tsc2***
and HIF2 α upregulation, renal cell carcinoma, 2675
loss of expression
VEGF production, 5173
- α -Tubulin**
mutations, Taxol resistance, 1207
- Tumor angiogenesis: See Angiogenesis**
- Tumor antigen**
EphA2, 8476
vaccinia-expressed
combined with GM-CSF, intratumoral vaccination, 6956
- Tumor-associated stromal cells**
migration stimulating factor expression, 8827
- Tumor cell-lined vascular spaces**
vasocrine formation, 1812
- Tumor cells**
CD80-decorated, cancer immunotherapy, 4067
CTL lysability
Hsp70 effects, 8212
death, DNA damage
dendritic cell effects, 5143
EGFR-dependent survival, 1
- IgG expression and, epithelial carcinoma, 6488
inhibitor of apoptosis protein targeting, 6815
intradermal injection
and immunogenicity, 2145
radiosensitization by heat-activated antisense Ku70, 3268
senescence, cancer treatment, 2705
VEGF expression, circadian, 7277
- Tumor growth: See also Cell growth**
angiotensin II effects, colon cancer, 6726
arxoxifene effects, breast cancer xenograft model, 6516
ERK^{MAPK} activity and p38^{SAPK}, 1684
glycosphingolipid metabolism and, melanoma, 3654
IG20, 8768
IgG expression and, epithelial carcinoma, 6488
inhibition
A12, 8912
anginex, 382
CDK2/cyclin A antagonists, 1020
chemokine receptor antagonist, breast tumors, 8360
combination DNA vaccine immunotherapy and Pan-IA DNA, 7920
hyaluronan-binding peptide, 5685
IL-10-mediated, ovarian cancer, 5091
IL-12-transduced macrophages, metastatic prostate cancer, 7853
Ink4a/Arf, colon tumors, 742
mPHD1, 8777
nitric oxide synthase, 3855
16-kDa prolactin fragment, prostate cancer, 386
PSP-94, 2072
reversible MetAP2 inhibitors, 7861
salmosin gene transfer, melanoma, 6458
selective cytokine inhibitory drugs, 8073
TF/TFIIa inhibitor mechanism, 2997
U19, prostate tumors, 4698
uPAR and MMP-9, glioma, 2454
natural killer T cells, 3058
promotion by endocan, 6084
promotion by IGF1BP-2, prostate tumors, 3575
prostaglandin E₂ effects, colon cancer, 6726
regrowth
prevention by SU11248 maintenance therapy, 4009
- Tumorigenesis**
Apc^{Min/+} mouse model, 5136
bioluminescence imaging, novel reporter mouse, 7042
developmental arrest of angioblastic lineage and, 7051
inhibition by Atm loss, 8188
susceptibility
Nbn heterozygosity and, mice, 7263
TIP30 and, 8763
- Tumorigenicity**
reversal by GATA-1, erythroleukemia, 6363
- Tumor-immunodominant antigen**
TS/A adenocarcinoma, 2158
- Tumor-infiltrating lymphocytes**
HLA-B46-restricted
mutated p53 recognition, 854
- Tumor necrosis factor α**
angiogenic factor upregulation, malignant glioma, 4181
combined with flavopiridol
apoptosis induction, 621
cytotoxicity
sensitization by pVHL, renal cell carcinoma, 7076
L19-TNF- α fusion
- combined with L-12-L19, therapeutic effects, 3202
single nucleotide polymorphisms
and colorectal cancer, 3560
- Tumor necrosis factor-related apoptosis-inducing ligand**
adenoviral gene transfer
hepatocyte toxicity, 2369
apoptosis
Bax and Bak effects, 1712
inhibition by IL-8, ovarian cancer, 4521
regulation by NF- κ B, 1059
chemotherapeutic drug interactions, breast cancer, 5390
combined with CPT-11
apoptosis induction, prostate cancer, 4713
combined with flavopiridol
apoptosis induction, 621
liver metastases, murine renal cancer, 207
promoter activity induction by IFN- β , 5299
receptor
caspase 8/TR2
restoration, and TRAIL sensitivity, neuroblastoma, 1122
sensitivity, neuroblastoma
caspase 8/TR2 restoration and, 1122
sensitization by paclitaxel, renal cancer, 1365
sensitization by rottlerin, colon cancer, 5118
- Tumor proliferation**
hydrogen peroxide and, 6370
inhibition
letrozole, 6523
mTNOS and, 6370
SDF-1 α and CXCR4, glioblastoma, 1969
- Tumor rejection**
CD8⁺ T cell-mediated, 4095
- Tumor rejection antigens**
EphA2, 8476
shared antigens, 6051
- Tumors**
apoptosis, near-infrared fluorescent imaging, 1936
architecture
and T-cell activation, 3682
bromodeoxyuridine distribution, 5707
CTL recruitment, tracking by MRI, 6838
endothelium
endothelial precursor cell model, 5866
erythropoietin and oxygenation, 6162
fibrosis induction by LOR-1, 1657
gangliosides
apoptosis induction, T cells, 1676
glycolysis
¹³C NMR spectroscopy, RIF-1 tumors, 8813
immune interactions, meeting report, 3005
Ink4c/p53-null mice, 5420
invasion induction by LOR-1, 1657
lymphangiogenic factor expression, 713
lysis
tumor-selective
Ad5-hTERT-E1 vector, 7936
metastasis
disaccharides and, 2775
microenvironment markers
regulation by ErbB receptors, 3764
microsatellite instability
gene therapy, 8113
MMPs and, melanoma metastases, 8221
origin
gene expression-based classification mapping, 4144
oxygen gradients and oxygenation manipulation, 4705
oxygen status measurement, melanoma xenograft model, 7232

progression
induction by LOR-1, 1657
promotion by FGF2, prostate cancer, 5754
promotion by Mdm2 splice variants, 5703
remission after HER-2/*neu* downregulation,
mouse model, 7221
S. typhimurium accumulation, 5188
small animal FDG-PET/CT imaging, 6252
stromal interactions
genes, 8939
T cells
activation by radiofrequency ablation, rab-
bits, 6496, 7543
Tumor spheroids
antibody targeting, 1288
Tumor supernatant
lymphocyte apoptosis, 642
Tumor suppressor genes
chromosome 3p, esophageal squamous cell
carcinoma, 3724
promoter hypermethylation
urine-based detection, kidney cancer, 8695
Tumor suppressor in lung cancer-1 gene
(*TSLC1*)
esophageal squamous cell carcinoma pro-
gression, 6320
tumor suppressor activity, non-small cell
lung cancer, 7979
Tumor vaccines
oncolytic
heat shock protein-mediated, 7321
Tumor vessel thrombosis
targeted tissue factor fusion proteins, 5046
Twist
upregulation by Wnt1, 1906
TXNIP/VDUP1
metastasis inhibition, melanoma, 432
Tyrphostin
pRB reactivation, melanoma, 1420

U

UbcH10
cancer-related E2 ubiquitin-conjugating en-
zyme, 4167
Ubiquitin-conjugating enzyme (E2)
cancer-related UbcH10, 4167
Ubiquitin-processing protease UBP41
proapoptotic activity, 682
U937 cells
PBN radioprotective effects, 6885
U19 gene
prostate tumor growth inhibition, 4698
Ulcerative colitis
epithelial and stromal microsatellite instabil-
ity, 6158
**Ulcerative colitis-associated colorectal can-
cer**
chromosome 6 genetic alterations, 3747
Ultrasound
antiangiogenic therapy monitoring, 8264
Ultraviolet A radiation
and benzo(a)pyrene diol epoxide mutagenic-
ity, 8708
genomic instability, fibroblasts, 1464
Ultraviolet B radiation
genomic instability, fibroblasts, 1464
Ultraviolet X radiation
genomic instability, fibroblasts, 1464
Uracil phosphoribosyltransferase
CD/UPRT fusion gene
vesicular stomatitis virus vector, 8366
Uridine phosphorylase
functional analysis, 4268
Urine
HuSNP chip assay, bladder cancer detection,
5723
promoter hypermethylation detection, kidney

cancer, 8695
proteins
proteomic profiling, renal cell carcinoma,
6971
Urokinase plasminogen activator receptor
invasion and growth inhibition, glioma, 2454
Urothelial cell carcinoma of the bladder
FGFR3 and *TP53* mutations, 8108
Ursodeoxycholic acid
Ras and COX-2 inhibition, colon cancer,
3517
Ursolic acid
NF- κ B activation inhibition, 4375
Uterine growth
inhibition by potent steroid sulfatase inhibi-
tors, 6442
Uterine leiomyomata
chromosome 12q15 rearrangements
HMG2 fusion transcripts, 1351
Uveal melanoma
BRAF mutation absence, 5761
BRAF mutations, 5712
chromosome 3, fine mapping, 8507
chromosome 3p25.1-p25.2 deletions, 8507
NRAS mutation absence, 5761
tumor classification, gene expression profil-
ing, 2578

V

Vaccines
ATRA and, 4441
B-cell lymphoma
CD154 and CpG-DNA, 4128
BCC-hLL2MUC1, development and preclini-
cal evaluation, 1270
dendritic cell-based
combined with TGF- β -neutralizing mAb
2G7, 1860
DNA
combined with Pan-IA DNA, tumor
growth inhibition, 7920
and LAG-3, mammary carcinogenesis
prevention, 2518
HPV oncogene, high-grade vulval intraepi-
thelial neoplasia, 6032
hsp110-gp100, antitumor immunity, 2553
intratumoral
vaccinia-expressed tumor antigen and
GM-CSF, 6956
peptide-based
CpG adjuvant and CTLA-4 blockade,
3281
tumor
heat shock protein-mediated oncolytic,
7321
Vaccinia-expressed tumor antigen
combined with GM-CSF, intratumoral vacci-
nation, 6956
Vaccinia virus Ankara, modified (MVA)
prime with fowlpox boost, antitumor ther-
apy, 7942
Vacuolating toxin VacA
H. pylori
gastric epithelial cell apoptosis induction,
951
Vascular adhesion protein 1
head and neck squamous cell carcinoma,
1920, 8555
Vascular endothelial cells
angiostatin₄₋₅-mediated apoptosis, 4275
GBM-mediated telomerase reactivation,
3750
Vascular endothelial growth factor
circadian expression, tumor cells, 7277
estrogen-independent growth promotion,
breast cancer, 4684
expression

regulation by β -catenin, colon cancer,
3145
stimulation by bombesin, prostate cancer,
3495
extracellular
inhibition by tamoxifen, 8742
gene promoter, haplotype analysis, 812
gene transcription, cholangiocellular carci-
noma, 1083
isoform expression, gliomagenesis, 1962
mRNA expression regulation by PTEN mu-
tation and EGFR, 236
PGE₂-induced expression
mediation by HIF-1, colon cancer, 2330
production induction by *Tsc1* and *Tsc2* loss,
5173
release induction by MMP9 and MMP2,
ovarian cancer, 5224
RNAi
angiogenesis inhibition, 3919
serum levels and tumor expression, hepato-
cellular carcinoma, 3121
tumor-derived
Ang-2 upregulation, epithelium, 3403
Vascular endothelial growth factor A
inhibition
ZFP TF-mediated, glioblastoma, 8968
isoforms
effects, mouse brain metastasis model of
melanoma, 5408
Vascular endothelial growth factor C
regulation by IGF-IR, 1166
tumor expression, 713
Vascular endothelial growth factor D
tumor expression, 713
Vascular endothelium
resistance to radiation-induced apoptosis,
7663
Vascular lesions
VHL knockout mice, 5320
Vascular spaces
tumor cell-lined, 2812
Vascular targeting
meeting overview, 1144
Vasculogenic mimicry
TFPIs, melanoma, 5381
Velban
NOVP chemotherapy-induced sperm aneu-
ploidy, Hodgkin's disease, 44
Velcade: See Bortezomib
Versican
cell adhesion inhibition, prostate cancer,
4786
Verteporfin
photodynamic therapy, 1025
Vesicles, shed
small molecule expulsion, 4331
Vesicular stomatitis virus
hepatocellular carcinoma treatment, 3605
recombinant rVSV
CD/UPRT fusion gene vector, 8366
Video angiography
fluorescein
microcirculation *in vivo*, basal cell carci-
noma, 3969
Vimentin
overexpression
and invasive phenotype, prostate cancer,
2306
transactivation by β -catenin, breast cancer,
2658
Vincristine
combined with G207
oncolytic activity, rhabdomyosarcoma,
1508
Virotherapy
oncolytic

antitumor efficacy, pharmacologic indicators, 4003

Virus replication
Ad5 knob substitution and, 1262

Visinin-like protein-1
growth and invasiveness effects, squamous cell carcinoma, 4997

Vitamin D₃
target genes, colon cancer, 7799

Vitamin E
selenium and, prostate cancer chemoprevention, 6988

Vitamin E succinate
apoptosis
mitochondrial events, 2483

von Hippel-Lindau-defective renal cell carcinoma
HIF-dependent replicative adenoviral treatment, 6877

von Hippel-Lindau disease
developmental arrest of angioblastic lineage arrest, 7051

von Hippel-Lindau gene (VHL)
methylation status and loss of heterozygosity, esophageal squamous cell carcinoma, 3724

VHL knockout mice
vascular lesions and sperm defects, 5320

von Hippel-Lindau protein pVHL
TNF α cytotoxicity sensitization, renal cell carcinoma, 7076

von Hippel-Lindau tumor suppressor-binding protein 1
hMSH4 interactions, 865

Vulval intraepithelial neoplasia
high-grade
HPV oncogene vaccination, 6032
HPV-16-positive
HLA polymorphisms, 400

W

Werner protein
topo I interactions, 7136

Werner syndrome
decatenation checkpoint, 3289

Wilms' tumor
IGF2 loss of imprinting, 1900

Wnt
COX-2 expression regulation, 728
pathway activation, mesothelioma, 4547
signaling
activation by SKI, melanoma, 6626
enhancement by BP75, 4792

Wnt1
Twist upregulation, 1906

Women
Asian-American
tea intake, *COMT* genotype, and breast cancer, 7526

Women's Health Initiative
breast cancer and NSAIDs, 6096

World Health Organization (WHO)
thymoma subtypes, allelotyping, 3708

WW domain-containing oxidoreductase gene (WWOX)
expression, non-small cell lung cancer, 878
protein expression analysis, 8629

X

Xenografts
opossum cancer model, 6121

X-irradiation
neurogenesis sensitivity, 4021

X-linked inhibitor of apoptosis protein (XIap)/Akt
-mediated chemoresistance
p53, 7081

X-linked inhibitor of apoptosis protein (XIAP)-associated factor 1
hypermethylation, gastric adenocarcinoma, 7068

X-linked juvenile-type granulosa cell tumors
susceptibility genes, mapping, 8197

X-ray microprobe mapping
platinum uptake, ovarian adenocarcinoma, 1776

X-ray repair cross-complementing gene 1 (XRCC1)
and breast cancer risk, 8536

X-ray repair cross-complementing gene 2 (XRCC2)
Xrcc2-knockout mice
genetic instability, 8181

X-ray repair cross-complementing gene 4 (XRCC4)/DNA ligase IV
gap filling, 22

Y

Yeast
DNA base excision repair, 549

Yeast two-hybrid assay
hMLH1 germ-line mutations, 3302

Yondelis (ET-743)
hepatotoxicity
dexamethasone protection against, rat, 5902

Z

ZASC1
amplification, esophageal squamous cell carcinoma, 5691

ZD1839
AKT dephosphorylation promotion, breast cancer, 7777
combined with LY294002, glioma, 8930
pulmonary fibrosis augmentation, 5054

ZD6126
vascular-targeting activity, 1534

Zinc deficiency
combined with cyclin D1 overexpression, forestomach carcinogenesis, 4244

Zinc finger protein 185
inactivation, prostate cancer, 3877

Zinc-finger transcription factors
VEGF-A inhibition, glioblastoma, 8968

Zinc protoporphyrin
pegylated
antitumor activity, 3567